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Despite dramatic improvements in the quantity and quality of life for Human 
Immunodeficiency Virus (HIV) positive people with the introduction of combination 
antiretroviral therapy (cART), all-cause mortality rates remain higher than the general 
population. Furthermore, treatment is a lifelong commitment and a substantial burden on 
patient life.  
 
The aim of this thesis was therefore to assess the long term durability of cART through 
assessing various clinical, virological and immunological outcomes including mortality in 
HIV-positive patients across Europe. The analyses were based on data from the EuroSIDA 
cohort, an observational cohort of more than 16000 HIV-positive patients from Europe, 
Israel and Argentina.  
 
Results showed that HIV-positive patients on a well-tolerated and fully suppressive cART 
regimen have a small risk of treatment failure occurring over the next 6 months and could 
therefore be monitored less frequently. In contrast patients who have spent a low 
percentage of time with a suppressed viral load whilst on cART or who have recently 
rebounded may require more intensive monitoring after making a treatment switch. In 
patients who have achieved an initial response and tolerated the first three months of 
treatment, nevirapine efavirenz and lopinavir based cART regimens all have similar 
durability based on risk of all-cause discontinuation and development of serious clinical 
events. Starting cART earlier to reduce the proportion of patients with a low CD4 count 
may decrease the rate of developing many common non-AIDS related malignancies. 
Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes 
in part due to differences in use of effective cART.  
 
In conclusion results from this thesis provide evidence that could help improve the long 
term durability of cART for HIV-positive patients through different measures of healthcare 
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Chapter 1 Introduction 
 
1.1 Introduction  
Over the past 30 years the HIV epidemic has moved from a single report of a cluster of 
infections1 to a worldwide pandemic2. HIV first appeared on the public health agenda in 
1981, when young gay men started dying of obscure diseases3. At this time, very little was 
known about the disease, and infection with HIV was usually fatal within months or years 
of the appearance of AIDS defining symptoms4. Since then, our knowledge and 
understanding of the disease has increased dramatically, and huge advances in treatment 
in the mid-90’s mean that HIV is now seen as more of a chronic and manageable infection 
in the developed world5;6. However, HIV remains among one of the leading causes of 
death worldwide, accounting for more lives than any other infectious disease7, and the 
incidence of HIV is still increasing in the majority of regions in the world8. In the most 
heavily affected countries HIV has reduced life expectancy by 20 years9, though treatment 
advances in the developed world have resulted in a dramatic decline in mortality rates 
from AIDS related causes10. However, in the majority of patients mortality rates remain 
higher than that of the general population11-13. Furthermore, with no significant 
development towards a cure or vaccine14;15, treatment is a life-long commitment and a 
substantial burden on the patient’s life, as well as being itself associated with a number of 
toxicities and adverse events16-18. Additionally, recent studies have also found that HIV-
positive patients are at a greater risk of death from other illnesses not thought to be 
directly associated with HIV infection19-21. More research needs to be done to understand 
and help improve the long term treatment and outcome for patients infected with HIV.  
 
1.2 The start of the epidemic  
HIV first came to prominence in 1981 with a spate of deaths of young gay men in the 
United States attributable to obscure diseases3;22 that had rarely been seen before, such 
as Pneumocystis carinii pneumonia (PCP)23;24 and Kaposi’s sarcoma, a rare cancer 1;6;22;25-
29. These diseases started to become very common in young, previously healthy 
homosexual men23;25;27. At first there was a lot of stigma surrounding the disease and 
names initially suggested for what is now called ‘AIDS’ included ‘gay compromised 
syndrome’, ‘gay related immunodeficiency syndrome (GRID)’ and ‘gay cancer’30;31.  
15 
 
However, similar symptoms were soon also reported in intravenous drug users32-36, 
haemophiliacs and other patients who had received blood transfusions36-38,as well as 
Haitians in the United States36;39. Similar symptoms were also seen in the same groups of 
patients in Europe27;28;40-46. Additionally, there were reports that children whose parents 
were in these risk groups were also experiencing these symptoms47;48. Reports in Europe 
of similar symptoms in previously healthy Africans began to emerge49, and doctors in 
Africa also began to report an increase in cases of Kaposi’s sarcoma50-52, giving rise to the 
idea that there might be a second epidemic in Africa not confined to particular risk 
groups52;53. It quickly became apparent that the underlying cause of these diseases was 
severe immunodeficiency3;23;24. In 1982, Acquired Immunodeficiency Syndrome (AIDS) 
was named and defined by the CDC36, in French it was referred to Syndrome d'immuno-
depression acquise (SIDA). Although immunodeficiency diseases were not unheard of , 
the striking difference with AIDS was that it had a 100% mortality rate3.  
 
1.3 The origins of HIV 
In 1983, France's Pasteur Institute discovered the virus believed to be responsible for 
AIDS, and named it Lymphadenpathy Associated Virus (LAV)54;55. Around the same time, 
Robert Gallo and his team discovered a virus which they named Human T-cell 
Lymphotropic Virus 3 (HTLV-III) and similarly provided evidence that it was this virus that 
was responsible for AIDS56-58. By 1985 it was recognised that these two viruses were the 
same. To avoid confusion, and because of its obvious detrimental effects on the human 
immune system, these viruses were renamed Human Immunodeficiency Virus (HIV)3;59;60. 
In the mid-80s it became apparent that there were two types of HIV, HIV-1 and HIV-23. 
These two types, HIV-1 and HIV-2, are not closely related to each other and within these 
two types are a variety of subgroups, some of which have considerable genetic diversity 61.  
 
Much speculation has existed over how humans became infected with the disease. One 
theory was that it came from a contaminated oral polio vaccine used in Africa in the late 
1950’s or that it was a biological weapon developed in America. These ideas have since 
been proven to be unfounded62;63. In 1999, a group of researchers announced that they 
had found a virus in chimpanzees that was almost identical to HIV64, and it is now 
accepted the HIV-1 is closely related to a virus found in Chimpanzees 64-66 and HIV-2 to 
Simian Immunodeficiency Virus (SIV) found in sooty mangabey monkeys61;67. The wide 
range of subgroups in both of these types suggest that cross species transmission has 




HIV-1 is the predominant form of the virus worldwide70;71 and the cause of the vast majority 
of infections. However, the spread of HIV-1 in the developed world is still mainly confined 
to those in high risk groups such as homosexuals, intravenous drug users, and sex 
workers72. It is thought that HIV-1 crossed into humans three times and this has resulted in 
three different subgroups M, N, and O3;61;65. M is the most common and widely spread 
across the world61. Within the M group so far 10 subtypes have been found, A-K, with B 
and D being the most similar to each other61;72. HIV-1 infections in North America and 
Europe are most likely due to group M subtype B, while subtype C is common in India and 
Southern Africa, and subtype E spread most rapidly through Southeast Asia3;61. Although 
HIV-1 group M subtype B accounts for fewer infections than subtype C, it is the more 
widespread73, and no other subtype has been found in as many countries around the 
world74. No subtypes have been found thus far in groups O or N3. Group O is currently 
restricted to west central Africa, and N has only been identified in cases from 
Cameroon3;61;75;76.  
 
It is thought that HIV-1 was introduced to the human population 60-90 years ago77 and 
there is now very little doubt that the disease originated in Africa, as many cases have now 
been found dating back to the 1960’s78. A study analysing plasma samples from Africa 
dated from 1959 to 1982 found an HIV positive sample from as early as 195978. Studies 
found that these samples had diversified substantially from the original strain that crossed 
over into humans, indicating that HIV had been circulating in the population for several 
years79. Further studies have since found that HIV-1 originated in central Africa, apparently 
around the 1930s65;77, coinciding with when the first towns were emerging in the same 
region of Africa71. The earliest reported evidence of AIDS in Africa has been found to be in 
the late 1950s-early 1960’s78;80. However, it is thought that a high number of tuberculosis-
caused mortality could actually have been undiagnosed AIDS-related mortality 73.  
 
Evidence has shown a high prevalence of HIV-1 among Haitian immigrants in the US81. 
There was debate over whether Haiti was the source from where the epidemic spread to 
the US77;82;83 or whether the Haitian HIV-1 epidemic was caused by sex tourism from the 
US in the mid-1970s84;85. However, a recent study has found that Haiti has the oldest 




We now know that HIV-1 was circulating in the USA for around 10 years before it was first 
recognised73, with the date of the US epidemic estimated to have started around 1968-
196973;86. Studies describing the prevalence of AIDS found 4.5% of homosexual men in 
San Francisco and 6.6% in New York were estimated to have AIDS in 197887;88. As there 
is a long interval between HIV seroconversion (initial infection with HIV) and symptomatic 
disease this evidence suggests that several thousand individuals in the US were already 
infected, therefore implying that the virus had already been circulating the US for several 
years73.  
 
Once established, HIV-1 was able to spread quickly through the pre-existing networks of 
gay men and injecting drug users it encountered in north America and Europe during the 
early 1980’s3. One of the oldest recorded cases of AIDS in the developed world is thought 
to be that of a sailor in Manchester, UK, who was reported to have died from an AIDS like 
illness in 195989.  
 
There are several theories as to why there was such a dramatic increase in the number of 
AIDS cases in the 1980s. One suggestion is that HIV had been spreading slowly in the 
heterosexual population before entering the homosexual male population, where it spread 
explosively73. There was a massive increase in the number of unsterile injections, mainly 
for antibiotics, in sub-Saharan Africa around in the mid twentieth century which likely aided 
the dispersion of HIV though the widespread re-using of needles and syringes90. Once 
established in the human population, overseas troops, overland trucks and increases in air 
travel enabled the rapid and widespread dispersion on the virus91.  
 
There is little debate over the origins of HIV-2. HIV-2 is less infectious than HIV-1 and 
spreads at a slower rate3. So far HIV-2 has been found to have 6 subtypes A-F. HIV-2 is 
much less prevalent and is predominately found in west Africa and India3;72. Wild sooty 
managabey monkeys, indigenous to the same region, are known to be infected with SIV. It 
is thought that humans first became infected with this type in rural west Africa where these 
monkeys are often eaten or kept as pets61.  
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1.4 Biology of HIV: how it works in the body 
1.4.1 The HIV virus 
HIV and SIV are retroviruses, belonging to a subgroup called lentiviruses or ‘slow’ 
viruses61;92. These viruses are characterised by the long interval between initial infection 
and the onset of serious symptoms7. HIV within the living cells of the host91. The primary 
cellular targets of HIV are the lymphocyte cells that express the CD4 cell protein, these 
CD4 cells are a vital part of the human immune system93 
 







Once the virus has been transmitted into the blood it hunts down the helper T-cells or CD4 
cells, so that it can bind to the CD4 receptor present on the surface of these cells and 
usually either the CCR5 or the CXCR4 co-receptors94. Once the HIV virus has bound to 
these cells, the contents of the virus are released. Once inside the cell the HIV enzyme 
reverse transcriptase (RT) helps convert the HIV RNA into DNA so that it is compatible 
with normal human genetic material95. This is known as the provirus. The provirus is then 
able to integrate into the host’s genomic DNA3. When the cell becomes active it treats the 
HIV DNA just like it would normal human genes. First it converts it to messenger RNA 
(using human enzymes) in a process called transcription. The messenger RNA is then 
transported outside the nucleus and is used as a blueprint for producing new HIV proteins, 








Figure not available due to copyright restrictions 
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Among the strand of messenger RNA produced by the cell are complete copies of HIV 
genetic material. The genes produced are much larger than those in the final model, and 
the protease enzyme is vital at this point as it is responsible for cutting the long protein 
strands into smaller functional pieces. They gather together with newly made HIV proteins, 
enzymes, to form new viral particles just inside the cell membrane. The virus then ‘buds’ 
(peels off the cell) and these matured particles are ready to go on and infect other cells. A 
single cell can make thousands of infectious HIV particles7. The host cell dies soon after 
the release of the new virus particle as it is significantly weakened through this process, 
and this is the reason for the destruction of the immune system. If the cell is not active, 
then the provirus may lie dormant within the cell for several years96. This has complicated 
attempts to eradicate HIV and also why therapy is a lifelong commitment97. 
 
1.4.2 Immunology and Virology 
The HIV-virus destroys mature CD4 T-cells and reduces the body’s ability for them to  be 
repalced93. The number of CD4 cell counts in a healthy person is between 500-1600 
cells/mm3 98;99 and natural daily variability is large, regardless of HIV status100;101. A 
persons CD4 count can change due to a number of different factors such as fatigue, time 
of day, stress, exercise, acute infections, drug use and diurnal variation101-103. Woman tend 
to have higher CD4 counts than men104.  
 
It has been shown that HIV-positive individuals have much lower CD4 counts than that of 
HIV-negative individuals99 and that the CD4 cell count gradually decreases during HIV 
infection, as shown in figure 1.2105-107. A lower CD4 count has been found to be associated 
with an increased risk of the development of AIDS and death108-112 
 
A major hindrance into completely understanding and explaining of how the virus impacts 
the immune system, is the inherent difficulty of studying the immune system in living 
humans93. However, techniques for measuring CD4 count have improved and the cost is 
relatively cheap (around $5113 in the developing world and $66 in the developed world) 
although there are still numerous sources of variability in the measured components114.  
 
CD4 counts were complimented by viral load measurements once this method became 
available for routine use in 1996. The method measures the amount of HIV genetic 
material (HIV-RNA) in the plasma (liquid part of the blood) and gives us the viral load115-117. 
During the initial stage of infection with HIV, the viral load can reach 10 million copies/ml 
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before it falls at the end of the acute phase following primary infection, (figure 1.2)118. Viral 
load has been shown to be a strong predictor of AIDS and death, independent of CD4 cell 
count116;119-121 with higher viral loads associated with a faster rate of disease 
progression115.  
 
The HIV-RNA test in the developing world costs around $25113 and in the developed world 
$119. Initially these tests were only able to detect quantitative levels of HIV-RNA in the 
plasma when the viral load was > 500 copies/ml. However, more recently assays with 
lower limits of detection below 50 copies/ml have been introduced122;123. 
 
Viral load and CD4 cell counts are both important predictors of HIV-related mortality124. 
HIV-RNA is considered to be a good long-term marker of risk of clinical progression, that 
is, a single value can determine the risk of AIDS or death 5-10 years thereafter116;125-128. 
However, CD4 count is considered to be a much better predictor of short-term risk of 
disease progression127;129-133. 
 
Figure 1.2 Progression of the HIV virus (HIV-RNA) and deterioration of immune system (CD4 





1.5 The stages of HIV disease progression 
 
The World Health Organisation (WHO) and the Centres for Disease Control (CDC) have 
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AIDS. Table 1.1 details the two classification systems; the main difference is that the CDC 
assesses the severity of HIV disease progression by CD4 count and HIV-specific 
conditions. The WHO classification systems on the other hand, can be used without CD4 
count measurements and allow for clinicians with varying levels of expertise and training to 
diagnose AIDS134, this is especially helpful in resource constrained settings.  
 














No AIDS-defining condition and either CD4+ T-
lymphocyte count of >500 cells/µL or CD4+ T-
lymphocyte percentage of total lymphocytes of >29 
2. Mild 
 (HIV infection) 
B. Symptomatic No AIDS-defining condition and either CD4+ T-
lymphocyte count of 200--499 cells/µL or CD4+ T-





B. Symptomatic No AIDS-defining condition and either CD4+ T-
lymphocyte count of 200-499 cells/µL or CD4+ T-
lymphocyte percentage of total lymphocytes of 14-
28. 
4. Severe (AIDS) C. AIDS AIDS defining condition or CD4+ T-lymphocyte count 
< 200cells/µL 
 
1.5.1 Primary HIV infection 
The first stage of HIV infection is generally called seroconversion. In the first few weeks 
after infection quite high levels of the virus are found in the blood stream137-139, and a 
patients viral load in this early stage can reach millions of virion per ml of blood7. After 
initial infection HIV replicates quickly, producing viral bursts that infect many CD4 cells. 
During this first stage of infection there is normally a slight dip in CD4 cell count and a 
substantial increase in viral load (figure 1.2). The majority of individuals experience a brief 
illness, in most cases mild flu-like symptoms137;140. About 6-8 weeks after primary infection 
the CD4 count increases, the viral load decreases and most individuals enter a relatively 
asymptomatic stage that can last for several years139;140.  
 
1.5.2 Chronic HIV infection 
This initial phase is followed by a gradual deterioration of immune function (figure 1.2)7. 
The body normally manages to compensate for the depletion in the immune system for 10-
12 years after infection, with some people infected for as long as 20 years before needing 
treatment141. In the absence of treatment, older patients have higher rates of progression 
than younger patients7. HIV-2 seems to be less pathogenic and progresses to AIDS more 




The decrease in CD4 count has been estimated to be relatively slow at 50-90 cells/mm3 
per year, until 18 months prior to AIDS diagnosis where between a 3 and 5 fold increase in 
CD4 cell depletion has been observed107;143. Once the CD4 cell count drops below 
500cells/mm3 half the immune reserve has been destroyed7. Patients with a CD4 count 
above 200/mm3 rarely have opportunistic infections, while those with a CD4 count of less 
than 50/mm3 have a high risk of infections100. Plasma HIV-RNA levels are correlated with 
CD4 count depletion, with higher viral loads predictive of a quicker progression to AIDS 
and death121;144.  
 
1.5.3 Clinical AIDS  
The final stage of HIV disease progression is the development of AIDS. Table 1.2 shows 
the list of AIDS-defining illnesses. In addition, in the CDC classification system a CD4 
count < 200cells/mm3 in the presence of HIV infection is also as an AIDS diagnosis. 
Survival time after an AIDS diagnosis varies according to the AIDS-defining events. In the 
absence of treatment, studies have reported median estimates for a single AIDS-defining 
condition of between 3-51 months and between a 1.5 and two-fold decrease in survival 




Table 1.2 CDC category C, list of AIDS defining illnesses, note diagnosis of one of these 
disease without the presence of HIV virus does not mean AIDS.
134;136
 
AIDS defining illnesses 
 Candidiasis bronchi, trachea, lungs or esophageal  
 Cervical cancer (invasive) 
 Coccidioidomycosis, disseminated or extrapulmonary  
 Cryptococcosis, extrapulmonary  
 Cryptosporidiosis, chronic intestinal (greater than 1 month's duration) 
 Cytomegalovirus disease (other than liver, spleen, or nodes) 
 Cytomegalovirus retinitis (with loss of vision) 
 Encephalopathy (HIV-related)  
 Herpes simplex (an infection lasting longer than 1 month or in an area other than the skin 
such as esophagus or lungs) or bronchitis, pneumonitis, or esophagitis  
 Histoplasmosis, disseminated or extrapulmonary 
 Isosporiasis chronic intestinal (greater than 1 month's duration) 
 Kaposi's sarcoma (KS)  
 Lymphoma Burkitt's (or equivalent term)  
 Lymphoma, immunoblastic (or equivalent term)  
 Lymphoma, primary, of brain  
 Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary 
 Mycobacterium tuberculosis, any site (pulmonary * or extrapulmonary) 
 Mycobacterium, other species or unidentified species, disseminated or extrapulmonary  
 Pneumocystis carinii pneumonia  
 Pneumonia, recurrent *  
 Progressive multifocal leukoencephalopathy  
 Salmonella septicemia, recurrent  
 Toxoplasmosis of brain  
 Tuberculosis  







1.6 Current Situation 
1.6.1 Global HIV epidemic 
The most recent UNAIDS epidemic update published in 20098 shows that the number of 
people living with HIV worldwide is continuing to grow. In 2008 this number was estimated 
to be around 33.4 million, a 20% increase on the estimate form 20008. 2.0 million people 
were estimated to have died due to an AIDS-related illness worldwide in 20088. Figure 1.3 
below is from the WHO showing the prevalence of HIV infection across the world. 
 





From Figure 1.3 it is apparent that sub-Saharan Africa is the most heavily infected region 
worldwide. In this region over two thirds of the population are infected with HIV, and AIDS is the 
leading cause of death
2
. In 2001 it was reported that AIDS was responsible for 1 in 5 deaths in sub-
Saharan Africa, twice as many as the second leading cause of death
147
. In 2008 22.4 million adults 
and children were estimated to be living with HIV in sub-Saharan Africa, just under 70% of the 
entire HIV epidemic, and 1.4 million died from an AIDS-related death
8
. Prior to the HIV epidemic, 
life expectancy in this region had increased to 62 years and it was hoped it would soon approach 
that of the developed world. However, due to the high number of HIV related deaths, life 
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Globally, the epidemic is mainly confined to those in particular risk groups: intravenous drug users 
(IDU), homosexual men, and sex workers. The exception is Sub-Saharan Africa, where the 
epidemic is so widespread that everyone is at risk
2;147
. Sub-Saharan Africa is the only region in the 
world where more women are infected with HIV than men (64%)
2
, as transmission of HIV is 




It is thought that the global incidence of HIV peaked in 1996, when 3.5 million new infections were 
estimated to have occurred
8
. In comparison, the estimated number of new infections in 2008 was 
thought to be 2.7 million, 30% lower than in 1996
8
. Although the epidemic appears to have 
stabilised in most regions, including Sub-Saharan Africa, the prevalence of HIV in Eastern Europe 




1.6.2 European HIV Epidemic 
In 2007, HIV/AIDS surveillance in Europe reported that 48,892 newly-diagnosed cases of HIV were 
reported across Europe, from 49 of the 53 countries in the WHO European region
149
. Figure 1.4 
shows the number of new infections by region of Europe and year of diagnosis
149
. Within Europe, 
the HIV epidemic varies across different regions and also by country to country. 
 
Figure 1.4 HIV/AIDS surveillance in Europe: Update 2007. HIV cases per million population in 
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1.6.2.1 Eastern Europe  
In 2008, UNAIDS estimated that 1.5 million people were living with HIV in Eastern Europe 
and Central Asia, a 66% increase from 2001150. Eastern Europe and Central Asia are 
considered together because of both their physical proximity to each other and their 
common epidemiological characteristics. This is the only region worldwide where HIV 
incidence is clearly on the rise (figure 1.4), and 110 000 new infections were estimated to 
have occurred in this region in 20088.  
 
The prevalence of HIV among adults in this region was estimated to be 0.7% in 2008, an 
increase of 0.2% from 2001. Ukraine, Estonia and Russia are reported to have the highest 
infection levels in all of Europe151. In 2007, the prevalence of HIV infection in Ukraine 
among adults was estimated to be 1.6%150, and for Estonia and Russia was estimated to 
be >1%150.  
 
The epidemic in these countries is mainly due to sex workers and intravenous drug users 
(IDUs)147. The overlap between these two groups has helped facilitate the spread of 
infection150. Nearly two-thirds (57%) of newly diagnosed infections in Eastern Europe were 
attributed to intravenous drug use and 42% from unprotected heterosexual sex149. An 
estimated 3.7 million people in Eastern Europe are current injection drug users, and one in 
four are thought to be HIV-positive152. The prevalence of HIV infection among IDUs in the 
Ukraine has been reported to be between 38.5% and 50.3%151, and in Russia 38%152. In a 
number of countries in Eastern Europe, rates of AIDS have been reported to be increasing 
between 2000 and 2007 (figure 1.5), with the biggest increase in Belarus and the Republic 
of Moldova149. Treatment coverage is low in Eastern Europe, as the patients most at risk of 
HIV infection (IDUs and sex workers) are the ones least likely to receive antiretroviral 
therapy153. By December 2008, only 22% of adults in need of antiretroviral therapy were 
receiving it8.  
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1.6.2.2 West and Central Europe 
In West and Central Europe the prevalence of HIV infection was estimated to be 0.3% in 
2008, with an estimated 850,000 people living with HIV alongside 30,000 new infections8. 
The total number living with HIV in this region is increasing. However, this is mainly due to 
antiretroviral therapy substantially increasing the life expectancy of patients as well as an 
increase in HIV testing in Western Europe leading to more diagnoses2. Within this region 
of Europe, rates of new HIV infection appear to be highest in Portugal149. In West Europe, 
24,202 new HIV cases were diagnosed in 2007, with the majority of new infections 
diagnosed in homosexual men (40%)149. In contrast to Eastern Europe, only 8% of new 
infections were due to intravenous drug use149. In Central Europe, 1,897 new HIV cases 
were diagnosed in 2007, 53% of these were through heterosexual contact, 30% though 
homosexual male contact and 13% through injection drug use149.  
 
Figure 1.5 HIV/AIDS surveillance in Europe: Update 2007. Number of newly diagnosed AIDS 
cases per million population in the geographic regions of WHO European Regions (West, 





In West and Central Europe, although the number of new infections appears to be 
relatively stable (figure 1.5), the number of new infections among homosexual men has 
increased over the past decade, whilst there has been a decline in the number of new 
infections due to intravenous drug use8. In the UK, HIV diagnosis in homosexual men rose 
by 74% between 2000 and 20078, with the resurgence tied to an increase in sexual risk 
behaviour8;154. Trends in AIDS diagnoses (figure 1.5) in West and Central Europe continue 
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There has been a significant decline in the number of AIDS-defining illnesses and deaths 
since the introduction of combination antiretroviral therapy (cART) in the mid 90s10;156-159. 
Figure 1.6 shows the declining incidence on AIDS in Europe from 1994-2001, based on 
data from the EuroSIDA study. Further progress in reducing AIDS events and HIV related 
mortality in this region will require an improved effort to diagnose HIV infection earlier. It is 
estimated that between 15% to 38% of patients in Europe are diagnosed after their 
disease has progressed to a level where they should have initiated treatment160.  
 
Figure 1.6 Decline in AIDS and death rates in the EuroSIDA study adjusted for, CD4 count, 
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1.7 Transmission of HIV 
As reported earlier, the continued rise in people living with HIV is due in part to the 
continued high rate of new infections8. HIV can be transmitted through unprotected sexual 
intercourse or oral sex with an infected person161, via blood though the sharing of 
contaminated needles or syringes162 or transfusions of contaminated blood163. It can also 
be transmitted from a mother to her baby during pregnancy, childbirth or through 
breastfeeding164. Risk of infection is largely dependent on the levels of the virus 
present22;165;166. For example, the virus can be found in a person’s tear, but in such a small 
quantity that it is virtually impossible for a person to become infected in this manner22. 
Repeated exposure to the virus increases a person’s risk of infection167. Additionally, the 
HIV virus dies quickly when outside the body so it cannot be transferred through shaking 
hands, or toilet seats for example22. 
  
1.7.1 Sexual transmission 
The most common mode of HIV transmission worldwide is via sexual intercourse22. The 
risk of HIV infection by sexual transmission varies depending on sexual partner, sexual act 
and condom use161. It is greatly increased by infection of other sexually transmitted 
diseases, rough sex or a partner with a high viral load7;168;169. 
 
Woman are at a higher risk than men during heterosexual intercourse7. Worldwide, nearly 
half of all the individuals living with HIV are now women, who acquire the virus largely by 
heterosexual exposure168. Choosing a partner who has tested negative for HIV rather than 
a partner who has not been tested for HIV was found to be associated with a 47 fold 
reduced risk of transmission in heterosexual relationships161 and the use of condoms a 20 
fold reduced risk161. Regular condom use between heterosexual couples, where one 
individual is HIV-positive and the other is uninfected, leads to a very low risk of 
transmission7. However, because of limited economic options and gender inequality many 
woman cannot negotiate safe sexual encounters leaving them very vulnerable to sexually 
transmitted infections and unwanted pregnancy168. In addition a significant proportion of 
men do not consistently use condoms during anal sex with men or women170. This has led 
to topical microbicide formulations, applied vaginally or rectally being investigated as 
another strategy for the prevention of HIV transmission7;168;171.  
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In July 2010 the Centre for AIDS Programme of Research in South Africa (CAPRISA) 004 
study team reported the first evidence that a microbicide was associated with a significant 
reduction in HIV acquisition172. However, the effect size was relatively modest (woman 
using tenofovir gel were overall 39% [95% CI 60%-6%] less likely to become infected with 
HIV) and adherence was poor173. Male circumcision has been found to be an important 
intervention in reducing the risk of heterosexually-acquired HIV infection in men by around 
60%174-176, and is recommended by the WHO as an intervention to reduce HIV 
transmission177. Male circumcision does not however directly reduce male to female 
transmission and condom use is essential178, but it can reduce the risk indirectly by 
reducing the risk of heterosexual men becoming infected179 
 
In the developed world, male to male sexual contact is the highest reported risk factor for 
HIV infection180. The greatest risk of transmission in men who have sex with men (MSM) 
has been found to be receptive anal intercourse with an HIV-positive partner161. In the last 
few years there has been a resurgence in HIV infection among MSM in the developed 
world8;181, as well as new epidemics in Asia, Africa and Latin America182. This increase, in 
some countries, is in part due to an increase in HIV testing183. However, there has been a 
reported increase in the number of MSM having unprotected anal intercourse184, and 
recent outbreaks in other STIs support an increase in sexual risk taking184-186. Many MSM 
who know they are infected with HIV believe they have a responsibility to protect their 
partners from infection187;188 and modify their behaviour accordingly189. However, some still 
engage in unprotected sexual behaviour190 and there are many who remain unaware of 
their HIV status191. Some interventions within the MSM population including individual 
counselling, social and behavioural support discussing attitudes and beliefs, relationship 
support, and community interventions including workshops and empowerment activities 
have been found to lead to a significant reduction in the risk of transmission192. The 
potential role of circumcision among men who have sex with men has not been fully 
investigated193. However, in a recent study it was associated with a reduction in HIV 
incidence among participants who reported a preference for the insertive role in anal 
intercourse194. Despite these various interventions current efforts have been unable to 
contain or reduce the spread of infection among MSM and studies into the most effective 




1.7.2 Transmission via blood 
 
HIV can also be spread through contact with infected blood7. The most common source of 
transmission via blood is through the reusing or sharing of syringes and needles in 
intravenous drug users (IDUs)196. Shared drug injection equipment can transmit HIV when 
residual infected blood remains on used syringes that are then reused by another 
person162. The number of HIV-positive IDUs and the number of IDUs at high risk continues 
to increase globally197. Incidence rates of transmission have been found to be between 10-
50 per 100 person years at risk in many IDU populations around the world197. In countries 
where there are community outreach programmes and access to sterile injection 
equipment, such as the UK198 and Australia199, HIV prevalence has been kept low. 
Treating IDUs with respect and providing them with information on the modes of HIV 
transmission, sterile injection equipment through needle exchange programs, and 
condoms have proved successful intervention methods for reducing the risk of 
transmission197.  
 
Health care workers are also at risk through accidental needle stick injuries or mucosal 
splash with contaminated blood7. The average risk of transmission among healthcare 
workers is estimated to be 0.3% after a needle stick and 0.09% after mucous membrane 
exposure200, although this varies according to the type of exposure i.e. depth of injury, viral 
load of person with HIV. Post exposure prophylaxis with antiretroviral therapy is now 
widely used after contact and thought to reduce the risk of HIV transmission by at least 
80%201 .  
 
In the early stages of the epidemic no tests were available to screen for HIV, and therefore 
a number of people were infected through exposure to infected blood products, such as 
blood transfusions. Infection after a transfusion with HIV-1 infected blood, has been found 
to occur in 90%-100% of recipients163;202. Since 1985, blood in the USA, Canada and 
Europe has been routinely screened for HIV7. However, universal access to safe blood 
cannot be achieved without systems for ensuring quality and continuity of screening203. 
Poor access to safe blood has been associated with weak healthcare systems and rural 
settings203. Additionally, proper training of healthcare workers into the proper use of blood 
can lower the risk of HIV infection, as up to 50% of blood transfusions have been found to 
be unnecessary 204. Ensuring the safety of blood transfusions has been found to be cost 
effective. For example the cost per HIV infection prevented through blood safety has been 
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found to be around $18205, due to the high efficiency of transmission via infected blood. 
WHO recommends cost effective strategies for cost effective blood safety206. However, 
many countries still fail to screen all donated blood for HIV in accordance with minimum 
quality standards203.  
 
1.7.3 Mother to child transmission 
HIV-positive pregnant woman have a significant risk of transmitting the virus to their child if 
effective interventions are not provided164. An estimated 2.1 million children under 15 were 
estimated to be living with HIV in 2008 and 430,000 new infections reported in 2008 were 
in children8, with almost all of these new infections due to mother to child transmission207. 
Transmission can occur during pregnancy, labour, delivery or through breastfeeding after 
birth164;208-211. Without any intervention, the risk of transmission ranges from 15-40%212. 
Effective prevention requires access to testing early in pregnancy coupled with the ability 
to deliver antiretroviral therapy to mothers and infants164.  
 
Prevention of mother to child transmission is an area where there are huge differences in 
treatment and care across the world164. In developed countries, therapeutic and 
prophylactic antiretrovirals, and the avoidance of breastfeeding have reduced mother to 
child transmission from around 25% to between 1% and 5%213. In Europe, current 
treatment guidelines for pregnant woman are similar to non-pregnant patients, although 
the avoidance of some antiretroviral drugs is recommended214. Zidovudine is a preferred 
antiretroviral to be included in the regimen214-216. In many developed countries, such as the 
UK and USA, HIV testing in pregnant woman is part of their routine antenatal care217;218. 
 
In sub-Saharan Africa, where approximately two-thirds of the World’s HIV-positive 
population live, woman make up approximately half of those infected and the majority are 
of child bearing age164. The rates of mother to child transmission remain high in this region, 
and breastfeeding is one of the key reasons for this213. About 40% of the total cases of 
mother to child transmission are due to breastfeeding219. Whilst significantly lower rates of 
transmission have been reported in non-breast fed compared to breast-fed populations, 
morbidity and mortality are often worse164. For the majority of women in resource poor 
countries, breast feeding is the only option164. Exclusive early breastfeeding has been 
associated with improved survival compared to other types of infant feeding219;220. Further 





Another key strategy is to increase testing, both early in pregnancy and at the time of 
delivery, as this is when mothers are likely to present for care164. Treatment and access to 
antiretrovirals is improving in the developing world. In 2008, 45% of pregnant women in 
low and middle-income countries received antiretrovirals to prevent transmission to their 
child. This has increased from 10% in 2004221 and the number of new infections from 
mother to child transmission in 2008 was roughly 18% lower than in 20018. In the past 
decade, the international community recognized the need for improved services for the 
prevention of mother to child transmission. The UN general assembly has set a target for 
80% of pregnant woman and their children to have access to prevention, treatment and 
care by 2010 to reduce the proportion of infants with HIV by 50%221. 
1.8 Treating HIV 
As well as the number of new infections, the other factor contributing to the rise in the 
number of people with HIV infection is the beneficial impact of antiretroviral therapy8. 
Although approximately one third of those in need of therapy don’t have access to it, 
antiretroviral coverage in low and middle income countries rose from 7% in 2003 to 52% in 
2010222. In 2008, approximately 4 million people in low and middle income countries were 
receiving antiretroviral therapy, a 10-fold increase in the last 5 years8. There are currently 
25 antiretroviral drugs approved for the treatment of HIV, and current treatment guidelines 
recommend that patients are given three active drugs from at least two different classes223. 
There are 6 different classes of drugs available, each of which attack different stages of 
the HIV life cycle. The classes are nucleoside reverse transcriptase inhibitor (NRTI), non-
nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), Fusion 
inhibitors, CCR5 inhibitors, and integrase inhibitors although some of these drugs are only 
infrequently used because of their side effects, such as high pill burden, inconvenient 
administration schedules or drug interactions224. 
 
HIV treatment guidelines concerning what specific regimens to use are derived mainly 
from the results of short-term clinical trials with viral load outcomes225. Before the 
introduction of cART, the death rate of HIV-positive patients was much higher, and 
conclusions could be reached from trials using clinical outcomes within only a few years226. 
One of the first clinical trials by Fischl et al.227 was terminated after only 7 months because 
of the obvious benefits of the drug, zidovudine. After the introduction of cART, to achieve 
the same power in clinical trials, the sample sizes and duration had to increase 




Although, a few early trials did use clinical outcomes227;228 since 1996 clinical trials with 
surrogate outcomes, such as changes in CD4 count or viral load, have predominantly 
replaced clinical outcomes in trials of anti-HIV drugs229. Compared to clinical outcomes, 
using viral load or CD4 counts has many practical advantages, as the measurements are 
taken routinely in clinical practice and are fairly reliably quantified. However, the 
disadvantage of using short-term surrogate outcomes is that by definition they provide no 
direct information on the long-term implications of using ART230. Only a small percentage 
of clinical events occur in the first 24 or 48 weeks of a study, where there is a 
comparatively small risk of AIDS or death229. Observational research has played a key role 
in supplementing research from randomised controlled trials as patients are often followed 
over longer periods of time allowing for all stages of treatment to be observed, providing 




1.8.1.1 Nucleoside reverse transcriptase inhibitors 
 
Table 1.3: NRTI drugs 





abacavir Ziagen 17/12/98 8/7/99 
didanosine Videx 9/10/91 * 
emtricitabine  Emtriva 2/7/03 24/10/03 
lamivudine Epivir 17/11/95 8/8/96 
stavudine Zerit 24/6/94 8/5/96 
tenofovir Viread 26/10/01 5/2/02 
zalcitabine Hivid 19/6/92 * 
zidovudine Retrovir 19/3/87 * 
*not licensed by agency 
 
NRTI are the earliest class of antiretroviral drugs approved for the treatment of HIV, with 
zidovudine being the first drug to be approved for the market, in 1987231. Nucleoside 
analogues are faulty versions of the building blocks necessary for HIV reproduction. When 
HIV's reverse transcriptase enzyme uses a nucleoside analogue instead of a normal 
nucleoside, reproduction of the virus's genetic material is halted. Nucleoside reverse 
transcript inhibitors attach themselves to the reverse transcriptase and prevent the RNA 
turning into DNA. Table 1.3 gives a summary of the NRTIs available for treatment of HIV, 
and when they were approved in the U.S. and Europe. Among NRTIs, the use of 
zalcitabine, stavudine and didanosine has dramatically declined or vanished, while 
zidovudine, lamivudine, abacavir and tenofovir have gained relevance233.  
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To lighten patient’s pill burdens, some drugs have been developed to contain combination 
of two or three NRTIs and these are listed in table 1.4.  
Table 1.4: Combined NRTI drugs 





abacavir and lamivudine Epzicom/Kivexa 2/8/04 17/12/04 
tenofovir and emtricitabine Truvada 2/8/04 21/2/05 
lamivudine and zidovudine Combivir 27/9/97 18/3/1998 
abacavir, zidovudine, and lamivudine Trizivir 14/11/00 28/12/00 
1.8.1.2 Protease Inhibitors (PI) 
 
Table 1.5: Licensed PI drugs 





amprenavir Agenerase 15/4/99 20/10/00 
atazanavir Reyataz 20/6/03 2/3/04 
darunavir Prezista 23/6/06 12/2/07 
fosamprenavir Lexiva 20/10/03 * 
indinavir Crixivan 13/3/96 14/10/96 
lopinavir and ritonavir  Kaletra 15/9/00 20/3/01 
nelfinavir Viracept 14/3/97 22/1/98 
ritonavir Norvir 1/3/96 26/8/96 
saqinavir (hard gel) Fortovase 7/11/97 20/8/98 
saquinavir (soft gel) Invirase 6/12/95 4/10/96 
tipranavir Aptivus 22/6/05 25/10/05 
*not licensed by agency 
 
Currently there are 10 protease inhibitors approved for the market, and these are listed in 
table 1.5. The introduction of PIs into HIV therapy saw a dramatic decline in HIV-related 
morbidity and mortality234. At the end of the 90’s ritonavir, saqinavir, indinavir and nelfinavir 
were the most widely used PIs235. Ritonavir had very potent activity against HIV 236, 
though, frequent adverse events were reported when used at the recommended dose 235, 
so ritonavir is currently used only at low doses as an enhancer to other PIs235. Many 
clinical trials have shown the effectiveness of PIs in HIV-positive patients235. Protease 
inhibitors restrict the function of the protease enzyme, so although the HIV virus is created 
it is unable to go on and infect other cells237. Indinavir and nelfinavir are now very rarely 
used because of their lower efficacy (nelfinavir) and greater toxicity (indinavir)235. Lopinavir 
is currently recommended as a first choice PI214;223 and is the most widely tested PI in 
treatment naïve individuals235. The M97-720 study has demonstrated patients on lopinavir 
have sustained efficacy and no PI resistance after 7 years of follow-up238. In drug-naïve 
subjects, regimens based on atazanavir have shown non-inferiority compared to lopinavir 
or fosamprenavir, generally with improved tolerance239. In developed countries, atazanavir 
and lopinavir are the PIs most commonly prescribed233, whilst tipranavir and darunavir are 
the two most recently approved PIs231;232.  
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From current evidence, tipranavir is regarded as a very potent antiretroviral with a high 
genetic barrier to resistance and is recommended for highly treatment experienced 
patients235. However, it has been linked with a number of toxicities240. Darunavir also has 
high activity against other PI-resistant strains241. The recent ARTEMIS study found that 
darunavir showed non-inferiority compared to lopinavir and also had a more favourable 
safety profile242. As a result of this study, darunavir is currently approved in the US and 
Canada for both treatment experienced and treatment naïve patients243. 
1.8.1.3 Non-nucleosides reverse transcript inhibitor (NNRTI)  
 
Table 1.6 Licensed NNRTI drugs. 





delavirdine Rescriptor 4/4/1997 * 
efavirenz Sustiva 17/9/98 28/5/99 
etravirine Intelence 18/1/08 28/8/08 
nevirapine Viramune 21/6/96 5/2/98 
*not licensed by agency 
 
NNRTIs in combination with other antiretroviral drugs have been used for over a 
decade224. Table 1.6 shows the 4 drugs in this class that have been approved for 
treatment of HIV, two other NNRTIs loviride and caprivirine reached the Phase III and 
Phase II trials but development was discontinued due to disappointing results244. 
Nevirapine, efavirenz and delavirdine are all classed as first generation NNRTIs and were 
approved in the late 90s231;232 . Efavirenz is often used in first line treatment regimens in 
the developed world223;233, whereas nevirapine is recommended for first line therapy in 
resource-limited countries224. Studies have shown that resistance to NNRTIs will emerge 
quickly if viral load is not kept below 50 copies/ml. Side effects associated with both 
nevirapine and efavirenz include hepatotoxicity, and severe rash224. The most recent of 
this class to be granted drug approval is etravirine which was granted FDA approval in 
2008231;232. It was developed as part of a new generation of NNRTIs with a better 
resistance profile224. The development of etravirine was conducted exclusively in treatment 
experienced patients245;246, and recently published results found a superior response in the 
etravirine arm247. The approval of etravirine has meant that patients with NNRTI resistance 
now have another durable NNRTI treatment option248;249. Rilipivirine is another new NNRTI 
currently in phase III trials that has been shown to be active in NNRTI resistant patients, 
and may offer some advantages over etravirine. A once daily 25mg dose is being trialled, 




1.8.1.4 Entry/fusion inhibitors 
 
Table 1.7 shows the licensed entry and fusion inhibitors. Maraviroc is an entry inhibitor, it 
was approval from the FDA and European commission in 2007231;232. Specifically, 
maraviroc blocks the chemokine co-receptor 5 (CCR5) which HIV uses as a co-receptor to 
bind and enter a human helper T cell251. It is the first example of an anti-HIV drug that 
blocks the cellular rather than viral function252. However, its use is limited to viruses that 
use the R5 co-receptor. Vicriviroc was another new entry inhibitor that reached phase III 
trials, but in July 2010 development was discontinued after trials failed to show superiority 
over existing treatments253. Enfurvitide, on the other hand, is a fusion inhibitor. It is costly 
and has an inconvenient dosing regimen, thus is used predominantly in salvage therapy. 
Enfurvitide was granted FDA approval in 2005. Integrase in an enzyme that inhibits the 
strand transfer activity of HIV-1 and integration into the host DNA254. Raltegravir selectively 
inhibits the activity of HIV integrase while avoiding interference with the normal cellular 
function254. 
 
Table 1.7 Licensed entry/fusion inhibitors 





Fusion inhibitor Fuzeon Enfuvirtide 13/3/03 27/5/03 
Entry inhibitor Selzentry/celsentri Maraviroc 6/8/07 18/9/07 
Integrase inhibitor Isentress Raltegravir 12/8/07 20/12/07 
 
1.8.1.5 Immune based therapies 
Most of HIV drug research has focused on the development of antiretrovirals to stop HIV 
replicating inside the body. However, there has also been some interest in another type of 
treatment called immune based therapy that boosts the immune system so it can fight HIV 
on its own. Interlukin-2 was one of the first immune-based therapies used to treat HIV. 
Early studies found that interlukin-2, given intravenously or subcutaneously, in combination 
with antiretroviral therapy increased the CD4+ cell count significantly compared with 
antiretroviral therapy alone. However, two large clinical trials, the Subcutaneous 
Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under 
Active Antiretroviral Therapy (SILCAAT) study and the Evaluation of Subcutaneous 
Proleukin in a Randomized International Trial (ESPRIT), found that despite substantial 
increases in CD4 count compared to antiviral therapy alone Interlukin-2 plus antiretroviral 




The exact reason why no difference was found in terms of deaths or AIDS diagnoses, 
despite producing CD4 cell increases, is unclear. While other immune based therapies are 
currently in the research phase, to date none have shown a clear clinical benefit.  
 
1.8.2 Treatment history 
1.8.2.1 Monotherapy 
When the first cases of HIV were diagnosed there was no treatment available for patients. 
In the mid-80’s the first antiretroviral was approved for treatment against HIV231. 
Zidovudine (AZT) was initially developed as an anti-cancer drug in the 1960’s256. The first 
large multicentre clinical trial was initiated in February 1986, and included 282 adult 
patients with AIDS. By September 1986, major differences in survival were apparent, and 
an independent data safety and monitoring board concluded that the study should be 
terminated and the placebo patients offered AZT256. The trial found that administering AZT 
could decrease mortality and the frequency of opportunistic infections227 over the 24 week 
study period, although serious adverse reactions were found in a higher frequency in 
patients receiving AZT rather than the placebo257. AZT was the first antiretroviral shown to 
lower the rates of AIDS death significantly in a placebo controlled trials 228;258;259 and was 
licensed in the United States in March 1987231. Until 1991, AZT was the only approved 
antiretroviral drug available and AZT mono therapy became the standard of care for all 
patients infected with HIV231. However, benefits were found to be transient 260;261. In 1989 
the first studies began reporting resistance mutations in patients taking AZT for more than 
6 months262-264. AZT was found to only prolong the life of patients by 6 to 18 months224, 
and other alternatives that were less toxic with greater or equal efficacy were sought265. 
 
Phase I trials of didanosine (ddI) were reported in 1990 and found that there was activity 
against HIV, and that the toxicities associated with ddI differed from those associated with 
AZT266-268. ddI was licensed in the US in 1991231 closely followed by zalcitabine (ddC) in 
1992231. Studies found that in patients showing clinical progression on AZT switching to 
ddI showed significant benefit 269. 
 
1.8.2.2 Dual therapy 
To try to overcome the development of resistance, studies into combinations of drugs were 
instigated. Using ddI or ddC in combination with AZT was found to delay death, and the 
development of new AIDS defining illnesses compared to AZT monotherapy 270. 
40 
 
ddI used in combination with AZT was found to be more effective than ddC and AZT 270. 
Studies using ddI and ddC in combination found that they had similar toxicities and cross 
resistance271 and therefore did not do as well in combination therapy. The introduction of a 
second class of drugs, Protease Inhibitors, in 1995 changed HIV treatment dramatically.  
 
1.8.2.3 The cART era 
Combination antiretroviral therapy (cART) was introduced in 1995 and remains the current 
standard of care for HIV-positive patients. cART initially involved a combination of three 
drugs; two NRTI’s and one PI. Shortly after the first protease inhibitors were approved, a 
third class of drugs (non-nucleoside reverse transcript inhibitors) was introduced224, 
leading to a choice of cART options. Current cART involves a combination of three or 
more antiretriovirals from at least two classes214. With this new treatment there was a 
dramatic decline in the development of AIDS-defining illnesses and death159;234;272. The risk 
of death for an HIV-positive patient in the cART era has been estimated to be >85% lower 
than in the pre-cART era272. A recent study in the developed world found that life 
expectancy in HIV-positive patients treated with combination antiretroviral therapy 
increased between 1996 and 2005, and the average number of years remaining to be lived 
at age 20 years was about two-thirds of that in the general population in these countries273. 
 
One of the first trials comparing dual therapy with cART was the ACTG 229 trial129. The 
authors compared saquinavir taken in combination with zidovudine and zalcitabine, to the 
dual therapy of zidovudine and zalcitabine alone. The results found the treatment with the 
three drug combination was well tolerated, reduced viral load and increased CD4 count to 
a greater extent than those on dual therapy129. The PISCES study found similar findings274. 
Indinavir in combination with 2 NRTIs was also shown to be superior to dual therapy of 2 
NRTIs 275;276. Indinavir quickly became the most frequently prescribed PI, but long term 
success was limited due to strict intake regulation and renal toxicity277. Although early 
studies found that ritonavir was potent against HIV278-280 it was found to have a high toxic 
profile at the standard dose 258;281;282. Clinical trials comparing ritonavir boosted PI based 
cART regimens found that the boosted PI regimen was superior to a non-boosted PI 
regimen and generally safe 283;284.The introduction of lopinavir boosted with ritonavir was 




As with PIs in combination antiretroviral therapy, several clinical trials demonstrated the 
superiority of NNRTIs in combination with 2NRTIs over dual therapy. The first NNRTI 
licensed was nevirapine231;232. Trials comparing dual therapy with triple-drug therapy 
including nevirapine and 2 NRTIs found that the addition of nevirapine was more effective 
at suppressing viral load287-290. The combined study compared NNRTI-based cART 
(nevirapine) with PI-based cART (nelfinavir) and found that nevirapine-based cART was at 
least as effective as nelfinavir-based cART291. Several studies evaluated the effect of 
switching from a PI-based cART regimen to nevirapine-based cART292-294, and found that 
patients could maintain a suppressed viral load, with some benefitting from improved 
quality of life and reduced toxicity.  
 
Efavirenz was licensed a couple of years later231;232 and was also found to be a viable 
treatment option295-297. Several studies have compared the efficacy of efavirenz and 
nevirapine298-300. The results from the 2NN clinical trial found that nevirapine and efavirenz 
showed similar efficacy, but did report differences in the safety profile of the two drugs300. 
Efavirenz is used in first line treatment regimens in the developed world223;233, although it is 
not recommended in pregnant woman214, whereas nevirapine is recommended for first line 
therapy in resource limited countries224, although caution is recommended in patients with 
higher CD4 counts214.  
 
1.8.2.4 Current treatment  
With so many different treatment options available, the optimal sequencing of cART 
regimens is important to ensure long term benefit. In the early cART era, a significant 
proportion of patients did not fully benefit from cART. Those who had been exposed to 
sub-optimal mono or dual therapy had accumulated resistance224. Moreover, new drugs 
were often added sequentially to their regimen, thus leading to substantially lower 
responses, compared to simultaneous administration of the same drug258. In the beginning 
of the cART era, treatments for HIV involved taking 10 tablets every 8 hours, thus daily, 
patients were taking up to 30 drugs. High pill burden, strict dietary restrictions, and serious 
toxicities associated with these early treatments led to poor tolerability6. In 1998, with the 
introduction of lamivudine /zidovudine combined and efavirenz, the standard was 5 tablets 
taken twice daily6. In 2002, this changed again to 2-3 tablets twice daily, and then again in 
2004, once daily treatment options were introduced. These drug combinations help 
improve adherence and tolerability. However, some problems with toxicities still remain6. 
42 
 
Atripla (table 1.8) is the first co-formulated drug approved for the market that provides the 
treatment option of one pill once a day301. It contains efavirenz co-formulated with tenofovir 
and emitricitabine.  
 
Table 1.8: Licensed multi-class drugs 





efavirenz, emtricitabine, and tenofivir Atripla 12/6/06 13/12/07 
 
Three long term studies ACTG 320, INITIO and Community Programs for Clinical 
Research on AIDS (CPCRA) Flexible Initial Retrovirus Suppressive Therapies 
(FIRST)86;302-306, have all tried to address the question of which combination of 
antiretrovirals is the optimal choice when initiating cART. All three studies detected a 
difference in virological response, preferring to initiate cART with a NNRTI rather than a 
protease inhibitor based regimen. However, none of the studies found a difference in CD4 
count between treatment groups. The CPCRA FIRST study306, the longest study at 5 
years, showed that even a consistent difference in viral suppression rates over a long 
period did not translate into a difference in AIDS-defining events.  
 
Current treatment guidelines recommend that either efavirenz or lopinavir, boosted with 
ritonavir, should be taken with two NRTIs as a first line regimen214;223. A recent clinical trial 
found that efavirenz plus two NRTIs was more effective than lopinavir plus 2 NRTIs for 
initial therapy, but that the margin of superiority was marginal, and that patients failing on 
efavirenz had a higher rate of NNRTI resistance than lopinavir resistance in patients falling 
lopinavir307. Advantages of NNRTI over a PI based regimen include better gastrointestinal 
tolerability, fewer metabolic side effects, lower pill burden, and avoidance of potentially 
dangerous inhibitory drug interactions250. However, studies have shown that resistance to 
NNRTIs will emerge quickly if viral load is not kept below 50 copies/ml. Due to many 
considerations, there is still a lot of debate over choice of first line regimen, though one of 
the most important factors of a first line cART regimen is its long-term durability. 
 
Recommendations for the initiation of treatment are based on CD4 T lymphocyte counts 
and plasma HIV-RNA levels124. Current guidelines recommend treatment should be started 
at a CD4 count of around 350cells/mm3 223. However, there is currently some debate over 
the optimum time to initiate cART. Viral load levels tend to change only moderately over 





Early therapy brings immediate treatment to the virus, decreasing the risk of early CD4 cell 
depletion and lowering the viral load, which in turn, decreases the risk of infection to 
others. Delayed therapy on the other hand, means avoiding the risk of toxic drug effects 
and relying on more potent and tolerable drugs becoming available by the time treatment 
begins. Phillips et al 309 found no strong evidence to suggest that starting therapy at a 
lower CD4 cell count or higher viral load was associated with a poorer outcome. However, 
they did find a slower rate in time to initial suppression in those with higher viral loads. The 
START (Strategic Timing of AntiRetroviral Therapy) study 310 is a randomised control trial 
of ART-naïve patients with a CD4 count greater than 500/mm3, that aims to compare 
patients randomised to start cART immediately with those who defer treatment until CD4 
declines to 350/mm3 . The objective of this study is to hopefully answer the question of 
when is the best time to start treatment. The entire study is expected to take about 6 
years, with follow-up ending December 2015.  
 
The main aim of cART is to prevent clinical disease progression. Treatment guidelines 
suggest that suppression of viral load below a level of quantification for as long as possible 
is one of the key goals of cART and one of the deciding factors when planning a patient’s 
treatment strategy243;311;312. Patients experience different immunological and virological 
responses after initiating cART313-315. After a patient has initiated cART, it is more clinically 
relevant to use the most recent laboratory markers and information on a patient to 
determine prognosis, as cART can reverse many of the pathological processes induced by 
HIV infection316-318. In clinical practice, 70-80% of patients starting cART achieve 
undetectable viral load319 . This number has increased in recent years320;321, although viral 
replication is still not fully controlled in large number of patients rendering the virus capable 
of developing resistance322. 
1.8.3 Limitations of cART 
Although the impact of treatment has transformed HIV from a terminal disease to a chronic 
illness6, cART remains a life-long commitment. Treatment failure is normally due to drug 
toxicity, poor adherence or drug resistance, and the three are very closely interlinked323;324.  
 
1.8.3.1 Toxicities 
Differentiating between complications of HIV disease and ART toxicity is often very 
difficult. EuroSIDA reported that the most frequent reason for discontinuation of a first line 
regimen was ARV toxicities19.  
44 
 
Toxicities may either be specific to a particular drug or to the class of drugs, and the 
adverse event caused by the toxicity can vary in severity from mild to fatal (table 1.9). 
Regardless of the severity of the adverse event, it may have an impact on adherence. 
Therefore, discussing potential side effects before patient and clinician decide on the 
treatment is important. Patients also need to learn how to recognise the symptoms and 
signs of severe toxicities.  
  
Table 1.9: Severity of toxicity
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Grade 1: Mild Transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required 
Grade 2: Moderate Limitation in activity- some assistance may be needed; no or minimal 
medical intervention/therapy required 
Grade 3: Severe Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required hospitalization possible. 
Grade 4: Severe life 
threatening 
Extreme limitation in activity, significant assistance required; significant 
medical intervention/therapy required; hospitalization or hospice care 
 
Due to the urgent need for treatment at the beginning of the epidemic, drugs were 
developed and licensed quickly, often with little known about their long term toxicity. 
Subsequently, the sustained benefits of cART have led to more patients being on cART for 
longer periods of time. Drug-related toxicity is being increasingly recognised because of 
the declining incidence of opportunistic infections17, and the type and timing of 
antiretroviral therapy is often influenced by potential toxicities17. In the current HIV-era, 
most ARV toxicities have been found to be moderate and can be well managed in out-
patient clinics326. Table 1.10 lists some of the toxicities commonly associated with ARVs.   
 
Table 1.10: Common ARV toxicities
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Haematological toxicity Drug-induced bone marrow suppression most 
commonly seen with AZT (anaemia, 
neutropenia) 
Mitochondrial dysfunction  Primarily seen with the NRTI drugs, including 
lactic acidosis, hepatic toxicity, pancreatitis, 
peripheral neuropathy, lipotrophy, myopathy 
Renal toxicity Nephrolithiasis, commonly seen with indinavir. 
Renal tubular dysfunction is associated with 
tenofovir  
Other metabolic abnormalities More common with PIs. Include 
hyperlipidaemia, fat accumulation, insulin 
resistance, diabetes and osteopenia 
Allergic reactions Skin rashes and hypersensitivity reactions 
more common with the NNRTI drugs but also 
seen with certain NRTI drugs, such as abacavir 




Clinical research has shown that different combinations of drugs have substantially 
different short and long term toxicities327. NRTI toxicities over medium and long term are 
mitochondrial, including myopathy (zidovudine), neuropathy (stavudine, didanosine, 
zalcitabine), hepatic steatosis and lactic academia (didanosine, stavudine, zidovudine), 
and lipoatrophy (possibly all predominately stavudine) and pancreatitis (didanosine)17. 
Drug hypersensitivity in HIV-positive patients is about 100 times more common than in the 
general population328. All NNRTIs (nevirapine, delavirdine, and efavirenz), abacavir and 
amprenavir are common antiretroviral drugs that cause hypersensitivity17. The risk factors 
for lipodystrophy syndrome, peripheral fat loss and central fat accumulation, include low 
body weight before therapy, total duration of cART, use of the dual PI combination ritonavir 
and saquinavir and use of stavudine16;17. PI use can result in increased rates of bleeding in 
haemophiliacs329 and most antiretrovirals have been associated with hepatic toxicity17. 
 
With the dangers of toxicities, the Strategies for the Management of Antiretroviral Therapy 
(SMART) study317 was set up to compare in a randomized fashion the use of episodic 
cART according to CD4 count with the recommended practice of continuous therapy on 
the risk of new or recurrent opportunistic disease or death. Originally, the trial was planned 
to include 6000 patients to be followed for at least 6 years. The study was terminated early 
after only an average of 16 months of follow-up due to an increased risk of disease 
progression when using ART episodically. The rates of non-opportunistic disease and 
death were also higher in the group using ART episodically, contrary to what was 
expected. 
 
1.8.3.2 Adherence to treatment 
Without adequate adherence, antiretroviral agents are not maintained at a sufficient 
concentration to suppress HIV replication in infected cells and to lower plasma viral 
load330. Patients who are more adherent to treatment are more likely to achieve sustained 
viral suppression331;332 and are less likely to show signs of disease progression333. Hogg et 
al. found that after adjusting for other prognostic factors, patients who used antiretroviral 
therapy <75% of the time in the first year were threefold more likely to die 334. The impact 
of adherence on change in CD4 count tends to be delayed and less apparent than the 
impact on viral load335. Patients have been found to take on average 70-75% of their 
prescribed medication 336;337.Paterson et al.331 found that adherence of 95% or more was 
necessary to achieve optimal viral suppression. However, other studies looking into 
disease progression have found that even adherence of 50% significantly decreases a 
46 
 
patients risk of progression to AIDS333;337. Reported differences in the degree of adherence 
required to achieve and maintain a successful virological response is probably due to 
differences in study design, the population and antiretroviral regimen studied and the 
difficulty in reliably measuring patient adherence335.  All studies are in agreement though, 
that emphasis should be placed on the importance of attaining 100% adherence, as 
relatively small declines in patient adherence can lead to an increase in treatment 
failure327.  
  
Adherence is also important to help prevent the development of resistance to certain 
regimens, as poor adherence has been linked to an increased risk of the development of 
drug resistance330. Different treatment regimens are affected in different ways336. For 
example, NNRTIs regimen are much less forgiving of missed doses than PI-based 
regimens because NNRTIs have a much lower genetic barrier to resistance and have a 
much longer half-life than the NRTI backbone. Patients on NNRTI regimens have been 
found to show greater signs of adherence to treatment as their regimens are generally 
simpler (decreased pill burden) and have less severe toxicities associated with them.  
 
Older patients have been found to adhere better to treatment 331. Whereas patients with a 
high pill burden331 and patients infected via IDU are less likely to be adherent to 
treatment330. The number of appointments missed by a patient has also been linked to 
poor adherence338.  
 
Different methods have been used to assess adherence to therapy330, including more 
straight forward measures such as patient or clinician reports339, to more advanced 
systems such as MEMS caps (Medication Events Monitoring System) which incorporate a 
counter on the pill bottle to track how often the bottle is opened, as well as the time and 
date, DOT (directly observed therapy) where patients take their medication whilst being 
observed by a clinician or nurse, and tests to measure the drug levels in the blood. All 
these methods have limits in the accuracy of the measurements331;339. Counselling of 
individual patients on the need for adherence has also been shown to be beneficial and 
affordable to individual patients340 Clinicians are recommended to emphasize the 
importance of adherence at scheduled clinic visits. Consideration needs to be made to 
assess the adherence abilities of different patient groups as they may have different 
reasons and concerns about adherence to treatment330;341.  
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1.8.3.3 HIV Drug Resistance 
Effective sustained cART is complicated by the prevalence or emergence of drug 
resistance342. In the context of HIV, drug resistance is the ability of the virus to adapt so 
that it can multiply in the presence of a drug that would normally suppress it. Any 
antiretroviral drug can select for resistance if given alone. The advantage of cART is that 
with multiple drugs from different classes, the virus is much less likely to develop 
resistance since the other drugs reduce the ability of the mutant virus to replicate343. 
However, a significant minority of patients are likely to develop resistance to at least one 
class of drug252. The primary cause of drug resistance is poor adherence to a regimen 7. 
Much of the drug development in recent years has been focussed on the discovery of 
drugs within new classes, or drugs within old classes that are active against resistant 
viruses252.  
 
Technological advances have made it possible to detect resistance, even when they are 
present as low-level minority species252. There are two different type of resistance test, the 
genotype and phenotype. Phenotypic assays measure the ability of a virus to grow in 
different concentrations of antiretroviral drugs, whereas genotypic assays detect drug 
resistance mutations when present in HIV genes. From a blood sample, a genotypic test 
pinpoints exactly where on the HIV gene a mutation (or mutations) has occurred, and what 
the new mutation is. However, interpretation of genotypic drug resistant tests is not always 
straightforward. The Rega algorithm is one of many algorithms that are used to interpret 
the genotypic drug resistance profile for a patient344. This method looks at the site where 
drug resistant mutations have been found, and codes each drug as either 1, 0.5, and 0 for 
sensitive, intermediate resistance, and resistant to that particular drug344. This can help 
clinicians decide which treatment a patient should be on. Drug resistance testing is not 
recommended in patients with a viral load <1000copies/l345 
 
Recently, several new antiretroviral drugs (such as etravirine and tipranavir), have been 
licensed in old classes of drugs that show a better resistance profile and do not appear to 
have cross resistance with first generation ARVs231;232. The first generation PIs had low 
bioavailability resulting in high pill burden and short half-life often necessitating in multiple 
daily dosing277. Due to these factors poor adherence was often observed and viral 
replication was not durably suppressed in a number of patients346. When failure occurred, 
multiple protease resistant mutations were detected277.  
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To combat this, PIs were combined with a low dose of ritonavir to boost the level of PI in 
the patient’s plasma, so the virus has to acquire more mutations to achieve resistance277. 
This led to improved bioavailability and half-life of the PIs347. 
 
It is rare for patients failing on lopinavir to show development of resistance mutation in the 
protease gene252. Most recently, darunavir and tipranavir have been licensed and are 
active against viruses with acquired resistance to earlier PIs and also have a high genetic 
barrier to the development of resistance252. Similarly, although nevirapine or efavirenz 
have a long half-life, they have a low genetic barrier to resistance with only one mutation 
required to confer high level resistance250;252. Etravirine, a second generation NNRTI, has 
been found to show activity against viruses resistant to the first generation NNRTIs252 and 
has a relatively high genetic barrier. Rilpivirine, another new NNRTI currently in phase III 
clinical trials, also retains activity against HIV viral strains resistant to other NNRTIs250. 
 
In addition, several new classes of drugs have been developed. Maraviroc, a CCR5 
inhibitor, has been found to be active against both B and non-B subtypes348. Resistance to 
maraviroc occurs either through the development of mutations that allow HIV-1 to use 
CXCR4 co-receptors, or mutations that continue to allow HIV to continue using the CCR5 
co-receptors. Currently the frequency of co-receptor switching is unknown, but it is of 
concern as the use of CXCR4 is associated with more rapid disease progression250. 
Raltegravir has a relatively low genetic barrier250, resistance to raltegravir has been shown 
to emerge rapidly if other components of the patients regimen are suboptimal252, and it is 
therefore important to combine it with two fully active NRTIs349.  
 
It is thought that certain HIV-1 subtypes may be more susceptible to developing 
antiretroviral resistance than others70. Most drugs are developed in North America and 
Western Europe, where subtype B is the most prevalent strain, thus the development of 
drugs is based on this strain and it may be that other strains have different responses. 
When individuals develop resistance to one antiretroviral agent, they often develop 
resistance to others with in the same class323. This is known as cross-resistance and 
further complicates the selection of appropriate drugs for treatment7, a big problem with 
NNRTI treatment252. Another complication is the transmission of drug resistant strains to 




Triple class resistance means a patient is resistant to the three original classes of 
antiretrovirals, NRTIs, NNRTIs and PIs. It is most commonly found in heavily treatment 
experienced patients. However, it has also been found in treatment naïve individuals350, 
although the incidence of triple class resistance has been reported to be low and fairly 
consistent over time351. Recent progress in drug development has improved patient 
treatment options considerably, with novel compounds being developed with reduced 
toxicity and enhanced susceptibility to resistant HIV277. Heavily treatment experienced 
patients with resistance to several classes of drug now have several different options 
available for salvage therapy. An optimal treatment regimen must be tailored to the patient 
based on antiretroviral history, genotype resistance, side-effects profile, drug interactions, 
pharmokinectics, schedule preferences and perceived adherence352.  
 
1.9 Non-AIDS Events  
Mortality rates remain high relative to the HIV-negative population155. However, with fewer 
AIDS-related deaths there has been an increase in the proportion of deaths in HIV-positive 
patients from non-AIDS related illnesses. This does not mean however, that there has 
been an increase in the risk of patients dying from non-AIDS related causes353. In fact, the 
introduction of cART has seen a decrease in the number of non-AIDS illnesses, as well as 
AIDS10;354, suggesting that perhaps HIV may play a role in other diseases that has not 
been fully investigated or understood353. As the HIV population ages, non-AIDS related 
illnesses have become an increasingly important factor in the long term treatment and care 
of HIV-positive patients, as age is a significant risk factor for illnesses such as 
cardiovascular disease, liver disease and many cancers, as in persons without HIV355. 
There is a strong relationship between decreasing CD4 count and increasing risk of non-
AIDS defining illnesses356;357, leading to the hypothesis that starting treatment earlier could 
possibly reduce the risk of many non-AIDS illnesses as well as AIDS events353. In patients 
on cART, more than 50% of deaths are from causes other than AIDS354;358-360. The three 
main causes of death in HIV-positive patients, after AIDS, have been reported to be 




1.9.1 Cardiovascular disease 
Cardiovascular disease contributes approximately 10% of the deaths among HIV-positive 
individuals361;364. The main risk factors for cardiovascular disease in the general population 
also appear to be associated with an increased risk in the HIV-positive population18;365. 
These risk factors include older age, male, smoking, family history, high cholesterol, 
hypertension (high blood pressure) and diabetes mellitus365-371, and studies have shown 
that there is a higher incidence of these risk factors in the HIV-positive population than in 
the general population372;373. 
 
Additionally, it has been reported that the use of cART is associated with an increased risk 
of cardiovascular disease18. In particular, the use of PIs have been found to be associated 
with an increased risk of heart disease in HIV-positive patients374;375. A study comparing an 
HIV-negative cohort of patients with HIV-positive patients who initiated a PI containing 
regimen found that there was higher risk of cardiovascular disease in the HIV-positive 
patients372. It is thought that risk factors for cardiovascular disease can be increased by the 
use of PI containing cART regimens376;377, as some of the side effects of PIs include 
hyperglycemia (high blood sugar), hyperlipidemia (raised lipids) and lypodystrophy 
(abnormal fat redistribution)373;378. Furthermore, two NRTI’s, didanosine and abacavir, have 
been found to increase the risk of cardiovascular disease in patients receiving cART, 
although the biological reasoning behind this increased risk is not fully understood379. 
Although an increased risk of cardiovascular disease has been associated with some 
antiretroviral drugs, the absolute risk has been found to be relatively low and must be 
balanced against the clear benefits of cART18. 
 
1.9.2 Liver related disease 
Liver disease is now a leading cause of death among HIV-positive patients361. A study of 
13 cohorts found that 7% of all deaths were due to liver related disease362. A high 
proportion of liver related death is attributable to Hepatocelluar Carcinoma (HCC)380, a 
non-AIDS defining malignancy (NADM).Similarly to risk factors for cardiovascular disease 
patients, HIV-positive patients have a higher incidence of liver related risk factors than the 
general population. High alcohol consumption360;381;382, being female381;383, older age382, 
intravenous drug use, and hepatitis B and C co-infection have all been associated with an 




Liver related deaths in HIV-positive patients have been found to be largely a consequence 
of Hepatitis B and C co-infection360;364;385-388. In the DAD study, more than 70% of liver 
related deaths were associated with Hepatitis B or C infection361. Progression to liver 
cirrhosis in patients infected with hepatitis C has been estimated to occur over 20 
years389;390. However, co-infection with HIV has been found to accelerate the progression 
of HCV disease progression391;392, probably due to a decrease in immune function.  
 
Immunosuppression is associated with more rapid progression to liver fibrosis and 
cirrhosis19;361 and the risk of liver related death has been found to decrease with increasing 
CD4 count. One study reported that per 100 cell increase in CD4 count, there was a 33% 
decreased risk of death from end stage liver disease363 
 
The use of cART has been found to improve immunodeficiency by suppressing the rate of 
viral replication. However, increased exposure to cART has been found to be associated 
with an increased risk of liver related deaths in patients with similar CD4 cell counts19. One 
reason for this is that some cART regimens have been found to lead to hepatotoxicity393-395 
which has become more prevalent in recent years396. In a study looking at mortality due to 
liver related disease, discontinuation due to hepatoxicity increased from 6% in 1996 to 
32% in 1999397. The reported incidence of severe liver related toxicity after cART initiation 
varies from 2-18%396. In particular hypersensitivity reactions have been reported in 
patients on nevirapine and abacavir398-401. The risk of these liver related toxicities in 
patients receiving cART has been found to be higher in those co-infected with Hepatitis B 
or C394;402;403. It is recommended that if any patient is experiencing severe liver toxicity, 
antiretroviral therapy should be discontinued396.  
1.9.3 Non-AIDS malignancies (NADM) 
Three different types of cancer have been classified as AIDS defining malignancies 
(ADM); Kaposi’s sarcoma (KS), Non-Hodgkin’s lymphoma (NHL), and more recently, 
cervical carcinoma136. These three cancers all occur at significantly higher rates in HIV-
positive patients than in the general population404. In the context of HIV-positive patients, 
all other cancers are classed as non-AIDS defining malignancies (NADM). In developed 
countries, where the use of cART has decreased the incidence of many ADM405, NADM 
are now more common than ADM406-408 and NADM now account for more morbidity and 
mortality in HIV-positive patients than ADM409. Many of these NADM have been found at 




Again, like cardiovascular and liver related disease, at least part of the increased risk of 
NADM in HIV-positive patients is explained by the higher prevalence of associated risk 
factors. Smoking, high alcohol consumption and co-infection with hepatitis B and C have 
been found at an increased level in HIV-positive patients18;372;411-413, and some studies 
have attributed the increased incidence to some NADM to these factors414-419.  
 
Some studies have shown immunodeficient patients have a higher risk of developing some 
NADM, regardless of HIV-infection status420-422. There is growing interest in the effects of 
immunodeficiency on the risk of NADM, and whether the use of cART, though improving 
immune function, may reduce the risk of HIV-positive patients developing particular 
NADM.  
 
1.10 Aims and objectives of this thesis 
In summary, since the introduction of cART around 15 years ago there have been 
dramatic improvements in the quantity and quality of life for HIV positive people. A 
consequence of this is that the focus of HIV research is changing to address different, but 
equally important, questions. Once initiated, treatment for HIV is a lifelong commitment, 
and in order for patients to maintain a high quality of life it is important that patients are 
initiating cART on the most effective, and safest, treatment regimen available to them. 
Equally they should be monitored by clinicians closely enough to receive effective 
treatment, but not too closely that it impacts unnecessarily on the patient’s life. 
Additionally, as a result of durable effective treatment, we now have an ageing HIV-
positive population who appear to be at an increased risk of developing a variety of 
different clinical events not traditionally seen as AIDS related, but that seem to occur at a 
higher rate than in the HIV-negative population. It is important to understand what factors 
are related to the development of these events and what impact these new clinical events 
are having on mortality rates across the HIV positive population in Europe. The results of 
this thesis attempt to address a number of different issues within one study, the EuroSIDA 
study, with an emphasis on the long term treatment and care of HIV positive people across 
Europe. The details of this study, the patients included and data collected are described in 
detail in chapter 2. This chapter also gives details on the statistical methods used to 





Chapter 3 investigates whether current treatment guidelines recommending that patients 
on antiretroviral therapy are seen at clinics every three months are necessary for all 
patients. In particular, the analysis focuses on patients that have been able to maintain a 
well-tolerated and fully suppressed cART regimen, and whether it might be safe to 
increase the time between clinic intervals in these patients. This would make the long term 
commitment of treatment less intrusive on patients’ lives, and also free up valuable 
resources for the increasing HIV population and those who do require closer monitoring, 
such as patients presenting for care late. The idea for this initially came from Professor 
Brian Gazzard who was interested in looking at reducing the frequency of monitoring ART-
naïve patients who had started cART and were doing well on therapy. After I had 
performed an initial feasibility analysis and found there was insufficient data to focus the 
analysis on solely on ART-naïve patients. Therefore I developed the analysis plan for the 
analysis presented in this chapter including both ARV-naïve and experienced patients who 
were responding well to treatment.   
 
Chapter 4 focuses on patients patterns of virological suppression after initiating cART. As 
discussed earlier, viral load is associated with disease progression and the main aim of 
cART is to maintain a suppressed viral load for as long as possible. There are many 
studies that have looked at virological suppression. This chapter investigates whether a 
patient’s history of virological suppression affects the durability of future cART regimens, 
and whether patients are able to re- suppress and maintain the suppression on a new 
treatment regimen. The idea for chapter 4 was mine and followed on from the work and 
supplementary analyses I had performed as part of the exploratory analyses in chapter 3.  
 
Chapter 5 compares the long term durability of nevirapine, efavirenz and lopinavir in 
clinical practice across Europe focussing on the development or progression to serious 
non-AIDS clinical events. Treatment guidelines in Europe recommend that treatment naïve 
patients initiating cART start either a nevirapine, efavirenz or lopinavir based cART. Each 
of these regimens have been shown to be effective in clinical trials, but these are over a 
relatively short period of time and the focus has been on virological suppression and AIDS 
related events. For treatment to be effective in the long term, it is also important to monitor 
the risk of developing serious events not thought to be AIDS related that may impact on 
whether it is safe for patients to maintain the regimen. The original idea for chapter 5 was 
proposed by Boehringer Ingelheim who were interested in comparing the long term 
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durability of patients on nevirapine to those on efavirenz and lopinavir. I began by drafting 
the analysis plan based on this proposal, but took the initiative to expand it to not just look 
at rates of discontinuation but also long term serious non-AIDS related events and 
mortality, as this is a particular interest of mine. 
 
Chapter 6 investigates the role of immunodeficiency caused by long term HIV infection on 
the development of non-AIDS defining malignancies. In addition to the risk of non-AIDS 
events in patients on specific cART regimens, it has been speculated that HIV infection 
may itself play a role in development of certain clinical events not classed as AIDS events. 
In particular, several malignancies not classed as AIDS related have been found at a 
higher rate in HIV-positive people than in age matched HIV-negative people.  
It is important to understand what factors may affect the development of these 
malignancies, and where some are more likely to occur than others, so that patients at a 
higher risk can be effectively treated to prevent, or screened to detect the development of 
any of these malignancies. Before analysing this data, Dr Csaba Kosa, based at the 
Copenhagen HIV Program (CHIP), helped by cleaning the data on non-AIDS defining 
malignancies. I wrote the proposal to investigate the role of immunodeficiency caused by 
long term HIV infection on the development of non-AIDS defining malignancies after 
discussion at meetings with CHIP. After I presented a poster of this work at 16th 
Conference on Retroviruses and Opportunistic Infections, I decided to group the 
malignancies by whether or not they were virus related after Professor Andrew Grulich 
suggested at the conference that this may make the data easier to interpret.    
 
Chapter 7 looks at the mortality rate of HIV positive people under routine follow-up in 
Europe in the current treatment era. In particular, the chapter investigates the proportion of 
deaths related to both AIDS and non-AIDS related causes and whether there are 
differences across regions of Europe. The focus of this analysis is whether differences in 
treatment and patient monitoring are having an impact on mortality rates and whether 
these have changed over time. EuroSIDA has previously looked at the all-cause mortality 
rates of the HIV positive individuals enrolled in the study however the last report was in 
2002. Through discussion with CHIP I decided it would be interesting to compare AIDS 
and non-AIDS related mortality rates across the different regions of Europe, and 
developed the proposal and analysis plan. Crucially, as the study now has collected a lot 
more data from East Europe, and EuroSIDA has developed an algorithm to enable all 
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causes of death could be coded as either AIDS or non-AIDS related, I thought the work 
could significantly add to pervious publications and volunteered to lead the project. 
 
For each chapter I presented an analysis plan, which I drafted with some guidance from 
my supervisor, Amanda Mocroft, for approval to the EuroSIDA steering committee. After 
approval of each of the analysis plans I was then responsible for analysing the data, 
interpreting the data, both with some supervision, and was solely responsible for drafting 
the first version of the manuscript upon which each chapter is based.  The first draft was 
then discussed among a core group of 4 or 5 people who were working on each project, 
including Amanda Mocroft, Jens Lundgren, Ole Kirk, Justyna Kowalska, and Daria 
Podlekereva. The clinicians involved provided help with clinical interpretation of the data, 
and also provided relevant background information.  After the initial discussions I 
performed any additional analysis or sensitivity analyses that may have been suggested. 
After agreement within the core group, I the results were then circulated for round the co-
authors and steering committee members for further comments and suggests.  
 
Chapter 8 summarises the findings and conclusions from each of the chapters in this 
thesis with a discussion of the overall limitations of these analyses, and the implications 
and applications of these results. 
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EuroSIDA is one of the largest European multicentre prospective observational cohort 
studies, and includes Argentina and Israel. The primary objective of EuroSIDA is to follow 
the long term clinical prognosis for the general population of HIV-positive people living in 
Europe, and to assess the impact of antiretroviral drugs on the outcome of HIV infection. It 
was initiated in May 1994 as the successor of a study called AIDS in Europe. AIDS in 
Europe was a retrospective study of 6,572 HIV-positive patients in Europe from 1979 until 
the 31st December 1989, and was one of the first studies to look at the spread of AIDS 
across Europe. There are now more than 16,000 patients enrolled in EuroSIDA, with 
patients from 103 centres across Europe (including Israel and Argentina), in 34 different 
countries as shown in figure 2.1.  
Figure 2.1 The European countries involved in EuroSIDA (Israel and Argentina are non-




EuroSIDA was set up primarily to look at the long term effects of antiretrovirals in HIV-
patients across Europe. However, like other observational studies, EuroSIDA is useful for 
assessing the natural history of disease, effects of different treatment strategies and long 
term side effects. One of the unique features of EuroSIDA, is that it has now been running 
for more than 15 years and has follow up data for more than 16000 patients. Therefore, 
EuroSIDA has been able to help track the course of the HIV epidemic across Europe, the 
effects of the introduction of cART, the use of cART in different areas of Europe and 
changes in the epidemic over time. Due to its size, relatively rare events, such as non-
AIDS malignancies, can be studied. Further, EuroSIDA has relatively low rates of loss to 
follow-up, <5 per 100 person years of follow-up (see section 2.1.5) and high data quality 
(see section 2.1.6). In addition, its collaboration with other studies has led to other 
research questions being addressed that EuroSIDA could not answer alone.  
 
EuroSIDA on its own, and in collaboration with cohort studies, has played an important 
role in helping increase our understanding HIV, the impact of cART, and influencing 
treatment guidelines across Europe. The study has published extensively, celebrating its 
100th publication in the autumn of 2008. EuroSIDA has also presented abstracts at most 
major HIV related conferences since 1997. Full details of all publications and presentations 
can be found at www.cphiv.dk. 
 
2.1.2 Enrolment of Patients  
Patients aged 16 years and over are enrolled into EuroSIDA. Patient inclusion was 
performed at predetermined time periods at outpatient clinics, and patients were required 
to have a routine booked outpatient appointment to be recruited, thus patients recruited 
are already under routine follow-up and care at the individual centres, ensuring as much 
as possible that the selection of patients is unbiased to gain a representative sample from 
each clinic. The EuroSIDA follow-up form is given in Appendix I. 
 
There have now been 8 periods of enrolment into EuroSIDA, and a total of 16,599 patients 
are currently enrolled in EuroSIDA (table 2.1). In each cohort, patients were enrolled until a 
predefined number was attained. The number of patients recruited from each centre is 
determined from the total number of patients under follow-up at the centre, the ability of 
the centre to provide follow-up data, and to ensure regional representation. The first 
enrolment of patients began on the 2nd May 1994 and continued until a predefined number 
of patients had been enrolled.  
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There were 3,115 patients enrolled in this cohort (cohort I), and it was originally defined as 
EuroSIDA I. In November 1995, enrolment began on the second cohort. 1,363 patients 
had been enrolled when it stopped in April 1996. 2837 patients were recruited in the third 
cohort between February 1997 and September 1997. Since then, a further 5 cohort 
enrolments have been complete (table 1). For cohort I-III, patients were only eligible if they 
had a CD4 count below 500 cells/mm3 measured in the 4 months prior to enrolment. From 
cohort IV, onwards this restriction was removed as cART was widely introduced across 
Europe and patients had higher CD4 counts423. In more recent years (cohort V onwards), 
there has been an effort to recruit more patients from Eastern Europe as these patients 
were less well represented, and it became clear the extent of the HIV epidemic in this 
region424. The most recent cohort, cohort VIII, began enrolment in November 2007 and 
enrolled 2,259 new patients. More than half of the new patients enrolled were from Eastern 
Europe. 
  
New cohorts are added to ensure an update of the patient population and to replace those 
who have died or been lost to follow-up.  
 
Table 2.1 Number of patients enrolled in EuroSIDA 
Cohort N of patients Enrolment date 
I 3115 Spring 1994  
II 1363 Winter 1995  
III 2837 Spring 1997  
IV 1225 Spring 1999  
V 1223 Autumn 2001  
VI 2119 Spring 2004  
VII 2458 Winter 2005 
VIII 2259 Winter 2007 
 
As shown in figure 2.2, for the purpose of analysis EuroSIDA is often split into 4, 5 or 6 
demographic regions, depending on the research question of interest. There are 30 
centres included in Southern Europe from Spain, Portugal, Italy, Greece, Serbia, 
Montenegro, Israel, and Argentina. Although where sufficient numbers allow, Argentina is 
classed as its own region. There are 20 centres included in West Central Europe from 
France, Belgium, south Germany, Luxemburg, Switzerland, and Austria. There are 23 
centres included in North Europe from, United Kingdom, Ireland, Netherlands, north 
Germany, Denmark, Sweden, and Norway.  
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There are 31 centres included from East Europe from, Belarus, Bulgaria, Croatia, Czech 
Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia, 
and Ukraine. From Cohort VII onwards there has been sufficient data available to split 
East Europe into two separate geographical regions East and East central Europe. In this 
case 17 centres from East Europe, Estonia, Latvia, Lithuania, Belarus, Ukraine and Russia 
and there are 14 centres included from East Central Europe Poland, Czech Republic, 
Slovakia, Hungary, Romania, Bulgaria, Croatia, and Serbia. 
 
Figure 2.2: EuroSIDA split into 6 demographic regions  
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2.1.3 The EuroSIDA organization 
 
Figure 2.3 gives an overview of the organization of the EuroSIDA study. The study is 
headed by a steering committee which consists of 14 members. The steering committee 
meets, on average, by telephone conference every 2 months to discuss the progress of 
current projects, the approval of new project proposals, and the overall running of 
EuroSIDA, funding and sponsorship. The steering committee consists of regional 
representatives from across Europe. A full list of the members of the EuroSIDA study 
group is given in Appendix II.  
 






The overall co-ordination of EuroSIDA is provided by the Copenhagen HIV program 
(www.cphiv.dk). The coordinating centre is responsible for the management of the 
EuroSIDA database. The statistical centre for EuroSIDA is based at the Royal Free 
Hospital, University College London Medical School, Royal Free Campus, London and 
works very closely with the coordinating centre. Additionally, there are three working 
groups, Virology, Hepatitis and Pharmacokinetics. A core group of clinicians and 
statisticians meet 3-4 times a year to discuss future projects and work priorities. This 
active collaboration between clinicians, statisticians, epidemiologists, HIV virologists, 
hepatologists, pharmacologists is crucial for the running and the development of the study 
but is not necessarily reflected by the members on the steering committee.  
EuroSIDA Steering Committee 
Coordinating Centre 
103 participating sites 
33 National Coordinators 2 Central Virology Coordinators 
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The Virology group is focused on research into all aspects of HIV drug resistance. In 
addition to the main EuroSIDA clinical database there is an extensive database on any 
HIV resistance tests that have been performed locally and reported to the coordination 
centres. A plasma sample is requested on all patients every 6 months. This plasma 
sample is stored locally (in general) at minus 80 degrees Celsius, and intermittently 
shipped to the central repository at the coordinating centre. The central repository contains 
more than 36,000 samples. There are also additional stored samples available for some 
patients which can be utilized for specific HIV projects as required. The database can be 
checked to see whether there is a sample available for each patient that would be eligible 
for inclusion into a specific analysis, extracted from freezers and analyzed. The EuroSIDA 
Virology Laboratory Group is constituted by two interactive centres one in the UK: ICVC 
International Clinical Virology Centre, London (up to 2004) and another one in Spain: 
IrsiCaixa Foundation, Badalona. The main objective is to evaluate the genotypic resistance 
as a factor associated to the virological, immunological and/or clinical outcome. Other 
objectives included supporting the development of the plasma bank, defining the 
prevalence of resistance in untreated patients across Europe, and understanding the 
impact of chronic viral co-infections on virological and clinical terms. Additionally, 
EuroSIDA has set up a computerised system to make the results of any additional 
samples tested available to the clinicians.  
 
As mentioned in the introduction, hepatitis co-infection is common within the HIV-positive 
population384;388. The EuroSIDA hepatitis group is built around the two central laboratories 
in Bonn and Madrid, and the group is headed by Jürgen Rockstroh, Vincent Soriano and 
Lars Peters. EuroSIDA includes the largest cohort of chronic viral hepatitis/HIV coinfected 
patients worldwide. Data on hepatitis B and C serology, viral load and genotype are 
reported on all patients once annually. Furthermore, in 2006, all patients with available 
plasma samples have been investigated at a central reference laboratory for relevant 
hepatitis B and C serology, viral load and genotype. Of all patients enrolled in EuroSIDA, 
around 25% were anti-HCV IgG positive. Of 1,940 seropositive patients with available 
plasma samples, 1,496 (77%) had detectable serum HCV-RNA. Around 7% of all patients 
in EuroSIDA were HBsAg positive. Of 474 HBsAg positive patients with stored plasma 
samples available 315 (66.5%) were HBV-DNA positive. The main objectives are to study 
the natural history of chronic hepatitis B and C in HIV patients, how these co-infections 
influence the outcome from and tolerability to ART, the roll-out and outcomes from 
hepatitis treatment and regional differences in these parameters. 
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Until now the EuroSIDA study has published eight papers in peer-reviewed journals on the 
epidemiology and clinical outcomes of HIV/hepatitis co-infection.  
 
The pharmokinetics group is run by David Burger at the Department of Clinical Pharmacy, 
Radboud University Medical Centre, Nijmegen in the Netherlands. In their lab, they 
analyse the pharmacokinetics of plasma samples, which measures the amount of drugs in 
the blood using a validated reversed-phase HPLC method425. So far this group has 
published one paper in EuroSIDA, looking at whether patients with high efavirenz plasma 
concentrations have an increased likelihood of toxicity-driven efavirenz discontinuations, 
no association was found426. They are currently working on a new project ‘Relating PI 
therapy failure with drug exposure’ to determine the role of non-adherence in patients 
(measured by the level of PI in the blood) presenting with virological failure. 
 
Primary support for EuroSIDA is provided by the European Commission BIOMED 1 
(CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773) and the 
6th Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, 
EuroCoord n° 260694) programmes. Current support also includes unrestricted grants by 
Gilead, Pfizer, BMS, Merck and Co. The participation of centres from Switzerland was 
supported by The Swiss National Science Foundation (Grant 108787). 
2.1.4 Data collection 
At recruitment, in addition to demographic and clinical information, a complete 
antiretroviral history is collected, together with the 8 most recent CD4 counts and viral load 
measurements. This is done through a EuroSIDA enrolment form. 
 
EuroSIDA is an observational study and the data collected by EuroSIDA is that which is 
already available. The study does not have any influence on the treatment or monitoring of 
the patients being followed. The patients are therefore followed and treated in agreement 
with requirements in the individual clinics. At 6 monthly intervals, relevant data are 
extracted from patient clinical charts onto follow-up forms (see Appendix I). This data is 
then used to create 6-monthly updates of the EuroSIDA data set so that the most recent 
and up to date information can be used for all analysis. Table 2.2 gives a summary of the 
data collected at enrolment, and at subsequent follow-up visits.  
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EuroSIDA patients also participate in the Data collection on Adverse Events of anti-HIV 
Drugs study (D:A:D study). EuroSIDA is one of the main contributors of data to the D:A:D, 
study whose main aim is to assess the incidence of myocardial infarction among HIV/AIDS 
patients who are receiving anti-retroviral therapy. Over time, the data collection form has 
been modified to capture additional information.  Variables collected include the date of 
diagnosis, date of any serious illness of interest, such as MI, non-AIDS defining cancer, 
liver disease or end stage renal disease, any cholesterol measurements or blood pressure 
measurements, as well as information on the use of any drugs to treat any of these 
illnesses, such a lipid lowering drugs or diabetic medication. Information on smoking status 
is also collected.  
Table 2.2 Summary of data collected in EuroSIDA 
 
 
EuroSIDA has recently begun collecting adherence data, although this has proved to be 
problematic. As the data is taken from patient notes and transferred onto the follow-up 
form, information on adherence is only collected if a comment has been made in the notes. 
Demographics Laboratory values 
Gender Serum total cholesterol 
Date of Birth  Serum HDL cholesterol 
Mode of infection Serum triglycerides 
Country of origin S-creatinine 
Race Heamoglobin 
Basic clinical information Platelet count 
Height ALT 
Weight AST 
Blood pressure INR 
Smoking Bilirubin 
Family history of MI S-lactate (not LDH) 
Clinical events S-amylase 
Cardiovascular events CD4 counts 
Metabolic events HIV RNA 
Other organ events Hepatitis virology/serology 
Pregnancy in woman Hepatitis B antigen 
Outcome of pregnancy Hepatitis B antibody 
Antiretroviral treatment HBV-DNA 
Dates of starting or stopping Hepatitis C antibody 
Reason for discontinuation HCV-RNA 
Adherence rating HCV-genotype 
Treatment against infection Toxoplasma antibody 
Dates of starting and stopping drugs CMV antibody 
Treatment related to cardiovascular risk Severe opportunistic infections 
Dates of starting and stopping drugs Dates and diagnosis (definitive presumptive, autopsy) 
Patients who have died Other severe infections 
Date of death Dates and diagnosis (definitive presumptive, autopsy) 
Autopsy performed AIDS defining malignancies 
Presumed cause Dates and diagnosis (definitive presumptive, autopsy) 
CoDe case report Non-AIDS defining malignancies 
 Dates and diagnosis (definitive presumptive, autopsy) 
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Additionally, there are only 3 categories of adherence, poor (<70%), perfect (>95%) and 
anything in between, and no information is collected on how adherence has been 
measured. The EuroSIDA follow up form is reviewed every 6 months by the coordinating 
centre and the core group to see if there are any extra variables that need to be collected. 
The steering committee also review the data collected every time they reapply for funding. 
2.1.5 Loss to follow-up 
An essential component of any observational cohort is complete follow-up of as many 
patients as possible427. It is important to consider loss to follow-up (LTFU) when analyzing 
data as it is a potential source for selection bias428. LTFU can be defined in a variety of 
different ways. Within EuroSIDA, LTFU occurs when no follow-up form is returned to 
EuroSIDA and no CD4 cell count or viral load measured at the clinic for over 1 year. LTFU 
within EuroSIDA is less than 5 per 100 PFYU and does not appear to have changed over 
time427. There are a number of initiatives within EuroSIDA to minimize LTFU, including 
educating sites on the importance of continued follow-up and reporting, annual monitoring 
at selected sites to check accurate data collection, and seeking further information from 
the clinic if the patient is thought to be lost to follow-up. If a patient has moved care, follow-
up can sometimes be continued at another EuroSIDA site. In addition, sites with high 
LTFU are approached to help investigate what the underlying reasons are and to provide 
extra support and strategies that may help reduce the level of LTFU. 
2.1.6 Data quality 
An extensive quality assurance programme has been established to secure correct patient 
selection and to verify that accurate data are supplied. This includes monitoring visits and 
data quality control at the coordinating centre. Members of the coordinating office visit all 
centres to ensure correct patient selection and that accurate data are provided, by 
checking the information provided against case notes for all reported clinical events and a 
random sample of 10% of all other patients. Centres have ethical approval according to 
their own local and national requirements, and the coordinating centre is required to have 
copies on file of the approvals.  
2.1.7 Data summary 
As the data is updated every 6 months, several versions of the data set are used in this 
thesis (see table 2.3). In general, each chapter is based on the most recent version of the 
database available at the time the manuscript was published or submitted for publication. 
Table 2.3 gives an overview of the number of patients included in each chapter and the 
inclusion criteria. 
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Table 2.3: Characteristics of the updated data sets 
Chapter EuroSIDA 
dataset 
N in dataset Median 
follow-up date 
(IQR) 
Brief summary of inclusion criteria N included in 
analysis  
Primary end points 
3 D27* 14241 5/07 
(9/02-11/07) 
All patients who have maintained a 
stable and fully suppressed cART 
regimen for one year, with CD4 count 
and viral load measurements 
available prior to cART initiation and 
during the year of stable therapy.  
2237 All cause failure defined as either: 
CD4 count <200 cells./mm3 
CD4 count below CD4 count at cART 
Two viral load > 500 copies/ml 
AIDS defining event 
Non-AIDS defining event 
Death  
4 D29 16599 6/08 
(3/04-12/08) 
All who were on cART for a least 6 
months prior to initiating a new cART 
regimen after 1/1/2000, with at least 6 
months follow-up available after the 
treatment change  
2721 
 
Virological failure defined as viral load 
>500 copies/ml at 4 months after 
treatment switch 
5 D30 16599 1/09 
(3/04-6/09) 
All patients who initiated either 
efavirenz, nevirapine or lopinavir 
based cART regimens, who had not 
been exposed to any of the three 
drugs previously , who achieved 
suppression and remained on the 
regimen for more than 3 months  
2906 
 
Discontinuation of treatment regimen, 
development of serious non-AIDS 
clinical event last visit or recorded 
measurement for laboratory events 
6 D29 16599 6/08 
(3/04-12/08) 
All patients enrolled in EuroSIDA with 
some prospective follow-up and a 
CD4 count available prior to 
recruitment into EuroSIDA 
14453 Development of a non-AIDS defining 
malignancy 
7 D32 16599 11/09 
(4/04-6/10) 
All patients enrolled in EuroSIDA with 
some prospective follow-up after 1/1/ 
2002 
13280 Death 
* Cohort VIII was added in D28 
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2.1.8 Ethical approval 
EuroSIDA is a non-intervention data collection study. The data obtained are collected from 
clinical sites participating in the EU Commission funded project and governed by the EU 
Grant Agreement, which includes ethical requirements. All sites have a contractual 
obligation to ensure that data collection and sharing is done in accordance with national 
legislation.  In the case that EuroSIDA sites have no requirement for ethical approval of 
observational research studies, the principal investigator of the site has to document this in 
a written statement.  The Co-ordinating Centre ensures that the holding of data complies 
with the local and national protections acts. All participating patients have to read a Patient 
Information Letter describing the study set-up and study details, including the fact that 
anonymised samples and data will be collected centrally and used in accordance with the 
Scientific Programme of EuroSIDA. All participants sign an Informed Consent Form 
confirming participation before enrolment into the study.   
2.2 Methodology 
 
Throughout this thesis a variety of different statistical methods have been used. A methods 
section at the start of each analysis chapter will describe the methods that were used to 
perform the analysis in that chapter. The inclusion criteria will also be described in detail in 
each of the methods sections, as well as summarized in table 2.3. The rest of this chapter 
will give an overview of the main statistical methods used throughout this thesis. All 
statistical analysis in the thesis has been performed using SAS version 9.1 (SAS institute, 
Cary, North Carolina, USA).  
 
2.2.1 Initial analysis 
When analysing data, it is important to provide summary statistics. Summary statistics give 
an overview of the population being analysed. They are also useful to check for any 
obvious data errors, and can be used to compare different groups of patients before any 
formal analysis is performed.  
 
For categorical variables, the total number of patients (N) and the percentage (%) in each 
category is reported and for continuous variables the mean and standard deviation (SD) 
are reported if the data are normally distributed and the median and interquartile range 
(IQR) if the data are skewed. If the data are approximately normally distributed then the 
mean and median will be similar. If the data are highly skewed then the mean and median 
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can be quite different. In the EuroSIDA study the majority of the continuous variables that 
describe patient characteristics are highly skewed therefore in most cases the median and 
the inter quartile range are given.  
 
To compare the characteristics of different groups of patients, the Pearson’s chi-square 
test is used when the variable of interest is categorical. However, if there are less than 5 
patients in any category then Fishers exact test is used. For normally distributed 
continuous data, un-paired t-tests are used to compare different groups. To compare two 
sets of values between the same patients, such as viral load at starting cART and at 6 
months, then a paired t-test could be used. When comparing continuous variables that are 
skewed the Wilcoxon rank sum test is used if two groups are being compared. If three or 
more groups are compared then the Kruskall-Wallis test is used, which is an extension of 
the Wilcoxon rank sum test. These tests are non-parametric and do not make any 
assumptions about the underlying distribution of the data 
 
All tests performed were two sided, and a p-value of less than 0.05 was taken to be 
statistically significant i.e. there was a significant difference between the groups and the 
null hypothesis of there being no difference could be rejected. Additionally, the clinical 
significance of results was also considered by looking at the size of the effect and the 
width of the confidence intervals.  
2.2.2 Statistical modelling  
Statistical models are developed to help quantify the relationship between the outcome of 
interest and various explanatory variables. They provide a mathematical representation of 
how the variability of a response can be explained in terms of explanatory variables. They 
also incorporate a random component to account for the deviation of the observed 
response values from the predicted values.  
 
In addition, statistical modelling can allow us to adjust for confounding from other 
variables. Before attributing any difference in outcome between the exposure groups to the 
exposure itself, it is important to examine whether the exposure-outcome association has 
been affected by other factors that differ between the exposure groups and which also 
affect the outcome. Such factors as said to confound the association of interest429. When 
looking at the effect of a variable on an outcome, another variable is a confounder if it is 
correlated with the variable of interest and it is also associated with the outcome. For 
example, in HIV epidemiology research we may be interested in assessing whether 
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patients on a PI based regimen have a lower risk of death than those on an NNRTI based 
regimen. The CD4 count at starting treatment is likely to be a confounder as it may be 
related to what treatment a patient is started on, and CD4 count is also known to be 
associated with risk of death. In randomized clinical trials the randomization should ensure 
that any factors that affect the outcome are equally distributed between the groups and it 
therefore controls for both known and unknown confounders. In cohort studies, such as 
EuroSIDA, this is not the case. Therefore, statistical methods have been developed to 
allow us to account for at least some of the confounding in the analysis by using 
multivariable statistical models. By including other variables in a model and ‘adjusting’ for 
the effect they have, we can remove most of the bias, so that we can see the effects of a 
particular treatment or intervention in a similar way to if we were comparing similar patients 
whose only difference was exposure to the intervention. The main limitations to analysing 
cohort studies are discussed in detail in the final conclusion (section 8.2.)  
 
Univariable models contain only one explanatory variable, and are used to investigate 
what effect this variable alone had on the response. They do not account for any 
confounding, showing the unadjusted relationship between one variable and the outcome 
of interest.  
 
In multivariable models, the impact of each explanatory variable is adjusted for all other 
variables in the model, e.g. in the above example the adjusted comparison is the effect of 
PI based regimen versus NNRTI among people with similar CD4 counts. 
 
Unfortunately, there are some variables that are not routinely collected in certain cohorts, 
and other variables that simply cannot be measured. This can, in some cases, lead to 
biases or confounding by indication. This is a particular limitation when analysing data 
from cohort studies, and will be discussed in detail in chapter 8.  
 
Three main methods of statistical modelling were used in this thesis: logistic regression, 
Poisson regression and survival analysis. Each of these methods are described in detail 
below 
2.2.2.1 Logistic regression 
 
Often in HIV analysis, we wish to investigate whether or not the person experiences an 
event of interest, for example, virological suppression, AIDS or death.  
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The risk on an event occurring by a certain time point (t) can be calculated by 
  Risk of event = Number of people with an event by time t 
  by time t     Total number of people followed 
 
 
In a similar way the odds of an event can be calculated by  
 
Odds of event = Number of people with an event 
            Number of people without an event 
 
Logistic regression is most commonly used for data where the outcome is binary, i.e. there 
are two possible outcomes, such as success/failure, alive/dead. In general, the outcome is 
referred to as an event, and we are interested in the probability of an event occurring. 
When looking at probability, (p) is a number between 0 and 1, but in order for us to 
perform regression analysis it has to be transformed so it takes the value between minus 
infinity (-∞) and infinity (+∞). Thus, p is used to calculate the odds of the event occurring, 
and logistic regression is used to model the log of the odds. The name logistic comes from 
the fact that we use the log transformation to do the analysis. When the outcome is rare, 
the odds of an event is similar to the probability of an event.  
 
Equation 2.1 Logistic regression model 
Log-odds (outcome) =β0+β1x1+β2x2+……+βnxn 
 
The β0… βn are regression coefficients, x1...xn are explanatory variables.  
 
In equation 2.1, the coefficient (βi) from the model reflects the independent effect of the 
variable (xi) that is not explained by the other factors. Anti–logging βi gives an estimate of 
the odds ratio association between xi and the event. The equation can be used to predict 
the probability that an event occurs for each individual.  
 
As you can see from equation 2.1, this type of model assumes a linear relationship 
between the explanatory variables and the log odds of an event. It can be used to estimate 
the odds ratio that compares the outcomes from two groups of patients. An odds ratio is 
defined as the ratio of the odds in one group compared to the odds in a second group. A 
value greater than one indicates the first group had greater odds of an event than the 
second, the opposite is true if the value is less than one. One limitation to investigating the 
risk of an event, or the odds, is that we cannot account for the fact that not all people are 
followed for the same amount of time.  
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2.2.2.2 Time to event data 
Poisson regression analysis and survival analysis are commonly used when dealing with 
time to an event data. They allows us to deal with data that has been censored. An 
observation is censored if the period of observation has stopped before the event of 
interest has occurred, so the time to an event is unknown. In the context of HIV, and in 
particular in cohort studies, many events of interest involve looking at censored data. Data 
can be right censored, left censored or interval censored. Figure 2.4 shows the three 
different kinds of censoring.  
Figure 2.4: Examples of different types of censoring 
 
 
The most common type of censoring, and the type found in HIV research, is right 
censoring, which is where some patients have not experienced the event of interest by the 
end of the period of follow-up. In EuroSIDA we also have left censoring. There is 
substantial data available about the patients history prior to recruitment, but all analyses 
are left censored at recruitment (or some other relevant time-point depending on the 
analysis in question). If censoring was ignored and only complete data considered, a lot of 
important information would be disregarded and could bias the conclusion on the 
distribution of event times. For example, if the analysis was survival following an AIDS 
event, and persons with AIDS events prior to recruitment were included, we would likely 
over estimate survival time because patients diagnosed with AIDS prior to recruitment are 
likely to have different survival times to those diagnosed with AIDS during prospective 









Baseline Study end 
Left censored 
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2.2.2.3 Poisson regression analysis 
 
Poisson regression analysis is similar to logistic regression, but the outcome variable is a 
rate. The incidence or event rate per year of follow up (PYFU) is shown in equation 2.2.  
 
Equation 2.2 
IR = number of events  
   PYFU 
 
To get the incidence rate per 100 PYFU the incidence rate is multiplied by 100. For rarer 
events, the IR per 1,000 PYFU is sometimes used. For example, if the incidence rate was 
X per 100 PYFU, this means that if we followed 100 people for 1 year we would expect X 
number of events to occur. An incidence rate is a number between 0 and infinity. If more 
than 20 events are observed then 95% confidence intervals are calculated using the 
normal approximation to the Poisson distribution. Where the number of events is ≤ 20 then 
the exact Poisson distribution is used to calculate the 95% confidence interval.   
 
Poisson regression analysis is used to model the rate ratios and again allows for 
adjustment of numerous different variables. As the assumptions of linear regression again 
are not met, the log of the rate, rather than the rate itself, is modelled and then it is 
transformed. The model is interpreted in a similar way to logistic regression, but instead of 
odds ratios the estimates are relative rates or rates ratios. 
 
Incidence rate ratios (IRR) are used to compare different groups of patients; one group is 
taken as the reference group and then the IR in each of the other groups is divided by the 
reference group. The value of IRR can take any value greater than 0. An IRR > 1 implies 
that there is an increased rate in the comparison group whereas if 0< IRR < 1 then there is 
a decreased rate compared to the reference group. This type of analysis is called time to 
event ,as it can account for the fact that some data may be censored.  
 
2.2.2.4 Kaplan Meier survival analysis 
Kaplan-Meier curves can be used to compare two groups but this is without adjustment for 
any other variables. This can be useful as it allows you to see the risk to each group at 
different time points, and thus to see whether there is a difference between the two groups 
and if the relationship changes over time or remains constant.  
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The survivor function S(t) is used to find the probability that an individual survives beyond 
a particular time. The survivor function takes the value 1 at t=0 and decreases to 0 at 
t=infinity. The survival function is normally highly skewed, and the most appropriate central 
summary of the distribution is by the median survival time, which is the value of t when 
S(t)=0.5. 
 
The most commonly used non-parametric estimator of the survivor function is in Kaplan 
Meier survival analysis. It is commonly used in time to event data, when the data to be 
analysed is censored. For example, the time to stopping a particular drug, time till viral 
load reaches a certain point, or time till death.  
 
 Equation 2.3   k 
SKM(t)= П (sj / rj)   for t(k) ≤ t < t(k+1), k=1,2,…,m 
   
  J=1 
 
Where rj is the number of individuals alive before time t(j) for j=1,2,..m and dj the number 
of individuals who die therefore s(j) = 1- dj/rj 
Number surviving beyond t 
       Number in the sample 
 
2.2.2.5 (Cox) Proportional Hazards Model 
The hazard function or hazard rate is defined as the rate at which an individual is likely to 
experience an event, in the next small interval of time, given that they have already 
survived up to that point.  
 
The proportional hazards model is defined in equation 2.4 for a baseline (i.e. at z = 0) 
hazard function h0(t) and where β is a set of unknown parameters. 
 
Equation 2.4 




It does not assume that the data fit any defined distribution or shape, it only assumes that 
the hazards are proportional i.e. they remain the same over time. To check the assumption 
of proportional hazards is true we test for an interaction, or graphically the Kaplan Meier 
plot can be used. 
  
This method is similar to logistic and Poisson regression, but the outcome variable is the 
hazard of an event occurring. Again it is the log of the hazard, and the anti-logged 
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parameter estimates are now relative hazards. The main difference between Cox 
regression and Poisson is that in Cox regression we need to have a time scale of interest, 
e.g. time from first viral suppression. However, this means that we cannot easily consider 
whether this rate increases or decreases over time. Further, with Cox proportional hazards 
models you assume the hazards are proportional over time.  
 
2.2.2.6 Competing risks 
 
In time to event analysis, the occurrence of an event of interest is often precluded by 
another event that prevents the event of interest from being observed. For example, 
looking at the time to discontinuation of an antiretroviral due to toxicities, an individual may 
discontinue the drug due to another reason, such as virological failure, before 
discontinuation due to toxicity. Competing risks are events that prevent an event of interest 
from occurring, rather than just preventing you from seeing it happen (censoring). 
Therefore, when looking at time to discontinuation of an antiretroviral due to toxicity, 
discontinuation of the drug due to virological failure is a competing risk.  
 
Any analysis where “censored” does not just mean end of follow-up or lost to follow-up is 
actually a competing risks analysis. In this example, patients are observed at study entry 
and followed until either the event of interest (discontinuation due to toxicities), a 
competing event (i.e. discontinuation for another reason), or censoring430. When 
competing events are censored, the complement of the Kaplan Maier survival curve may 
not appropriately estimate the cumulative incidence430 
 
A number of nonparametric and regression methods exist for analysing data with 
competing risks430. In this thesis, an approximation of the sub distribution hazard has been 
used for performing competing risks analysis in Kaplan Maier survival and Cox 
Proportional Hazards models. In this method, all patients who experience a competing 
event remain in the risk set and the individual is then censored administratively at the last 
study visit. For the competing risks analysis in this thesis, patients with a competing event 
remained in the data set and were censored at the median date of last follow-up visit. In 
order to do this, where information was missing for the patient with the competing event, 
the last observation was carried forward.  
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2.2.3 Performing analysis 
2.2.3.1 Model selection 
In this thesis, all the explanatory variables are defined prior to starting the analysis. The 
majority of the variables are already well established in HIV research. The explanatory 
variables of interest are first entered into univariable models and any that are significant at 
the 10% level i.e. p value < 0.1 (to be conservative) are entered into the multivariable 
model. A stepwise selection method was then used to confirm whether or not, after 
adjustment, other variables might be confounders, and all additional potential confounders 
were added. Details of the model building approaches used in each chapter are described 
in further detail in the methods section of each chapter. 
2.2.3.2 Fixed or time updated variables 
Most analysis in this thesis uses fixed variables, i.e., variables measured at baseline that 
remain unchanged over time. These fixed variables consider long-term association 
between the variable at the outcome of interest. In time updated analysis, the short-term 
outcome between two variables is considered. For example, CD4 count can be included in 
a model in a variety of different way. There is the CD4 count at baseline, or the nadir CD4, 
which are both fixed variables, but it can also be included as an updated variable that 
changes depending on the most recent CD4 count measurement.  
 
In order to include time-updated covariates in the models developed in this thesis, the 
follow-up time was split into monthly intervals. At each new month, the value of each 
variable was assessed and updated accordingly. Monthly intervals were chosen as a 
number of the dates recorded in EuroSIDA in the early period of data collection were only 
recorded to the nearest month. Generalised estimating equations were used to account for 
the fact that repeated measures of the same subject were then included in the models  
and measurements from the same individual over time will be more correlated than those 
between different individuals. 
2.2.3.3 Manipulating data 
 For certain variables that are highly skewed and do not follow a normal distribution for 
statistical analysis, it is often sensible to transform variables. In HIV the viral load 
distribution is highly skewed, therefore it is often transformed using the logarithmic 
transformation to the base 10, if x =10u then by definition u is the logarithm (base10 ) of x, 
i.e. 100 =102, 2 = log10(100)
431. So a viral load of 50 copies/ml = 1.69 log10 copies/ml and a 
viral load of 5000 copies/ml = 3.69 log10 copies/ml.  
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Another common transformation in HIV analysis is to use log2 (base2) when looking at CD4 
count as predictor of an event. For example, if risk of death is estimated to be 20% lower 
per log2 increase in CD4 count, this means that patients with a CD4 count of 100/mm
3 
have a 20% lower risk of death than patients with a CD4 count 50/mm3 and similarly 
patients with a CD4 count of 200/mm3 have a 20% lower risk of death than those with a 
CD4 count of 100/mm3. When the log2 transformation is used it is often described as per 
doubling or 2 fold increase. 
 
Another option for continuous variables is to redefine them as a categorical variables, 
based on commonly used cut-offs. For example, CD4 count could be split into 5 categories 
i.e. ≤50, 51-200, 201-350, 351-500 and >500. The advantage of this is that it is easily 
understood and interpreted by clinicians, the disadvantage is that the actual risk of the 
event for someone with a CD4 count of, for example, 51/mm3 will not be greatly different 
from the risk of someone with a CD4 count of 49/mm3, yet the risks produced may be 
significantly different for different categories. 
2.2.3.4 Statistical interactions 
The statistical modelling methods described above assume that the effect of each variable 
in the model does not depend on the value of other variables. If this is not true, for 
example if the effect of CD4 count on risk of discontinuation of treatment is bigger in males 
than in females, then there is a statistical interaction. The first step in dealing with 
statistical interactions, is to test for interaction by incorporating an interaction term into the 
model. If the interaction term is significant then the model should be fitted separately for 
the different levels of the factor.  However, test for interaction are typically underpowered. 
2.2.3.5 Endpoints 
Clinical endpoints in HIV are normally defined as either disease progression or death. 
Many clinical trials, because of time constraints, use surrogate end points. In HIV, these 
are often CD4 counts or viral load. A summary of the endpoints used in each of the 
chapters is given in table 2.3 and also in the methods section of each of the analysis 
chapters. A variety of sensitivity analyses using slightly different versions of endpoints are 
also used to check the robustness of the results. For example there are a variety of 
different endpoints that can be used to define virological failure, such as one viral load 
measured above 500copies/ml, or 2 consecutive viral loads measured above 







A number of different methods commonly used for analysing observational data have been 
described in this chapter. These methods are not without disadvantages and the biases in 
cohort studies can be great, as discussed in more detail in chapter 8. There is a detailed 
methods section at the start of each chapter that provides further details on the patients 
selected, the specific statistical methods used, and the endpoints analysed in that chapter.  
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Chapter 3 Investigation into whether frequency of monitoring 
can be reduced in a subgroup of HIV-positive people? 
 
3.1 Introduction 
As discussed in chapter 1, the introduction of cART in the early 90’s had a dramatic effect 
on the treatment of HIV-positive patients and their survival rates6;10;156;157;159;272. Since then, 
huge developments have been made in the treatment and care of patients. Drug regimens 
are now less toxic, once daily regimens have been developed432-434, drugs have been 
made in combination to decrease pill burden435;436, and more sensitive monitoring tools 
have been developed437;438.  
 
The improvements made in technology have meant that viral load and CD4 testing are 
common practice for all HIV-positive patients in the developed world although they are still 
relatively expensive. Routine diagnostic tests in the developed world such as viral load and 
CD4 counts cost around $119 and $66 respectively per test439-441. Treatment guidelines 
such as the WHO, BHIVA and EACS, are constantly updated and modified in order to 
keep as up to date as much as possible with the newest drugs and treatment strategies so 
that patients get the best possible treatment available to them based on current evidence. 
For example, looking at when to start treatment, guidelines stated in 1997 that patients 
should start with a CD4 count <200/mm3 and that treatment should be considered in those 
with a CD4 count 200-350/mm3 depending on their viral load442. However, as studies found 
that patients starting treatment earlier had a better prognosis443, treatment guidelines have 
subsequently been changed to recommend treatment is started in all patients with a CD4 
count <350/mm3 214;223. A new randomized control trial, START, has been designed to 
investigate whether there are benefits in starting cART at even higher CD4 cell counts 
(>500/mm3) compared to delaying the start of cART until the CD4 count falls to below 
350/mm3 as current treatment guidelines recommend444. 
 
Populations of patients with HIV under routine care have increased dramatically over the 
past decade. For example in 1997, 16,645 patients were treated in the UK, and in 2007 
this number had more than tripled to 55947445. Similarly, in a Southern Alberta cohort 
study which includes all HIV-positive patients living in the area, the number of patients 
increased by 74% from 526 to 920 from 1997 to 2006446.  
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There are several reasons for this increase. There has been an increase in number of 
patients diagnosed with HIV; for example in the UK just under 3,000 patients were newly 
diagnosed in 1997 compared to over 7,000 in 2005183. This is, in part, due to an increase 
in the number of HIV tests being performed183. Further, the introduction of cART has 
meant that patients infected with HIV are living longer, with lower rates of AIDS defining 
illnesses. EuroSIDA found that there was an 8% decrease in the incidence of AIDS or 
death per 6 month period after 199810. Patients are living longer so are remaining on 
treatment longer; this means the number of patients in care and on treatment is larger183. 
Also, an increase in immigrants infected with HIV has added to the UK HIV-positive 
population. In the UK in 1998, the number of black Africans infected heterosexually was 
2,557. This has increased 16-fold to 19,013 in 2007445. A similar pattern has been reported 
in other countries446.  
 
However, a large number of infected patients in both the developed and the developing 
world remain unaware of their HIV status, with estimates suggesting that approximately 
one quarter of patients in the developed world infected with HIV are unaware of their HIV 
status447. These patients are at a higher risk of transmitting the virus to uninfected 
individuals than those aware of their HIV status448, and patients presenting for care late in 
their infection tend to have poorer outcomes and make larger demands on clinical 
resources449 than those who start treatment according to guidelines. Attempts are being 
made to increase the number of patients infected with HIV who know they are infected, 
and if these are successful then patient populations will increase further.  
 
The increase in patient populations has in turn meant that there has been an increase in 
the number of patients who need to be seen routinely for management and care of HIV. 
With patients living longer, and the number of patients infected with HIV rising, there is a 
growing burden being placed on clinical services, health care providers and financial 
resources. 
 
HIV-positive patients are seen at clinics for a whole variety of reasons, such as testing of 
viral load and CD4 cell count, complete blood count liver and renal function, lipid profile 
and glucose levels311;312;450;451. Some treatment regimens can be quite complex, with 
different toxicities and dietary requirements depending on the regimen. Patients on 
salvage therapy require particularly close monitoring452.  
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In addition to emphasizing the importance of adherence and discussing any side effects of 
treatment, clinicians may also discuss other issues and risk factors associated with cART, 
including advice on smoking cessation and the benefits of and having a healthy lifestyle, 
which may particularly benefit patients at high risk of other diseases such as 
cardiovascular disease452. Patients may also be counselled on practicing safer sex and the 
risk of transmission452.  
 
Currently, treatment guidelines in developed countries such as Britain and across most of 
Europe and the US recommend patients on antiretroviral therapy should be seen every 3-4 
months for CD4 count and viral load monitoring311;453-455; this has been the case for several 
years now. These guidelines are not based on results of clinical trials but have been based 
on the expert clinical opinion456. CD4 count was first recognized as a predictor of short 
term risk of opportunistic infections and death129;457, but some studies reported that it had 
limited ability to predict disease progression over prolonged period of time100;458. Then, 
after improvements in HIV-RNA testing459-461, both baseline viral load and CD4 count were 
found to independently predict clinical events462;463 and viral load monitoring was added to 
the treatment guidelines456;464. The frequency of viral load monitoring, recommended at 3-4 
monthly intervals, was chosen as that was the frequency already recommended by expert 
clinical opinion for CD4 count monitoring 465. 
 
Although there has been an increase in patient populations, fewer patients are being 
admitted to hospital, developing AIDS defining illnesses or serious opportunistic 
infections10;234;297;466, which means the costs associated with in-patient care have 
decreased. In the cART era, the total cost per patient has not increased substantially over 
time446;467. The average monthly cost of patients in care in developed countries has been 
estimated to be between $1,000 -$2,000439;468, and the total life time cost of care over $380 
000439. The annual cost of outpatient visits for patients on cART in Western and Central 
Europe is around $240 per patient per visit469. A Canadian study reported that between 
1997 and 2006, the cost of care for all patients within the region increased by 69%446. 
They also reported that the cost of outpatient costs had increased slightly from $169 to 
$186 with patients in poorer health requiring more disease management and more clinic 
visits446.  
 
Despite the improvements in antiretroviral regimens and constant updating of treatment 
guidelines, recommendations for monitoring a patient after starting cART are the same 
regardless of how they respond to treatment or how advanced the disease is312;450;451;470. 
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Patients who respond poorly to treatment or have newly initiated cART may require 
particularly close monitoring, to ensure good adherence and check for toxicities452. This 
may not be true for patients who have remained on a stable regimen for several years. 
Previous modelling work, using a simulated cohort based on initial clinical presentation of 
HIV-positive adults in the US, has shown that a strategy of monitoring patients less 
frequently (e.g. every 12 months) prior to a pre specified warning point where monitoring is 
then increased (e.g. every 3 months) confers the same clinical benefit to constant 3 
monthly monitoring, but at a much lower cost440. 
 
Previous studies have shown that the greatest risk of treatment failure is in the first few 
months after starting treatment471;472. The risk of clinical disease progression (new 
AIDS/death) was also found to be significantly higher in patients starting cART with low 
CD4 counts473 and those who could not maintain an undetectable viral load466. Thus we 
hypothesized that there may be a group of patients, who have responded well to treatment 
and are on a well-tolerated and fully suppressed cART regimen, where it may be safe to 
reduce the frequency of clinic visits to every 6, 9 or 12 months. This would potentially save 
time for both patients and health care providers. It could also help reduce the impact of 
infection with HIV and intrusion into people’s lives, as the current 3-monthly monitoring 
frequency may act as a regular reminder of their illness, and an inconvenience to daily 
living, including having to take time off work to attend clinic appointments. 
3.2 Aim 
The aim of this chapter was to investigate whether the current recommendation of 
monitoring patients at 3-monthly intervals is necessary for all patients, or whether there is 
a sub group of otherwise healthy patients, who have responded well to therapy and are on 
a well-tolerated and fully suppressive cART regimen, who could safely have their visit 
interval extended to 6-monthly. 
3.3 Methods 
3.3.1 Patient selection 
There were 14,241 patients in the D27 EuroSIDA update. Figure 3.1 shows how patients 
were selected for inclusion. All patients must have maintained a stable fully suppressive 
cART regimen for a period of at least 1 year. A stable and fully suppressed cART regimen 
was defined as a period of at least one year during which all CD4 counts were above 
200/mm3 and at least 100/mm3 above the CD4 count at starting cART, and all viral loads 
were <500 copies/ml.  
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cART was defined as a regimen containing at least 3 antiretrovirals of which at least 2 
must be nucleosides or nucleotides and 1 must be either a protease inhibitor or a non-
nucleoside reverse transcript inhibitor. 3,760 patients were excluded who had not started 
cART. Patients without a CD4 count measured in the 6 months prior to starting cART were 
excluded (4,300 patients). Patients were required to have at least 2 CD4 counts and 2 viral 
loads measured during the 1 year period over which the regimen was considered to be 
stable and fully suppressed. Patients were additionally required to have made no changes 
to the cART regimen (stopping or starting any drugs) during the 1 year period, and for no 
serious illness to have occurred during the 1 year period. A serious illness was defined as 
an AIDS defining illnesses, a non-AIDS defining malignancy, other serious opportunistic 
infection (OI), cardiovascular disease (CVD), diabetes, hypertension or grade III/IV liver 
failure. However, non-AIDS events were only systematically collected in EuroSIDA after 1st 
January 2000.  
 
Each patient was included in the analysis only once, after the first year they maintained a 
stable and fully suppressive cART regimen. 3776 patients were excluded who did not meet 
the requirements of 1 year on a stable and fully suppressed cART regimen. A further 168 
patients were excluded as they had insufficient follow-up after the year of stable therapy 
(at least 2 CD4 count and viral load measurements recorded). 2,237 patients maintained a 
stable and fully suppressive cART regimen for at least a year with sufficient follow-up data 
and thus were included in the study. 
 
Figure 3.1 Patient selection 
 
14,241 patients in EuroSIDA D27 
10,481 patients started cART 
6,181 patients had both a CD4 count and viral load measurement available within 6 months prior to starting 
cART  
2,405 patients maintained and stable and fully suppressed cART regimen for 1 year, with at least 2 CD4 
count and viral load measurements available for that year 
2,237 patients had at least 2 CD4 count and viral measurements available after 1 year of stable therapy 
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3.3.2 Statistical analysis: 
 
For each patient, baseline was defined as the end of the first year the patient maintained a 
stable a fully suppressed regimen, as defined above. 
 
Kaplan Meier survival analysis was used to find the probability (risk) of disease 
progression within the next 3, 6, and 12 months.  
 
Disease progression was defined as 
 CD4 count below 200/mm3 
 CD4 count decrease to lower than the CD4 count at starting cART 
 Two consecutive viral load measurements above 500 copies/ml 
 Development of any AIDS defining illnesses 
 Development of any non-AIDS defining illnesses or serious opportunistic infections  
 Death  
Non-AIDS defining illnesses included any non-AIDS related malignancies, pancreatitis, 
end stage renal disease, other liver related disease, myocardial infraction, stroke or other 
cardiovascular disease.  
 
The risk of failing using each of the 6 categories above was investigated separately, and 
as a composite end point. For immunological events, patients were censored at the date of 
their last recorded CD4 count if they did not experience an event. Similarly, for virological 
failure events, patients were censored at their last recorded viral load measurement if they 
had not experienced an event. For each other event (AIDS event, non-AIDS event and 
death) patients were censored at their last recorded visit. For the composite end point, 
failure was the time of the first one of any of the events above occurring, and follow-up 
was until the date of last recorded visit. 
 
Univariable Cox Proportional Hazards models were used to identify factors associated with 
disease progression in the 12 months after baseline. These included CD4 and viral load at 
starting cART and at baseline, in addition to the diagnosis of any previous AIDS defining 
illnesses. Also tested were age, gender, race, HIV exposure group, hepatitis B and C 
status, the length of time the patient was on cART before a stable and fully suppressed 
regimen was found, which cART regimen (NNRTI, single PI or ritonavir-boosted PI) the 
patient was on, the number of treatment changes prior to baseline, and time a patient 
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spent on cART with viral load <500 copies/ml. Individuals were classed as Hepatitis B 
positive if they had a positive HBV surface antigen test recorded and Hepatitis C positive if 
they had a positive HCV antibody test. A treatment change was defined as stopping or 
starting at least one antiretroviral, apart from dose modification.  
 
When looking at the time a patient spent on cART with suppressed viral load, the first 4 
months after starting a new cART regimen were excluded to allow time for the patient to 
respond to treatment, as were any periods when the patient was off treatment (see Figure 
3.2).  
 
Changes to the cART regimen after baseline, specifically decreasing the number of 
antiretrovirals included in the regimen, or stopping the regimen, was included as a time-
updated binary variables. Any factors with a p-value <0.1 were included in the 
multivariable Cox Proportional Hazard models. All Cox proportional hazards models were 
stratified by centre.  
 






Time on cART 
Time VL included 
4 months 4 months 4 months 
Start cART 
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3.4 Results 
3.4.1 Patient characteristics 
 
10,481 patients started cART but only 2,237 patients who maintained a stable and fully 
suppressed regimen for one year were included in the analysis (figure 3.1). In general, 
demographic characteristics were similar between patients who were excluded and those 
included. However, a higher proportion of patients whose mode of transmission was IDU 
were excluded (24% vs. 17%, p<.0001) and a higher proportion of patients from East 
Europe were excluded (20% vs. 14% p<.0001). Table 3.1 describes the baseline 
characteristics of the patients included in this study. Patients were mainly male 76% 
(1,703), white 86% (1,933), and were thought to have been infected with HIV via 
homosexual sex, 49% (1,091). The median age was 40 (interquartile range [IQR] 35-47). 
52% of patients were antiretroviral-naïve at starting cART and 25% had a previous AIDS 
diagnosis. Median CD4 count at starting cART was 218/mm3 (IQR 108-327), and viral load 
4.64 log10copies/ml (IQR 3.79-5.24). At baseline, the median CD4 count was 520/mm
3 
(IQR 396-693) and median increase in CD4 count from starting cART to baseline was 
290/mm3 (IQR 412-208). 4% of patients had had a positive test for Hepatitis B and 14% for 
Hepatitis C. The median time between start of cART and baseline was 2.8 years (IQR 1.9- 
4.3). Median time between successive CD4 and viral load measurements was 3 months 
(IQR 3–4 months) in addition the median time between baseline and the next CD4 or viral 
load measurement was 2 months (IQR 1-3 months). 
 
  85 
Table 3.1: Baseline characteristics of 2237 included patients 
  All Patients Event within 1 year No event after 1 year Chi-squared 
  N % N % N % p-value 
Total  2237 100.0 131 5.9 2106 94.1  
Gender  Male 1703 76.1 95 72.5 1608 76.4 0.01 
Race White 1933 86.4 111 84.7 1822 86.5 0.86 
Exposure group Homosexual 1091 48.8 56 42.8 1035 49.2 0.06 
IDU 372 16.6 30 22.9 342 16.2  
Heterosexual 624 27.9 36 27.5 588 27.9  
Other 150 6.7 9 6.9 141 6.7  
Hepatitis B Status HBV negative 1558 69.7 80 61.1 1478 70.2 0.07 
HBV positive 90 4.0 5 3.8 85 4.6  
Hepatitis C Status HCV negative 1140 51.0 55 42.0 1085 51.5 0.10 
HCV positive 325 14.5 23 17.6 302 14.3  
Region of Europe South/Argentina 646 28.9 58 44.3 588 27.9 0.0003 
Central 507 22.7 29 22.1 478 22.7  
North 801 35.8 38 29.0 763 36.2  
East 283 12.7 6 4.6 277 13.2  
Treatment at baseline PI 777 34.7 55 42.0 722 34.3 0.13 
PI boosted 633 28.3 37 38.2 596 28.3  
NNRTI 827 37.0 39 39.0 788 37.4  
Naïve  Yes 1161 51.9 55 42.0 1106 52.5 0.01 
Prior AIDS  Yes 562 25.1 35 26.7 527 25.0 0.66 
  Median IQR Median IQR Median IQR Kruskal-Wallis 
Age  Years 40.3 35.2-47.3 38.8 34.2-45.1 40.4 35.3-47.8 0.07 
CD4 /mm
3
 520 396-693 546 376-691 520 397-693 0.91 
Time since started cART Years 2.8 1.9-4.3 2.8 2.0-4.3 2.8 1.9-4.3 0.51 
CD4 at starting cART /mm
3
 218 108-327 232 106-376 218 108-324 0.32 
Viral load at starting cART log10copies/ml 4.64 3.79-5.24 4.65 3.78-5.24 4.04 3.80-5.24 0.57 
% time on cART with RNA<500 copies/ml 95.0 83.3-100.0 91.7 66.0-100.0 95.2 84.2-100 0.62 
nadir CD4  /mm
3
 157 66-252 167 69-273 156 66-252 0.27 
Peak viral load (log10copies/ml)  4.96 4.39-5.44 5.00 4.37-5.47 4.96 4.39-5.44 0.63 
Baseline date (month/year)  05/02 04/00-10/04 03/02 05/00-03/04 05/02 04/00-10/04 0.27 
Time between CD4 measurements (Days) 94 91-121 92 78-115 95 91-121 0.001 
Time between viral load measurements (Days) 98 91-122 92 89-115 98 91-122 <.0001 
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3.4.2 Disease Progression 
131 patients (6%) experienced disease progression in the first year after baseline. Figure 
3.3 shows the first disease progression event experienced by each patient i.e. those 
included in the composite end point. 99 patients (4.6%) experienced virological failure, 4 
patients (0.2%) experienced a CD4 count less that 200/mm3, 6 patients (0.3%) 
experienced a CD4 count >100/mm3 below pre-cART levels, 7 patients (0.3%) developed a 
new AIDS defining illness (2 developed tuberculosis, 1 cryptosporidiosis, 1 toxoplasmosis, 
2 non-Hodgkin’s Lymphoma, and 1 oesophageal candidiasis). 15 patients (0.7%) 
experienced a non-AIDS defining malignancy or serious OI, of which 10 were non-AIDS 
defining cancers and the remainder were serious OIs and there was one death.  
Figure 3.3: Number of disease progression events observed (cumulative failure end point) 
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Of these 131 patients, 121 patients experienced only 1 event in the year after stable 
therapy and 10 of these patients experienced 2 events in the year after stable therapy. In 
addition to failing virologically, 3 patients had CD4 count < 200/mm3, 4 had a CD4 count 
<100/mm3 above their CD4 count at starting cART, and 1 died. In addition to a non-AIDS 
event, 1 patient also had a CD4 count <200/mm3 and 1 had an AIDS event. Therefore the 
total number of events observed was 141.  
 
From the baseline characteristics in table 3.1 there is very little difference between those 
patients that experienced disease progression within 1 year and those that did not. Median 
baseline CD4 count was 520 (IQR 376-691) in patients who did not experience an event 
and 546 (IQR 376-691) in those who did (p=0.91). Patients had been on cART for a 
median of 2.8 years in both groups (p=0.51), although a higher proportion of treatment 
naïve patients did not experience disease progression, 53% vs. 42% (p=0.01). Patients 
who had an event had spent a lower percentage of time on cART with a suppressed viral 
load, median 92% (IQR 66%-100%) of the time compared to median 95% (IQR 84%-
100%) of the time in patients who did not experience disease progression, though these 
differences were not significant (p=0.62) 
 
Table 3.2 describes the characteristics of the patients who experienced disease 
progression at the time of their first event. Median CD4 count at the time of first event was 
higher than the median CD4 count at starting cART: median increase 224cells/mm3 (IQR 
101-328). There was a median decrease of 78cells/mm3 (IQR -217 – 58) in CD4 count 
from baseline to disease progression. Patients had been on cART for a median of 3.5 
years prior to disease progression. Additionally, the majority (64.2%) of patients 
experiencing disease progression had a viral load > 1000 copies/ml at the time of first 
event. 
Table 3.2: Characteristics at time of disease progression (cumulative failure end point) 
  N Percentage 
Patients experienced an event  131 100 
Viral load at first event  <500copies/ml 32 24.4 
 500-999copies/ml 15 11.5 
 1000-9999 copies/ml 45 34.4 
 ≥10000copies/ml 39 29.8 
  Median IQR 
Age at first event  39 35 – 45 
CD4 count at first event (/mm
3
)  436 336 – 597 
CD4 count change from starting cART  224 101 – 328 
CD4 count change from baseline  -78 -217 – 58 
Time on cART at first event  3.50 2.7– 4.9 
Year of failure  2002 2000 – 2004 
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Figure 3.4 shows the Kaplan Meier figure of the probability of disease progression in the 
year after baseline. At 3 months after baseline, there was an estimated 0.3% risk of any 
disease progression (95% CI 0.1, 0.5), which increased to 2.2% at 6 months (95% CI 1.6, 
2.8) and 6.0% (95% CI 5.0, 7.0) after 12 months. As mentioned previously, virological 
failure was the main reason for disease progression. There was an estimated 1.5% (95% 
CI 1.0, 2.0) risk of virologic failure after 6 months, which increased to 4.6% (95% CI 3.7, 
5.5) after 12 months. In contrast, there was less than a 1% probability of any of the other 
disease progression events occurring in the 12 months after baseline. The risk of non-
AIDS failure is shown in figure 3.4 in addition to the risk of overall disease progression and 
virological failure. The 4 other disease progression events in Kaplan Meier analysis had a 
lower risk than developing a non-AIDS defining illnesses and are not shown.  
 
Figure 3.4: Kaplan Meier estimates of disease progression after a year of stable cART: the 
probability of having a CD4 count < 200/mm
3
 or < CD4 at initiation of cART, developing new AIDS, 
or dying, one year after baseline, were all less than the probability of developing a non-AIDS 
defining illness and are not shown. 
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Table 3.3 gives the number of patients who failed, and the number of patients remaining 
under follow-up at 3, 6 and 12 months, for each disease progression event. After 3 months 
no patient had failed immunologically (all CD4 counts above 200/mm3 and above pre-
cART levels), only 1 patient had developed an AIDS defining illness (TB), 4 patients 
developed non-AIDS defining illness, (3 cancers and 1 bacteremia) and 3 patients failed 
virologically (viral load > 500 copies/ml). After 6 months, although still quite low, the 
number of patients that had failed virologically had increased to 33. At 6 months, patients 
had a 0.04% risk of having a CD4 count < 200 mm3 and 0.1% risk of a CD4 count 
100/mm3 below the CD4 count at starting cART. In addition, patients had a 0.1% and 0.4% 
risk of developing AIDS or a non-AIDS defining illness after 6 months. The risk of 
immunological failure, developing AIDS or non-AIDS defining illness or death in the 12 
months after a year of stable therapy were less than 1%. 
 
Table 3.3: Percentage of patients experiencing disease progression at 3, 6, and 12 months after baseline 
 % with 
an event 




Disease progression: CD4<200 
3 months 0 - 0 2238 
6 months 0.04 0-0.1 1 2199 
12 months 0.4 0.1-0.7 8 2088 
Disease progression: CD4 < CD4 at initiation of cART 
3 months 0 - 0 2238 
6 months 0.1 0-0.2 3 2197 
12 months 0.5 0.2-0.8 10 2086 
Disease progression: Confirmed HIV-RNA>500 
3 months  0.1 0-0.3 3 2234 
6 months 1.5 1.0-2.0 33 2166 
12 months 4.6 3.7-5.5 99 1986 
Disease progression: AIDS Defining illness 
3 months  0.04 0-0.1 1 2237 
6 months 0.1 0-0.3 3 2208 
12 months 0.4 0.1-0.7 8 2113 
Diseases progression: Non AIDS Defining illness 
3 months  0.2 0-0.4 4 2234 
6 months 0.4 0.1-0.7 10 2201 
12 months 0.7 0.4-1.0 15 2106 
Disease progression: Death 
3 months  0 - 0 2235 
6 months 0.05 0-0.1 1 2208 
12 months 0.05 0-0.1 1 2116 
Disease progression: (any of the above) 
3 months  0.3 0.1-0.5 7 2228 
6 months 2.2 1.6-2.8 48 2161 
12 months 6.0 5.0-7.0 131 1992 
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3.4.3 What baseline variables were predictive of disease progression? 
 
Cox proportional hazards models were used to investigate the factors associated with a 
lower risk of ‘disease progression events’ in patients who have maintained a stable and 
fully suppressed cART regimen for at least 1 year. Table 3.4 show the results from the 
univariable Cox proportional hazards models. 
 
 Table 3.4: Cox proportional hazards model: Any disease progression  
  Univariable 




Gender Male 1.00 - - 
 Female 1.27 0.85-1.90 0.25 
Race White  1.00 - - 
 Other 1.13 0.65-1.98 0.67 
Age Per 10 yrs older 0.83 0.68-1.03 0.08 
Exposure Group IDU 1.00 - - 
 Homosexual  0.64 0.39-1.05 0.08 
 Heterosexual 0.83 0.50-1.39 0.47 
 Other 0.78 0.35-1.71 0.53 
Hepatitis B status Negative 1.00 - - 
 Positive 0.99 0.40-2.49 0.99 
 Unknown 1.54 1.01-2.35 0.04 
Hepatitis C status Negative 1.00 - - 
 Positive 1.21 0.71-2.04 0.49 
 Unknown 1.09 0.63-1.88 0.75 
Treatment group PI 1.00 - - 
 PI boosted 1.09 0.70-1.69 0.70 
 NNRTI 0.72 0.47-1.11 0.13 
Naïve at starting cART  0.87 0.59-1.29 0.49 
Previous AIDS   1.06 0.72-1.58 0.76 
Year started cART Per year 1.02 0.93-1.11 0.76 
Time since started cART  Per year  1.01 0.92-1.01 0.89 
Treatment at starting cART PI 1.00 - - 
 PI boosted 0.89 0.54-1.48 0.65 
 NNRTI 1.05 0.66-1.68 0.82 
Baseline CD4 per 2 log higher 1.00 0.73-1.37 0.99 
CD4 at starting cART per 2 log higher 1.04 0.92-1.17 0.52 
CD4 nadir per 2 log higher 1.06 0.96-1.17 0.27 
Viral load at starting cART Per 1 log higher 1.13 0.96-1.35 0.14 
Peak viral load  Per 1 log higher 1.19 0.96-1.47 0.11 
Time to first suppression after initiation of cART Per 3 months 1.00 0.96-1.05 0.96 
% time with RNA <500 whilst on cART prior to 
baseline 
Per 10% 0.85 0.78-0.93 0.0002 
Number of treatment changes due to toxicities 
 (from starting cART to baseline) 
Per treatment 
change 
0.91 0.78-1.07 0.26 
Reducing number of ARV’s in regimen after 
baseline 
Time updated 
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From table 3.4, patients are at an increased risk of a ‘disease progression event’ if they 
stop all antiretrovirals (IR 21.44, 95% CI 8.22-55.99, p<0.0001). The percentage of time a 
patient has spent on cART prior to baseline with a viral load < 500 copies/ml was also 
highly significant. The more time spent with a suppressed viral load the less likely the 
patients were to experience a ‘disease progression event’. Age may be a significant 
predictor of future disease progression with older patients being at a higher risk of disease 
progression. However, this difference was marginally significant p=0.08. No other factors 
were significant at the10% level, and thus only age, time with suppressed viral load whilst 
on cART, and stopping all ARV ’s were included in the multivariable model.  
 
Table 3.5 Cox proportional hazards model: Any disease progression (% time on cART included as a 
continuous variables). 
  Multivariable 
  Hazard 
Ratio 
95% CI p-value 
Age Per 10 yrs 
older 
0.83 0.67-1.03 0.08 
% time with RNA <500 whilst on cART 
prior to baseline 
Per 10% 0.84 0.77-0.92 0.0002 
Stopping all ARV’s after baseline No 1.00 - <.0001 
Yes 20.94 7.93-55.29 
 
Table 3.5 shows the results of the multivariable Cox proportional hazards model. After 
adjustment, stopping all antiretrovirals in the regimen after baseline increased the risk of 
disease progression (hazard ratio [HR] 20.94, 95% CI 7.93, 55.29, p<0.0001). In addition, 
there was a 16% reduction in the risk of disease progression per 10% increase in the 
proportion of time spent on cART with viral suppression < 500 copies/ml prior to baseline 
(HR 0.84; 95% CI 0.77, 0.92, p=0.0002). Age was also associated with a marginally 
significant 17% lower risk of disease progression per 10 years older (HR 0.83, 0.67-1.03, 
p=0.08). 
 
Age was also investigated as a categorical variable. The results of the univariable cox-
proportional hazards model are shown in figure 3.5. The marginal trend of an increased 
rate of disease progression with decreasing age appears to be roughly linear; therefore the 
continuous variable was used for the remainder of this analysis.  
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Figure 3.5 Univariable cox proportional hazards model age and rate of disease progression 
 
Similarly, results might be easier to interpret and apply to individual patients if the 
proportion of time with HIV-RNA < 500 copies/ml prior to baseline is categorized. This also 
helps to suggest whether there may be a useful cut-off value for the proportion of time 
suppressed, to which the risk of a disease progression event is significantly different from 
the next category of proportion of time suppressed.  
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Figure 3.6: Univariable analysis percentage of time with viral load <500 copies/ml whilst on 
cART prior to baseline (excluding the first four months after starting cART or making a 
treatment switch to allow for patients to re-suppress) 
 
From figure 3.6 it appears that patients who are suppressed more than 70% of the time 
they are on cART prior to baseline have a lower risk of disease progression in the 12 
months after maintaining a year of stable therapy. Table 3.6 gives the results of the 
multivariable analysis when % time suppressed is included in the model as a binary 
variable (suppressed more than 70% vs suppressed less than 70%). Patients were at 
almost 3 times the risk of disease progression within the next 12 months if they have spent 
less than 70% of their time on cART prior to baseline with a viral load <500copies/ml, (HR 
2.82, 95% CI 1.87-4.26, p<0.001). 
 
Table 3.6 Cox proportional hazard model: Any disease progression (% time on cart included as a 
categorical variable).  
  Multivariable 




Age Per 10 yrs older 0.82 0.66-1.01 0.06 
% time with RNA <500 whilst on 
cART prior to baseline 
≥70% 1.00 - - 
<70% 2.82 1.87-4.26 <.0001 
Stopping all ARV’s after baseline Time update from baseline 22.03 8.33-58.27 <.0001 
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Figure 3.7 shows the probability of disease progression in all patients compared to the 
subset of 1,972 patients who spent more than 70% of the follow-up on cART with 
suppressed viral load prior to baseline, of whom 57 (2.9%) patients experienced disease 
progression in the 12 months after baseline; 40 of the disease progression events were 
due to virologic rebound. The proportion of patients estimated to have experienced 
disease progression for any reason at 6 months was 1.5% (95%CI 0.9, 2.1) and 3.3% 
(95%CI 2.6, 4.4) after 12 months.  
 
Figure 3.7: Kaplan Meier risk of disease progression in 12 months after baseline 
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3.4.4 Sensitivity analysis 
 
Treatment switches were not included as a ‘disease progression event’ in the main 
analysis. This decision was made after discussion with clinicians; patients in the study 
population had been on their current regimen for at least 1 year, had responded well and 
had been able to tolerate it well. Most drug switches would presumably be due to 
convenience rather than toxicity or treatment failure, which would have been captured by 
viral rebound. However, identifying treatment switches due to treatment failure are 
important to detect viral failure as early as possible in patients who are seen regularly. It is 
possible that treatment switches may have been made before the confirmatory viral load 
measurement above 500copies/ml, and this information would not be captured as quickly if 
patients were seen less often. Thus the analysis was repeated with treatment switches 
due to insufficient virologic response (i.e. switched treatment with a single viral load > 
500copies/ml) included as a ‘disease progression event’.  
 
A total of 22 patients made a treatment switch in the 12 months following a year of stable 
therapy. However, this resulted on only 11 additional patients being classed as having a 
‘disease progression event’ as the other 11 had already experienced a different ‘disease 
progression event’. Thus, 142 patients were classed as failing due to any ‘disease 
progression event’ when treatment switches were included. The estimated probability of a 
treatment switch following viral rebound at 3, 6 and 12 months was 0%, 0.3% (95% CI 0.0, 
0.4) and 1.0% (95% CI 0.6, 1.4) respectively. The cumulative estimated probability of 
disease progression increased to 0.3% (95% CI 0.1, 0.5), 2.3% (95% CI 1.7, 2.9) and 
6.4% (95% CI 5.4, 7.4) at 3, 6 and 12 months respectively when this definition of treatment 
failure was added to the cumulative definition of disease progression. 
 
Analyses were also repeated with a stable cART regimen defined on the basis of all viral 
loads < 50 copies/ml. As not all patients have a viral load measured with a lower limit of 
detection (LOD) of 50 copies/ml or less, the sample size was substantially reduced in this 
analysis. 1053 patients had viral load measurements that were consistently measured at a 
LOD ≤50 copies/ml and thus were included in the analysis.  
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A total of 76 patients experienced at least one ‘disease progression event’ in the 12 
months following a year of stable therapy, of whom 64 patients failed due to 2 consecutive 
viral loads above 50 copies/ml. The cumulative estimated probability of disease 
progression was 0.5% (95% CI 0.1, 0.9), 2.5% (95% CI 1.5, 3.5) and 7.5% (95% CI 7.9, 
9.1) at 3, 6 and 12 months respectively. 
 
As there has been debate about when to start therapy, and many treatment guidelines 
now state that treatment should be initiated at CD4 counts around 350/mm3, the inclusion 
criteria were redefined to include only a subset of 1871 patients on a stable regimen with 
CD4 counts consistently 350/mm3 or above. Disease progression events based on CD4 
counts were defined as a CD4 count < 350/mm3; all other definitions of failure remained 
the same. The results were similar to the main analysis. In the 12 months following 
baseline 3 patients failed due to CD4 count falling below 350/mm3 and 102 patients 
experienced any ‘disease progression event’. The risk of the CD4 count falling below 
350/mm3 was 0, 0.1(95% CI 0, 0.2), and 0.2 (95% CI 0, 0.4) and of any ‘disease 
progression event’ was 0.3 (95% CI 0.1, 0.5), 1.9 (95% CI 1.3, 2.5) and 5.6 (95% CI 4.6, 
6.6) at 3, 6, and 12 months respectively.  
 
The results from the sensitivity analysis are summarised in table 3.7. For each of the three 
sensitivity analysis effect of the predictors on rate disease progression were similar. 
Although, the proportion of time on cART with a suppressed viral load was no longer 
significant when stable cART was defined as a maintaining a viral load <50 copies/ml. 
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Table 3.7 Summary of sensitivity analysis results 
Sensitivity analysis N included N events Multivariable cox proportional hazard model Hazard 
Ratio 





2237 142 Age Per 10 yrs older 0.83 0.68-1.03 0.08 
  % time with RNA <500 whilst 
on cART prior to baseline 
≥70% 1.00 - - 
  <70% 2.85 1.92-4.24 <.0001 
  Stopping all ARV’s after baseline 22.17 8.94-54.99 <.0001 
Stable cART 
defined as a viral 
load <50 copies/ml 
1053 76 Age Per 10 yrs older 1.09 0.97-1.23 0.16 
  % time with RNA <500 whilst 
on cART prior to baseline 
≥70% 1.00   
  <70% 1.35 0.90-2.01 0.14 
  Stopping all ARV’s after baseline 9.36 5.78-15.15 <.0001 
Stable regimen 
defined as CD4 
count >350 
cells/mm3 
1871 102 Age Per 10 yrs older 0.83 0.65-1.06 0.14 
  % time with RNA <500 whilst 
on cART prior to baseline 
≥70% 1.00 - - 
  <70% 2.90 1.80-4.69 <.0001 
  Stopping all ARV’s after baseline 12.85 4.61-35.78 <.0001 
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3.5 Discussion 
 
Patients in this study were found to have a low chance of disease progression, 
measured in a variety of different ways, occurring in the next 3-6 months. The most 
common reason for disease progression was viral rebound. Very few of the disease 
progression events observed were ‘serious’. The probability of developing an AIDS 
defining illness, non-AIDS defining illness, serious opportunistic infection or dying in the 
next 12 months was less than 1% among patients on a stable and fully suppressed 
cART regimen. The probability of the CD4 count dropping substantially to either below 
200/mm3 or below the CD4 at starting cART was also less than 1%. Our findings 
suggest that the interval between clinic visits in HIV-1 positive patients that have 
tolerated a fully effective cART regimen for extensive periods of time may be extended 
to 6 months.  
 
It was surprising that more variables were not significant in the univariable analysis. 
However, as all patients in the study population were required to be on a stable 
treatment regimen for at least a year, with a suppressed viral load (<500 copies/ml) and 
a CD4 count above 200/mm3, the reason for the lack of significant factors may be due 
to the initial selection criteria. A recent study analysed gender, age, level of education, 
marital status, mode of HIV acquisition, viral load, and CD4 cell count and found only 
gender and marital status to be significant predictors of treatment failure in patients who 
had already achieved suppression474. Another study looking at the risk of treatment 
failure after viral suppression for a year found that both gender and choice of regimen 
(PI vs NNRTI) were independent predictors of virological failure475. From the baseline 
characteristics (table 3.1) there did appear a lower proportion of males experiencing a 
disease progression event. Overall very few events were observed; repeating the 
analysis in a larger study population that is not predominately male, would increase the 
power and our ability detect if gender and other variables were significance predictors 
of a disease progression event. No treatment difference was found in our analysis, this 
again maybe due to our choice of patients.  
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Older age was found to lower the risk of experiencing a ‘disease progression event’, 
this is consistent with other studies that have reported that older patients are less likely 
to modify or discontinue cART476;477, more likely to be more adherent to treatment331 and 
have virologic success478.  
 
Patients who have spent less time with uncontrolled viremia whilst on cART were less 
likely to experience disease progression, and we identified that less than 70% of follow-
up time with virological suppression was associated with an increased risk of disease 
progression. A previous study, by Lapadula et al.479, considered disease progression in 
HIV positive patients with CD4 counts above 200 cells/mm3 and found that time with 
undetectable viremia was a significant predictor in clinical progression. The authors 
speculated that the length and extent of viral replication may induce immune 
dysfunction which is not completely captured by CD4 cell count or completely reversed 
by cART. 
 
The time a patient spends on cART with incomplete viral suppression could also be an 
indicator of a patient’s adherence to treatment480;481. A strong relationship has been 
found between virological suppression and different measures of adherence480;482;483. 
Several studies have been published reporting the optimal level of adherence 
necessary to maintain virologic suppression, with varying results, from greater than 
95% to 53%331;337;482;484;485. EuroSIDA has only recently begun collecting data on 
adherence and so this could not be studied directly in these analyses. However, all the 
patients had controlled viremia for over 1 year, and so must have been adherent to their 
regimen for some time. Previous studies have found a variety of reasons why patients 
may not be adherent to therapy. Common reasons are side effects, depression, 
relationship with physician or simply forgetting330. Different patient groups have also 
been shown to have different concerns about treatment and non-adherence341. Younger 
patients331, regimens with a high pill burden331 and patients with a history of intravenous 
drug use330 have been found in some studies to be less adherent. Studies have found 
that including the patient in treatment decisions and trying to tailor their care to suit the 
individual patient are beneficial in improving patient adherence330;341.  
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Treatment changes were not included as disease progression events in the main 
analysis. One of the inclusion criteria was to have been on a stable regimen for at least 
one year with no treatment changes.  
 
Most short-term treatment related toxicities emerge within 6 months of starting 
treatment such as hypersensitivity, CNS, dyslipideamia, and mitochondrial toxicity486;487. 
Therefore the included patients were those who were not only on stable therapy, but 
also tolerating the chosen therapy well. Thus, treatment discontinuations not captured 
by virological failure were most likely to be a change due to convenience or concern for 
long term toxicity, and can be made at the next clinic visit in 3 or 6 months time. There 
may always be a risk of unexpected toxicities arising between clinic visits and patients 
with concerns should of course continue to present themselves immediately for 
assessment at the clinic responsible for their care. 
 
Previous studies have investigated the required frequency of visits. A clinical trial 
investigated the risk of increasing the visit times in clinical trials associated with missing 
important laboratory related toxicities from every 8 weeks to every 16 or 24 weeks488. 
They concluded that study visits could not be safely increased without potentially 
harming the subject’s health. However, the study population was predominately patients 
with a low CD4 count (median CD4 count at entry was 41cells/mm3), who were not 
necessarily virologically suppressed and were on investigational drug regimens that 
require close monitoring. The authors speculated from their findings that it may be 
possible to safely increase the time between clinic visits in patients with a higher CD4 
count. They found that a higher CD4 count at entry was associated with fewer drug 
toxicities being missed as those subjects were healthier in general with fewer 
opportunistic infections and better able to tolerate the medications. Additionally, the 
effect of an increase in missed drug toxicities was found to be more dramatic in the 
case of protease inhibitors. Another study investigated the interval between viral load 
monitoring and found that frequent HIV RNA monitoring (every 2 months) resulted in 
better treatment management, measured by improvement in HIV viral load suppression, 
compared with infrequent monitoring (twice yearly)489. However, differences in CD4 
counts and overall survival were not statistically significant. This study included patients 
with low CD4 counts, high viral loads >5,000copies/ml and patients who had recently 
started treatment.  
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In contrast, our study focused on a very select patient population who would be 
expected, a priori, to have a low risk of disease progression and where the risks 
associated with less frequent clinical monitoring were much lower than those in 
previous studies.  
 
Extending the time between clinic visits for example to 6 months would benefit the 
patients in several ways. Patients would save time and, if working, would take less time 
off for appointments. There would be fewer reminders to patients of their illness; 
reinforcing the view that HIV-1 can be thought of as a chronic long term illness in some 
patients. Considerable resources in the out-patient clinic setting could be saved by a 
less frequent monitoring of the stable patients, which is warranted due to increasing 
numbers of HIV-positive patients in most settings, be it in the developed or the 
developing world2. This would also allow clinicians to allocate more resources to those 
patients at greatest risk of treatment failure and clinical disease progression.  
 
Finally, halving the number of tests performed each year for selected patients could 
substantially reduce costs for the monitoring of patients who are on stable therapy. For 
example, in EuroSIDA approximately 15% of the patients were maintaining a stable and 
fully suppressed cART regimen. Potentially, the cost of monitoring these patients would 
be cut by 50% each year, resulting in a substantial decrease in cost and resources that 
could be redistributed to patients in need of closer monitoring.  
 
The current recommendation of monitoring every 3 months311;450;451;453 is not necessarily 
to prevent clinical disease. Clinical diseases in this group of patients are now 
comparatively rare490. Rather, it is used to help identify virologic failure as early as 
possible after it first occurs to prevent the accumulation of drug resistance which limits 
future treatment options491. However, a recent study looking into cost effective 
monitoring strategies in developing countries found that the use of antiretroviral therapy 
without viral monitoring did not have marked detrimental effect on a patients 
development of resistance compared to CD4 count or clinical monitoring492. A 
consequence of increasing the time between clinic visits, is patients may spend longer 
with detectable viremia before it is identified, thus increasing the risk of developing 
resistance322. 
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The importance of patients presenting for care as soon as they develop any new 
symptoms or have worries about any aspect of treatment should continue to be 
emphasized to patients. Clinicians may also choose to see patients on a more regular 
basis to consider comorbidities, detect/monitor long term adverse events, discuss risk 
reduction behaviours to reduce onward transmission or to emphasize adherence452. 
These results highlight the need for the individualization of the clinical management of 
patients.  
 
There are a few limitations to this study which should be noted. We have no information 
on what is discussed between patient and clinician during each clinic visit, or the extent 
to which this is standardized across Europe. Part of the consultation might include 
counselling about adherence and minimizing the risk of transmission to others. The 
impact on adherence or risk of HIV transmission if patients were counselled at 6 
monthly or 12 monthly intervals cannot be estimated from this study. It is possible that 
less frequent monitoring will result in poorer adherence, in turn leading to a higher risk 
of treatment failure335;493. In addition, there may be other factors which benefit the 
patient from more regular clinic visits that are unknown and therefore cannot be 
accounted for. Additionally, as mentioned earlier there were very few events observed, 
repeating the analysis in a study with a bigger sample size would increase the power. 
Also, the EuroSIDA cohort predominately consists of white men, looking at the 
frequency of monitoring required in other patients groups would also be of benefit.  
 
To conclude, we have shown HIV-positive patients who are on a well-tolerated and fully 
suppressive cART regimen who have at least 12 months of complete viral suppression 
have a small risk of disease progression occurring over the next 6 months. Therefore in 
this subgroup of otherwise healthy patients it may be reasonable to consider increasing 
visit intervals from 3 months to 6 months. 
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3.6 After completion of analysis and publication results 
Current treatment guidelines published in January 2011494 recommend that, in patients 
with consistently suppressed viral loads whose CD4 cell count has increased well 
above the threshold for opportunistic infection risk, the CD4 count may be monitored 
every 6 to 12 months, unless there are changes in the patient’s clinical status. The 
recommendations also state that adherent patients with suppressed viral load and 
stable clinical and immunologic status for >2–3 years, the interval between HIV RNA 
monitoring may be extended to every 6 months. However, at this time the 
recommendation was only based on expert opinion. This analysis provides some direct 
evidence to support these recommendations. 
 
A manuscript of this analysis was published in AIDS in November 2008 and can be 
found in Appendix IV. 
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Chapter 4 History of viral suppression on cART as a 
predictor of virological failure after starting at least 
one new antiretroviral 
 
4.1 Introduction 
In the previous chapter considering the frequency of monitoring required for healthcare 
in an HIV-positive patient, the proportion of time a patient had spent with a suppressed 
viral load on cART prior to maintaining a stable and fully suppressed cART regimen 
was found to a strong predictor of the risk of future treatment failure. In addition, studies 
have found that increasing time with viral suppression decreases the risk of viral 
rebound495;496, and that with increasing numbers of episodes of viral failures, the goal of 
viral suppression becomes harder to achieve497. Figure 4.1 is from Benzie et. al and 
shows the relative rate of viral rebound per additional regimen failed, stratified by 
duration of viral load suppression. An increased rate of viral rebound was found per 
additional regimen failed, but this association was reduced the longer patients had 
maintained suppression. Patients who had remained virologically suppressed for less 
than 1 year had a 43% increased chance of viral rebound per extra regimen failed. This 
decreased to 23% in those who remain suppressed for 1–2 years. 
 
Figure 4.1 Relative rate of viral rebound (95% confidence interval), per additional antiretroviral 











Figure not available due to copyright restrictions 
  105 
The aim of cART is the suppression of viral load for as long as possible223;498. Results 
from observational studies show that over 70% of those initiating cART from 
antiretroviral naïve achieve complete virological suppression within 6 months499. 
However, a significant proportion of patients fail to achieve viral suppression in the first 
6 months of starting cART and many others go on to experience viral rebound 
sometime thereafter500. Many studies have looked into the risk factors and reasons for 
virological failure, either due to poor initial virological response to treatment or 
virological rebound. Table 4.1 summarises some of the factors these studies have 
identified. 
Table 4.1 Various factors that have been found to be associated with virological failure 
Factors investigated Studies that found an 
increased risk of poor 
virological response 
Studies that found an 
increased risk virological 
rebound 
Female  Geretti et al.
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In clinical practice, around 70-95% of patients starting cART achieve an undetectable 
viral load319;517;518, and this proportion has increased in recent years320;321;502;518. This 
increase is partly due to a high proportion of treatment failure in the early cART era 
being observed in patients who had previously been exposed to mono or dual 
therapy131;495, who had already developed resistance to nucleoside drugs prior to 
initiating cART519. Additionally, newer antiretrovirals that are less toxic, easier to 
tolerate, have less stringent dietary requirements and have less complex dosing 
regimen have resulted in better adherence from the patients520-523. Furthermore, some 
new antiretrovirals are available in the same class without cross resistance to other 
antiretrovirals in the class524;525. In a retrospective study of 542 antiretroviral naïve 
patients initiating therapy at the University of Alabama, two periods of antiretroviral 
initiation were identified, prior and after August 2004526. The median durability, defined 
as duration of initial regimen, of cART regimens introduced after August 2004 was 
found to be 263 days longer than those who started prior to 2004. Once daily regimens 
had the longest durability; 543 days longer than twice daily regimens. Regimens were 
primarily discontinued due to toxicity rather than virologic failure526. Another study by 
the Swiss HIV cohort found that the durability of initial regimens has not significantly 
improved over time518. They reported that 48.8% of 625 patients during 2000–2001, 
43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART 
within 1 year (p=0.15). However, they did observe improvements in virological (viral 
load <50copies/ml) and immunological (increases in CD4 counts) outcomes518. 
 
Despite these improvements viral replication is still not fully controlled in all patients at 
all times. The three main reasons for this are interlinked, including treatment limiting 
toxicities, poor adherence, and the development of resistance, which are all discussed 
in detail in Chapter 1 section 1.8.3 ‘Limitations of cART’. Different combinations of 
drugs have substantially different short and long term toxicities327, and in the current 
HIV-era most have been found to be moderate and can be well managed in outpatient 
clinics326. However, regardless of the severity of the adverse event experienced due to 
toxicities it may have an impact on adherence330. Patients who are more adherent to 
treatment are more likely to achieve sustained viral suppression331;332;352;512;513 and are 
less likely to show signs of disease progression331;333;336;337;527;528.  
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Poor adherence has been linked to an increased risk in the development of 
resistance330. However, certain regimens maybe more susceptible to development of 
resistance than others at differing levels of adherence481.  
 
Previous analyses have found that a patient is more likely to fail in the first few months 
after initial viral suppression472. Smith et al.529 found that the risk of viral rebound 1-2 
years, 2-3 years and >3 years after viral suppression was reduced by 70%, 79% and 
86% respectively compared to the first year of viral suppression. One possible 
explanation for this finding is a selection effect, in which patients who were more likely 
to experience virological rebound have been selected out as the time from initial 
response has increased472. Those that experience more or potentially serious toxicities, 
are less adherent, or have developed a greater degree of resistance may thus have a 
rebound in viral load more quickly. Additionally, treatment interruptions with detectable 
viral load increase the risk of rebound 511, as does pre-cART exposure to nucleoside 
reverse transcript inhibitor (NRTI) regimens495;530. These factors all affect a patient’s risk 
of treatment failure on a particular treatment regimen. With increasing numbers of 
episodes of viral failures the goal of viral suppression becomes harder to achieve497 as 
on-going viral replication while receiving cART generally promotes the emergence of 
drug resistance which in turn compromises treatment options531. Further, having failed 
multiple lines of therapy may be an indicator that a person is more likely to be 
chronically poorly adherent532.  
 
In the previous chapter, treatment failure was defined as either, virological (viral load 
>500 copies/ml), immunological (CD4 count <200 cells/mm3 or CD4 count < 100 
cell/mm3 CD4 count at starting cART), or clinical (the development of any AIDS defining 
illness, non-AIDS defining illness or death). However, the main reason for treatment 
failure was virological, with an estimated 4.6% (95% CI 3.7, 5.5) risk of virological 
failure after 12 months and less than a 1% probability of any of the other treatment 
failure defining events occurring in the 12 months after baseline.  
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It is important to understand what role prior virological suppression has on a patients’ 
risk of future virological failure after a treatment switch. As mentioned earlier, the main 
aim of cART is the suppression of viral load for as long as possible, but this is just a 
means of achieving the real goal, which is ultimately to reduce the risk of patients 
developing AIDS or non-AIDS events and dying prematurely. Numerous studies have 
demonstrated the link between uncontrolled viral replication and the development of 
AIDS, non-AIDS defining illnesses and death533-537. Additionally, patients successfully 
treated with cART, achieving and maintaining a suppressed viral load, have been found 
to have the lowest mortality rates, which although higher than the general population 
are comparable to patients with other chronic conditions13;538-542. Therefore, if we can 
identify markers that may be used to help reduce the risk of future virological failure we 
can hopefully indirectly reduce the risk of mortality in HIV-positive patients on cART.  
4.2 Aim 
The aim of this chapter was therefore to investigate whether a patient’s prior history of 
viral suppression on cART was predictive of future virological failure. In particular the 
aim was to investigate, in patients already on cART, whether after starting at least one 
new antiretroviral (ARV), for any reason, a patient’s risk of future virological failure was 
associated with their previous history of viral suppression and whether different patterns 
of virological suppression and rebound after cART initiation were associated with 
differing risks of future virological failure. This may help guide clinicians as to whether 
certain patients are at an increased risk of virological failure after a treatment change, 
and may require closer monitoring and adherence counselling.  
4.3 Methods 
4.3.1 Patient selection  
There were 16599 patients included in the D29 EuroSIDA update. Figure 4.2 shows 
how patients were selected for inclusion. All patients who were on cART and started 
any new ARV(s) > 1st January 2000, during prospective follow-up, were included in the 
analysis. As this analysis is looking at prior patterns of virological suppression on cART, 
baseline was defined as the date of starting new ARV(s). cART was defined in the 
same way as the analysis in chapter 3, a regimen containing at least 3 antiretrovirals of 
which at least 2 must be nucleosides or nucleotides and 1 must be either a protease 
inhibitor or a non-nucleoside reverse transcript inhibitor. The 1st January 2000 was 
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chosen to ensure that all patients were on a contemporary cART regimen. Starting new 
ARV(s) could be for any reason apart from dose modification or formulation change i.e. 
switching from taking 2 lopinavir/ritonavir tablets (400mg/100mg) twice daily to 4 tablets 
(800mg/200mg) once daily or switching from taking lamivudine and zidovudine as 
individual drugs to taking combivir would not count as starting new ARV(s) changes. 
Patients could start as little as one new antiretroviral e.g. from one NNRTI to another 
because of toxicity, up to changing their whole regimen, e.g. the NRTI backbone and an 
NNRTI could be replace with a new NRTI backbone and a ritonavir boosted PI.  
 
To ensure there was sufficient data to look backwards from baseline (time of starting 
new ARV(s)) at the patients history of viral suppression on cART up to the time starting 
new ARV(s), patients had to have been on cART for > 6 months prior to starting the 
new ARVs. Additionally, to allow for patients to have experienced virological failure after 
starting the new ARVs patients had to have at least 6 months follow-up and at least one 
viral load measurement after starting the new ARV(s). Furthermore, as we were 
interested in prior patterns of virological suppression, patients were required to have 
achieved viral suppression (viral load< 500 copies/ml) at least once after cART initiation 
and prior to starting new ARV(s). 2,721 patients started at least 1 new antiretroviral 
after 1/1/2000 and were included in the analysis. Patients starting new ARV(s) whilst 
virologically suppressed and those starting new ARV(s) whilst virologically failing were 
analysed separately. 1,827 patients were virally suppressed at the time of starting a 
new antiretroviral and 894 were virologically failing.  
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16599 patients in EuroSIDA D29 
11423 patients started cART 
6727 patients had both a CD4 count and viral 
load available within 6 months prior to starting 
cART  
3189 patients started ≥ 1 new ARV after 
1/1/2000 and had a CD4 count and viral load 
available 
2943 patients had at least 6 months follow-up 
and viral load measured after baseline  
2721 patients achieved suppression after cART 
initiation and prior to baseline 
1827 patients were suppressed at baseline 
(viral load < 500copies/ml) 
894 patients were not suppressed at baseline 
(viral load ≥ 500 copies/ml) 
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To help explain the inclusion criteria, figure 4.3 gives an example of a patient (Mr Blue) 
included in the analysis. Mr Blue started cART in 1997 with an unsuppressed viral load. 
Mr Blue achieved a suppressed viral load around 8 months after starting cART. In 1999 
he experienced two small viral rebounds before re-suppressing his viral load. He then 
experienced a third viral rebound in late 2000 and in early 2001 he started a completely 
new cART regimen. On this new cART regimen, Mr Blue quickly suppressed his viral 
load and it remained suppressed until spring 2004 when he experienced a viral 
rebound.  
 
Baseline for Mr Blue is January 2001 and he would be in the unsuppressed group. His 
history of viral suppression is the period from starting cART prior to baseline. The time 
to virological failure after baseline would be 3 years and 2 months.  
 








Start new ARV(s)  
Viral load 
97 98 99 00 01 02 03 04 05 
History of viral suppression Time to virological failure 
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4.3.2 Statistical analysis 
 
Virological failure was defined as a viral load measured >500 copies/ml at least 4 
months after baseline. Patient follow-up was measured from baseline to date of 
virological failure or date of last viral load measurement, whichever occurred first. 
Poisson regression analysis was used to investigate factors associated with virological 
failure after starting new ARVs. Potential explanatory variables included age, gender, 
year of starting cART, antiretroviral-naïve at starting cART, risk group, ethnicity, region 
of Europe, baseline CD4 count, CD4 nadir, peak viral load, previous AIDS diagnosis, 
time on cART, current treatment regimen, number of previous treatment regimens, time 
spent on cART prior to baseline, the number of antiretrovirals previously exposed to 
and the reason reported for stopping the previous antiretroviral in the regimen.  
 
In addition to the traditional explanatory variables investigated above, variables that 
summarised the history of viral suppression after cART initiation prior to baseline were 
investigated. The variables used to summarise the history of viral suppression after 
cART initiation were: 
1. Months to initial suppression (HIV-RNA ≤ 500 copies/ml) after starting cART 
2. Number of viral rebounds after initial suppression 
3. Size of the highest viral rebound  
4. Time since most recent viral rebound (for patients virologically suppressed at 
baseline) 
5. Viral rebound above viral load at first starting cART (yes versus no) 
6. Proportion of time spent with a viral load ≤ 500 copies/ml while receiving cART 
 
Viral suppression was defined as a single measurement of HIV-RNA ≤ 500 copies/ml. 
Viral rebound was defined as a single viral load > 500copies/ml measured after a period 
of suppression prior to the regimen change. Variable 3 was investigated as a numerical 
variable and categorically as either no-rebound, low (500-1,000 copies/ml), medium 
(1,000-1,0000copies/ml) and high (>10,000). Variable 6, the proportion of time on cART 
with a suppressed viral load, was defined in the same way as in the previous chapter, 
any period of time where the patient was off cART or the first four months after 
starting/restarting a new cART regimen were excluded (see figure 3.2). Thus only time 
when the patient was on cART and should have been suppressed were included. 
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Any variable that was significant at the 10% level in the univariable model was then 
included in a multivariable model.  
 
To explain why these variables were chosen figure 4.4 shows some of the different 
patterns of viral suppression that could be observed after cART initiation. Graph 1, for 
example, shows that after starting cART Mr Blue takes longer to suppress his viral load 
than Mr Red (variable 1). Graph 2 shows that Mr Blue experienced one viral rebound 
prior after starting cART, Mr Red experienced two viral rebounds (variable 2) and graph 
6 shows that Mr Blue spent a longer time after starting cART with a suppressed viral 
load than Mr Red (variable 6). Variables 1-6 were thought to best describe the most 
commonly occuring different patterns that could be observed.  
 
Figure 4.4: Summary of possible different patterns of viral suppression that could be observed in 
two fictional patients Mr Red and Mr Blue.  
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Sensitivity analysis considered confirmed virological failure after baseline (i.e. two 
consecutive viral load measurements above 500 copies/ml) and virological failure after 
baseline defined as a viral load above 50 copies/ml in the subgroup of patients who 
have viral load measurements, using an assay with a lower limit of detection of 50 
copies/ml. Additionally, the analyses were also repeated in a sub-group of patients who 
had resistance data available at baseline. In this sensitivity analysis, the multivariable 
Poisson regression models were additionally adjusted for the patients genotypic 
sensitivity score (GSS) at baseline. Data from the most recent resistance test available 
prior baseline was used and the GSS was calculated using the REGA algorithm, 
version 7.1344.  
4.4 Results 
4.4.1 Patient characteristics 
2,721 patients were included in the analysis, 1827 (67%) patients were virologically 
suppressed and 894 (33%) were virologically failing at the time of starting new ARV(s). 
Table 4.2 describes the characteristics of these patients at baseline. There were 
significant differences between these two groups of patients. A higher percentage of 
patients virologically suppressed at baseline were ARV naïve at starting cART, 878 
patients (48%) compared to 321 patients (36%) virologically failing, p<.0001. For those 
virologically suppressed at baseline, median CD4 count at baseline was 500cells/mm3 
(Inter-quartile range [IQR] 350-690) whereas those virologically failing had a lower 
median CD4 count 301cells/mm3 at baseline (IQR 201-444), p<.0001. 
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Table 4.2: Baseline characteristics, baseline was defined as the date of starting new ARV(s) after 1/1/2000 





  N % N % Chi squared 
Total  894 32.9 1827 67.1  
Gender  Male 639 71.5 1394 68.6 0.007 
Race White 132 14.8 246 13.5 0.36 
Exposure group Homosexual 317 41.5 841 46.0 0.006 
 IDU 208 23.3 315 17.2  
 Heterosexual 261 29.2 550 30.1  
 Other 54 6.0 121 6.6  
Region of Europe South/Argentina 309 34.6 433 23.7 <.0001 
 Central 252 28.2 438 24.0  
 North 243 27.2 739 40.5  
 East 90 10.1 217 11.9  
Hepatitis B Status HBV negative 758 84.8 1505 82.4 0.28 
 HBV positive 51 5.7 123 6.7  
 Unknown 85 9.5 199 10.9  
Hepatitis C Status HCV negative 556 62.2 1197 65.5 0.0008 
 HCV positive 237 26.5 373 20.4  
 Unknown 101 11.3 257 14.1  
Naïve  Yes 321 35.9 878 48.1 <.0001 
Previous AIDS  Yes 233 26.1 517 28.3 0.22 
  Median IQR Median IQR Kruskal wallis 
Age  years 40 36-47 42 37-50 <.0001 
CD4 per mm
3
 301 201-444 500 350-690 <.0001 
base VL log10copies/ml 4.22 3.48-4.92 1.69 1.60-1.69 <.0001 
cART CD4 per mm
3
 245 130-375 220 102-335 <.0001 
cART viral load log10copies/ml 4.43 3.56-5.06 4.54 3.60-5.20 0.07 
CD4 nadir  per mm
3
 150 60-240 142 54-238 0.17 
Peak viral load log10copies/ml 5.13 4.67-5.60 4.94 4.34-5.42 <.0001 
ARVs taken previously Number 6 4-8 5 4-7 <.0001 
Time since started cART years 4.5 3.2-5.9 4.4 2.5-6.2 0.22 
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Table 4.3 shows the reasons for starting new ARV(s) and the regimens patients were on 
after starting new ARV(s). The majority (56%) of patients virologically suppressed at 
baseline were on a NNRTI after starting new ARV(s), whereas the majority (51%) of 
patients who were virologically failing at baseline were on a boosted PI regimen after 
starting new ARV(s). The main reason reported for starting new ARV(s) was toxicity or 
patient/physician choice in those who were virologically suppressed at baseline. In those 
virologically failing at baseline, 1/3 reported the reason for starting new ARV(s) as 
treatment failure and 1/3 toxicity or patient/physician choice. Of those virologically 
suppressed at baseline, 932 (51%) started only 1 new ARV at baseline and 349(19%) 
started a completely new cART regimen (≥3 ARVs). Of those virologically failing at 
baseline the majority of patients started a completely new cART regimen (67%), 167 
patients (17%) virologically failing started only one new antiretroviral. The majority of 
additions without stopping any ARV(s) were due to patients adding ritonavir to a PI 
regimen.  
 
Table 4.3: Regimen change characteristics 





Total (N,%)  894 32.9 1827 67.1  
Baseline date  
(Median, IQR) 
Month/Year 02/05 01/04-12/05 12/03 04/02-10/05 <.0001 
Treatment started 
(N, %) 
NNRTI 311 34.8 1029 56.3 <.0001 
PI 130 14.5 214 11.7  
PI+ri 453 50.7 584 32.0  
Number of new 
antiretrovirals 
started (N, %) 
1 167 16.7 932 51.0 <.0001 
2 124 13.9 546 29.9  
3 453 50.7 295 16.1  
4 150 16.7 54 3.0  
Reason for starting 
new ARV(s) 
(N, %) 
TF 287 32.1 108 5.9 <.0001 
TOXPC 303 33.9 1089 59.6  
Other/unknown 304 34.0 630 34.5  
* TF- treatment failure, TOXPC-toxicity or patient/physician choice,  
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4.4.2 Incidence of virological failure after starting new ARV(s) 
according to viral suppression history after cART initiation 
prior to baseline 
 
After starting new ARV(s), 451(24.7%) patients virologically suppressed at baseline 
experienced virological failure, over median 3.0 years follow up, with an incidence rate 
[IR] of 7.3 per 100 person year of follow-up [PYFU] (95% confidence interval [CI] 6.7-
8.0). 543 (60.7%) patients virologically failing at baseline experienced virological failure, 
over a median 1.28 years follow-up, with an IR of 28.3 per 100 PYFU (95% CI 25.9-
30.7). Patients virologically suppressed at baseline had a 74% lower risk of virological 
failure after baseline compared to those virologically failing at baseline (unadjusted IRR 
0.26, 95% CI 0.23-0.29, p<.0001). 
 
Figure 4.5 Kaplan Meier risk of virological failure after baseline  
 
Figure 4.5 shows the Kaplan Meier risk of virological failure after baseline, patients 
virologically failing at baseline had a higher risk of virological failure after starting new 
ARV(s) (p<.0001). At 12 and 48 months respectively, those virologically failing had a 
48.4% (95%CI 45.1-51.7) and a 54.6% (95% CI 51.2-58.0) risk of virological failure after 
starting new ARV(s). Patients virologically suppressed at baseline had a 9.8% (95% CI 
8.74-11.2) and an 18.0% (95%CI 16.2-19.8) risk of virological failure, 12 and 48 months 
after starting new ARV(s).  
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4.4.3 Variables describing the prior history of virological suppression 
4.4.3.1 Months to initial suppression (HIV-RNA ≤ 500 copies/ml) after 
starting cART 
 
Those who were virologically suppressed at baseline had a median time to first 
suppression after cART initiation of 3.0 months (IQR 1.3-7.4). Patients who were 
virologically failing at baseline took slightly longer time to achieve suppression after first 
initiating cART, median 3.6 months (IQR 2.0 -10.1), p=0.001. Figure 4.6 shows the 
incidence rate of virological failure by time to first suppression. Patients who took longer 
to achieve initial suppression after cART initiation had an increased rate of virological 
failure after baseline, IRR 1.04 per 6 months longer to achieve suppression (95% CI 
0.99-1.09, p=0.14) in those suppressed at baseline and IRR 1.06 per 6 months longer to 
achieve suppression (95% CI 1.02-1.10, p=0.003) for those virologically failing at 
baseline. This increased rate was only significant in patients who were virologically 
failing at baseline. However the incidence rate ratios were similar for both groups.  
 
Figure 4.6: Incidence rate of virological failure and 95% confidence intervals for time to first 
suppression after cART initiation 
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4.4.3.2 Number of viral rebounds after initial suppression 
 
1,238 (67.8%) patients virologically suppressed at baseline had not experienced a viral 
rebound prior to baseline after initial suppression from cART initiation. 30 (3.4%) patients 
virologically failing at baseline experienced their first rebound at the time of starting new 
ARV(s). Figure 4.7 shows the rate of virological failure after baseline by the number of 
viral rebounds the patient had experienced prior to baseline. There was a 41% increased 
rate of virological failure after baseline for each viral rebound experienced prior to 
baseline (IRR 1.41, 95%CI 1.31-1.51) in those virologically suppressed at baseline. In 
those virologically failing at baseline there was a 6% increased rate of virological failure 
after baseline for each viral rebound experienced prior to baseline (IRR 1.06, 95%CI 
0.99-1.14, p=0.11).  
 
Figure 4.7 Incidence rate of virological failure and 95% confidence intervals by number of viral 
rebounds experienced prior to baseline  
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4.4.3.3 Size of the highest viral rebound  
 
Of those patients virologically suppressed at baseline who experienced a rebound, 206 
patients (35%) had experienced a high viral rebound (>10,000 copies/ml) a higher 
proportion, 434 (49%) of patients virologically failing at baseline had experienced a high 
viral rebound, p<.0001. In patients virologically suppressed at baseline those who had a 
low viral rebound (501-1,000 copies/ml) prior to baseline had a 30% lower rate of 
virological failure after baseline (IRR 0.70, 95% CI 0.49-1.01, p=0.06) and those who 
had a medium viral rebound (1,001-10,000 copies/ml) had a 18% lower rate (IRR 0.82, 
95%CI 0.60-1.10, p=0.19) compared to patients who had experienced a high viral 
rebound (>10,000 copies/ml) prior to baseline (Figure 4.8). The median maximum 
rebound in those virologically supressed at baseline who had experienced a prior 
rebound was 3,400 copies/ml (IQR 1,100-25,600), compared to 10,250 copies/ml (IQR 
2,301-51,000) in those virologically failing at baseline. Fitted continuously rather than 
categorically, patients suppressed at baseline had 21% higher rate of virological failure 
per log10 increase in size of highest rebound (95% CI 1.15-1.26, p<.0001). There was 
no significant difference in the size of the highest rebound patients virologically failing at 
baseline had experienced and the rate of future rebounds either fitted categorically 
(p=0.53) or continuously (p=0.70). 
Figure 4.8 Incidence rate of virological failure and 95% confidence intervals by size of highest 
rebound 
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4.4.3.4 Time since most recent viral rebound (for patients suppressed at 
baseline) 
 
Time since last rebound was not investigated as a predictor of virological failure after 
baseline in patients with virological failure at baseline, as by definition they were all 
failing at baseline. In those who were virologically suppressed at baseline, 137 (23.2%) 
patients had experienced a viral rebound in the year prior to baseline. In those who had 
experienced a rebound after cART initiation, the median time since last viral rebound 
was 2.3 years (IQR 1.1-4.0). There was a higher rate of virological failure in patients who 
had virally rebounded more recently before baseline (figure 4.9). For example, patients 
who had virally rebounded in the year prior to baseline had a 3.4 times higher rate of 
virological failure compared to patients who had never virally rebounded (IRR 3.37, 95% 
CI 2.59-4.39, p<.0001), whereas there was no significant difference in the rate of 
virological failure in patients whose last viral rebound was more than 3 years prior to 
baseline and those who had never rebounded (IRR 1.10, 95%CI 0.81-1.49, p=0.54).  
 
Figure 4.9 Incidence rate of virological failure and 95% confidence intervals by time prior to baseline 
since last viral rebound  
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4.4.3.5 Viral rebound above viral load at first starting cART (yes versus no) 
 
212 patients (11.6%) virologically suppressed and 353 patients (39.5%) virologically 
failing at baseline had experienced a viral rebound above their viral load at the time of 
starting cART. Figure 4.10 shows that patients virologically suppressed at baseline had 
almost double the rate of virological failure after baseline if they had experienced a 
rebound above their viral load at starting cART (IRR 1.91, 95% CI 1.51-2.42, p<.0001). 
However, restricting this analysis to only those who had rebounded prior to baseline this 
effect was no longer significant (IRR 1.18, 95%CI 0.90-1.56, p=0.23). There was no 
significant difference between those who had experienced a viral rebound above their 
viral load at starting cART and those who had not in patients who were virologically 
failing at baseline (IRR 0.89, 95%CI 0.75-1.06,p=0.21).  
 
Figure 4.10 Incidence rate of virological failure and 95% confidence intervals by whether or not the 
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4.4.3.6 Proportion of time spent with a viral load ≤ 500copies/ml while 
receiving cART 
 
Overall, virologically suppressed patients had spent a median of 98% (IQR 86%-100%) 
of time on cART suppressed (viral load <500 copies/ml) after cART initiation. Patients 
virologically failing at baseline had spent a lower percentage of time on cART 
suppressed (viral load <500 copies/ml) after cART initiation, median 58% (IQR 22%-
90%), p<.0001. There was a decreased risk of virological failure with increasing 
percentage of time a patient had spent with a suppressed viral load whilst on cART prior 
to baseline (figure 4.11). Of those suppressed at baseline, patients who were 
suppressed for <50% of the time they were on cART had almost a 3 times higher rate of 
virological failure compared to patients suppressed more than 90% of the time they were 
on cART (IRR 2.91, 95% CI 2.23-3.81, p<.0001). Similarly, in those who were 
virologically failing at baseline patients who were suppressed for <50% of the time they 
were on cART had almost a 2.5 times higher rate of virological failure compared to 
patients suppressed more than 90% of the time they were on cART (IRR 2.57, 95% CI 
2.07-3.25, p<.0001). 
Figure 4.11 Incidence rate of virological failure and 95% confidence interval by the percentage of 
time with a supressed viral load 
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4.4.4 Demographic predictors of virological failure after starting new 
ARV(s) 
 
In addition to the variables describing the patients' history of viral suppression prior to 
baseline, demographic variables found in analysis to be associated with rate of 
virological failure were also included in the analysis. Table 4.4 shows the results of the 
univariable analysis and multivariable Poisson regression analysis for patients 
virologically suppressed at baseline. Demographic variables associated with rate of 
virological failure after baseline in patients virologically suppressed were, gender, age, 
HIV exposure group, region of Europe, Hepatitis C status, being naïve at starting cART, 
having been diagnosed with AIDS previously, CD4 nadir, CD4 count at starting cART, 
time on cART prior to baseline, number of ARVS exposed to prior to baseline, date of 
baseline, treatment regimen on at baseline, the reason for starting new ARV(s) at 
baseline and the number of new drugs started.  
 
Similarly, table 4.5 shows the results of the univariable and multivariable Poisson 
regression analysis for patients who were virologically failing at baseline. Demographic 
variables associated with rate of virological failure after baseline in patients virologically 
failing were, region of Europe, Hepatitis C status, being naïve at starting cART, age, 
baseline CD4 count, viral load at starting cART, date of baseline, date of starting cART, 
number of ARVS exposed to prior to baseline, the reason for starting new ARV(s) at 
baseline and the number of new drugs started.  
 
These two multivariable models were used to find the best fitting model including the 
variables describing the patients history for virological suppression.  
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Table 4.4 Poisson regression analysis investigating demographic predictors of virological failure in 
patients virologically suppressed at baseline 
  Virologically suppressed 
  Univariable Multivariable 
  IRR 95% CI Global 
p-value 
IRR 95% CI p-value 
Gender Male 1.00  <.0001 1.00   
 Female 1.54 1.26-1.88  0.99 0.77-1.27 0.93 
Race White 1.00  0.36    
 Other 1.13 0.87-1.47     
Exposure 
group 
Homosexual 1.00  <.0001 1.00   
IDU 2.34 1.84-2.97  1.26 0.90-1.76 0.18 
Heterosexual 1.74 1.40-2.17  1.51 1.15-1.97 0.002 
Other 0.99 0.64-1.53  0.90 0.57-1.42 0.65 
Region South 1.00  <.0001 1.00   
 West 0.55 0.43-0.71  0.60 0.46-0.78 0.0001 
 North 0.40 0.32-0.51  0.52 0.41-0.66 <.0001 
 East 0.46 0.32-0.67  0.54 0.37-0.80 0.001 
Hepatitis B 
status 
Negative 1.00  0.85    
Positive 1.06 0.75-1.51     
unknown 0.94 0.70-1.26     
Hepatitis C 
status 
Negative 1.00  <.0001 1.00   
Positive 2.05 1.66-2.52  1.55 1.15-2.08 0.004 
Unknown 0.57 0.43-0.76  0.66 0.47-0.92 0.01 
Naïve at start 
cART 
No 1.00  0.0003 1.00   
Yes 0.71 0.58-0.85  1.02 0.81-1.29 0.84 
Prior AIDS 
diagnosis 
No 1.00  0.04 1.00   
Yes 0.80 0.64-0.98  0.90 0.72-1.14 0.38 
Regimen Single PI 1.00  0.002 1.00   
 Boosted PI 0.74 0.56-0.98  0.87 0.65-1.16 0.33 
 NNRTI 0.62 0.48-0.81  0.70 0.54-0.92 0.009 
Reason for 
stopping 
TF 1.00  0.002 1.00   
TOXPC 0.58 0.41-0.81  1.11 0.66-1.87 0.68 
Other/unknow 0.73 0.52-1.04  0.87 0.62-1.23 0.43 
Age per 10 years 0.76 0.69-0.84 <.0001 0.82 0.73-0.92 0.0005 
Base CD4  per 2 fold increase 1.02 0.91-1.14 0.75    
cART CD4 per 2 fold increase 1.09 1.04-1.15 0.0008    
CD4 nadir per 2 fold increase 1.15 1.08-1.23 <.0001 1.13 1.05-1.21 0.001 
cART viral load   per log10 increase 0.96 0.89-1.04 0.31    
Peak viral load   per log10 increase 0.94 0.85-1.04 0.25    
Baseline date           per year 0.90 0.85-0.95 0.0002 0.92 0.86-0.97 0.004 
Date started cART        per year 0.98 0.94-1.02 0.29    
Time on cART           per year 0.96 0.92-1.00 0.07 1.00 0.95-1.05 0.90 
Number new drugs started  per drug 1.10 0.99-1.22 0.07 1.03 0.92-1.14 0.65 
Number of drug exposed to per drug 1.10 1.06-1.14 <.0001 1.11 1.06-1.17 <.0001 
* IDU – intravenous drug user, TF- Treatment failure, TOXPC – toxicity or patient/physician 
choice 
 
  126 
Table 4.5 Poisson regression analysis investigating demographic predictors of virological failure in 
patients virologically failing at baseline 
  Virologically failing 
  Univariable Multivariable 
  IRR 95% CI Global 
p-value 
IRR 95% CI p-value 
Gender Male 1.00  0.40    
 Female 1.08 0.90-1.30     
Race White 1.00  0.66    
 Other 1.05 0.84-1.32     
Exposure 
group 
Homosexual 1.00  0.15    
IDU 1.28 1.04-1.58     
Heterosexual 0.98 0.80-1.21     
Other 1.15 0.79-1.69     
Region South 1.00  0.002 1.00   
 West 0.84 0.68-1.03  0.78 0.63-0.97 0.02 
 North 0.66 0.53-0.81  0.61 0.49-0.76 <.0001 
 East 0.88 0.64-1.20  1.07 0.76-1.51 0.69 
Hepatitis B 
status 
Negative 1.00  0.20    
Positive 1.01 0.70-1.46     
unknown 1.30 0.99-1.72     
Hepatitis C 
status 
Negative 1.00  0.01 1.00   
Positive 1.31 1.08-1.58  1.16 0.95-1.42 0.15 
Unknown 0.96 0.73-1.27  1.23 0.92-1.64 0.16 
Naïve at start 
cART 
No 1.00   1.00   
Yes 0.69 0.57-0.83 <.0001 0.81 0.64-1.02 0.06 
Prior AIDS 
diagnosis 
No 1.00  0.25    
Yes 1.12 0.93-1.35     
Regimen Single PI 1.00  0.38    
 Boosted PI 1.01 0.79-1.29     
 NNRTI 0.89 0.68-1.15     
Reason for 
stopping 
TF 1.00  0.24    
TOXPC 1.10 0.89-1.35     
Other/unknow 0.92 0.75-1.13     
Age per 10 years 0.87 0.79-0.96 0.004 0.86 0.78-0.95 0.003 
Base CD4  per 2 fold increase 0.91 0.85-0.97 0.003 0.94 0.89-1.00 0.06 
Base viral load   per log10 increase 1.02 0.93-1.12 0.63    
cART CD4 per 2 fold increase 0.98 0.93-1.02 0.28    
CD4 nadir per 2 fold increase 0.96 0.91-1.01 0.14    
cART viral load   per log10 increase 1.09 1.01-1.18 0.02 1.18 1.08-1.28 0.0001 
Peak viral load   per log10 increase 1.08 0.96-1.23 0.22    
Baseline date           per year 0.89 0.84-0.94 <.0001 0.91 0.85-0.96 0.001 
Date started cART        per year 0.95 0.91-0.99 0.03 1.03 0.98-1.08 0.27 
Time on cART           per year 0.97 0.93-1.01 0.11    
Number new drugs started  per drug 0.81 0.74-0.88 <.0001 0.86 0.79-0.94 0.0008 
Number of drug exposed to per drug 1.11 1.08-1.15 <.0001 1.12 1.08-1.16 <.0001 
* IDU – intravenous drug user, TF- Treatment failure, TOXPC – toxicity or patient/physician 
choice 
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4.4.5 Risk of virological failure after starting new ARV(s) in patients 
virologically suppressed when starting new ARV(s)  
 
The results of the univariable Poisson regression analysis investigating each variable 
describing the history of virological suppression as a predictor of future virological failure 
are shown in table 4.6. Each variable describing the history of virological suppression 
was then entered separately into the multivariable model, developed in section 4.4.4, 
that included all the demographic variables. The results of these models are shown in 
table 4.6.  
 
In each of the 6 models, after adjustment for demographic variables: gender, HIV 
exposure group, region of Europe, hepatitis C status, naïve, prior AIDS diagnosis, 
baseline treatment regimen, reason for starting new ARV(s), age, CD4 nadir, baseline 
date, time on cART, number of new antiretrovirals started, and number of antiretrovirals 
previously exposed to the variable describing history of virological suppression was 
significantly associated with the rate of future virological failure (table 4.6). 
 
These 6 variables describing the history of virological suppression were highly correlated 
with each other. Therefore, the best fitting model was selected using stepwise selection. 
This model contained variable 4: the time since last rebound, and variable 6: the 
percentage of time on cART with a suppressed viral load, in addition to the demographic 
variables already selected. The results of this model are shown in figure 4.12.   
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Table 4.6 Poisson regression analysis investigating history of virological suppression as a predictor of virological failure in patients  
virologically suppressed at baseline 
  Virologically suppressed 
  Univariable Multivariable* 
  IRR 95% CI Global 
p-value 
IRR 95% CI p-value 
1. Months to initial suppression Per 6 months 1.04 0.99-1.09 0.13 1.05 1.00-1.11 0.05 
2. Number of rebounds after initial suppression No rebound 1.00  <.0001 1.00   
1 1.67 1.34-2.10  1.62 1.27-2.06 <.0001 
2 2.48 1.85-3.34  2.52 1.82-3.49 <.0001 
≥3 3.37 2.47-4.59  3.16 2.21-4.53 <.0001 
3. Size of highest rebound >10000 1.00  <.0001 1.00   
1001-10000 0.82 0.60-1.10  0.70 0.52-0.96 0.02 
500-1000 0.70 0.49-1.01  0.65 0.44-0.94 0.02 
No rebound 0.41 0.32-0.52  0.39 0.30-0.53 <.0001 
4. Time since last rebound Never 1.00  <.0001 1.00   
≤1year 3.37 2.59-4.39  2.69 2.02-3.56 <.0001 
1-2 years 2.48 1.82-3.37  1.98 1.43-2.74 <.0001 
2-3 years 2.68 1.93-3.72  2.31 1.63-3.29 <.0001 
>3years 1.10 0.81-1.49  1.10 0.78-1.54 0.57 
5. Viral rebound above viral load at starting cART No 1.00  <.0001 1.00   
Yes 1.91 1.51-2.43  1.46 1.12-1.89 0.004 
6. Percentage of time with suppressed viral load ≥90 1.00  <.0001 1.00   
70-89 1.53 1.21-1.94  1.35 1.05-1.73 0.02 
50-69 2.85 2.06-3.94  2.35 1.66-3.28 <.0001 
<50 2.91 2.23-3.81  2.25 1.66-3.04 <.0001 
*Multivariable model also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, naïve, prior AIDS diagnosis, baseline 
treatment regimen, reason for starting new ARV(s), age, CD4 nadir, baseline date, time on cART, number of new antiretrovirals started, and number of 
antiretrovirals previously exposed to.
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Figure 4.12 shows the adjusted models describing risk of virological failure after starting 
new ARV(s) in patients who were virologically suppressed at baseline. There was no 
significant difference in the rate of virological failure in patients whose last viral rebound 
was more than 3 years prior to baseline (IRR 1.06, 0.75-1.50, p=0.74), whereas patients 
who had virally rebounded in the year prior to baseline had a 2.4 times higher rate of 
virological failure after baseline compared to patients who had never rebounded (IRR 
2.37, 95%CI 1.74-3.21, p<.0001). The lower the percentage of time a patient had spent 
suppressed prior to baseline, the higher the rate of virological failure. Patients who had 
spent less than 50% of the time they were on cART prior to baseline with a suppressed 
viral load had a 86% (95% CI 1.36-2.53, p<.0001) higher rate of virological failure after 
baseline compared to patients who were suppressed more than 90% of the time they 
were on cART. Additionally, older patients had a lower rate of virological failure (IRR 
0.84 per 10 years older, 95% CI 0.75-0.94, p=0.002). Patients with a higher CD4 nadir 
had an increased rate of virological failure (IRR 1.13 per 2 fold increase, 95%CI 1.05-
1.22, p=0.0008). Furthermore, the more antiretrovirals a patient had been exposed to 
prior to baseline the higher the rate of virological failure (IRR 1.06 per drug, 95%CI 1.01-
1.12, p=0.03). Patients on a boosted PI containing cART regimen had a 24% (IRR 0.76, 
95% CI 0.57-1.01, p=0.05) and patients on a NNRTI regimen had a 30% (IRR 0.70, 95% 
CI 0.54-0.91, p=0.008) lower rate of virological failure compared to patient on a non-
boosted PI regimen. Patients in north Europe had a 39% lower rate of virological failure 
compared to patients in the south Europe (IRR 0.61, 95%CI 0.417-0.78, p<.0001). After 
adjustment for these variables, none of the other variables describing the patients history 
of viral suppression and rebound prior to baseline were independently associated with 
the risk for future virologically failure after starting new ARV(s).  
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Figure 4.12 Univariable and multivariable Poisson regression models for patients virologically 
suppressed at baseline  
 
Multivariable model also adjusted for gender, HIV exposure group, region of Europe, hepatitis C 
status, naïve, prior AIDS diagnosis, baseline treatment regimen, reason for starting new ARV(s), age, 
CD4 nadir, baseline date, time on cART, number of new antiretrovirals started, and number of 
antiretrovirals previously exposed to. 
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4.4.6 Risk of virological failure after starting new ARV(s) in patients 
virologically failing when starting new ARV(s)  
 
Table 4.7 shows the results of the univariable and multivariable Poisson regression 
analysis for each variable describing the history of virological suppression, in patient who 
were virologically failing at baseline. Each variable describing the history of virological 
suppression was entered separately into the multivariable model, developed in section 
4.4.4, that included all the demographic variables.  
 
In patients virologically failing at baseline, similarly to those virologically suppressed at 
baseline, the lower the percentage of time spent with a suppressed viral load whilst on 
cART prior to baseline the higher the rate of future virological failure (figure 4.13). 
Compared to patients suppressed more than 90% of the time they are on cART, patients 
suppressed between 70-90% had a 1.37 times higher rate of virological failure (95%CI 
1.01-1.86, p=0.04). Those suppressed between 50-70% of the time had a 1.65 times 
higher rate of virological failure (95% CI 1.21-2.26, p=0.001) and those suppressed less 
than 50% of time they were on cART had almost double the rate of virological failure 
compared to those suppressed more than 90% of the time (IRR 1.91, 95%CI 1.46-2.49, 
p<0.0001). In addition, older patients had a lower risk of virological failure (IRR 0.87 per 
10 years older, 95%CI 0.79-0.96, p=0.007) as did patients with a higher viral load at 
starting cART (IRR 1.13 per log10 increase, 95%CI 1.04-1.23, p=0.003). Patients who 
had been exposed to more ARVs prior to baseline had a 9% increased rate of virological 
failure per additional ARV (95%CI 1.05-1.14, p<.0001). The more new drugs a patient 
stated at baseline the lower the rate of virological failure (IRR 0.88 per additional drug 
started, 95%CI 0.81-0.96, p=0.004). Patients from north Europe had a 33% lower rate of 
virological failure compared to patients in south Europe (IRR 0.67, 95%CI 0.54-0.84, 
p=0.0005). No other variables describing patterns of virological suppression after 
baseline were independently associated with risk of virological failure after adjustment 
(table 4.7).  
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Table 4.7 Poisson regression analysis investigating history of virological suppression as a predictor of virological failure in patients  
virologically failing at baseline 
*Multivarible analysis also adjusted for region of Europe, hepatitis C status, naïve, age, baseline CD4 count, viral load at starting cART, baseline date, 
date of starting cART, number of new antiretrovirals started at baseline, number of antiretrovirals previously exposed to. 
  Univariable Multivariable* 
  IRR 95% CI Global 
p-value 
IRR 95% CI p-value 
Months to initial suppression Per 6 months 1.06 1.02-1.10 0.002 1.02 0.97-1.07 0.37 
Number of rebounds after initial suppression No rebound 1.00  0.13 1.00   
1 1.09 0.67-1.78  1.08 0.65-1.79 0.76 
2 1.25 0.76-2.06  1.11 0.65-1.87 0.70 
≥3 1.30 0.78-2.17  1.07 0.62-1.85 0.80 
Size of highest rebound >10000 1.00  0.53 1.00   
1001-10000 1.12 0.94-1.34  1.16 0.96-1.39 0.12 
500-1000 0.99 0.74-1.33  1.08 0.80-1.46 0.69 
No rebound 0.89 0.55-1.46  0.98 0.59-1.64 0.95 
Viral rebound above viral load at starting cART No 1.00  0.20 1.00   
Yes 0.89 0.75-1.06  1.02 0.82-1.28 0.86 
Percentage of time with suppressed viral load ≥90 1.00  <.0001 1.00   
70-89 1.58 1.18-2.11  1.33 1.00-1.78 0.04 
50-69 1.89 1.40-2.54  1.65 1.22-2.25 0.001 
<50 2.57 2.03-3.26  1.90 1.47-2.44 <.0001 
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Figure 4.13: Univariable and multivariable Poisson regression models for patients virologically 
failing at baseline 
 
4.4.7 Sensitivity analysis 
A number of different sensitivity analyses were performed from varying the definition of 
virological failure to only including patients who were naïve at starting cART. Table 4.8 
summarises the number of patients included in each of the sensitivity analyses.  
Table 4.8 Summary of patients included in sensitivity analysis 
Sensitivity analysis Virologically 
suppressed at 
baseline 






Virological failure defined as 2 
consecutive viral loads >500 copies/ml 
Yes 1827 (100%) 278 (15%) 
No 894 (100%) 456 (51%) 
Lower limit of detection <50 copies/ml Yes 901 (49%) 369 (41%) 
No 389 (43%) 273 (70%) 
Restistance data available at baseline Yes 544 (29%) 135 (25%) 
 No 479 (53%) 291 (61%) 
Naïve at cART initiation Yes 878 (48%) 168 (19%) 
No 321 (36%) 156 (49%) 
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4.4.7.1 Virological failure defined as two consecutive viral loads >500 
copies/ml 
The analyses were repeated with virological failure defined as 2 consecutive viral loads 
measured >500 copies/ml. In patients suppressed at baseline, 278 (15%) experienced 
confirmed virological failure after baseline with an incidence rate of 4.2 per 100 PYFU 
(95% CI 3.7-4.7). 51% (456) of patients virologically failing at baseline experienced 
confirmed virological failure after baseline with an incidence rate of 20.5 per 100 PYFU 
(95% CI 18.6-22.4). The results of the multivariable model are shown in table 4.9 and 
were consistent with the main analysis.  
Table 4.9 Multivariable Poisson regression analysis where virological failure was defined as 2 viral 
loads >500 copies/ml 
  Virologically suppressed* Virologically failing
+
 




Never 1.00      
≤1year 3.11 1.84-5.25 <.0001    
1-2 years 1.61 0.98-2.65 0.05    
2-3 years 1.77 1.04-3.02 0.03    
>3years 1.08 0.65-1.79 0.77    
Percentage 
of time with 
suppressed 
viral load 
≥90 1.00   1.00 - - 
70-89 1.17 0.83-1.65 0.38 1.33 0.94-1.88 0.11 
50-69 2.12 1.34-3.34 0.001 1.82 1.28-2.60 0.0009 
<50 2.36 1.58-3.53 <.0001 2.47 1.84-3.32 <.0001 
* also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, naïve, prior 
AIDS diagnosis, baseline treatment regimen, reason for starting new ARV(s), age, CD4 nadir, 
baseline date, time on cART, number of new antiretrovirals started, and number of antiretrovirals 
previously exposed to and genotypic sensitivity score 
+
also adjusted for region of Europe, hepatitis C status, naïve, age, baseline CD4 count, viral load 
at starting cART, baseline date, date of starting cART, number of new antiretrovirals started at 
baseline, number of antiretrovirals previously exposed to, and genotypic sensitivity score. 
 
4.4.7.2 Sub-group analysis in patients with viral load measured at a lower 
limit of detection of 50 copies/ml 
 
The analyses were also repeated using a lower limit of detection for viral load of 
50copies/ml; 901 patients virally suppressed at baseline were included in this analysis 
and 41% of those experienced virological failure (defined as a viral load >50 copies/ml) 
with an incidence rate of 14.3 per 100 PYFU (95% CI 12.8-15.8). The results of the 
multivariable Poisson regression analysis are shown in table 4.10. Those who had virally 
rebounded in the year prior to baseline had 85% higher rate of virological failure 
compared to patients who had never virally rebounded, and patients suppressed <50% 
of the time they were on cART had a 13% higher rate of virological failure (95% CI 0.79-
1.64, p=0.50) compared to those suppressed more than 90% of the time, although this 
  135 
was not statistically significant after adjustment. 389 patients virologically failing at 
baseline had viral load measurements available using a lower limit of detection of 50 
copies/ml. Of these virologically failing patients 273 (70%) experienced virological failure 
after baseline with an incidence rate of 37.5 per 100 PYFU (95%CI 33.1-42.0). After 
adjustment, similarly to the main analysis, the lower the proportion of time a patient had 
spent virologically suppressed whilst on cART the higher the rate of future virological 
failure (table 4.10). 
 
Table 4.10 Multivariable Poisson regression analysis in patients with viral load measured at a lower 
limit of detection of 50 copies/ml 
  Virologically suppressed* Virologically failing
+
 







Never 1.00      
≤1year 1.85 1.33-2.57 0.0003    
1-2 years 1.37 1.00-1.88 0.04    
2-3 years 1.01 0.67-1.53 0.96    
>3years 0.60 0.40-0.91 0.01    
Percentage 
of time with 
suppressed 
viral load 
≥90 1.00   1.00 - - 
70-89 0.98 0.75-1.29 0.89 1.06 0.63-1.78 0.83 
50-69 1.11 0.78-1.57 0.56 1.59 0.97-2.59 0.06 
<50 1.13 0.79-1.64 0.50 2.15 1.38-3.32 0.0006 
* also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, naïve, prior 
AIDS diagnosis, baseline treatment regimen, reason for starting new ARV(s), age, CD4 nadir, 
baseline date, time on cART, number of new antiretrovirals started, and number of antiretrovirals 
previously exposed to and genotypic sensitivity score 
+
also adjusted for region of Europe, hepatitis C status, naïve, age, baseline CD4 count, viral load 
at starting cART, baseline date, date of starting cART, number of new antiretrovirals started at 
baseline, number of antiretrovirals previously exposed to, and genotypic sensitivity score. 
 
 
4.4.7.3 Sub-group analysis in patients with resistance data  
 
1023 (37.6%) patients had some resistance data available at baseline (544 patients 
(29%) virologically suppressed at baseline and 479 (53%) virologically failing at 
baseline). In those virologically suppressed at baseline the median time since the most 
recent resistance test was 4.00 years (IQR 2.23-5.76) and in those virologically failing at 
baseline the median time since last resistance test was more recent, only 0.75 years 
(IQR 0.12-2.98) prior to baseline.  
 
Of those virologically suppressed with data available, 405 (75%) had a GSS score ≥ 3 
for their baseline cART regimen. 135 (25%) patients virologically suppressed at baseline 
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experience virological failure. The results of the multivariable Poisson regression 
analysis are shown in table 4.8. Consistent with the main analysis, a higher rate of 
virological failure was associated with a lower percentage of time spent with a 
suppressed viral load. The trend for time since last rebound is less clear, probably due to 
lack of power. Further, there was no significant difference in rate of virological failure in 
patients with a GSS <3 compared to those with a GSS ≥ 3 (IRR 1.41, 95%CI 0.89-2.23, 
p=0.14) after adjustment for all demographic variables, percentage of time suppressed 
and time since last rebound.  
 
Similarly, in those virologically failing with some resistance data available, 356 (74.3) 
had a GSS score ≥ 3 for their baseline cART regimen. 291 (61%) patients experienced 
virological failure. The results of the multivariable Poisson regression analysis are shown 
in table 4.8 and are consistent with the main analysis. Additionally, there was no 
significant difference in the rate of virological failure in patients with a GSS <3 compared 
to those with a GSS ≥ 3 (IRR 0.96, 95%CI 0.72-1.27, p=0.75).  
 
Table 4.11 Multivariable Poisson regression analysis in patients with resistance data available 
  Virologically suppressed* Virologically failing
+
 




Time since last 
rebound 
Never 1.00      
≤1year 2.73 1.46-5.09 0.0016    
1-2 years 0.95 0.50-1.82 0.87    
2-3 years 3.60 1.99-6.51 <.0001    





≥90 1.00   1.00   
70-89 1.39 0.80-2.41 0.24 1.44 0.91-2.27 0.11 
50-69 1.39 0.69-2.83 0.35 1.88 1.18-3.00 0.008 
<50 2.17 1.23-3.83 0.007 1.84 1.21-2.80 0.004 
* also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, naïve, prior 
AIDS diagnosis, baseline treatment regimen, reason for starting new ARV(s), age, CD4 nadir, 
baseline date, time on cART, number of new antiretrovirals started, and number of antiretrovirals 
previously exposed to and genotypic sensitivity score 
+
also adjusted for region of Europe, hepatitis C status, naïve, age, baseline CD4 count, viral load 
at starting cART, baseline date, date of starting cART, number of new antiretrovirals started at 
baseline, number of antiretrovirals previously exposed to, and genotypic sensitivity score. 
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4.4.7.4 Sub-group analysis in patients antiretroviral naïve at starting cART 
 
1,199 patients were treatment naïve at starting cART. Of these patients 878 (73.3%) were 
virologically suppressed at the time of starting a new ARV(s) and 168 (19%) experienced 
virological failure after baseline. In adjusted analysis the time since last virological rebound 
remained a significant predictor of virological failure and an increased rate of virological 
failure was also observed with less time spent suppressed however the trend was not as 
clear in this group of patients. 321 (26.7%) patients naïve at starting cART were 
virologically failing at baseline of those 158 (49%) experienced virological failure. These 
results were consistent with the main analysis with patients suppressed less than 50% of 
the time having double the rate of virological failure compared to those suppressed > 90% 
of the time. 
 
Table 4.12 Multivariable Poisson regression analysis in patients with resistance data available 
  Virologically suppressed* Virologically failing
+
 




Time since last 
rebound 
Never 1.00      
≤1year 2.84 1.63-4.97 0.0002    
1-2 years 3.13 1.72-5.72 0.0002    
2-3 years 1.92 0.92-4.02 0.08    





≥90 1.00   1.00   
70-89 1.03 0.67-1.60 0.88 1.30 0.79-2.16 0.30 
50-69 2.46 1.30-4.64 0.0005 0.98 0.25-1.12 0.95 
<50 1.48 0.82-2.67 0.19 1.98 1.28-3.05 0.002 
* also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, naïve, prior 
AIDS diagnosis, baseline treatment regimen, reason for starting new ARV(s), age, CD4 nadir, 
baseline date, time on cART, number of new antiretrovirals started, and number of antiretrovirals 
previously exposed to and genotypic sensitivity score 
+
also adjusted for region of Europe, hepatitis C status, naïve, age, baseline CD4 count, viral load at 
starting cART, baseline date, date of starting cART, number of new antiretrovirals started at 
baseline, number of antiretrovirals previously exposed to, and genotypic sensitivity score. 
4.5 Discussion 
 
A patient’s history of viral suppression can provide important information about the risk of 
viral failure after a change in antiretrovirals. The variables describing the history of 
suppression after cART initiation, but before a change in regimen, were highly predictive in 
addition to the traditional baseline predictors in predicting future virological failure. The 
most important factor was the percentage of time spent with a suppressed viral load whilst 
on cART prior to starting a new ARV(s), both in patients virologically suppressed and 
those virologically failing at the time of starting new ARV(s). In addition, in patients who 
were virologically suppressed at baseline, time since last viral rebound prior to starting 
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new ARV(s) was also an important factor in predicting the risk for future virologically 
failure. After adjustment for these factors none of the other markers of previous patterns of 
suppression were significant predictors of virological failure after baseline.  
 
Table 4.13 Comparison of rates of virological rebound observed in different studies with varying 
inclusion criteria 
Study Patient inclusion Definition of viral 
rebound 
Viral rebound 
rate per 100 
PYFU (95% CI) 
This 
study 
All patients on cART who had achieved a viral 
load <500 copies/ml and starting new ARV(s) 







All patients on cART who achieved a viral load 
<50copies/ml 
two consecutive 







All patients on cART who achieved a viral load 
<50copies/ml 
Two consecutive 







All patients who started cART and achieved 
viral load < 400 copies/ml by week 24 
Two consecutive 







Patients achieving a viral load <50 copies/mL 
for the first time 
Two consecutive 







Patients who had failed ≥1 antiretroviral 
regimen in all three main drug classes and ≥3 
previous ARV regimens and subsequently 
achieved viral load < 50 copies/mL 
Two consecutive 




Table 4.13 summarises the rate of virological rebound observed in different studies with 
varying inclusion criteria. In the majority of the studies follow-up was from first suppressed 
viral load after initiating cART and therefore the rate of virological failure in these studies is 
lower than in ours495;496;508;511. Smith et. al529 reported the rate in highly treatment 
experienced patients and this was higher than the rate observed in our study. However, 
patients virologically suppressed at the time of starting new ARV(s) were analysed 
separately to those virologically failing as the risk of future virological failure in these two 
groups was quite different. Patients virologically suppressed at the time of the starting new 
ARV(s) had an incidence rate of virological failure of 7.3 per 100 PYFU, which is very 
close to the rate observed in those studies following patients from first viral suppression. 
Unsurprisingly patients virologically failing at baseline had a higher rate of virological 
failure of 28.3 per 100 PYFU.  
 
There was a clear relationship with increasing time suppressed prior to baseline, and 
decreasing risk of future virological failure. This variable only includes the time patients are 
recorded as receiving cART, therefore time spent with uncontrolled viraemia could be an 
indicator of poor adherence. In the previous chapter, patients who were on a stable and 
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fully suppressed cART regimen had an increased risk of a treatment failure event if they 
were suppressed less than 70% of the time they were on cART compared to those 
suppressed more that 70% of the time. The analysis in patients suppressed at the time of 
starting new ARV(s) is consistent with this. A study in patients with CD4 counts above 200 
cells/mm3 found that time with undetectable viraemia was a significant predictor in clinical 
progression479. In addition, previous studies have found that patients with a history of 
persistent low level viraemia (51-1000 copies/ml) were more likely to experience virological 
failure509, as were those with intermittent viraemia above 400copies/ml compared to those 
who sustained an undetectable viral load516. However, some studies have shown that 
although moderate viraemia and viral rebounds may increase your risk of future rebounds, 
this may not translate into an increased risk of clinical disease progression466;543. 
 
In those who were virologically suppressed at baseline, after adjustment, time since last 
viral rebound was highly predictive of virological failure after starting new ARVs, consistent 
with findings from other studies. For example, Benzie et al.496 reported that up to four 
years of sustained viral suppression was necessary in patients with previous treatment 
failures for them to achieve rebound rates similar to those with no prior treatment failures.  
 
As mentioned in the introduction to this chapter, the greatest risk of viral rebound has been 
shown to be in the first few months after initial suppression472, therefore it follows that 
increasing time since last virological rebound decreased the risk of virological failure after 
baseline. One potential explanation is that patients who were more likely to experience 
virological rebound have been selected out as the time from initial response has 
increased. 
 
In contrast to previous findings490, the association with virologic failure for size of each viral 
rebound prior to baseline was not significant after adjustment. The number of previous 
viral rebounds before baseline was important, and consistent with other studies544. 
However, after adjustment for the percentage of time a patient had spent suppressed and 
the time since last rebound, this variable added very little additional information. These 
analyses would suggest that a patient with 3 or more viral rebounds prior to baseline would 
have a very high rate of viral rebound. Palella et al. found that successive cART regimens 
were progressively less effective in suppressing viral load, and were generally shorter in 
duration545. In addition, treatment interruption strategies that have been used to combat 
the risk of long term drug toxicities and the cost of therapies, have been found to result in 
rapid viral rebound546. In the UK CHIC study, patients with undetectable viral load who had 
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previously interrupted ART had a raised risk of future viral rebound511;534 compared with 
those who had not interrupted. Our results highlight the need for patients to be placed on a 
suitable regimen when initiating cART, emphasising the importance of adherence, and that 
consideration should also be given to future treatment strategies in order to decrease the 
risk of future viral rebounds.  
 
In contrast to the previous chapter, where a subgroup of patients who had a low risk of 
disease progression in the next 12 months was identified, who could be monitored less 
frequently, these results may help identify patients who are at a higher risk of viral failure 
and may need to be monitored closely. 
 
The reason for starting new ARV(s) was defined using information recorded on EuroSIDA 
follow-up forms (see chapter 2 section 2.1.4 ‘Data Collection’ and Appendix I). If a patient 
has stopped an antiretroviral since their last follow-up visit, the date of stopping the 
antiretroviral is recorded. There is also a box for recording the reason for stopping. Only 
one reason is given per drug, and no information is collected on the reasons for starting 
new ARV(s). For this analysis, the reason for starting new ARV(s) was therefore defined 
as the reason recorded for stopping their most recent ARV either at, or prior to baseline.  
 
The reason for starting new ARV(s) was not a significant predictor of future virological 
failure in either multivariable models. The most likely reason is that starting  ARV(s) due to 
virological failure of the previous regimen was the most important factor, and the analyses 
were already stratified by this.  
 
Earlier EuroSIDA studies have found differences in virological response to cART across 
Europe320;424;547. However, improvements in response have been observed over time most 
notably in East Europe320;424. In this study, in both patients who were suppressed and 
those who were virologically failing at a baseline a significantly lower rate of virological 
failure was observed in North compared to South Europe. There was no significant 
difference between South Europe and the other regions.  
 
One limitation to this analysis, was the definition of virological suppression and failure. 
Defining virological failure is complicated. Viral load levels generally need to be between 
250-500copies/ml to detect the presence of antiretroviral drug resistantance mutations522. 
Additionally, there is random variation in the results of viral load assays548. Low level 
viraemia or blips often defined as a single viral load measured above 50copies/ml but 
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below 1000copies/ml is often an isolated event and has not been found to be associated 
with treatment failure or accumulation of drug resistance549. In all the main analyses in this 
thesis, viral load suppression is defined using a viral load cut-off of 500copies/ml and 
virological failure a viral load >500 copies/ml as this was the lower limit of detection for 
many of the assays used. Table 4.13 shows that across different studies several different 
definitions are used, making comparisons between studies harder to interpret. In current 
clinical practice a viral load less than 50 copies/ml is the aim of cART312;550. The sensitivity 
analysis performed on the subgroup of patients with assays consistently measured with a 
lower limit of detection ≤ 50 copies/ml and viral suppression defined as a viral load <50 
copies/ml showed consistent results with the main analysis.  
 
Another limitation is that in the main analysis the patients' resistance profile was not 
accounted for. As discussed in the chapter 1 (section 1.8.3.3) effective sustained cART is 
complicated by the prevalence or emergence of drug resistance. Patients may be infected 
with a drug-resistant virus or drug resistant mutation which may lead to lower sensitivity to 
antiretroviral agents and subsequent rebound in viral load342. On average, resistance 
mutations are seen in 50-60% of individuals with detectable viral load on antiretroviral 
therapy551. Resistance data were available in a minority of patients; however the majority 
of those with data available were predicted to be on a fully active regimen.  
 
The patient’s resistance profile at baseline was not independently associated with the risk 
of future virological failure, regardless of whether the patient was virologically suppressed 
at baseline or not. However, as some resistance tests were performed several years prior 
to baseline these patients could have acquired new mutations. This analysis may also be 
limited by power, or the variables that were significant in our main analysis captured 
information that was also measured by the availability of resistance data. As the patients 
resistance profile was not found to be associated with the risk of virological failure, with 
most patients on a fully active regimen it is reasonable to speculate that in the majority of 
cases poor adherence may be the reason for the rebound.  
  
The importance of good adherence is also discussed in more detail in chapter 1 (section 
1.8.3.2). In brief, without adequate adherence, antiretrovirals are not maintained at a 
sufficient concentration to suppress HIV replication in infected cells and to lower plasma 
viral load330. Patients have been found to take on average 70-75% of their prescribed 
medication336;337, and those who are more adherent to treatment are more likely to achieve 
sustained viral suppression331;332 and are less likely to show signs of disease 
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progression333. Studies looking into disease progression have found that even adherence 
of 50% significantly decreases a patients risk of progression to AIDS333;337. As mentioned 
in chapter 2 (section 2.1.4) EuroSIDA has only recently begun collecting data on 
adherence and the data are very limited. The data currently collected consist of two 
questions. The first is whether any comment has been made on adherence in the patient 
notes. If the answer to this is yes the second section records the date of comment and 
also the opportunity to tick whether adherence as poor/inadequate (defined as <70%), 
excellent/full (defined as >95%) or anything in between. The main limitation to this data is 
that we do not collect any information on how adherence was measured, and thus it is 
hard to know how accurate or reliable this data is. However, the portion of time a patient 
has spent with an undetectable viral load since starting cART could help serve as an 
indicator to a patient’s adherence, as the initial 4 months after starting or changing a cART 
regimen, when the viral load would not be expected to be undetectable, was excluded 
from analyses. Thus, patients who are suppressed for longer must be adherent to their 
therapy, and those with a poor history of viral suppression are those with poor adherence.  
 
To summarise, when considering future treatment and monitoring strategies after a patient 
has started a new ARV(s), the previous response to cART regimens may provide an 
indication of the risk of future virological failure. Patients making a change to their cART 
regimen while maintaining a suppressed viral load have an increased risk of virological 
failure if they have spent a low percentage of time on cART with suppressed viral load, or 
experienced a viral rebound close to the time of starting new ARV(s). Patients with a low 
percentage of time suppressed whilst on cART, and those who have recently rebounded 
may require more intensive monitoring after starting new ARV(s), and consideration should 
also be made to increasing adherence counselling. The history of patterns of viral 
response to cART regimens should be an integrated component in deciding monitoring 
strategies and adherence counseling for patients whenever a change in cART is made.  
 
A manuscript of this analysis was published in HIV Medicine in August 2010 and can be 
found in Appendix V.  
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Chapter 5 A comparison of the long term durability of 
nevirapine, efavirenz and lopinavir in routine clinical 
practice across Europe 
 
5.1  Introduction 
One of the findings of the analysis described in the previous chapter was that, in 
individuals on cART who made a treatment switch, those who had spent a low 
percentage of time on cART with a suppressed viral load and those who had 
experienced a viral rebound close to the time of the switch were at an increased risk of 
virological rebound after the treatment switch, compared to those whose viral load was 
previously mostly supressed. Virological and immunological outcomes to cART have 
improved in recent years321;518. In a recent Swiss study including patients enrolled 
between 2004-2005, virological failure was a reason for regimen change in only 7% of 
individuals compared to 51% changing due to tolerability issues518. Additionally, an 
Italian cohort reported that virological failure rates, defined as a viral load > 400 
copies/ml, had declined from 42% in 1997 to 11% in 2004 after 12 months of therapy552. 
In order to significantly reduce the risk of morbidity and mortality, cART regimens 
should show short-term virological potency as well as durability.  
5.1.1 Current treatment guidelines and common side effects of third 
drugs used in initial regimens 
 
In Europe, nevirapine, efavirenz and lopinavir are currently recommended for initial 
therapy of HIV-positive naïve patients in combination with two nucleosides214;223. BHIVA 
guidelines state that efavirenz should be considered as the first choice for all 
patients223. The most commonly observed adverse events associated with efavirenz are 
rash and central nervous system (CNS) symptoms553. CNS symptoms have been 
reported in 25%-70% of patients receiving efavirenz295;554-556. Symptoms include 
dizziness, abnormal dreaming, headache, difficulty sleeping, anxiety and confusion. 
These symptoms normally occur within the first few days of treatment and can lead to 
early discontinuation of efavirenz in a small proportion of patients556;557.  
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However, if therapy is continued the prevalence of these symptoms declines within a 
few weeks554;555;557. Efavirenz has a low genetic barrier to resistance, it has been 
reported that 6-8% of patients on efavirenz plus 2 NRTIs for 2-3 years develop 
resistance558.  
 
Nevirapine instead is mainly recommended for women trying to become pregnant and 
patients with mental health problems223. However, serious drug related toxicity has 
been associated with nevirapine300 especially at high CD4 counts in female patients559. 
The most common side effects of nevirapine are rash, hypersensitivity reactions, 
headache, nausea, Stevens-Johnson syndrome, hepatitis and liver problems and these 
are experienced in between 1 and 10 patients in 100560. Analyses of the EuroSIDA 
database have previously shown that treatment experienced patients starting 
nevirapine at high CD4 counts had a significantly lower risk of discontinuation due to 
toxicity or patient/physician choice than those who were ARV-naïve and had high CD4 
counts400, and other studies have supported the finding that in treatment experienced 
patients there is no increased risk of discontinuation due to hypersensitivity reaction in 
patients with high CD4 counts and undetectable viral loads401;561;562. 
 
Due to problems with accumulation of drug resistance in people not fully adherent to 
NNRTI-based therapies, a PI based regimen may be recommended as in initial choice 
of regimen in patients where adherence is thought to be a problem223. Lopinavir 
boosted with ritonavir is one of the most widely used PI combinations. The most 
common side effects with lopinavir/ritonavir are diarrhoea, and an increase in 
cholesterol and triglycerides. These are normally seen in 1 out of 10 patients563. 
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5.1.2 Comparison of virological outcomes between nevirapine, 
efavirenz and lopinavir 
 
Evidence from clinical trials suggests that efavirenz provides similar virological 
response to nevirapine in treatment naïve patients. For example the 2NN study found 
that, based on the proportion of patients with treatment failure (defined as less than a 1 
log10 decline in plasma HIV-1 RNA in the first 12 weeks or two consecutive 
measurements of more than 50 copies per mL from week 24 onwards), disease 
progression (defined as a new Centers for Disease Control and Prevention grade C 
event or death), or change of allocated treatment, nevirapine was comparable to 
efavirenz300. Additionally, the FIRST study564 found that in treatment naïve patients, 
starting either efavirenz or nevirapine based cART, there was no significant difference 
in the primary outcome, defined as a viral load ≤50 copies per ml after 8 months or 
death. Rates of CD4 cell count recovery, or clinical outcomes were also similar, 
although the risk of virological failure, and virological failure with resistance, to any class 
of antiretroviral was lower in those on efavirenz564.  
 
However, data from observational studies have observed some difference in virological 
outcome. EuroSIDA has previously investigated differences in viral load outcome 
between patients on efavirenz and those on nevirapine298. This analysis included 2,203 
patients enrolled up to cohort 4 who had started nevirapine or efavirenz based cART 
regimen, had not been exposed to any NNRTI previously and had CD4 count and viral 
load measurement available within the 6 months prior to starting cART. Virological 
failure was defined as the first of 2 consecutive viral loads >500 copies/ml 6 months 
after starting the regimen, and clinical outcome was measured in terms of new-AIDS or 
death. Only 6% of those starting nevirapine and 4% of those starting efavirenz were 
treatment naïve. Patients on efavirenz were found to have a 43% lower risk of 
virological failure compared to nevirapine (HR 0.57, 95%CI 0.47-0.69, p<.0001), and 
51% lower risk of clinical disease progression (HR 0.49, 95%CI 0.46-0.96, p=0.03) after 
adjustment for previous antiretroviral use, previous AIDS, year started NNRTI, CD4 cell 
count (baseline [treatment initiation], nadir), and viral load (baseline, maximum). A 
follow up to this analysis investigated genotypic resistance profiles and virological 
response of patients on nevirapine or efavirenz565.  
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After adjustment for the same factors listed previously and baseline drug resistance 
patients on efavirenz had a 50% lower hazard of virological failure compared to 
efavirenz (HR 0.50, 95% CI (0.39-0.65, P < 0.001). Results from other cohort studies 
have also reported superior virological response associated with efavirenz compared to 
nevirapine299;566-570. 
 
Another study, looking at pre-treated patients with a suppressed viral load (<200 
copies/ml), switching from a PI based regimen to efavirenz, nevirapine or abacavir 
found no difference in outcome, defined as death, development of AIDS or virological 
failure (viral load ≥200 copies/ml) between efavirenz and nevirapine after 12 months of 
follow-up571. After three years of follow-up, there was still no significant difference in the 
probability of virological failure between patients on nevirapine and efavirenz572.  
 
Efavirenz has been found to have a favourable outcome compared to some boosted 
and unboosted PI regimens or triple NRTI regimens in clinical trials295;573. The AIDS 
clinical trial study group (ACTGS) recently compared the virological efficacy of efavirenz 
to boosted lopinavir in ART naïve patients and found that virological failure was less 
likely to occur in the efavirenz group compared to the lopinavir group307. Additionally, 
several observational studies have reported a superior virological response in patients 
receiving efavirenz compared to those starting PI based regimens296;574. In particular, 
compared to a boosted lopinavir regimen, analyses of the data of cohort studies have 
shown that efavirenz has virological efficacy at least as high575 or superior to that of 
lopinavir576. Immunological outcome and clinical outcome has been reported to be 
similar296;574;575 between efavirenz and lopinavir, with one study favouring lopinavir when 
immunological outcome was compared over 48 weeks576.  
 
As mentioned in the previous chapter, one of the main goals of antiviral therapy is the 
maximal suppression of viral load for as long as possible223;498, and the virological 
potency of nevirapine, efavirenz and lopinavir is well documented. However, the 
ultimate goal of any HIV treatment is to prevent clinical progression and death. 
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5.1.3 Viral load as a Surrogate endpoint vs. Clinical endpoints 
 
In the beginning of the cART era, the advances in therapy were progressing faster than 
new results could be published577, and therefore since 1996 clinical trials with surrogate 
outcomes have predominately replaced clinical outcomes in trials of anti-HIV drugs. 
Only a small percentage of clinical events occur in the first 24-48 weeks of a study, 
particularly in antiretroviral naïve patients229, and therefore the use of a surrogate 
outcome was advocated.  
 
A surrogate outcome is an outcome that reliably predicts the effects of a drug on the 
clinical outcome578. Surrogacy requires that a valid test of the difference between the 
treatment groups based on the marker is also a valid test based on clinical endpoints579. 
A perfect surrogate should not only be a good predictor of clinical outcome but should 
also completely explain the treatment effect on clinical outcome580. They can allow for 
trials to run for a much shorter time and therefore reduce the cost and the time from 
initial development of a drug to government approval230.  
 
Both CD4 count and viral load have been shown to have independent prognostic values 
for the development of new AIDS or death in HIV-positive persons, in the natural history 
of HIV infection, and have been applied as surrogate markers in treatment trials226. 
Currently, clinical trials are typically powered to detect between regimen differences in 
short-term suppression of HIV-RNA rather than clinical outcomes225.   
 
However, there are problems with using surrogate outcomes as, by definition, they 
provide no direct information on the long term efficacy of cART230. For example, one 
problem with using HIV-RNA as a surrogate marker is that viral rebound can occur 
sometime after suppression, so with relatively short trial periods the benefits of the drug 
may be overestimated581.  
 
The SMART study provided good evidence of the need for long term studies with 
clinical endpoints317. Several small studies had indicated it might be possible to safely 
interrupt treatment for varying periods of time582;583.  
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The SMART study was set up to compare the use of episodic cART according to CD4 
count with the recommended practice of continuous therapy with respect of the risk of 
new disease (AIDS and non-AIDS related) or death317. Contrary to what was expected, 
rates of non-opportunistic disease and death mainly occurred when people were off 
ART and therefore were higher in the group using cART episodically. This study helped 
to illustrate that much remains to be understood about the detrimental effects of 
uncontrolled HIV replication and the benefits of ART584. The contrasting results from 
small short studies and the long term SMART trial highlight that there remains a need 
for adequately powered trials to look at the long term effects of cART based on clinical 
outcomes in addition to virological outcomes.  
 
Other studies have found that virological differences do not necessarily translate into 
clinical differences, thus questioning the role of surrogate markers. The Antiretroviral 
Cohort collaboration (ART-CC) found that in ART-naïve patients, differences found in 
short term virological failure between regimens did not necessarily translate into 
differences in clinical outcome570. The Community Programs for Clinical Research on 
AIDS (CPCRA) investigated the optimum sequencing of cART regimens to ensure long-
term benefit, and found that although there were differences in virological suppression 
rates these differences did not translate into a difference in AIDS defining events306. 
Similarly, a meta-analysis including 178 randomised clinical trials found that differences 
observed in CD4 count and HIV RNA between treatments did not result in meaningful 
differences in AIDS/death during relatively short time periods585. These studies show 
that there is a difference between looking at viral response of the first regimen initiated, 
and the success of a long term treatment strategy that includes the first treatment 
regimen.  
 
Long term trials provide vital information not only on the risk of clinical disease 
progression, but also to our fundamental understanding of the disease and how the 
drug works. The development of clinical adverse events other than AIDS defining 
illnesses, such as long-term toxicities, liver failure and heart disease cannot be 
captured in 24-48 week trials. Additionally, viral load has not been shown to be related 
to many non-AIDS events experienced by patients in the modern cART era18;586. These 
factors can only be investigated over long-term studies that monitor clinical outcomes. 
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They require the collaboration of a large number of investigators and are very time 
consuming. Further, many drugs are now available that differ in toxicity, adverse 
events, their ability to suppress viral replication, development of resistance and patient 
adherence587. These newer drugs will not have been included in the early studies 
looking at using CD4 count and viral load as surrogate markers. 
5.1.4 Assessing the long term durability 
Choosing an antiretroviral treatment regimen for patients therefore requires 
consideration of a number of factors in addition to virologic and immunologic potency, 
including comorbidities, likely adherence, convenience, adverse events and the 
potential for drug interactions with other treatment345.  
 
Adverse effects have been reported with all antiretrovirals and are one of the most 
common reasons for discontinuation of treatment16;588;589, even after the initial months of 
therapy 590. Mocroft et al. reported a high rate of discontinuation of cART in the first 12 
months due to toxicities, patient choice or poor compliance476. Some adverse events, 
such as gastrointestinal problems and hypersensitivity occur rapidly, within the first few 
months of starting treatment, while other adverse events, such as cardiovascular 
disease and pancreatitis, can take much longer to develop18;399;591;592. Such long-term 
adverse events can influence the durability of a regimen.  
 
Many cohort studies have compared the short-term and long-term efficacy of different 
cART regimens566;593-596, but less is known about the durability of different regimens, 
particularly in patients who have started a cART regimen more recently. If a regimen is 
virologically effective, durability can then be assessed as the time to discontinuation of 
the regimen, discontinuations due to toxicity or the rate at which potential markers of 
toxicity, such as increasing liver transaminases and cholesterol changes occur to 
assess the risk of future toxicities. 
 
As mentioned above, nevirapine, efavirenz, or lopinavir boosted with ritonavir together 
with two NRTIs are the recommended choices for first line cART regimens214;223. 
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Studies have previously investigated the virological efficacy and incidence of AIDS 
related events in patients on these three regimens, but less is known about the long 
term durability of each regimen, in particular the differences in the rate and reasons for 
treatment discontinuation and the risk of developing long term adverse event or non-
AIDS related diseases.  
 
5.2 Aim 
The aim of this chapter was to compare the long term durability of nevirapine based 
cART regimens with that of efavirenz and lopinavir-based cART regimens to provide 
additional information to help aid the choice of initial cART regimen. Long term 
durability was measured in terms of: 
1. Rate and time to discontinuation of either nevirapine, efavirenz or lopinavir and 
the reasons for discontinuation 
2. Incidence of severe liver-related events, pancreatitis, non-AIDS defining 
malignancies, end stage renal disease and MI/stroke 
3. Risk of deterioration in surrogate markers for clinical disease, such as risk of 
developing (or worsening of) anaemia, losing >10% of body weight, increase in 
total/HDL cholesterol ratio (>6.5), change in ALT or AST >2 times the upper limit 
of normal 
4. Incidence of all-cause mortality 
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5.3 Methods 
5.3.1 Patient selection 
There were 16,599 patients in the D30 update. Figure 5.1 shows how patients were 
selected for inclusion into this analysis. Patients starting nevirapine, efavirenz or 
lopinavir together with exactly 2 nucleosides or nucleotides after 1 January 2000, during 
prospective follow-up, were included in the analysis, as by this time, all three drugs 
were routinely available in Europe. Baseline was defined as either the date of first 
virological suppression (defined as a single viral load < 500 copies/ml), or 3 months 
after the date of starting treatment, whichever occurred later. As the focus was on long 
term durability, patients were only included once virologic suppression had been 
achieved, and after at least 3 months exposure to the drug to exclude discontinuations 
due to early-onset, potentially treatment limiting toxicities. Patients were excluded if 
they did not have a CD4 count or viral load measured in the 6 months prior to starting 
the new regimen or if they did not have any prospective follow-up. Treatment 
experienced patients were included provided they had not previously been exposed to 
any of the drugs of interest. 
 
Of the 6,634 potentially eligible patients, 1,600 started nevirapine (24%), 3,109 
efavirenz (47%) and 1,925 lopinavir (29%), based cART regimen after 1/1/2000. 1,279 
(19%) patients were excluded because of previous exposure to any of the three drugs, 
412 on nevirapine (26%), 379 on efavirenz (12%) and 488 on lopinavir (25%). 1,510 
(28%) patients were excluded because they had no CD4 count or viral load 
measurement prior to starting treatment, 337 (28%) on nevirapine, 806 (30%) on 
efavirenz, and 367 (26%) on lopinavir. 959 (25%) patients did not achieve suppression, 
had stopped treatment within the first three months or did not have sufficient follow-up 
and therefore were excluded, 248 (29%) on nevirapine, 459 (24%) on efavirenz, and 
252 (24%) on lopinavir. Therefore a total of 2886 patients were left to be included in the 
analysis, 603 (21%) patients were on a nevirapine based cART regimen, 1,465 (51%) 
on an efavirenz based regimen, and 818 (28%) on a lopinavir based cART regimen. 





16599 in EuroSIDA D30 
1600 patients started 
nevirapine 
3109 patients started 
efavirenz 
 1925 patients started 
lopinavir 
1188 on nevirapine had 
not been exposed to any 
of the three drugs 
previously  
851 on nevirapine had a 
CD4 count and viral load 
measured prior to staring 
treatment 
2730 on efavirenz had 
not been exposed to any 
of the three drugs 
previously  
 
1437 on lopinavir had not 
been exposed to any of 
the three drugs 
previously 
603 on nevirapine 
achieved suppression 
and did not discontinue 
treatment in the first three 
months 
1924 on efavirenz had a 
CD4 count and viral load 
measured prior to staring 
treatment 
 
1070 on lopinavir had a 
CD4 count and viral load 
measured prior to staring 
treatment 
 
1465 on efavirenz 
achieved suppression 
and did not discontinue 
treatment in the first three 
months 
818 on lopinavir  
achieved suppression 
and did not discontinue 
treatment in the first three 
months 
Figure 5.1 Patient selection 
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5.3.2  Statistical analysis 
Logistic regression was used to identify factors associated with starting nevirapine 
compared to efavirenz; patients starting lopinavir were excluded from this analysis. A 
similar analysis was used to identify factors associated with starting nevirapine 
compared to lopinavir, after excluding those taking efavirenz.  
 
Nevirapine was chosen as the comparator in this analysis as the original idea for this 
work came from a request for a safety report by Boehringer Ingelheim who were 
interested in comparing the long term durability of patients on nevirapine to those on 
efavirenz and lopinavir. 
 
The rate and time to discontinuation was investigated in a number of different ways: 
1. Time to discontinuation of the third drug (nevirapine, efavirenz, or lopinavir) in 
the regimen 
2. Time to discontinuation of any drug in the regimen 
 
The incidence of discontinuation of the third drug was calculated and the reasons for 
discontinuation were compared in those who stopped between the 3 regimens. Time to 
discontinuation was determined using Kaplan-Meier methodology. Patients were 
followed until discontinuation or their last recorded clinical visit in EuroSIDA. 
 
Consistent with previous EuroSIDA work400;589, in addition to discontinuation for any 
reason, analyses considered separately discontinuation due to toxicities and 
patient/physician choice, or because of treatment failure. Reasons given for 
discontinuation were taken from patients notes and reported on standardised EuroSIDA 
follow-up forms (see Appendix I). One reason for discontinuation per antiretroviral is 
collected (the main reason according to the treating physician). Discontinuation due to 
reported treatment failure included virological, immunological or clinical failure and it 
was not based on a predefined definition but at the clinician’s discretion as to whether 
they felt this was the reason for stopping treatment.  
 
Again two different methods were adopted when investigating discontinuations due to 
specific reasons 
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1. Follow-up for patients discontinuing for a reasons different to the one of interest 
was censored at the time of discontinuation 
2.  Follow-up for patients discontinuing for reasons different to the one of interest 
was censored administratively at the time of last follow-up visits (competing 
risks analysis). 
Cox proportional hazards models, stratified by centre to minimise biases due the 
different clinical experience in different centres, were used to compare the risk of 
discontinuation between the 3 regimens. Variables significant in univariable analysis 
(p< 0.1) were included in the multivariable model. Additionally a sub-group analysis 
investigated rates of discontinuations in treatment naïve patients separately.  
 
The rate of development of any serious non-AIDS clinical events, changes in clinical 
markers, or death was compared between the 3 treatment groups using Poisson 
regression. For each event variables were selected for inclusion into the multivariable 
anslysis if they were significant (p<0.1) in the univariable model. A non-AIDS clinical 
event was defined at the date of the development of a non-AIDS defining malignancy, 
pancreatitis, end stage renal disease, grade III or IV hepatic encephalopathy, 
myocardial infarction, stroke or other cardiovascular disease356;597. Changes in major 
clinical or laboratory markers were defined as; developing or worsening anaemia, losing 
>10% of body weight at baseline, increasing total cholesterol to >6.2mmol/l or 
decreasing HDL cholesterol to <0.9mmol/l, AST or ALT levels increasing to > 2 times 
the upper limit of normal (ULN). Anaemia was defined as a haemoglobin level ≤ 12 or 
≤14 (mg/dl) for females and males respectively598. Patients could either develop 
anaemia, or for those with anaemia at baseline, worsening anaemia was defined as a 
haemoglobin level ≤ 8 mg/dl598. For the liver function tests, 40IU/L was taken as ULN599.  
 
This analysis was an intent to treat analysis in that patients were followed from baseline 
until they experienced an event or the date of their last measurement for each clinical or 
laboratory marker in EuroSIDA, regardless of whether they were still receiving the initial 
third drug. It should be noted that not all patients in all groups had information on these 
markers available for all analyses; therefore the number of patients included in each 
analysis differed according to the availability of data. Patients with the event at baseline 
were excluded from analyses. For example individuals whose total cholesterol was 
>6.2mmol/l at baseline were excluded from that analysis.  
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5.4  Results 
5.4.1 Comparison of included versus excluded patients 
2886 (44%) patients who had started on nevirapine, efavirenz or lopinavir based cART 
were included in the analysis and 3748 (56%) were excluded. Table 5.1 compares the 
characteristics of the patients who were excluded to those who were included. Patients 
excluded had similar characteristics to those included, but were more likely to have 
previous cART exposure (64% versus 57%, p<.0001) and to have a prior AIDS 
diagnosis (32% versus 26%, p<.0001). A very low proportion of patients from East 
Europe were included; 214 patients, compared to 638 patients excluded (p<0.0001). 
The main reason for patients from East Europe being excluded was due to missing CD4 
counts and viral loads at starting treatment, 477 patients in East Europe had a missing 
CD4 count or viral load. These patients could have been included by modelling CD4 
count and viral load as categorical variables each with an unknown category. However, 
as the focus of this analysis was on long term durability, it was therefore important to 
have a viral load measurement available to know that the individual had initially 
responded to their regimen and was not discontinuing due to lack of initial virological 
response.  
Table 5.1 Characteristics of the patients included compared to those excluded from the analysis 






N (% of total) 2886 43.5 3748 56.6  
Gender (N,%) Male 2122 73.5 2590 69.1 <.0001 
Risk (N,%) Homosexual 1168 40.5 1236 33.0 <.0001 
 IDU 593 20.6 935 24.9  
 Heterosexual 931 22.3 1227 34.0  
 Other 194 6.7 300 8.0  
Region of Europe (N,%) South 934 32.4 1183 31.5  
West Central 483 16.7 815 31.6 <.0001 
North  712 24.7 680 18.1  
East Central 543 18.8 432 11.5  
East 214 7.4 638 17.0  
Race (N,%) White 2586 89.6 3250 86.7 0.0003 
Prior AIDS (N,%) Yes 754 26.1 1198 32.0 <.0001 
Hepatitis B status (N,%) Negative 2061 71.4 2354 62.8 <.0001 
Positive 139 4.8 193 5.2  
Hepatitis C status (N,%) Negative 1555 53.9 1641 43.8 <.0001 
Positive 588 20.4 854 22.8  
Nave (N,%) Yes 1036 35.9 1129 30.1 <.0001 
Age (median, IQR) 40 34-46 39 33-45 0.0004 
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5.4.2 Patient characteristics 
Table 5.2 compares the characteristics of the patients in each group at the time of 
starting their new regimen. A lower proportion of patients starting nevirapine were 
treatment naïve, 28% compared to 38% of patients starting efavirenz and 38% of 
patients starting lopinavir (p=<.0001). Patients on nevirapine had a higher median CD4 
count 359 cells/mm3 (IQR 230-583) and a lower viral load 2.70log10 copies/ml (IQR 
1.70-4.56) compared to those on efavirenz, median CD4 count 323cells/mm3 (IQR 190-
535) and viral load 3.59log10 copies/ml (IQR 1.70-4.95) and lopinavir, median CD4 
count 252cells/mm3 (IQR 131-439) and viral load 4.05log10 copies/ml (IQR 2.07-5.14) 
(p= <0001 for both). A high proportion of patients infected via IDU were on lopinavir, 
25% compared to 19% on efavirenz and nevirapine (p=0.004). Lopinavir was started, 
on average, more recently than the other two drugs: median date March 2004 
compared to October 2001 for nevirapine and October 2002 for efavirenz. The majority 
of patients in the three treatment groups were on a NRTI backbone of zidovudine (AZT) 
and lamivudine (3TC), 46%, 46% and 48% on nevirapine, efavirenz and lopinavir 
respectively. 24%, 18% and 14% respectively were on stavudine (D4T) and lamivudine, 
this was the second most common NRTI for those on nevirapine and efavirenz. For 
patients on lopinavir the second most common NRTI backbone was tenofovir with 1 
other NRTI. The median follow-up time was 2.6 years (IQR 1.1-4.8) when the endpoint 
of interest was discontinuation of the third drug for any reason.  
 
In multivariable logistic regression analysis comparing the odds of starting efavirenz to 
nevirapine, after adjustment for gender, region of Europe, CD4 count and viral load at 
stating regiment and date of starting regimen patients starting nevirapine were 33% 
more likely to be female and have a higher CD4 count at starting their regimen (table 
5.3). Further, patients from North Europe had lower odds of starting nevirapine 
compared to those from South Europe (OR 0.55, 95% CI 0.42-0.71, p<.0001). Similarly, 
after adjustment for HIV exposure group, race, region of Europe, hepatitis B and C 
status, CD4 count and viral load at stating regiment and date of starting regimen, 
compared to patients starting lopinavir, patients starting nevirapine had higher CD4 
counts (OR 1.44 per doubling, 95% CI 1.30-1.58, p<.0001), and compared to patients 
from South Europe patients had lower odds of starting nevirapine in West Central (OR 
0.66, 95% CI 0.46-0.94, p=0.02), North (OR 0.28, 95%CI 0.20-0.40, p<.0001), and East 
(OR 0.55, 95%CI 0.39-0.76, p=0.0004) Europe (table 5.3).  
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Table 5.2 Patient characteristics at time of starting regimen 
  Nevirapine Efavirenz Lopinavir P-value 
N (% of total)  603 20.8 1465 50.7 818 28.3%  
Gender (N,%) Male 423 70.2 1102 75.2 597 73.0 0.05 
HIV exposure 
group (N,%) 
Homosexual 241 40.0 596 40.7 331 40.5 0.004 
IDU 113 18.7 280 19.1 200 24.5  
Heterosexual 213 35.3 494 33.7 224 27.4  
Other 36 6.0 95 6.5 63 7.7  
Ethnic origin (N,%) White 550 91.2 1309 89.4 727 88.9 0.31 
Region of Europe 
(N,%) 
South/Argentina 255 42.3 501 34.2 178 21.8 <.0001 
West Central 128 21.2 228 15.6 127 15.5  
North 99 16.4 392 26.8 221 27.0  
East central  96 15.9 229 15.6 218 26.6  
East 25 4.1 115 7.8 74 9.0  
Prior AIDS (N,%) Yes 146 24.2 369 25.2 239 29.2 0.05 
Hepatitis B status 
(N,%) 
Negative 417 69.2 1047 71.5 597 73.0 0.01 
Positive 28 4.6 58 4.0 53 6.5  
Hepatitis C status 
(N,%) 
Negative 320 53.1 804 54.9 431 52.7 <.0001 
Positive 106 17.6 272 18.6 210 25.7  
Prior ARV 
treatment (N,%) 
Naive 166 27.5 561 38.3 309 37.8 <.0001 
ART 57 9.5 93 6.3 38 4.6  
cART 380 63.0 811 55.4 471 57.6  
NRTI backbone 
(N,%) 
AZT & 3TC 275 45.6 677 46.2 396 48.4 <.0001 
DDI & D4T 47 7.8 117 8.0 55 6.7  
D4T & 3TC 142 23.6 259 17.7 110 13.5  
tenofovir + 1 46 7.6 144 9.8 127 15.5  
abacavir + 1 47 7.8 147 10.0 59 7.2  
Other 46 7.6 121 8.3 71 8.7  
Age (median, IQR)  40 34-47 40 34-46 40 33-46 0.74 
CD4 count (median, IQR) cell/mm
3
 359 230-583 323 190-535 252 131-439 <.0001 
Nadir CD4 (median, IQR) cells/mm
3
 190 98-287 170 70-258 114 48-210 <.0001 
Viral load (median, IQR) log10 copies/ml) 2.70 1.70-4.56 3.59 1.70-4.95 4.05 2.07-5.14 <.0001 
Regimen start date (month/year) 10/01 9/06-10/03 10/02 4/01-10/04 03/04 7/02-3/06 <.0001 
Time to baseline*    ( days) 91 91-131 91 91-144 91 91-153 0.26 
*baseline was the date of first virological suppression or three months after starting treatment, whichever occurred later  
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Table 5.3 Multivariable logistic regression investigating the odds of starting nevirapine compared to either efavirenz or lopinavir  
  Odds of starting nevirapine 
compared to efavirenz 
Odds of starting nevirapine 
compared to lopinavir 
  Odds 
Ratio 
95% CI P-value Odds 
Ratio 
95% CI P-value 
Gender Male 1.00      
 Female 1.33 1.07-1.65 0.01    
HIV exposure group (N,%) Homosexual    1.00   
IDU    0.73 0.46-1.15 0.17 
Heterosexual    1.52 1.12-2.05 0.006 
Other    0.76 0.46-1.25 0.27 
Region South  1.00   1.00   
West Central 1.11 0.85-1.45 0.42 0.66 0.46-0.94 0.02 
North 0.55 0.42-0.71 <.0001 0.28 0.20-0.40 <.0001 
East 1.11 0.83-1.48 0.48 0.55 0.39-0.76 0.0004 
Hepatitis B status  Negative    1.00   
Positive    0.67 0.39-1.14 0.13 
Unknown    0.98 0.65-1.49 0.93 
Hepatitis B status  Negative    1.00   
Positive    0.77 0.49-1.19 0.23 
Unknown    1.44 0.86-2.42 0.17 
CD4 count at starting regimen Per doubling 1.14 1.04-1.25 0.006 1.44 1.30-1.58 <.0001 
Viral load at starting regimen Per log10 increase 0.96 0.89-1.03 0.23    
Calendar year of starting regimen Per year later 0.87 0.83-0.91 <.0001 0.67 0.63-0.71 <.0001 
Variables included in the mulitvariable models were significant (p<0.1) in univariable analysis 
  159 
5.4.3 Discontinuation of treatment  
5.4.3.1 All-cause discontinuation of third drug  
A total of 1,417 (49%) patients discontinued nevirapine, efavirenz or lopinavir whilst 
under follow-up. 299 (50%) discontinued nevirapine, 748 (51%) patients discontinued 
efavirenz and 370 (45%) patients discontinued lopinavir. Figure 5.2 shows the Kaplan 
Meier estimation of the probability of all-cause discontinuation of these regimens. By 24 
months after starting the regimen, 30.4% (95% CI 26.6-34.2) were estimated to have 
discontinued nevirapine, compared to 28.1% (95% CI 25.7-30.5) for efavirenz and 
31.7% (95% CI 28.4-35.2) for lopinavir. The corresponding figures at 48 months were 
47.2% (95%CI 42.9-51.5), 44.3% (95%CI 41.5-47.1), and 51.2% (95% CI 47.1-55.3) 
respectively (p=0.02). 
 
In a multivariable Cox proportional hazards model (table 5.4), stratified by centre, 
compared to patients starting nevirapine there was no significant difference in the risk of 
discontinuation of efavirenz (Hazard ratio [HR] 1.06, 95%CI 0.91-1.23, p=0.43) or 
lopinavir (HR 1.14, 95%CI 0.96-1.36, p=0.13). There was a higher risk of 
discontinuation in female patients (HR 1.17, 95%CI 1.03-1.33, p=0.01), those with a 
lower nadir CD4 count (HR 1.07 per doubling, 95%CI 1.03-1.10, p<0.0001) and higher 
viral load (HR 1.07 per log10 increase, 95% CI1.03-1.11, p=0.0006). Older patients had 
lower odds of discontinuation (HR 0.94, 95%CI 0.89-1.00, p=0.05). Patients on a 
backbone of DDI / D4T had 39% higher risk of discontinuation of the third drug 
compared to patients with a backbone of AZT and 3TC (HR 1.39, 95% CI 1.14-1.69, 
P=0.0001).  
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Figure 5.2 Kaplan Meier risk of discontinuation of the third drug for any reason 
 
*baseline was defined as either the date of first virological suppression (defined as a single viral 
load < 500 copies/ml), or from 3 months after starting treatment, whichever occurred last  
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Table 5.4 Cox proportional hazards model investigating risk of all cause discontinuation  of the 
third drug (both univariable and multivariable stratified by centre) 
 
  Univariable Multivariable 
  Hazard 
ratio 
95% CI p-value Hazard 
ratio 
95% CI p-value 
Regimen Nevirapine 1.00 - 0.13    
 Efavirenz 1.09 0.94-1.27  1.06 0.91-1.23 0.43 
 Lopinavir 1.19 1.00-1.41  1.14 0.96-1.36 0.13 
Gender Male 1.00 - 0.001 1.00   
 Female 1.23 1.09-1.39  1.17 1.03-1.33 0.01 
HIV exposure group Homosexual 1.00 - 0.23    
IDU 1.14 0.97-1.34     
Heterosexual 1.01 0.88-1.16     
Other 0.90 0.71-1.13     
Ethnic Origin  White 1.00 - 0.76    
Other 1.03 0.85-1.25     
Prior AIDS No 1.00 - 0.23    
 Yes 0.93 0.82-1.05     
Hepatitis B status Negative 1.00 - 0.82    
Positive 1.08 0.84-1.39     
Unknown 1.00 0.87-1.15     
Hepatitis C status Negative 1.00 - 0.09 1.00 - - 
Positive 1.18 1.01-1.67  1.15 0.99-1.34 0.07 
Unknown 0.91 0.77-1.09  0.90 0.75-1.07 0.23 
Prior ARV Naïve 1.00 - 0.41    
 Art 1.17 0.93-1.47     
 cART 1.04 0.90-1.20     
Age per 10 years 
older 
0.91 0.86-0.96 0.001 0.94 0.89-1.00 0.05 
CD4 count  per 2 fold higher 1.02 0.97-1.06 0.47    
Nadir CD4 per 2 fold higher 1.06 1.03-1.10 <.0001 1.07 1.03-1.10 0.0001 
Viral load  log10 copies/ml 1.09 1.05-1.13 <.0001 1.07 1.03-1.11 0.0006 
Max viral load log10 copies/ml 1.04 0.99-1.10 0.15    
Date started regimen per more recent 
year 
1.00 0.97-1.03 0.98    
NRTI backbone AZT & 3TC 1.00 - 0.01 1.00 - - 
DDI & D4T 1.38 1.13-1.68  1.39 1.14-1.69 0.0001 
D4T & 3TC 0.99 0.85-1.16  1.03 0.88-1.21 0.72 
Tenofovir + 1 1.08 0.89-1.32  1.06 0.86-1.29 0.59 
abacavir + 1 1.10 0.90-1.35  1.12 0.91-1.37 0.29 
Other 1.23 0.99-1.52  1.23 0.99-1.52 0.05 
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5.4.3.2 Discontinuation of the third drug due to treatment failure 
74 (12%) patients discontinuing nevirapine, 101 (7%) patients discontinuing efavirenz 
and 33 (4%) patients discontinuing lopinavir did so because of reported treatment 
failure (virological, immunological or clinical). 155 (75%) patients discontinuing due to 
reported treatment failure (i.e. on patient follow-up forms) had a viral load >500 
copies/ml measured in the 6 months prior to discontinuation when the viral load 
reported was assessed (62 [84%] nevirapine, 73 [72%] efavirenz, 20 [61%] lopinavir). 
Figure 5.3 shows the Kaplan Meier risk of discontinuation due to treatment failure. By 
24 months after starting the regimen, 8.6% (95% CI 6.1-11.1) were estimated to have 
discontinued nevirapine , compared to 4.9% (95% CI 3.65-6.15) for efavirenz and 3.0% 
(95% CI 1.6-4.4) for lopinavir and after 48 months after starting the regimen, 13.9% 
(95% CI 10.6-17.2) were estimated to have discontinued nevirapine, compared to 8.6% 
(95% CI 6.8-10.4) for efavirenz and 7.2% (95% CI 4.6-9.8) for lopinavir (p<0.0001). 
  
Figure 5.3 Kaplan Meier risk of discontinuation of the third drug due to treatment failure 
 
*baseline was defined as either the date of first virological suppression (defined as a single viral 
load < 500 copies/ml), or from 3 months after starting treatment, whichever occurred last  
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After adjustment for HIV exposure group, prior ARV treatment, viral load at starting 
regimen, date of starting regimen and NNRTI backbone, compared to patients starting 
nevirapine, patients starting efavirenz had a 48% lower risk of discontinuation due to 
treatment failure (HR 0.52, 95% CI 0.37-0.73, p=0.0002) and those starting lopinavir 
had a 63% lower risk of discontinuation due to treatment failure (HR 0.37, 95%CI 0.23-
0.61, p<.0001) (table 5.4).  
 
Furthermore, patients who had been exposed to cART previously had almost a 4-fold 
higher risk of discontinuation due to treatment failure (HR 3.83, 95% CI 2.28-6.45, 
p<.0001). A higher viral load at starting treatment was also associated with an 
increased risk of discontinuation due to treatment failure (HR 1.43 per log10 higher, 
95%CI 1.27-1.61, p<.0001). In addition starting on the regimen more recently was 
associated with a 15% lower rate of discontinuation due to treatment failure per 
additional year (HR 0.85, 95% CI 0.77-0.95, p=0.005). A higher risk of discontinuation 
due to treatment failure was found in those not on a NRTI backbone of AZT and 3TC.  
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Table 5.5 Cox proportional hazards models to investigate the risk of discontinuation of the third 
drug due to treatment failure (both univariable and multivariable stratified by centre) 
 
  Univariable Multivariable 








Regimen Nevirapine 1.00 - <.0001 1.00 - - 
 Efavirenz 0.56 0.40-0.78  0.52 0.37-0.73 0.0002 
 Lopinavir 0.41 0.26-0.64  0.37 0.23-0.61 <.0001 
Gender Male 1.00 - 0.74    
 Female 0.95 0.97-1.33     
HIV exposure 
group 
Homosexual 1.00 - 0.04 1.00 - - 
IDU 0.62 0.40-0.96  0.66 0.42-1.04 0.07 
Heterosexual 0.87 0.62-1.22  0.91 0.64-1.29 0.57 
Other 0.42 0.19-0.93  0.45 0.19-1.05 0.06 
Ethnic Origin White 1.00 - 0.73    
Other 0.91 0.51-1.61     
Prior AIDS No 1.00 - 0.41    
 Yes 1.14 0.83-1.57     
Hepatitis B 
status 
Negative 1.00 - 0.72    
Positive 1.04 0.54-2.01     
Unknown 0.86 0.69-1.25     
Hepatitis C 
status 
Negative 1.00 - 0.79    
Positive 0.90 0.91-1.34     
Unknown 0.99 0.62-1.59     
Prior ARV Naïve 1.00 - 0.0003 1.00 - - 
 ART 3.00 1.68-5.37  3.58 1.94-6.63 <.0001 
 cART 2.19 1.41-3.40  3.83 2.28-6.45 <.0001 
Age per 10 years 
older 
0.89 0.76-1.04 0.14    
CD4 count (per 2 fold higher) 1.03 0.92-1.15 0.65    
Nadir CD4 (per 2 fold higher) 1.02 0.95-1.11 0.54    
Viral load (log10 copies/ml) 1.16 1.05-1.28 0.003 1.43 1.27-1.61 <.0001 
Max viral load (log10 copies/ml) 1.01 0.88-1.16 0.91    
Date started regimen (per year) 0.83 0.75-0.91 <.0001 0.85 0.77-0.95 0.005 
NRTI 
backbone 
AZT & 3TC 1.00 - <.0001 1.00 - - 
DDI & D4T 3.37 2.14-5.29  2.26 1.41-3.65 0.0007 
D4T & 3TC 1.50 0.97-2.31  1.28 0.82-2.01 0.27 
Tenofovir + 1 1.56 0.91-2.66  1.91 1.05-3.47 0.03 
abacavir + 1 2.63 1.59-4.33  2.31 1.37-3.89 0.001 
Other 2.34 1.36-4.05  2.42 1.39-4.23 0.001 
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5.4.3.3 Discontinuation of third drug due to toxicity or patient/physician 
choice (TOXPC) 
139 (23%) patients discontinuing nevirapine, 436 (30%) patients discontinuing efavirenz 
and 247 (30%) patients discontinuing lopinavir did so due to reported toxicity or 
patient/physician choice. As shown in table 5.6, the most commonly recorded toxicity 
for discontinuing nevirapine (21%) was associated with the GI tract, liver or pancreas; 
this was also the case for lopinavir (22%). Only 7% of patients discontinued efavirenz 
due to toxicities associated with the GI tract, liver or pancreas, the most common 
reported toxicities for efavirenz were associated with the central nervous system (26%).  
 
Table 5.6 Toxicities reported as reason for discontinuing third drug 
Reported toxicity nevirapine efavirenz lopinavir 
 N(%) N(%) N(%) 
Total 139 (100%) 436 (100%) 247 (100%) 
Abnormal fat redistribution 7 (5%) 12 (3%) 25 (10%) 
Concern of cardiovascular disease 1 (1%) 6 (1%) 7 (3%) 
Dyslipidemia 4 (4%) 18 (4%) 26 (11%) 
Cardiovascular disease 0 (0%) 1 (0%) 0 (%) 
Hypersensitivity reaction 4 (3%) 2(0%) 0 (0%) 
Toxicity, from abdomen/GI tract 11 (8%) 12 (3%) 19 (8%) 
Toxicity - GI tract 2 (1%) 3 (1%) 30 (12%) 
Toxicity - Liver 15 (11%) 11 (3%) 3 (1%) 
Toxicity - Pancreas 1 (1%) 1 (0%) 2 (1%) 
Toxicity, from nervous system 2 (1%) 112 (26%) 4 (2%) 
Toxicity, from kidneys 0 (0%) 1 (0%) 2 (1%) 
Toxicity, from the endocrine system 2 (1%) 1 (0%) 1 (0%) 
Diabetes 0 (0%) 0 (0%) 0 (0%) 
Hematological toxicity 1 (1%) 1 (0%) 1 (0%) 
Hyperlactataemia/lactic acidosis 0 (0%) 3 (1%) 0 (0%) 
Toxicity, not specified above 7 (5%) 26 (6%) 11 (4%) 
Patient's wish/decision  48 (35%) 110 (25%) 62 (25%) 
Physician's decision 34 (24%) 116 (27%) 54 (22%) 
 
The risk of discontinuation due to TOXPC 24 months after starting the regimen was 
estimated to be 15.9% (95% CI 12.7-19.1) for patients discontinuing nevirapine, 
compared to 18.1% (95% CI 16.0-20.2) for efavirenz and 24.0% (95% CI 20.8-27.2) for 
lopinavir (figure 5.4). By 48 months after starting the regimen, 25.7% (95% CI 21.6-
29.8) were estimated to have discontinued nevirapine, compared to 28.1% (95% CI 
25.4-30.4) for efavirenz and 37.5% (95% CI 33.3-37.5) for lopinavir p<0.0001).  
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Figure 5.4 Kaplan Meier risk of discontinuation of the third drug due to TOXPC 
 
*baseline was defined as either the date of first virological suppression (defined as a single viral 
load < 500 copies/ml), or from 3 months after starting treatment, whichever occurred later  
 
After adjustment for gender, HIV exposure group, hepatitis C status, age, nadir Cd4 
count, and viral load at starting regimen patients on efavirenz had 31% higher risk (HR 
1.31, 95% CI 1.06-1.62, p=0.01) of discontinuation due to toxicities or patient/physician 
choice and patients on lopinavir had a 66% higher risk (HR 1.66, 1.31-2.10, p<.0001) of 
discontinuing due to toxicity or patient/physician choice, compared to those on 
nevirapine (Table 5.7). Additionally female patients had 22% higher risk of 
discontinuation due to TOXPC (HR 1.22, 95% CI 1.01-1.49, p=0.03) and higher nadir 
CD4 count was associated a higher risk of discontinuation (HR 1.08, 95%CI 1.04-1.13, 
p=0.0003).  
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Table 5.7 Cox proportional hazards models to investigate the risk of discontinuation of the third 
drug due to toxicity or patient choice (both univariable and multivariable stratified by centre) 
 
5.4.3.4 Discontinuation of any drug  
A secondary analysis investigated patients discontinuing any drug in the regimen 
(rather than nevirapine, efavirenz or lopinavir specifically). Where more than one of the 
drugs was discontinued, the first drug stopped was taken as the date of discontinuation. 
2,143 patients (75%) discontinued at least one of the three/four drugs in the initial 
regimens. After adjustment for gender, hepatitis C, age, nadir CD4 count, viral load at 
starting regimen and NNRTI backbone, there was no significant difference in risk of 
discontinuation for any reason for patients on efavirenz (HR 0.91 95% CI 0.81-1.03, 
  Univariable Multivariable 
  Hazard 
ratio 
95% CI p-value Hazard 
ratio 
95% CI p-value 
Regimen Nevirapine 1.00 - <.0001 1.00   
 Efavirenz 1.32 1.07-1.63  1.31 1.06-1.62 0.01 
 Lopinavir 1.67 1.33-2.10  1.66 1.31-2.10 <.0001 
Gender Male 1.00 - 0.02 1.00   




Homosexual 1.00 - 0.03 1.00   
IDU 1.30 1.06-1.60  1.22 0.81-1.39 0.66 
Heterosexual 0.97 0.91-1.17  1.06 0.70-1.07 0.18 
Other 0.97 0.72-1.31  0.87 0.67-1.25 0.58 
Ethnic 
Origin 
White 1.00 - 0.39    
Other 1.11 0.87-1.41     
Prior AIDS No 1.00 - 0.13    
 Yes 0.88 0.74-1.04     
Hepatitis B 
status 
Negative 1.00 - 0.57    
Positive 0.98 0.81-1.61     
Unknown 1.33 1.10-1.19     
Hepatitis 
C status 
Negative 1.00 - 0.01 1.00   
Positive 1.33 1.10-1.61  1.17 0.91-1.50 0.20 
Unknown 0.86 0.68-1.08  0.93 0.71-1.21 0.57 
Prior ARV Naïve 1.00 - 0.62    
 Art 1.02 0.74-1.41     
 cART 1.09 0.91-1.32     
Age (per 10 years) 0.93 0.86-1.00 0.05 0.96 0.89-1.04 0.32 
CD4 count (per 2 fold higher) 1.02 0.96-1.08 0.51    
Nadir CD4 (per 2 fold higher) 1.08 1.03-1.12 0.0008 1.08 1.04-1.13 0.0003 
Viral load (log10 copies/ml) 1.06 1.01-1.11 0.02 1.03 0.98-1.09 0.23 
Max viral load (log10 copies/ml) 1.07 0.99-1.15 0.08    
Date started regimen (per year) 1.02 0.98-1.07 0.27    
NRTI 
backbone 
AZT & 3TC 1.00 - 0.53    
DDI & D4T 1.25 0.96-1.63     
D4T & 3TC 1.05 0.86-1.28     
Tenofovir + 1 1.11 0.86-1.44     
abacavir + 1 1.01 0.77-1.33     
Other 1.21 0.91-1.61     
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p=0.15) or patients on lopinavir (HR 0.93, 95% CI 0.81-1.08, 0.35) compared to 
nevirapine (table 5.8). Of those patients who discontinued at least one drug in the 
regimen, 473 discontinued due to treatment failure; 74 (35%) on a nevirapine based 
regimen, 248 (20%) on efavirenz and 153 (23%) on lopinavir. After adjustment, there 
was a decreased risk of discontinuation due to treatment failure for patients on 
efavirenz (HR 0.49, 95%CI 0.35-0.69, p<.0001) and lopinavir (HR 0.40, 95% CI 0.25-
0.64, p<.0001) compared to patients on nevirapine. 1110 patients discontinued due to 
TOXPC, 98 (46%) on nevirapine, 663 (53%) on efavirenz and 349 (52%) on lopinavir. 
After adjustment, there was an increased rate of discontinuation due to TOXPC for 
patients on lopinavir (HR 1.36, 95% CI 1.13-1.64, p=0.001) compared to nevirapine. 
There was no significant difference between patients on nevirapine and efavirenz (HR 
1.12 95% CI 0.95-1.32, p=0.17).  
 
Table 5.8 Multivariable analysis for discontinuation of any drug 
Discontinuation due to  Regimen HR 95% CI P-value 
1
All cause  nevirapine 1.00 - - 
efavirenz 0.91 0.81-1.03 0.15 
lopinavir 0.93 0.81-1.08 0.35 
2
Treatment failure nevirapine 1.00 - - 
efavirenz 0.49 0.35-0.69 <.0001 
lopinavir 0.40 0.25-0.64 <.0001 
3
Toxicity or patient/physician nevirapine 1.00 - - 
efavirenz 1.12 0.95-1.32 0.17 
 lopinavir 1.36 1.13-1.64 0.001 
1 also adjusted for gender, hepatitis C status, age, CD4 nadir, viral load, and NRTI backbone.  
2 also adjusted for HIV exposure group, prior ARV treatment, viral load, date started regimen, 
and NRTI backbone.  
3 also adjusted for gender, HIV exposure group, hepatitis C status, age, CD4 nadir, and viral 
load. 
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5.4.3.5 Competing risks for discontinuation of  the third drug due to 
specific reasons  
 
Competing risks analysis showed results consistent with those of the main analysis 
(table 5.9). After adjustment, compared to patients starting nevirapine, patients starting 
efavirenz had a 46% lower risk of discontinuation due to treatment failure (HR 0.54, 
95% CI 0.39-0.76, p=0.0003) and those starting lopinavir had a 65% lower risk of 
discontinuation due to treatment failure (HR 0.35, 95%CI 0.22-0.56, p<.0001). 
Additionally, patients on efavirenz had 41% higher risk (HR 1.41, 95% CI 1.15-1.74, 
p=0.001) of discontinuation due to toxicities or patient/physician choice and patients on 
lopinavir had a 80% higher risk (HR 1.80, 1.43-2.27, p<.0001) of discontinuing due to 
toxicity or patient/physician choice, compared to those on nevirapine after adjustment 
(Table 5.9). 
 
Table 5.9 Multivariable competing risks analysis for discontinuation of the third drug 
Discontinuation due to  Regimen HR 95% CI P-value 
1
Treatment failure nevirapine 1.00 - - 
efavirenz 0.54 0.39-0.76 0.0003 
lopinavir 0.35 0.22-0.56 <.0001 
2
Toxicity or patient/physician nevirapine 1.00 - - 
efavirenz 1.41 1.15-1.74 0.001 
 lopinavir 1.80 1.43-2.27 <.0001 
1 also adjusted for HIV exposure group, prior ARV treatment, viral load, date started regimen, 
and NRTI backbone.  
2 also adjusted for gender, HIV exposure group, hepatitis C status, age, CD4 nadir, and viral 
load. 
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5.4.3.6 Subgroup analysis of discontinuation of the third drug in 
Antiretroviral Naïve patients  
 
1,036 patients were antiretroviral naïve at starting their regimen (166 [16%] on 
nevirapine, 561 [55%] on efavirenz and 309 [29%] on lopinavir). The test for interaction 
between treatment regimen and being naïve was significant for all-cause 
discontinuation of the third drug (p=0.0008). 412 patients discontinued either nevirapine 
(68, 41%), efavirenz (217, 39%) or lopinavir (127, 41%) for any reason whilst under 
follow-up. After adjustment for gender, age, nadir CD4 count, viral load at starting 
regimen and NNRTI backbone, patients on lopinavir had a marginally significantly 
higher rate of discontinuation for any reason (HR 1.39, 95%CI 0.96-2.01, p=0.07) than 
patients on nevirapine, there was no significant difference between patients on 
efavirenz and those on nevirapine (HR 0.92, 95%CI 0.67-1.28, p=0.62). Only 32 
antiretroviral naïve patients discontinued due to treatment failure; 13 (8%) on 
nevirapine, 16 (3%) on efavirenz and 3 (1%) on lopinavir, limiting the ability to do further 
analyses. A higher number of patients discontinued due to toxicity or patient choice vs. 
failure; 34 (20%) discontinued nevirapine, 118 (21%) efavirenz and 84 (27%) lopinavir. 
Patients on lopinavir had a significantly higher rate of discontinuation due to toxicity or 
patient choice compared to patients on nevirapine (HR 1.69, 95% CI 1.06-2.76, 
p=0.02), the magnitude of effect is similar to the main analysis. There was no significant 
difference between patients on efavirenz and those on nevirapine (HR 0.98, 95%CI 
0.64-1.48, p=0.91) after adjustment for nadir CD4 and hepatitis C status (table 5.10).  
 
Table 5.10 Multivariable subgroup analysis in naïve patients 
Discontinuation of third drug due to  Regimen HR 95% CI P-value 
1
All cause  nevirapine 1.00 - - 
efavirenz 0.92 0.67-1.28 0.62 
lopinavir 1.39 0.96-2.01 0.07 
2
Treatment failure nevirapine    
efavirenz    
lopinavir    
3
Toxicity or patient/physician nevirapine 1.00 - - 
efavirenz 0.98 0.64-1.48 0.91 
 lopinavir 1.69 1.06-2.76 0.02 
1 also adjusted for gender, hepatitis C status, age, CD4 nadir, viral load, and NRTI backbone.  
2 also adjusted for HIV exposure group, prior ARV treatment, viral load, date started regimen, 
and NRTI backbone.  
3 also adjusted for gender, HIV exposure group, hepatitis C status, age, CD4 nadir, and viral 
load. 
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5.4.4 Incidence of serious non-AIDS related clinical events  
 
Table 5.11 describes the number of serious non-AIDS related events developed after 
starting each regimen. Overall, there was a low rate of serious non-AIDS events. A total 
of 183 (6%) patients developed at least 1 non-AIDS related event whilst under follow-up; 
49 (8%) on nevirapine, 81 (6%) on efavirenz and 53 (7%) on lopinavir.  
 
Table 5.11 Number of patients experiencing a serious non-AIDS related event 
  Nevirapine Efavirenz Lopinavir 
Total person years of follow-up 3238.6 7086.2 3134.3 
Any clinical event (N,%) 49 (8.1) 81 (5.5) 53 (6.5) 
NADM (N,%) 18 (3.0) 26 (1.8) 16 (2.0) 
Liver related (N,%) 5 (0.8) 9 (0.6) 11 (1.3) 
Pancreatitis (N,%) 3 (0.5) 3 (0.2) 5 (0.6) 
End stage renal disease (N,%) 2 (0.3) 4 (0.3) 4 (0.5) 
Stroke (N,%) 7 (1.2) 9 (0.6) 5 (0.6) 
MI (N,%) 10 (1.7) 21 (1.4) 10 (1.2) 
Other CVD events (N,%) 10 (1.7) 20 (1.4) 6 (0.7) 
NADM=non AIDS-defining malignancies; MI=myocardial infarction 
CVD=cardiovascular disease 
 
Figure 5.5 shows the Kaplan Meier estimation of the probability of developing a serious 
non-AIDS event after baseline. The probability of developing a serious non-AIDS event 
was marginally lower on efavirenz than for the other 2 drugs (p=0.06). For example, by 
24 months after starting the regimen, 1.5% (95% CI 0.5-2.4) of patients treated with 
nevirapine were estimated to have developed a serious non-AIDS event, compared to 
1.0% (95% CI 0.5-1.5) for efavirenz and 1.4% (95% CI 0.6-2.2) for lopinavir. The 
corresponding figures at 48 months were 2.1% (95%CI 0.9-3.3), 1.7% (95%CI 1.1-2.3), 
and 2.5% (95% CI 1.4-3.6) respectively (log-rank p=0.06). 
 
Overall, the incidence of serious non-AIDS related events was 1.5 per 100 PYFU (95% 
CI 1.1-1.9) for patients on a nevirapine regimen. Patients on efavirenz had a lower 
incidence of non-AIDS related events of 1.1 per 100 PYFU (95% CI 0.9-1.4), and on 
lopinavir had a higher incidence of 1.7 per 100 PYFU (95% CI 1.2-2.2). However, these 
differences were not significant, p=0.12 and p=0.57 respectively. 
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Figure 5.5 Kaplan Meier risk of developing a serious non-AIDS event 
 
*baseline was defined as either the date of first virological suppression (defined as a single viral 
load < 500 copies/ml), or from 3 months after starting treatment, whichever occurred last 
 
The results of the Poisson regression analysis are given in table 5.12. After adjustment 
for the factors shown in table 5.12, patient who had started an efavirenz based regimen 
had a non-significant lower incidence of non-AIDS related events compared to those 
who started a nevirapine regimen (IRR 0.75, 95% CI 0.51-1.09, p=0.13). There was no 
significant difference between who had started a lopinavir based regimen and those who 
started nevirapine (IRR 1.10, 95% CI 0.71-1.69, p=0.66). Female patients had a lower 
incidence of non-AIDS related events (IRR 0.51, 95%CI 0.32-0.83, p=0.007). Older 
patients (IRR 2.17 per 10 years older, 95%CI 1.84-2.56 p<.0001), those testing hepatitis 
C positive (IRR 2.21 vs. negative, 95%CI 1.31-3.75, p=0.003) and patients from north 
Europe compared to south Europe (IRR 1.92, 95%CI 1.26-2.91, p=0.002) had an 
increased incidence of non-AIDS related events.  
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Table 5.12 Poisson regression analysis: Risk of developing a non-AIDS clinical event 
  Univariable Multivarible 
  IRR 95% CI P value IRR 95% CI P value 
Treatment Nevirapine 1.00 - 0.06 1.00 - - 
 Efavirenz 0.76 0.53-1.08  0.75 0.52-1.09 0.13 
 Lopinavir 1.18 0.76-1.65  1.10 0.72-1.69 0.66 
Gender Male 1.00 -  1.00 - - 
 Female 0.39 0.25-0.61 <.0001 0.51 0.32-0.83 0.007 
Ethnic origin White 1.00 -  1.00 - - 
Other 0.50 0.27-0.92 0.02 0.63 0.33-1.19 0.15 
Exposure 
Group 
Homosexual 1.00 - 0.001 1.00 - - 
IDU 1.12 0.78-1.60  1.50 0.86-2.59 0.15 
Heterosexual 0.51 0.34-0.76  0.90 0.58-1.39 0.62 
Other 1.29 0.77-2.14  1.29 0.75-2.22 0.35 
Region of 
Europe 
South 1.00 - 0.0002 1.00 - - 
West Central 1.35 0.89-2.05  1.50 0.94-2.39 0.09 
North 1.76 0.23-2.51  1.92 1.26-2.91 0.002 
East Central 0.71 0.42-1.20  1.22 0.69-2.15 0.49 
East  0.38 0.09-1.56  1.13 0.26-4.87 0.87 
Hepatitis B Negative 1.00 - 0.43    
Positive 1.45 0.82-2.57     
Unknown 0.96 0.68-1.35     
Hepatitis C Negative 1.00 - 0.01 1.00 - - 
Positive 1.70 1.19-2.42  2.21 1.31-3.75 0.003 
Unknown 0.74 0.50-1.09  0.68 0.40-1.16 0.15 
Prior AIDS No 1.00 - 0.08 1.00   
 Yes 1.31 0.96-1.78  1.12 0.80-1.56 0.52 
Prior 
treatment 
Naïve 1.00 - <.0001 1.00 - - 
ARV 2.29 1.23-4.27  1.67 0.84-3.33 0.14 
cART 2.31 1.55-3.46  1.05 0.64-1.72 0.85 
Anaemia No 1.00 - 0.006 1.00 - - 
 Yes 1.50 1.02-2.21  1.14 0.76-1.70 0.52 
Diabetes No 1.00 - 0.09 1.00 - - 
 Yes 1.78 0.94-3.37  0.90 0.46-1.75 0.75 
Hypertension No 1.00 - <.0001 1.00 - - 
 Yes 2.19 1.47-3.25  1.22 0.80-1.49 0.34 
Smoking 
status 
No 1.00 - 0.03 1.00 - - 
Yes 1.94 1.08-3.46  1.63 0.89-2.98 0.11 
Previous 1.21 0.60-2.46  0.88 0.43-1.82 0.74 
Age per 10 years 2.01 1.77-2.29 <.0001 2.17 1.84-2.56 <.0001 
CD4 count (per 2 fold increase) 0.98 0.88-1.09 0.72    
Nadir CD4 (per 2 fold increase) 0.94 0.88-1.01 0.09 0.99 0.91-1.07 0.83 
Viral load (per log10 higher) 0.87 0.89-0.95 0.003    
Peak viral load (per log10 higher) 0.80 0.70-0.90 0.0004 0.80 0.69-0.91 0.001 
Date of starting regimen (per year) 0.90 0.83-0.98 0.01 0.88 0.79-0.99 0.03 
NRTI 
backbone 
AZT & 3TC 1.00 - 0.04 1.00 - - 
DDI & D4T 1.41 0.87-2.28  1.23 0.73-2.05 0.44 
D4T & 3TC 1.12 0.75-1.66  0.90 0.59-1.36 0.60 
Tenofovir + 1 1.35 0.81-2.24  1.03 0.59-1.80 0.72 
abacavir + 1 1.93 1.24-3.02  1.53 0.96-2.44 0.07 
Other 0.72 0.36-1.45  0.62 0.31-1.26 0.19 
IRR=incidence rate ratio 
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5.4.5 Deterioration of surrogate markers for clinical disease  
 
As mentioned in the methods section, not all patients had information on surrogate 
markers such as, body weight or total cholesterol available for all analyses, therefore the 
number for patients included in each analysis focusing on each of these markers 
separately differed according to the availability of the data. In general, patients included 
and those excluded from each of the analysis were similar. However, a high proportion 
of patients in east Europe were excluded from the analysis focusing on haemoglobin 
measurements (93% of patients in east Europe did not have a measurement and were 
excluded), and HDL cholesterol measurements (90% of patients in east Europe were 
excluded). Table 5.13 summarises the number of patients included in each analysis, as 
well as the number of events observed during follow-up.  
 
Table 5.13 Summary of patients included in each analysis 
1.Developing or Worsening anaemia 
Regimen N included Baseline haemoglobin (mg/dl), median (IQR) n events 
Nevirapine 360 (59.7) 14.3 (13.2-15.3) 110 (30.6) 
Efavirenz 721 (49.2) 14.4 (13.2-15.3) 222 (30.8) 
Lopinavir 351 (42.9) 13.8 (12.8-14.8) 75 (21.4) 
2.Losing >10% of body weight 
Regimen N included Baseline weight (Kg), median (IQR) n events 
Nevirapine 299 (49.6) 69 (61-77) 50 (16.7) 
Efavirenz 755 (51.5) 71 (63-79) 134 (17.8) 
Lopinavir 435 (53.2) 69 (61-78) 67 (15.4) 
3.Total cholesterol >6.2mmol/l 
Regimen N included Baseline total cholesterol (mmol/l), median (IQR) n events 
Nevirapine 309 (51.2) 5.1 (4.3-6.0) 103 (33.3) 
Efavirenz 699 (47.7) 5.1 (4.3-6.0) 228 (32.6) 
Lopinavir 386 (47.2) 5.0 (4.1-6.0) 120 (31.9) 
4.HDL cholesterol <0.9mmol/l 
Regimen N included Baseline HDL cholesterol (mmol/l), median (IQR) n events 
Nevirapine 194 (32.2) 1.2 (0.9-1.5) 46 (23.7) 
Efavirenz 489 (33.4) 1.1 (0.9-1.4) 123 (25.2) 
Lopinavir 256 (31.3) 1.1 (0.9-1.3) 81 (31.6) 
5.AST >2 times upper limit of normal 
Regimen N included Baseline AST (IU/L), median (IQR) n events 
Nevirapine 296 (49.1) 25 (18-36) 38 (12.8) 
Efavirenz 637 (43.5) 26 (19.39) 65 (10.2) 
Lopinavir 454 (55.5) 23 (16-33) 48 (10.6) 
6.ALT >2 times upper limit of normal 
Regimen N included Baseline ALT (IU/L), median (IQR) n events 
Nevirapine 310 (51.4) 30 (20-48) 74 (23.9) 
Efavirenz 811 (55.4) 30 (19.52) 175 (21.6) 
Lopinavir 491 (60.0) 26 (17.45) 77 (15.7) 
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Table 5.14 shows the incidence rates for deterioration of each marker of clinical disease 
by treatment regimen started at baseline. For patients who started on a nevirapine 
based regimen, the highest incidence rate was for total cholesterol increasing to >6.2 
mmol/l, IR 7.9 per 100 PYFU (95%CI 6.4-9.5), this was also true for patients who started 
on efavirenz IR 8.9 per 100 PYFU (9%CI 7.7-10.0). The incidence rate of total 
cholesterol increasing to >6.2 mmol/l was also higher in the lopinavir group IR 10.6 per 
100 PYFU (95%CI 8.1-12.5), but a higher incidence rate was observed for HDL 
cholesterol decreasing to <0.9mmol/l, IR 11.0 per 100 PYFU (8.6-13.4). This was almost 
double the incidence rate observed in the nevirapine and efavirenz groups. In all three 
groups there was a relatively low rate of AST increasing to >2 times the upper limit of 
normal (table 5.14).  
 
Table 5.14 Crude incidence rates (IR) per 100 person years of follow-up (PYFU) for worsening of 
surrogate markers for clinical disease across the three treatment regimens 
 1.Developing or Worsening anaemia 
Regimen N events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 110 (30.6) 1723.8 6.4 (5.2-7.6) 
Efavirenz 222 (30.8) 2888.2 7.7 (6.7-8.7) 
Lopinavir 75 (21.4) 1276.8 5.9 (4.5-7.2) 
2.Losing >10% of body weight 
Regimen n events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 50 (16.7) 1304.0 3.8 (2.8-4.9) 
Efavirenz 134 (17.8) 3085.9 4.3 (3.6-5.1) 
Lopinavir 67 (15.4) 1446.1 4.6 (3.5-5.7) 
3.Total cholesterol >6.2mmol/l 
Regimen n events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 103 (33.3) 1299.1 7.9 (6.4-9.5) 
Efavirenz 228 (32.6) 2564.3 8.9 (7.7-10.0) 
Lopinavir 120 (31.9) 1134.3 10.6 (8.4-12.5) 
4.HDL cholesterol <0.9mmol/l 
Regimen n events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 46 (23.7) 791.6 5.8 (4.1-7.5) 
Efavirenz 123 (25.2) 1782.0 6.9 (5.7-8.1) 
Lopinavir 81 (31.6) 735.4 11.0 (8.6-13.4) 
5.AST >2 times upper limit of normal 
Regimen n events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 38 (12.8) 1455.4 2.6 (1.8-3.4) 
Efavirenz 65 (10.2) 2770.6 2.4 (1.8-2.9) 
Lopinavir 48 (10.6) 1619.3 3.0 (2.1-3.8) 
6.ALT >2 times upper limit of normal 
Regimen n events PYFU IR per 100 PYFU (95% CI) 
Nevirapine 74 (23.9) 1371.6 5.4 (4.2-6.6) 
Efavirenz 175 (21.6) 3297.6 5.3 (4.5-6.1) 
Lopinavir 77 (15.7) 1701.3 4.5 (3.5-5.5) 
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Table 5.15 Poisson regression analysis investigating the incidence of worsening of surrogate markers 
for clinical disease across the three treatment regimens 
1.Developing or Worsening anaemia 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.07 1.00   
Efavirenz 1.20 0.96-1.51  1.16 0.91-1.46 0.23 
Lopinavir 0.92 0.69-1.23  0.82 0.29-1.13 0.22 
2.Losing >10% of body weight 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.58 1.00   
Efavirenz 1.13 0.82-1.57  1.13 0.81-1.56 0.46 
Lopinavir 1.21 0.84-1.74  1.15 0.78-1.67 0.46 
3.Total cholesterol >6.2mmol/l 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.09 1.00   
Efavirenz 1.12 0.89-1.42  1.04 0.58-1.32 0.72 
Lopinavir 1.33 1.03-1.74  1.22 0.92-1.64 0.17 
4.HDL cholesterol <0.9mmol/l 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.0006 1.00   
Efavirenz 1.19 0.85-1.67  1.16 0.82-1.65 0.39 
Lopinavir 1.90 1.32-2.72  1.80 1.22-2.66 0.003 
5.AST >2 times upper limit of normal 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.47 1.00   
Efavirenz 0.90 0.60-1.34  0.86 0.57-1.29 0.46 
Lopinavir 1.14 0.74-1.74  1.14 0.72-1.80 0.59 
6.ALT >2 times upper limit of normal 
 Univariable Mulitvariable 
Regimen IRR 95% CI Global p-value IRR 95% CI p-value 
Nevirapine 1.00  0.43 1.00   
Efavirenz 0.98 0.75-1.29  0.98 0.73-1.30 0.87 
Lopinavir 0.84 0.61-1.15  0.84 0.60-1.18 0.30 
Multivariable analysis: 
1 adjusted for HIV exposure group, region of Europe, Hepatitis B and C status, NRTI backbone, 
prior treatment, maximum viral load, year of starting regimen and haemoglobin level at baseline 
2 adjusted for HIV exposure group, hepatitis C status, CD4 count at starting treatment and weight 
at baseline.  
3 adjusted for gender, ethnic origin, HIV exposure group, region of Europe, hepatitis B and C 
status, current BMI, age, date of starting regimen and total cholesterol at baseline 
4 adjusted for gender, ethnic origin, HIV exposure group, region of Europe, hepatits C status, 
age, date of starting regimen and HDL cholesterol at baseline 
5 adjusted for HIV exposure group, region of Europe, hepatitis C status, age, viral load, date of 
starting regimen and baseline AST level  
6 adjusted for gender, HIV exposure group, region of Europe, Hepatitis B and C status, prior 
AIDS diagnosis, NRTI backbone, age and ALT level at baseline 
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The results of the univariable and multivariable Poisson regression analysis of each 
event are shown in table 5.15.  After adjustment for gender, ethnic origin, HIV exposure 
group, region of Europe, hepatitis C status, age, date of starting regimen and HDL 
cholesterol at baseline there was a higher rate for decreasing HDL cholesterol to < 0.9 
mmol/l (IRR 1.80, 95%CI 1.22-2.66, p=0.003) in those who had started on a lopinavir 
based regimen compared to those who had started on nevirapine. There was no 
significant difference between efavirenz (IRR 1.16, 95%CI 0.82-1.65, p=0.39) and 
nevirapine. In univariable analysis a higher incidence rate of total cholesterol increasing 
to >6.2mmol/l was also observed in patients who had started on lopinavir based cART 
(IRR 1.33, 95%CI 1.03-1.74), compared to nevirapine. A non-significant increased rate 
was observed after adjustment for gender, ethnic origin, HIV exposure group, region of 
Europe, hepatitis B and C status, current BMI, age, date of starting regimen and total 
cholesterol at baseline, (IRR 1.22, 95%CI 0.92-1.64, p=0.17) this may be due to lack of 
power. As shown in figure 5.6, no other significant differences in the incidence rates of 
deterioration of the other surrogate markers for clinical disease was observed between 
nevirapine and efavirenz and lopinavir, after each model was adjusted for the factors 
listed below table 5.15.  
 
Figure 5.6 Poisson regression analysis models investigate the incidence of worsening of surrogate 
markers for clinical disease across the three treatment regimens 
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5.4.6 Incidence of all-cause mortality 
23 patients on nevirapine died with an incidence rate of 0.68 per 100 PYFU (95% CI 0.40-
0.96), 61 patients on efavirenz died with an incidence on 0.84 per 100 PYFU (95% CI 
0.63-1.05) and 50 patients on lopinavir with an incidence rate of 1.55 per 100 PFYU (95% 
CI 1.12-1.98). Patients on lopinavir had a significantly higher crude rate of death than 
those on nevirapine (IRR 2.27, 95%CI 1.39-3.72, p=0.001). In contrast, there was no 
significant difference in crude mortality rates between patients on efavirenz and nevirapine 
(IRR 1.23, 95% CI 0.76-1.99, p=0.39). 
 
Table 5.9 shows the cause of death reported for each patient who died. In patients on 
nevirapine only 1 death was due to AIDS related causes, compared to 14 on efavirenz and 
10 on lopinavir. After AIDS related causes, hepatitis related deaths were the second 
biggest cause of death accounting for 17% of the deaths. Of note, liver cancer was 
included in hepatitis related causes. All other non-AIDS malignancies (NADM) were 
grouped together and 12% of the deaths were due to these cancers.  
 
Table 5.16 Cause of death by treatment group 
 All  Nevirapine Efavirenz Lopinavir P-value 
All-cause 134 (4.6) 23 (3.8) 61 (4.2) 50 (6.1) 0.05 
AIDS related death 25 (18.7) 1 (4.3) 14 (23.0) 10 (20.0) 0.09 
Non-AIDS infection 11 (8.2) 2 (13.0) 5 (8.2) 3 (6.0) 0.86 
Hepatitis related 23 (17.2) 4 (17.4) 8 (13.1) 11 (22.0) 0.11 
NADM 16 (11.9) 4 (17.4) 8 (13.1) 4 (8.0) 0.90 
CVD 13 (9.7) 1 (4.4) 8 (13.1) 4 (8.0) 0.49 
Violent 13 (9.7) 4 (17.4) 6 (9.8) 3 (6.0) 0.67 
Other 7 (5.2) 1 (4.4) 3 (4.9) 3 (6.0) 0.68 
Unknown 26 (19.4) 5 (21.7) 9 (14.8) 12 (24.0) 0.11 
 
After adjustment for HIV exposure group, hepatitis C status, prior antiretroviral treatment, 
age, CD4 count at starting regimen, anaemia, hypertension, smoking status and NRTI 
backbone, patients on lopinavir had a marginally significant increased risk of death (IRR 
1.66, 95%CI 0.99-2.78, p=0.05) compared to patients on nevirapine. There was no 
significant difference in the risk of death between patients on efavirenz and those on 
lopinavir (IRR 1.19, 95%CI 0.73-1.94, p=0.48).  
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5.5 Discussion  
 
The analyses presented in this chapter aimed at comparing the long term durability of 
nevirapine, efavirenz and lopinavir based cART regimens. As the focus was on long term 
durability, patients were only included once virologic suppression had been achieved, and 
after at least 3 months exposure to the drug to exclude discontinuations due to early-onset 
potentially treatment limiting toxicities. No significant difference was found in the rate of 
discontinuation for any reason between the three treatment regimens, although differences 
were found in the rate of discontinuation for specific reasons. In particular, patients starting 
nevirapine had a higher rate of discontinuation due to reported treatment failure and a 
lower rate of discontinuation due to toxicity or patient/physician choice compared to those 
on efavirenz and lopinavir. There was no significant difference in the development of any 
non-AIDS clinical events. However, the number of non-AIDS clinical events was quite 
small and this may have been due to lack of power. Additionally, the incidence rate of 
worsening in anaemia, severe weight loss, or increasing in ALT or AST levels was not 
significantly different between those who had started a nevirapine based cART regimen 
and those who started efavirenz or lopinavir. Patients on lopinavir had a higher rate of 
decline of HDL cholesterol compared to patients on nevirapine, while there was no 
difference in low HDL cholesterol between patients on efavirenz and nevirapine. 
Furthermore, patients on lopinavir had a marginally higher mortality rate compared to 
nevirapine but there was no significant difference between efavirenz and nevirapine, again 
perhaps due to lack of power. 
  
Randomised controlled trials have found that nevirapine and efavirenz have similar rates 
of treatment failure300;600. The definition of treatment failure in the 2NN clinical trial300 was 
defined as a combined endpoint of virological failure, disease progression or therapy 
change and the main reason given for treatment failure was a change in therapy. Annan et 
al.600 defined treatment failure as either virological failure or discontinuation of therapy. In 
addition, the ARTEN study601 demonstrated non-inferiority between nevirapine and 
atazanavir, a ritonavir boosted PI, in a population of antiretroviral naïve patients where the 
primary endpoint was two consecutive viral loads <50copies/ml measured prior to week 48 
from treatment initiation.  
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The analyses reported in this chapter were based on a reported reason for discontinuation 
of treatment rather than treatment failure defined through virologic or immunologic 
measurements, in patients who had initially tolerated and responded to treatment. This 
definition is closer to the more recent study definition of treatment failure and the results 
presented here are consistent with their findings.  
 
Previous analyses of patients enrolled in cohort studies299;567;568 have found that in both 
antiretroviral naïve and experienced patients298, efavirenz had a significantly lower rate of 
treatment failure compared to nevirapine; the outcome in these analyses made use of the 
actual viral loads instead of the reason for stopping a drug given by the treating clinicians. 
When the analysis on this chapter was restricted to discontinuations due to reported 
treatment failure, rather than all cause discontinutations, our findings were similar to these 
observational studies in that a decreased rate of discontinuation due to reported treatment 
failure was found in those on efavirenz compared to nevirapine. This difference between 
cohort studies and RCT’s is likely due to the fact that many people starting nevirapine and 
efavirenz in a routine clinical setting differ in a number of ways, many of which are not 
measured in the observational setting, e.g. people likely to have central nervous system 
(CNS) toxicity are put on nevirapine, and CNS abnormality may have an impact of some 
other factors related to virologic failure, such as adherence.  
 
It has previously been reported that the choice of nucleoside reverse transcript inhibitor 
(NRTI) backbone is a significant predictor of virological success and treatment failure600, 
and therefore the pair of nucleosides is a potential confounding factor for the comparison 
of interest. However, even after adjustment for NRTI backbone, significant differences 
remained in the risk of discontinuation due to reported treatment failure. A systematic 
review by Bartlett et al.602 found that 4%-16% of patients on efavirenz discontinued 
treatment due to adverse events, and that discontinuations appeared to be higher in 
patients on an NRTI backbone of lamivudine plus zidovudine or abacavir, and lower in 
regimens with a backbone of tenofovir and emtricitabine, tenofovir and lamivudine, 
stavudine and lamivudine, and didanosine and emtricitabine, although no statistical tests 
for differences were performed. In contrast to these findings, the analysis in this thesis 
found that patients with a NRTI backbone of stavudine and didanosine had a higher risk of 
discontinuation for any reason compared to those with a backbone of zidovudine and 
lamivudine.  
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Further, when looking at discontinuation due to reported treatment failure a higher risk of 
discontinuation were found in patients on a different backbone to zidovudine and 
lamivudine. In patients with extensive resistance to other drug classes nevirapine has 
been found to be associated with an inferior virological outcome compared to patients on 
efavirenz565. However, the same analysis showed that after accounting for resistance there 
was still a difference in virological outcomes between nevirapine and efavirenz565.  
 
In the analysis reported here, very few discontinuations in ART-naïve patients, in any 
group, were due to reported treatment failure. Therefore in treatment naïve patients, the 
results suggest that if the regimen can be successfully tolerated in the first few months and 
viral suppression achieved nevirapine is a durable treatment strategy, in terms of 
discontinuation due to treatment failure, compared to efavirenz and lopinavir 
 
Patients on lopinavir and efavirenz had a higher rate of discontinuation due to toxicities or 
patient/physician choice. Other studies have found that nevirapine was associated with a 
higher rate of toxicities when compared to efavirenz300;345, and the ARTEN study603 found 
that discontinuation was higher in those on nevirapine compared to atazanavir. However, 
most of the discontinuations due to toxicity in nevirapine have been reported in the first few 
months on therapy299;400;603. The principle adverse event associated with nevirapine is 
hypersensitivity289;290;299;604. Additionally ,life threatening hepatotoxicity605 and hepatitis 
have also been reported in patients on nevirapine. These side effects mainly occur in the 
first 6 weeks of therapy223. As mentioned previously, this analysis focused on patients who 
had tolerated the first 3 months of therapy. Thus short term toxicities, such as 
hypersensitivity, leading to early discontinuation would have been excluded. Lodwick et 
al606 found that, compared to patients on efavirenz, there was no significant difference in 
the rate of treatment change due to toxicities in patients on nevirapine, but a significantly 
increased rate of changes due to toxicity in patients on lopinavir. This study used similar 
inclusion criteria to this analysis but only included antiretroviral naïve patients, consistent 
with our sensitivity analysis in antiretroviral-naïve patients.  
 
Non-AIDS related malignancies and cardiovascular related events were the most 
commonly observed non-AIDS related events. A lower incidence of non-AIDS related 
events was found in to those who started an efavirenz based cART regimen compared to 
nevirapine. Although this difference was non-significant, it may be due to lack of power as 
a small number of events were observed.  
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Further, the lower limit of the 95% confidence interval was 0.52 indicating that there could 
be up to a 50% lower incidence of non-AIDS events in those who started on efavirenz. No 
significant difference was also observed in the incidence rate of non-AIDS events in the 
lopinavir group compared to nevirapine.  
 
Older patients were found to be at a significantly increased risk of non-AIDS related events 
and so were patients in north Europe compared to patients in south Europe. Previous 
studies have reported that increasing age is an important risk factor for a number of non-
AIDS events such as cancer, liver and cardiovascular disease377;586. The higher incidence 
in north Europe is surprising but may be partly due to better surveillance and reporting of 
events in this region, or higher underlying event rates in the general population, due to diet 
and other environmental factors. These differences are discussed in more detail in chapter 
7 comparing differences in mortality rates across Europe.  
 
To investigate the long term durability of the regimens investigated, in addition to clinical 
events, changes in laboratory values were also used, as they may give an indication of 
early problems before a serious event occurs. No significant differences between the 
regimens was found in the risk of developing or worsening anaemia, severe weight loss, or 
increasing AST or ALT levels committee, although this may in part be due to low power, 
particularly for developing or worsening anaemia. There may also be problems with 
selection bias in these analyses as those patients with measurements available may be 
different to those without measurements and there may have been a difference in those 
without measurements. Patients on lopinavir had a higher incidence of developing HDL 
cholesterol < 0.9 compared to patients on nevirapine. Nevirapine and efavirenz have both 
been found to increase HDL cholesterol 607;608. There also appears to be some evidence of 
an increase in total cholesterol in there how started on lopinavir compared to nevirapine, 
all the difference was non-significant. The ARTEN study also found that nevirapine had a 
more favourable lipid profile to atazanavir603. In this study there was no significant 
difference in the incidence of developing a high total cholesterol or low HDL cholesterol 
between patients on efavirenz and nevirapine, however the 2NN study609 found 
significantly larger increased in HDL cholesterol on nevirapine compared to efavirenz.  
 
A marginally higher mortality rate was found in patients on a lopinavir based regimen 
compared to nevirapine. A higher proportion of intravenous drug users and patients who 
had tested positive for hepatitis C at baseline were on lopinavir compared to nevirapine. 
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This is probably due to concerns over poor adherence from intravenous drug users330, 
and the related high risk of the development of resistance associated with NNRTIs224, 
as well as the increased risk of liver related toxicities associated with nevirapine605. 
Therefore, it is possible that individuals on lopinavir had a higher underlying risk of 
death, as there was a high rate of hepatitis/liver related death in the lopinavir group 
(22% of all deaths). Typically those on lopinavir also have higher viral loads. However, 
the multivariable estimates were adjusted for hepatitis C status and HIV exposure 
group. Although current IDU status could not be adjusted for as this information has 
only very recently been added to the EuroSIDA follow-up forms (Appendix I).  
 
There are a number of limitations to this analysis which should be noted. Data were 
collected as part of an observational cohort study, and although many imbalances 
between people starting different regimens can be accounted for in the adjusted 
analysis, there may still be unmeasured confounders that we did not account for that 
are either unmeasured or unknown. Cohort studies are not randomised and bias due to 
confounding by indication or some other unknown factors is difficult to exclude. 
Additionally, some selection bias may have been introduced as a higher proportion of 
patients on nevirapine were excluded due to having been exposed to prior treatment of 
one of the 3 drugs. Furthermore, there was a very high rate of patients excluded from 
this analysis from Eastern Europe, mainly due to having no CD4 count or viral load 
available at baseline, and even more exclusions in the analysis involving laboratory 
markers such as haemoglobin levels or cholesterol. These limitations are discussed in 
more detail in the Conclusion chapter of this thesis (Chapter 8).  
 
This analysis differs from previous analyses comparing nevirapine based cART 
regimens with efavirenz or boosted PI regimens in that a significant number of both 
treatment naïve and treatment experienced patients were included. This analysis also 
looked at time to discontinuation of treatment rather than virological end points and 
addresses a different study population (only patients who had achieved an initial 
response to the regimen were included).  
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In conclusion, based on data collected as part of routine clinical practice across Europe 
in patients who had achieved an initial response and tolerated the first three months of 
their regimen, based on risk of all-cause discontinuation and development of serious 
clinical events nevirapine based cART regimens have similar durability to that of 
efavirenz and lopinavir. However, patients on nevirapine had a higher rate of 
discontinuation due to reported treatment failure and those on efavirenz or lopinavir 
which was compensated by a lower rate of discontinuation due to toxicity or patient 
physician choice compared to lopinavir. Analysis restricted to people starting these 
drugs when they were ART-naïve showed a very low incidence of discontinuations, 
regardless of the drug started due to reported treatment failure. The rate of 
discontinuation due to toxicity or patient/physician choice remained significantly 
increased in patients on lopinavir compared to nevirapine, and the effect was of similar 
magnitude.  
 
Results are consistent with those of clinical trials and current guidelines indicating 
NNRTI and PI/r as recommended choices for first line regimens. Clinical trials typically 
have short follow-up, so these results are important because they extend the 
comparisons to events occurring long after the first weeks of treatment. The median 
follow-up time for the main analysis, discontinuation of the third drug for any reason, 
was 2.6 years. Although, it is also worth noting that treatment for HIV is currently 
expected to be lifelong and this still may not be long enough to assess the long term 
durability of cART. It is possible that there will be longer term differences in outcomes 
for those who discontinued treatment due to treatment failure and those who 
discontinue due to toxicities or patient/physician choice due to the rate at which 
available alternative regimens are used and new drugs become available. This is partly 
addressed by the intent to treat analysis looking at development of clinical events, 
deterioration of lab markers and death rates.  
 
A manuscript of this analysis was published in HIV Medicine in May 2011 and can be 
found in Appendix VI. 
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Chapter 6 The relationship between current level of 
immunodeficiency and non-AIDS defining 
malignancies 
6.1 Introduction 
Three different types of cancer have been classified as AIDS defining malignancies 
(ADM): Kaposi’s sarcoma (KS), Non-Hodgkin’s lymphoma (NHL) and, more recently, 
cervical carcinoma136. These three cancers all occur at significantly higher rates in HIV-
positive patients than in the general population404 
 
KS is rare in the general population and is mainly found in immune compromised 
patients after an organ transplant, or in patients over the age of 60610. Studies have 
found that people with HIV are 100 to 300 times more likely to develop KS20. However, 
the incidence of KS in HIV-positive patients has declined dramatically since the 
introduction of cART611-615. The EuroSIDA study has previously reported that the 
incidence of KS in 2003 among patients with HIV was less than 10% of the incidence 
reported in 1994612. KS in HIV-positive patients is associated with the human 
herpesvirus 8 (HHV-8), also called Kaposi’s sarcoma herpes virus (KSHV)419;616;617, the 
transmission of which is thought to be sexual610;618. Although there is no evidence that 
HHV-8 directly causes KS20 in either HIV-positive or HIV-negative patients, risk of KS 
increases relative to increasing levels of HHV-8619. Additionally, some studies have 
found a link between decreasing immunosuppression and increasing risk of KS421.  
 
There are several different types of NHL including primary central nervous system 
(CNS), primary effusion lymphoma and Burkitt’s lymphoma610;620. Like KS, patients 
infected with HIV are at a higher risk of developing NHL with studies reporting a 100-
200 times higher risk of NHL in the HIV-positive population610;621. There has been a 
reported decrease in the incidence of NHL since the introduction of cART615;622;623, 
although EuroSIDA reported that the decreasing incidence of NHL was not as great as 
for other AIDS defining events. This means that in more recent times a higher 
proportion of AIDS defining events are due to NHL159.  
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Differences in the rate of decline have been observed depending on the type of NHL622, 
CNS lymphomas have shown the most significant decline407;624 whereas HIV does not 
appear to be directly responsible for Burkitts NHL610 and Engels et al. reported no 
significant decline in the incidence of Burkitts NHL407. The Epstein - Barr virus (EBV) 
has been found to be associated with the two most common NHL subtypes found in 
HIV-positive patients419;625. EBV is present in two-thirds of AIDS-related lymphomas626. 
However, the proportion of tumours containing the EBV genome varies according to the 
type of NHL: almost all CNS lymphomas, about 90% immunoblastic lymphomas and 
less than 50% of Burkitt’s626;627.  
 
In 1993 cervical carcinoma was added to the CDC list of AIDS defining illnesses136. It is 
the second most common cancer among women628. The principal risk factor is infection 
with the human papillomavirus (HPV)628-630 which has been detected in all cases of 
cervical cancers; it is generally accepted that the virus is required for the development 
of cancer628. Studies have found that the introduction of cART has not resulted in a 
decrease in the incidence of cervical cancer in HIV-positive patients407;614;631 and no 
correlation has been found between immunosuppression and risk of developing cervical 
carcinoma421.  
 
In the context of HIV infection, all other cancers are classified as non-AIDS defining 
malignancies (NADM). In developed countries, where the use of cART has been 
followed by a reduction in many ADM405, NADM are now more common than ADM406-
408. An urban cohort study reported that between 1996 and 2005 NADM rates increased 
from 3.9 to 7.1 cases/1000 person-years405. Worryingly, as with ADM, many NADM 
occur at a higher rate in the HIV-positive population than the general 
population407;409;410;632. The most recent and large studies have shown a 1.7-3-fold 
increased risk of developing non-AIDS malignancies in HIV-positive patients as 
compared with the general population633. The incidence of Hodgkin’s lymphoma, 
malignancy of liver, lung, anus, and oral cavity/pharynx have all been found to be higher 
among the HIV-positive population than in the general population407;410, and a similar 
finding has been reported for melanoma, leukemia, vaginal, colon, rectal, and kidney 
cancer in some studies 410. The increasing incidence of some NADM and the decrease 
in ADM in the cART era has meant that NADM now account for a greater proportion of 
morbidity and mortality in HIV-positive patients than ADM 409.  
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At least part of the increased risk of NADM in HIV-positive patients is explained by the 
higher prevalence of associated risk factors. Smoking has been found at an increased 
level in HIV-positive patients18;372, and some studies have attributed the increased 
incidence of lung cancer to high rates of cigarette smoking414;415. Furthermore, 
excessive alcohol use has been shown to be significant in predicting the risk of 
developing cancer 416 and has been found at an increased level in the HIV-positive 
population compared to the general population18;411. Additionally, co-infection with 
oncogenic viruses (viruses capable of causing tumours) could account for some of the 
increased risk418;620;629;634. The proportion of cancers in the general population that are 
caused by infectious agents is estimated to be around 20%419. This is true for the three 
ADM625;627;630 and for many NADM that occur at an increased rate in HIV-positive 
patients418;620;629;634.  
 
Hodgkin’s lymphoma (HL) has been found at a higher rate in HIV-positive persons 
compared to the general population with between 5 to 15 fold increased risk410;635-638. 
Similarly to NHL, HL has been linked to the EBV virus419;620;634 but, as the prevalence of 
EBV in the general population is very high419, it is not thought that co-infection can 
account for all of the increased risk255. There is also some evidence of an association of 
EBV with nasopharyngeal carcinoma and around 10% of gastric carcinomas639, 
although some types of gastric cancer are associated with the bacterium Helicobacter 
pylori640.  
 
Rates of anal cancer have been found to be around 40 times higher in the HIV-positive 
population compared to the general population410. Multiple risk factors are thought to 
contribute to the development of anal cancer including HPV infection; Frisch et al. 
reported that 95% and 83% of anal cancers in woman and men respectively were 
positive for HPV641. Additional risk factors include anoreceptive intercourse, cigarette 
smoking, number of previous sexual partners and immunnosuppression629;642;643. HIV-
positive patients tend to develop more aggressive anal cancer and have a poorer 
prognosis than patients of the same age who are HIV-negative629. The HPV virus has 
also been linked to cancer of the vulva, vagina, penis, oral cavity, oropharynx and tonsil 
with some limited evidence of an association with cancer of the larynx419;628. Although 
HPV is accepted as a risk factor for oral and pharyngeal cancer the major risk factors 
are tobacco and alcohol644 
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Some studies have reported that the incidence of liver cancer in HIV-positive patients is 
increasing over time407;410. Hepatocellular carcinoma (HCC) is the fifth most common 
cancer worldwide645. It is associated with infection with hepatitis B and C viruses417-
419;646 that are reported to infect over 300 million and 170 million people respectively 
worldwide419. HIV-positive patients have a greater incidence of infection with hepatitis B 
and C than the general population, with this being especially true for injecting drug 
users647. Liver disease is now a leading cause of death among HIV-positive patients361 
with a high proportion attributable to HCC380. Almost all reported cases of HCC in HIV-
positive patients are in individuals co-infected with either hepatitis B or C413. As well as 
infection with hepatitis, heavy alcohol use is also related to an increased risk of HCC417, 
and this could explain some of the increased risk in HIV-positive patients.  
  
Many of these viruses (EBV, HPV, and hepatitis) however, are common in the general 
adult population but the development of tumours occurs in only a small fraction of those 
infected620. A recent study by Silverberg et al.255 found that 70% of all cancers in HIV-
positive persons were infection related, compared with only 12% in HIV-negative 
patients of a similar age and sex. However, HIV-positive patients have also been found 
to have a 30% increased risk of non-infection NADM compared to HIV-negative 
patients255. Thus, although some of the increased risk can be accounted for by a higher 
prevalence of related risk factors it does not account for all of the increased risk.  
 
It is thought that impaired immune function may result in the general reduced immune 
surveillance for malignant cells or it may impair the ability to suppress oncogenic 
viruses that may result in a higher risk of these cancers255. There is growing interest in 
the correlation between immunodeficiency and NADM, with some studies supporting 
the theory that NADM become more frequent in immunodeficient patients with or 
without HIV infection420-422. As HIV-positive individuals are surviving longer on cART 
and the population is aging, more are at risk of developing a serious non-AIDS clinical 
event such as NADM. It is important that any risk factors, particularly those that are 
related to HIV infection, are identified and understood so that any excess risk can 
potentially be reduced.  
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6.2 Aim 
The aim of this chapter was to investigate the incidence of NADM across Europe in 
HIV-positive patients and to identify the risk factors associated with the development of 
NADM. In particular we sought to investigate the link with immunodeficiency to 
determine whether current CD4 count was independently associated with risk of NADM 
after accounting for associated risk factors measured in EuroSIDA. Finally, in those that 
developed a NADM, we investigated the risk of death and patterns of survival. 
6.3 Methods 
6.3.1 Patient selection 
As mentioned in earlier chapters 16,599 patients were included in the D29 EuroSIDA. 
Figure 6.1 shows how patients were selected for inclusion into this analysis. All patients 
who had some prospective follow-up and a CD4 count measured prior to enrolment into 
EuroSIDA were included in the analysis, giving a total of 14,453 patients. 
 
 
6.3.2 Statistical analysis 
 
Baseline was defined as the date of enrolment into EuroSIDA. Patients were followed 
until either death or their last recorded visit in EuroSIDA, if they were not known to have 
died. Therefore patients could develop more than one distinct NADM whilst under 
follow-up. Any NADM diagnosed before enrolment into EuroSIDA was classed as a 
prior NADM and recurrences of the same NADM were excluded.  
 
16,599 patients in EuroSIDA D29 
15,293 patients had some prospective follow-up  
14,453 had a CD4 count available prior to enrolment into EuroSIDA 
Figure 6.1 Patient selection 
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NADM were classified using the ICD-10 code classification system648. The incidence of 
NADM per 1000 person years of follow-up (PYFU) was calculated, and stratified by 
current (time-updated) CD4 count. PYFU accrued within current CD4 count strata, and 
PYFU were censored when the most recent CD4 count was more than 6 months old 
and started again when a new CD4 count became available. Poisson regression 
analysis was used to determine the factors associated with the development of NADM. 
Factors investigated included gender, age, race, exposure group, region of Europe, and 
nadir CD4. In addition CD4 count, viral load, year of follow-up, smoking status, 
anaemia, hepatitis B and C status, starting cART and diagnosis of any NADM, ADM or 
other AIDS defining event were included as time updated covariates. cART was defined 
as any regimen including three or more ARVs. Patients were classed as Hepatitis B 
positive if they had a positive HBV surface antigen test recorded and Hepatitis C 
positive if they had a positive HCV antibody test. Anaemia was defined as a 
haemoglobin level ≤ 12 or ≤14 (mg/dl) for females and males respectively598. Factors 
that were significant in univariable analysis (p<0.1) were included in multivariable 
analyses. 
 
NADM were categorized into 3 categories: ‘virus-related’; ‘non-virus-related epithelial’; 
and ‘other’ cancers (Table 6.3). These groups were defined a priori before starting 
analyses and after review by several study group clinicians. Several viral infections are 
considered to be the causative organism of certain cancers in humans, with nearly 15% 
of all cancers thought to have an infectious agent in their etiology610. As previous 
studies have found a link between virus related cancers such as HL635, HCC647, and 
anal cancer636 with immunodeficiency determined by time to AIDS diagnosis635;636 or 
CD4 count within 1 year of diagnosis 647, it was decided to group these ‘virus related’ 
NADM together.  
 
The most common non-virus related epithelial cancers (e.g. lung and prostate) remain 
difficult to treat, and the majority remain incurable with very little improvement in 
survival over the past decade649. In addition, based on onco-epidemiologic studies, risk 
of epithelial cancers starts to increase from the age of 30650.  
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Therefore, all non-virus-related epithelial cancers were grouped together. Although 
stomach cancer has been linked to EBV, only 5-10% of carcinomas worldwide are 
thought to be due to EBV419;639, and therefore stomach and gastric cancers were 
included in the ‘non-virus related epithelial’ group. Similarly, cancers of the nasopharynx 
have been reported to differ histologically and aetiologically compared to other oral 
cancers that are HPV related628. The final group (‘other’) consisted of NADM which 
were not easily categorised into the other two groups including leukaemia, myeloma, 
brain tumours and melanoma, as well as any cancers that were not well defined within 
the database. Non-melanoma skin cancer was excluded as it was not systematically 
ascertained and not thought to cause significant morbidity or mortality405.  
 
The analysis was performed on all NADM combined, and separately for each NADM 
group. Where there was a sufficient number of events (>30) for a specific NADM, the 
analysis was repeated for that NADM alone. In addition, previous studies have shown 
that rates of breast, prostate and colorectal cancers are not raised in people with HIV420; 
therefore an additional sub-group analysis focused on these 3 cancers combined. 
 
In patients diagnosed with NADM, Kaplan Meier survival analysis was used to estimate 
a patient’s risk of dying after diagnosis and to compare the risk of death across the 
three different cancer groups. Cox proportional hazards models, stratified by centre, 
were used to investigate the factors that were significantly associated with a patient’s 
risk of death after NADM diagnosis. Factors investigated included gender, age, race, 
exposure group, region of Europe, and nadir CD4. In addition, baseline CD4 count, viral 
load, year of follow-up, smoking status, anaemia, hepatitis B and C status, starting 
cART and diagnosis of any NADM, ADM or other AIDS defining event were also 
considered. For this analysis, nadir CD4 was defined as the lowest CD4 count 
measured prior to baseline. Factors that were significant in univariable analysis (p<0.1) 
were included in multivariable analyses. 
 
The data collected on NADM only became part of the routine data collection and the 
EuroSIDA quality assurance exercise in 2003. Therefore a sensitivity analysis in which 
follow-up was left censored at 1st January 2003 was performed.  
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6.4 Results 
6.4.1 Patient characteristics 
 
There were 14,453 patients included in the analysis. Table 6.1 gives the baseline 
characteristics for patients included in the study stratified by those who did and did not 
develop an NADM.  
 
Patients were mainly male (75.3%), of white ethnic origin (88.7%), with a median age of 
36 (interquartile range [IQR] 31-44 years). 9,772 (67.6%) patients were on cART when 
they were enrolled into EuroSIDA, only 10.9% were treatment naïve. 3,486 (24.1%) had 
experienced at least one AIDS defining illness (not including ADM) prior to baseline and 
680 (4.7%) had previously been diagnosed with a malignancy (either ADM or NADM). 
Median CD4 count at enrolment was 300/mm3 (IQR 150-453) and median viral load in 
patients with data available was 2.70 per log10 copies/ml. As mentioned in the 
introduction, possible risk factors for the development on certain cancers include 
smoking and co-infection with other viruses: 645 (4.5%) patients were hepatitis B 
positive and 2,782 (919.3%) were hepatitis C positive. 2,809 (19.4%) patients were 
recorded as current smokers and an additional 890 (6.2%) had reported having smoked 
previously. 
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Table 6.1: Patient characteristics at baseline* 
  All  Patients Did not develop NADM Developed NADM 
  N % N % N % 
All patients   14453 100 14106 97.6 347 2.4 
Gender Male  10879 75.3 10590 75.1 289 83.3 
Ethnic origin White 12822 88.7 12497 88.6 325 93.7 
Exposure Group Homosexual 5965 41.3 5773 40.9 192 55.3 
IDU 3488 24.1 3424 24.3 64 18.4 
Heterosexual 4017 27.8 3951 28.0 66 19.0 
Other 983 6.8 733 5.2 25 7.2 
Region of Europe South 4192 29.0 4098 29.1 94 27.1 
Central 3324 23.3 3268 23.2 106 30.5 
North 3724 25.8 3598 25.5 126 36.3 
East  1455 10.1 1442 10.2 13 3.7 
 East Central 1329 9.2 1324 9.4 5 1.4 
 East 379 2.6 376 2.7 3 0.9 
Hepatitis B status Negative 9194 63.6 8983 63.7 211 60.8 
Positive 645 4.5 616 4.4 29 8.4 
Unknown 4614 31.9 4507 32.0 107 30.8 
Hepatitis C status Negative 6263 43.3 6121 43.4 141 40.6 
Positive 2782 19.3 2731 19.4 51 14.7 
Unknown 5409 37.4 5254 37.2 155 44.7 
Treatment started at or prior to 
baseline 
Naive 1569 10.9 1539 10.9 30 8.6 
ART 3112 21.5 2971 21.1 141 40.6 
cART 9772 67.6 9596 68.0 176 50.7 
Prior diagnosis of AIDS or 
malignancy 
None 10287 71.2 10047 71.2 240 69.2 
Prior AIDS (not ADM) 3486 24.1 3403 24.1 83 23.9 
Prior ADM  573 4.0 551 3.9 22 6.3 
Prior NADM 107 0.7 105 0.7 2 0.6 
Smoking status  Current 2809 19.4 1492 10.6 18 5.2 
Previous 890 6.2 2758 19.6 51 14.7 
Never 1510 10.4 876 6.2 14 4.0 
Unknown 9244 64.0 8980 63.7 264 76.1 
Viral load
+ 
 ≤500 copies/ml 4776 50.9 4663 50.8 123 60.1 
 >500 copies/ml 4613 49.1 4525 49.2 79 39.1 
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Patient characteristics at baseline* (continued) 
  All  Patients Did not developed 
NADM 
Developed NADM 
  Median IQR Median IQR Median IQR 
Age  Years 36 31-44 36 31-44 42 34-50 
CD4 count /mm
3
 300 153-453 300 154-456 243 133-366 
CD4 nadir  /mm
3
 177 64-302 179 64-304 144 67-242 
Viral load
+
 log10 copies/ml 2.70 1.70-4.23 2.79 1.69-4.22 3.03 2.30-4.36 
Recruitment  month/year Jam 99 Jan96-Jan 
04 




*baseline was defined as date of enrolment into EuroSIDA,
+
5064 (35.0%) patients had no viral load data available at baseline, IDU: Intravenous 
Drug User, ADM: AIDS defining malignancy, NADM: non-AIDS defining malignancy, IQR: inter quartile range 
  
6.4.2 Non-AIDS defining malignancies 
338 patients developed one NADM whilst under follow-up and 9 patients developed 2 different NADM during 83,398 person years of 
follow-up [PYFU] to give an incidence rate [IR] of 4.3 per 1000 PYFU (95% confidence interval [CI] 3.8-4.7). The characteristics of 
patients at the time of their first NADM diagnosis whilst under follow-up in EuroSIDA are shown in table 6.2. The median age of 
patients at the time of diagnosis was 47 years, around 10 years older than the median age of all patients at enrolment into the study. 
Median CD4 count at the time of diagnosis was 315 cells/mm3 (IQR 190-532) and median viral load was 1.90 per log10 copies/ml (IQR 
1.70-3.30). The majority of patients were on cART (92.8%); 14.4% were hepatitis B positive, 19.6% were hepatitis C positive and 
51.3% were either current or previous smokers.  
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Table 6.2: Characteristics of patients at time of first NADM diagnosis whilst under follow-up in 
EuroSIDA 
  All Patients 
  N % 
All patients   347 100 
Gender Male  289 83.3 
Ethnic origin White 325 93.6 
Exposure Group Homosexual 192 55.3 
IDU 64 18.4 
Heterosexual 66 19.0 
Other 25 7.3 
Region of Europe South/Argentina 97 27.9 
Central 106 30.6 
North 126 36.5 
East  17 5.2 
Hepatitis B status Negative 255 73.5 
Positive 50 14.4 
Unknown 42 12.1 
Hepatitis C status Negative 216 62.3 
Positive 68 19.6 
Unknown 63 18.2 
Treatment started at or prior to 
diagnosis 
Naive 4 1.2 
ART 21 6.0 
cART 322 92.8 
Prior diagnosis of AIDS or 
malignancy 
None 185 53.3 
Prior AIDS (not ADM) 120 34.6 
Prior ADM  35 10.1 
 Prior NADM 7 2.0 
Smoking status  Current 51 14.7 
Previous 127 36.6 
Never 72 20.8 
Unknown 97 27.9 
Viral load
+ 
 ≤500 copies/ml 212 66.0 
 >500 copies/ml 109 34.0 
  Median IQR 
Age   48 41-56 
CD4 count /mm
3
 315 190-532 
CD4 nadir  /mm
3
 90 29-188 
Viral load* log10 copies/ml 1.90 1.70-3.30 
Maximum viral load*  log10 copies/ml 4.92 3.97-5.45 
Date of diagnosis month/year 05/03 01/00-06/06 
* 26 patients had no viral load measurement available 
 
172 NADM developed while under follow up in EuroSIDA were classed as ‘virus-
related’, 135 were classed as ‘non-virus-related epithelial’ and 49 ‘other’. The specific 
cancers included in each category are shown in table 6.3. The most commonly 
observed cancer was anal cancer (n=69), followed by Hodgkin’s lymphoma (n=69) and 
lung cancer (n=31). 
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HPV related Lung (31) Unspecified (20) 
Anal (69) Breast (17) Melanoma (13) 
Oral (12) Prostate (15) Brain (4) 
Larynx (8) Rectal (12) Multiple Myeloma (4) 
Vulval (5) Colon (11) Myeloid Leukaemia (3) 
Pharynx (2) Pancreas (7) Leukaemia (3) 
Penile (2) Stomach (7) Liposarcoma (1) 
EBV related Oesophagus (6) Lymphoid Leukaemia (1) 
Hodgkin (52) Kidney (6)  
HBV and HCV related Bladder (6)  
Liver (22) Testicular (4)  
 Lip (2)  
 
Thyroid (2)  
Uterine (2)  
Ovarian (2)  
Urinary unspecified (2)  
Nasopharynx (1)  
Gall bladder (1)  
Gastric (1)  
 
 
  197 
6.4.3 Association with immunodeficiency 
 
There was a decreasing incidence of all NADM combined with increasing current CD4 
count (figure 6.2). For example, at a current CD4 count ≤200/mm3, the incidence was 
6.4 per 1000 PYFU (95% CI 5.1-7.7) compared to 3.4 per 1000 PYFU (95% CI 2.7-4.1) 
at a current CD4 count >500/mm3, p<.0001.  
 
Figure 6.2 Incidence of NADM 1994-2008 by current CD4 count 
 
 
Figure 6.2 also shows that there is a clear decrease in incidence of ‘virus-related’ 
NADM with increasing CD4 count, from 3.6 at CD4 counts ≤200/mm3 (95% CI 2.7-4.6) 
to 1.3 at CD4 count >500/mm3 (95% CI 0.9-1.7) p<.0001. The incidence of ‘non-virus-
related epithelial’ cancer showed a small but marginally significant decrease as current 
CD4 count increased (p=0.06), while no significant difference in the incidence of ‘other’ 
cancers as found (p=0.35), which may be due to lack of power in this group.  
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The results of the multivariable Poisson regression analysis are shown in table 6.4. For 
any NADM, after adjustment, a higher current CD4 count was associated with a lower 
incidence of NADM (incidence rate ratio [IRR] 0.87 per doubling, 95% CI 0.82-0.94, 
p<.0001). Nadir CD4 count was not found to be significant after adjustment (IRR 1.03, 
95%CI 0.98-1.09, p=0.26). Hepatitis B antigen positive patients had double the 
incidence rate of NADM compared to those who were hepatitis B antigen negative (IRR 
2.14, 1.58-2.90, p<.0001). A previous diagnosis of AIDS (excluding malignancies) 
increased the incidence of NADM by 39% (IRR 1.39, 1.09-1.78, p=0.007), and a prior 
malignancy (either AIDS or non-AIDS) almost doubled the incidence of NADM (IRR 
1.84, 1.30-2.59, p=0.0005) compared to no prior diagnosis. Age and ethnicity were also 
associated with the incidence of NADM; non-white patients had a 51% lower incidence 
of NADM (IRR 0.49, 0.32-0.77, p=0.002) and older patients had a 51% increased 
incidence per 10 year increment (IRR 1.51, 1.37-1.67, p<0.0001).  
 
In the ‘virus-related’ group, lower incidence of NADM was associated with higher 
current CD4 counts (IRR per doubling 0.84, 95% CI 0.77-0.91, p<.0001). Higher current 
CD4 count was also associated with a lower incidence of ‘non-virus-related epithelial’ 
cancers (IRR 0.84, 95% CI 0.75-0.95, p=0.004). However, current CD4 count was not a 
significant factor in predicting the incidence in the ‘other’ NADM group (IRR 1.04, 0.83-
1.31, p=0.73). Nadir CD4 count was not associated with development of any of the 
cancer groupings after adjustment for current CD4 count. A prior malignancy diagnosis 
(IRR 2.45, 1.56-3.84, p<.0001) and a hepatitis B positive diagnosis (IRR 2.53, 1.69-
3.77, p<.0001) were associated with an increased incidence of ‘virus-related’ cancers. 
Older age was associated with a higher incidence of ‘non-virus-related epithelial’ (IRR 
2.02, 1.77-2.36, p<.0001) and ‘other’ (IRR 1.35, 1.05-1.73, p=0.02) cancers. Year of 
follow-up was also associated with an increased rate of ‘non-virus related epithelial’ 
cancer (IRR 1.06, 1.01-1.11, p=0.01).  
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Table 6.4 Multivariable Poisson regression analysis 
  All NADM Virus-related Non-virus related epithelial Other 
  IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value 
Gender Male 1.00 - - 1.00 - -    1.00 - - 
 Female 1.08 0.78-1.50 0.64 0.87 0.52-1.46     0.18 0.04-0.77 0.02 
Ethnic 
origin 
White 1.00 - - 1.00 - - 1.00 - -    





Homosexual 1.00 - - 1.00 - -    1.00 - - 
IDU 1.01 0.69-1.50 0.94 1.12 0.75-1.65 0.58    0.55 0.12-2.44 0.43 
Heterosexual 0.74 0.54-1.03 0.07 1.51 0.29-0.88 0.02    1.34 0.66-2.75 0.42 
Other 0.80 0.53-1.22 0.30 0.47 0.22-1.02 0.06    1.40 0.53-3.69 0.50 
Region of 
Europe  
South/Argentina 1.00   1.00 - - 1.00 - - 1.00 - - 
Central 1.22 0.94-1.62 0.14 1.40 0.96-2.04 0.08 0.91 0.58-1.43 0.67 2.36 0.91-6.11 0.08 
North  1.11 0.84-1.45 0.47 1.04 0.71-1.53 0.85 1.07 0.76-1.63 0.76 2.38 0.95-5.96 0.06 
East 0.59 0.36-0.97 0.04 0.30 0.12-0.76 0.01 0.53 0.25-1.15 0.11 3.13 0.92-10.62 0.07 
Hepatitis B 
status 
Negative  1.00 - - 1.00 - - 1.00 - -    
Positive  2.14 1.58-2.90 <.0001 2.53 1.69-3.77 <.0001 1.77 1.03-3.04 0.04    
Unknown 0.71 0.50-1.03 0.07 0.68 0.42-1.12 0.13 0.75 0.44-1.28 0.29    
Hepatitis C 
status 
Negative  1.00 - -       1.00 - - 
Positive  0.95 0.66-1.37 0.79       0.59 0.18-1.94 0.39 
Unknown 1.03 0.67-1.59 0.88       1.62 0.42-6.30 0.49 
Ever 
smoked 
Never  1.00 - -       1.00 - - 
Current 1.37 0.99-1.90 0.06       5.01 1.15-21.87 0.03 
Previous 1.39 0.97-1.98 0.07       4.32 0.93-20.01 0.06 
Unknown 1.75 1.23-2.48 0.002       12.31 2.81-53.82 0.0009 
Prior 
diagnosis 
None 1.00 - - 1.00 - -    1.00 - - 
AIDS* 1.39 1.09-1.78 0.007 1.40 0.97-2.01 0.07    1.79 0.94-3.40 0.07 
Malignancy 1.84 1.30-2.59 0.0005 2.45 1.56-3.84 <.0001    1.78 0.64-4.95 0.27 
Age per 10 yr  1.51 1.37-1.67 <.0001 1.13   2.02 1.77-2.36 <.0001 1.35 1.05-1.73 0.02 
CD4 doubling  0.87 0.82-0.94 <.0001 0.84 0.78-0.91 <.0001 0.84 0.75-0.95 0.004 1.04 0.83-1.31 0.73 
CD4 nadir  1.03 0.98-1.09 0.26 1.01 0.95-1.09 0.65    0.97 0.84-1.12 0.65 
Year of follow-up       1.06 1.01-1.11 0.01    
Ever started cART 1.52 1.10-2.11 0.01 1.48 0.93-2.33 0.09    2.26 0.81-6.28 0.12 
*AIDS did not include any AIDS related malignancies; all malignancies both ADM and NADM were included in the malignancy category. 
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Figure 6.3: Adjusted incidence of NADM by current CD4 count 
 
All NADM also adjusted for gender, ethnic origin, HIV exposure group, region of Europe, 
hepatitis B and C status, ever smoked, prior diagnosis of AIDS or malignancy, age, CD4 nadir, 
and having started cART; Virus-related also adjusted gender, ethnic origin, HIV exposure group, 
region of Europe, hepatitis B, prior diagnosis of AIDS or malignancy, age, CD4 nadir, and having 
started cART, Non-virus related epithelial also adjusted for ethnic origin, region of Europe, age, 
and year of follow-up, Other also adjusted for gender, HIV exposure group, region of Europe, 
hepatitis C status, ever smoked, prior diagnosis of AIDS or malignancy, age, CD4 nadir, and 
having started cART 
 
Figure 6.3 shows the incidence rate ratio per doubling in current CD4 count, after 
adjustment, for each of NADM groupings.  
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6.4.4 Specific NADM 
The three most frequently observed cancers were anal cancer (n=69), HL (n=52), and 
lung cancer (n=31). Each of these cancers was investigated separately. In addition, as 
mentioned in the methods, previous studies have shown that rates of breast, prostate 
and colorectal cancers are not raised in people with HIV420; therefore an additional sub-
group analysis focused on these 3 cancers combined.  
 
6.4.4.1 Anal cancer 
For anal cancer, after adjustment, there was a significantly decreased incidence with 
increasing current CD4 count (IRR 0.86 per doubling, 95% CI 0.75-0.99, p=0.03), nadir 
CD4 count was also found to be marginally significant (IRR 0.93 per doubling, 95% CI 
0.84-1.01, p=0.09). Homosexual transmission group had a higher incidence of anal 
cancer compared to patients infected via heterosexual transmission (IRR 2.96, 95% CI 
1.40-6.24, p=0.04). Patients with a prior malignancy diagnosis (IRR 3.25, 95% CI 2.71-
6.16, p=0.0003), those who were hepatitis B antigen positive (IRR 2.29, 95% CI 1.25-
4.18, p=0.007) and those with a later year of follow-up (IRR 1.10, 1.02-1.18, p=0.01) 
also had a higher incidence of anal cancer (table 6.5). 
 
6.4.4.2 Hodgkin’s lymphoma (HL) 
As there is some uncertainty about the association of HL at intermediate levels of 
immunodeficiency and debate over whether there is a linear relationship with CD4 
count and the risk of developing HL, the association of current CD4 count was initially 
investigated in different CD4 count strata. Figure 6.4 shows the crude incidence rate of 
HL by current CD4 count strata, indicating a linear relationship. 
 
In univariable analysis, compared to patients with a current CD4 count ≥500/mm3, 
patients with a current CD4 count <200/mm3 had a 6.4 times higher incidence of HL 
(IRR 6.40, 95%CI 2.76-14.84, p<.0001) and those with a CD4 count between 200-
349/mm3 had 2.5 times the incidence of HL (IRR 2.55, 1.00-6.40, p=0.0.04), and those 
with a CD4 count between 350-499 had double incidence of HL (IRR 1.92, 0.71-5.14, 
p=0.19)  
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Figure 6.4 Crude incidence rate of Hodgkin’s Lymphoma by CD4 count strata 
 
Therefore in adjusted analysis current CD4 count was included as a continuous 
variable. Table 6.5 shows the results of the adjusted analysis. A Higher current CD4 
count was associated with a lower incidence of HL (IRR 0.83 per 2 fold higher, 95%CI 
0.73-0.95, p=0.005), while a prior AIDS diagnosis (IRR 1.78, 95% CI 0.94-3.37, p=0.08) 
was marginally associated with a higher incidence of HL.  
 
6.4.4.3 Lung cancer 
Table 6.5 shows that after adjustment for smoking status, prior AIDS diagnosis and 
age, the incidence of lung cancer was significantly decreased with a higher current CD4 
count (IRR 0.76, 95%CI 0.64-0.90, p=0.0002). Additionally, being a current smoker 
compared to having never smoked (IRR 16.80, 95%CI 2.23-126.2, p=0.0006) and older 
age (IRR 2.79 per 10 years older, 95% CI 2.22-3.50, p<.0001) were also significantly 
associated with an increased the rate of lung cancer.  
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6.4.4.4 Combined analysis of breast, colon and prostate cancer 
There were 55 diagnoses of breast, colon or prostate cancer (table 6.5). There was no 
significant relationship with the incidence of these cancers combined and current CD4 
count (IRR 1.01 per 2 fold higher, 95% CI 0.79-1.30, p=0.92), after adjustment for HIV 
exposure group, region of Europe, hepatitis B and C status, smoking status, age, and 
year of follow-up (table 7.5) . Older age (IRR 1.87 per 10 years older, 95%CI 1.48-2.35, 
p<.0001) and increasing year of follow-up (IRR 1.15 per year, 95%CI 1.06-1.25, 
p=0.0005) were associated with an increased rate of these combined cancers. 
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Table 6.5 Multivariable Poisson regression analysis for specific NADM 
  Anal cancer Hodgkin’s Lymphoma Lung cancer Breast, colon and prostate 
cancer combined 
  IRR 95% CI p-
value 
IRR 95% CI p-
value 
IRR 95% CI p-
value 
IRR 95% CI p-value 
Gender Male 1.00 - - 1.00 - -       
 Female 0.78 0.24-2.55 0.68 0.72 0.29-1.77 0.47       
Ethnic 
origin 
White 1.00            
Other 0.23 0.06-0.95 0.04          
Exposure 
group 
Other 1.00   1.00      1.00   
Homosexual 2.96 1.40-6.25 0.004 1.67 0.89-3.12 0.11    1.57 0.91-2.74 0.10 
Region of 
Europe  
South 1.00   1.00      1.00   
Central 1.62 0.83-3.14 0.15 1.54 0.84-2.83 0.16    1.70 0.81-3.55 0.15 
North  1.52 0.81-2.86 0.19 0.45 0.19-1.03 0.05    1.40 0.67-2.91 0.37 
East 0.18 0.02-1.45 0.10 0.72 0.19-2.70 0.62    0.68 0.19-2.43 0.55 
Hepatitis B 
status 
Negative  1.00         1.00   
Positive  2.29 1.25-4.20 0.007       2.83 1.40-5.71 0.003 
Unknown 0.53 0.21-1.30 0.16       0.32 0.08-1.30 0.11 
Hepatitis C 
status 
Negative  1.00         1.00   
Positive  0.46 0.17-1.25 0.12       1.14 0.46-2.79 0.78 
Unknown 2.20 0.71-6.83 0.17       1.37 0.41-4.56 0.60 
Ever 
smoked 
Never        1.00   1.00   
Current       16.80 2.24-126.21 0.006 0.43 0.18-1.04 0.06 
Previous       4.68 0.53-41.41 0.16 1.05 0.51-2.15 0.90 
Unknown       6.60 0.81-53.82 0.07 1.82 0.87-3.80 0.11 
Prior 
diagnosis 
None 1.00   1.00   1.00      
AIDS* 1.44 0.79-2.63 0.23 1.78 0.94-3.37 0.07 1.53 0.73-3.20 0.26    
Malignancy 3.25 1.71-6.16 0.0003 1.94 0.77-4.88 0.16 2.32 0.82-6.59 0.11    
Age per 10 yr        2.79 2.22-3.50 <.0001 1.87 1.48-2.35 <0.0001 
CD4 doubling  0.86 0.75-0.99 0.03 0.83 0.73-0.95 0.005 0.76 0.64-0.90 0.001 1.01 0.79-1.30 0.91 
CD4 nadir  0.93 0.85-1.01 0.09          
Year of follow-up 1.10 1.02-1.18 0.01 0.96 0.89-1.04 0.28    1.15 1.06-1.25 0.0005 
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6.4.5 Survival after NADM diagnosis 
Individuals who were diagnosed with a NADM were followed from their first diagnosis of 
NADM until either their last recorded visit in EuroSIDA or death. The median follow-up 
time was 1.7 years after diagnosis. 
Table 6.6 Characteristics of individuals at the time of NADM diagnosis who died  
  Patients 
  N % 
All patients   145 100 
Cancer group Virus related 58 40 
 Non-virus related epithelial 64 44.1 
 Other 23 15.9 
Gender Male  126 86.9 
Ethnic origin White 135 93.1 
Exposure Group Homosexual 80 55.2 
IDU 33 22.8 
Heterosexual 24 16.6 
Other 8 5.5 
Region of Europe South/Argentina 37 25.5 
Central 41 28.3 
North 57 39.3 
East  10 6.9 
Hepatitis B status Negative 101 69.7 
Positive 23 15.9 
Unknown 21 14.5 
Hepatitis C status Negative 83 57.2 
Positive 29 20.0 
Unknown 33 22.8 
Treatment started at or prior to 
diagnosis 
Naive 1 0.7 
ART 9 6.2 
cART 135 93.1 
Prior diagnosis of AIDS or 
malignancy 
None 59 40.7 
Prior AIDS (not ADM) 69 47.6 
Prior ADM  15 10.3 
 Prior NADM 2 1.4 
Smoking status  Current 12 8.3 
Previous 45 31.0 
Never 31 21.4 
Unknown 57 39.3 
  Median IQR 
Age   47 41-56 
CD4 count /mm
3
 233 121-398 
CD4 nadir  /mm
3
 62 14-162 
Viral load* log10 copies/ml 2.30 1.70-3.50 
Maximum viral load*  log10 copies/ml 4.96 3.32-5.51 
Date of diagnosis month/year 03/02 11/98-12/03 
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145 patients died after a NADM diagnosis whilst under follow-up in EuroSIDA. Table 6.6 
gives the characteristics at the time of diagnosis in those who died.  
 
The cause of death was reported for 119 (82.1%) of these patients. Of those with a 
known cause of death, 74 patients (62.2%) died from their NADM; 26 (21.8%) were 
classed as HIV related, 9 (7.6%) were liver or hepatitis related complications (excluding 
HCC), 3 (2.5%) were from an MI, 2 (1.7%) due to pneumonia, 1 pancreatitis, 1 diabetes 
related, 1 sepsis, 1 septic shock and 1 peritonitis.  
 
The Kaplan Meier risk of death in the 6 months after a NADM diagnosis was 17.6% 
(95% CI 13.0-22.2) and 27.4 % (95% 22.5-32.3) in the first year after diagnosis. Figure 
6.5 shows the risk of death stratified by different cancer groupings. Patients developing 
a virus related NADM appear to have the lowest rate of death.  
 
Figure 6.5 Kaplan Meier risk of death after a NAMD diagnosis 
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In adjusted models (table 6.7), patients diagnosed with either non-virus related 
epithelial cancer had a 1.8 times higher risk of death compared to patients diagnosed 
with virus related cancers. Patients with a higher CD4 count had a 32% lower risk of 
death per doubling in CD4 count. Patients who had had a prior AIDS diagnosis or who 
had been infected via IDU transmission also had a higher risk of death.  
 
Table 6.7 Hazard rate of death after diagnosis with a NADM  
  Univariable Multivariable 
  HR 95% CI p-value HR 95% CI p-value 
Cancer group Virus related 1.00  0.03 1.00   
Non-Virus epithelial 1.59 1.02-3.48  1.85 1.1-3.08 0.01 
Other 1.90 1.05-3.41  1.82  0.92-3.61 0.08 
Gender Male 1.00  0.09 1.00   
 Female 0.62 0.36-1.08  0.68 0.36-1.30 0.24 
Ethnic origin White 1.00  0.81    
Other 1.12 0.44-2.87     
Exposure group IDU 1.00  0.04 1.00   
Non-IDU 0.57 0.32-1.00  0.48 0.25-0.92 0.02 
Hepatitis B status Negative  1.00  0.15 1.00   
Positive  1.51 0.91-2.50  2.31 1.29-4.13 0.004 
Unknown 1.54 0.85-2.79  0.94 0.46-1.92 0.86 
Hepatitis C status Negative  1.00  0.50    
Positive  1.41 0.79-2.51     
Unknown 0.79 0.40-1.55     
Ever smoked Never  1.00  <.0001 1.00   
Current/previous 1.98 0.91-4.29  1.63 0.70-3.80 0.26 
Unknown 5.01 2.24-11.20  4.28 1.73-10.59 0.001 
Prior diagnosis None 1.00  0.001 1.00   
AIDS* 2.21 1.44-3.39  2.00 1.2-3.30 0.006 
Malignancy 1.23 0.63-2.41  1.34 0.64-2.82 0.43 
Anaemia No 1.00  <.0001 1.00   
 Yes 3.10 1.80-5.32  1.74 0.95-3.19 0.07 
 Unknown 1.46 0.81-2.65  0.82 0.34-2.00 0.66 
Age per 10 yr  1.07 0.88-1.31 0.48    
CD4 doubling  0.67 0.59-0.76 <.0001 0.68 0.58-0.80 <.0001 
CD4 nadir  0.84 0.77-0.92 <.0001    
Viral load        log10 higher 1.04 0.89-1.23 0.60    
Peak viral load    log10 higher 0.96 0.85-1.08 0.47    
Year of follow-up 0.92 0.87-0.98 0.006 1.10 0.98-3.19 0.07 
Ever started cART 1.62 0.71-3.70 0.25    
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6.4.6 Sensitivity analysis 
 
In the main analysis, all patients in EuroSIDA were included from the time of first 
enrolment into EuroSIDA. However, in the early period of data collection there was very 
little interest in non-AIDS defining events. As a consequence of this, the data collected 
on NADM only became part of the routine data collection and the EuroSIDA quality 
assurance exercise in 2003. Therefore, a sensitivity analysis in which follow-up was left 
censored at 1st January 2003 was performed. A total of 11,106 patients were included 
in the analysis and were followed for a total of 42,385 PYFU. During this time a total of 
187 NADM occurred.  
 
Table 6.8 Multivariable Poisson regression analysis with follow-up left censored at 1/1/2003 
Cancer type N 
events 
Adjusted IRR per doubling of 
current CD4 count 
95 %CI P-
value 
All NADM 187 0.81 0.74-0.88 <.0001 
Virus related 86 0.76 0.70-0.83 <.0001 
Non-virus related epithelial 79 0.92 0.18-1.08 0.29 
Other 22 0.79 0.56-1.11 0.17 
All NADM also adjusted for gender, ethnic origin, HIV exposure group, region of Europe, 
hepatitis B and C status, ever smoked, prior diagnosis of AIDS or malignancy, age, CD4 nadir, 
and having started cART;  
Virus-related also adjusted gender, ethnic origin, HIV exposure group, region of Europe, 
hepatitis B, prior diagnosis of AIDS or malignancy, age, CD4 nadir, and having started cART, 
Non-virus related epithelial also adjusted for ethnic origin, region of Europe, age, and year of 
follow-up,  
Other also adjusted for gender, HIV exposure group, region of Europe, hepatitis C status, ever 
smoked, prior diagnosis of AIDS or malignancy, age, CD4 nadir, and having started cART 
 
The results from the multivariable Poisson regression analysis are consistent with the 
main analysis. A higher current CD4 count associated with a 19% lower rate of NADM 
diagnosis (IRR 0.81, 95% 0.74-0.88, p<.0001). Similarly, a higher current CD4 count 
was associated with a lower rate of ‘virus related’, ‘non-virus related epithelial’ and other 
cancers, although the associations were not significant for ‘non-virus related epithelial’ 
and other cancers (table 6.8). 
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Further as a number of patients had missing data relating to their hepatitis B and C 
status and also their smoking history a sensitivity analysis was performed only including 
individuals with complete data to check that the estimates for the association between  
current CD4  count development of an NADM were robust. A total of 9138 individuals 
were included in this analysis, and 218 NADM were observed during follow-up. The 
results were consistent with the main analysis (table 6.9). 
Table 6.9 Multivariable Poisson regression analysis including only those with complete data 
Cancer type N 
events 
Adjusted IRR 





All NADM 218 0.81 0.75-0.88 <.0001 
Virus related 113 0.78 0.72-0.85 <.0001 
Non-virus related epithelial 83 0.85 0.72-1.00 0.05 
Other 22 0.82 0.57-1.18 0.29 
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6.5 Discussion 
The incidence of NADM in EuroSIDA from 1994-2007 was 4.3 per 1000 PYFU. After 
adjustment, a higher current CD4 count was independently associated with a decreased 
incidence of NADM. In addition, an increased rate of ‘virus-related’ cancers and ‘non-virus 
related epithelial’ cancers was found in immunodeficient patients. Hodgkin’s lymphoma, 
anal and lung cancers were all found at a higher rate in patients with lower current CD4 
counts after adjustment for other demographic and traditional risk factors.  
 
The findings in this chapter confirm results from other studies that have found a link 
between immunodeficiency and certain NADM420;422;586;635;636;647;651 although others have 
not found an association415;421;652. However, only a few of these studies focused on current 
CD4 count as a measure of immunodeficiency586;647;651. It is important to distinguish 
between CD4 count nadir and current CD4 count; the former measures the lowest point 
the CD4 count has reached and will address the long term risk of NADM. In contrast, the 
current CD4 count measures the short term risk of NADM, based on the latest information, 
and takes account of increases in CD4 count which are associated with starting cART. In 
the analysis presented here, current CD4 count and not CD4 nadir was found to be 
important for the development of NADM, a finding also found by the Swiss HIV Cohort 
Study (SHCS) where the latest CD4 count was associated with the risk of HCC but that 
CD4 nadir was insensitive in predicting the risk of HCC647.  
 
Patients with HIV are now living longer10 and aging, which may allow other comorbidities 
such as NADM to develop. Older age was a strong predictor of the development of any 
NADM. This is not surprising given that around 77% of all cancers are diagnosed in 
patients over the age of 55416;653. Individuals in East Europe had a lower risk of developing 
an NADM. This may, in part, be due to competing risks from other events as individuals in 
East Europe have been found to have a higher rate of AIDS events and increased 
mortality424;654. 
 
An increased risk of developing ‘virus-related’ cancers was found in immunodeficeint 
patients. Similar findings were reported in a meta-analysis looking at ‘virus related’ cancer 
in immunodeficient patients, irrespective of the cause of immundeficiency420. Additionally, 
prior malignancy diagnosis was associated with an increased incidence, the majority of 
which were ADM (87%) which are caused by oncogenic viruses627;630.  
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This may be an indicator that if you lose immunosurveillance that otherwise protects you 
against oncogenic viruses, you are at an increased risk of all types of cancer caused by 
oncogenic viruses. HIV transmission group was also associated with an increased 
incidence of virus-related cancers, particularly when focusing on anal cancers. 
 
Studies prior to the HIV epidemic found an increased risk of HPV related anal cancer in 
homosexual men655;656. This increased risk has been found to be even higher in those 
infected with HIV630;656;657. Homosexual HIV transmission was found to be associated with 
almost a 3 times higher risk of anal cancer. Immunodeficiency was also significantly 
associated with an increased risk as also found in other studies636;642;657-659, measured by 
either time to AIDS diagnosis636 or low CD4 counts657;658. Guiguet et al.660 looked at the 
effect of immunodeficiency, HIV viral load and antiretroviral therapy on the risk of 
malignancy (Kaposi's sarcoma, non-Hodgkin lymphoma, cervical cancer, Hodgkin’s 
lymphoma, lung cancer, liver cancer, and anal cancer), and found that current CD4 count 
was the most predictive risk factor for all malignancies apart from anal cancer. They found 
that anal cancer was significantly associated with the duration of immunosuppression 
defined as CD4 count < 200 cells/mm3. 
 
The development of HL was found to be associated with immunodeficiency. A number of 
studies support this finding420;661;662. The incidence of HL has also been linked to 
immunodeficiency determined by time to AIDS diagnosis635. Other studies, however, have 
found no association421. Biggar et al. found that the incidence of HL is highest at moderate 
CD4 counts (150-199 cells/mm3)661, and another study663 found that the risk of HL 
increased for CD4 counts less than 350cells/mm3 and peaked at 50-99cells/mm3. This was 
investigated in this chapter, and evidence of a linear relationship between decreasing CD4 
count and increasing incidence of HL was found. CD4 count was split into four categories 
(<200, 200-349, 350-499, ≥500 cells/mm3). It may be that if there had been sufficient 
events to split the CD4 count into more categories, particularly in the <200 category, a 
non-linear relationship may have been observed.  
 
Although there were insufficient numbers of liver related cancer (including HCC) to analyse 
independently of other virus related cancers, an association between immunodeficiency 
and increasing risk of HCC has been observed previously647. A current CD4 count 
<200cells/mm3 was found to be associated with a 7-fold increased rate of liver cancer 
compared to patients with CD4 count >500cells/mm3 647.  
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However, another study found that the incidence of HCC after adjustment for HCV 
infection and alcohol use was not found to be significantly associated with HIV infection417. 
EuroSIDA does not currently collect data on alcohol use, so no adjustment could be made 
for this. 
 
Non-virus-related epithelial cancers were also found at an increased rate in 
immunodeficient patients. A meta-analysis by Grulich et al 420 comparing rates of cancer in 
HIV-positive patients and transplant patients found little evidence of an increased risk of 
epithelial cancers in either group compared to the general population. Rates of prostate 
cancer have actually been reported to be lower than in the general population410;420;614. The 
combined analysis, reported in this chapter, looking at prostate, breast, rectum and colon 
cancer found no relationship between immune deficiency and the development of these 
cancers, which supports findings that these cancers have not been found at an increased 
rate in HIV-positive patients420.  
 
HIV-positive patients have been found to have a 7-fold increased rate of lung cancer 
compared to the general population664-666. It is speculated that this increased risk is due to 
unmeasured confounding, and the higher rates of smoking in HIV-positive patients18;372;667. 
However, some studies have found that the increased risk remains even after adjustment 
for smoking668-670. Lung cancer has been linked to immunosuppression through studies 
into HIV-positive patients with AIDS407;635;668. However, other studies have reported no 
association with severe immunodeficiency665. Grulich et al420 reported an increase in rates 
of lung cancer. Lung cancer was the most common cancer in the epithelial group in our 
study and was found to be associated with current CD4 count. This may explain the 
association found with immunodeficiency and ‘non-virus related epithelial cancer’. 
Additionally, being a current smoker, one of the main risks for lung cancer671, and older 
age were associated with an increased risk of lung cancer status.  
 
No association was found with immunodeficiency in the ‘other’ group, which was 
predominately malignant melanomas and cancers at an unspecified location. Older age 
and smoking status were significantly associated with an increase risk in this group. This is 
supported by other studies that have reported that the most common non-AIDS defining 
skin cancers, including basal cell carcinoma, squamous cell carcinoma and malignant 
melanoma among HIV-positive patients have not been found to be significantly associated 
with immune function, but rather are related to traditional factors such as aging and skin 
colour672.  
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Malignancies are the most frequent cause of death in HIV-positive patients accounting for 
around one third of all deaths633, and one of the most frequent causes of hospitalization673. 
The results from this chapter suggest that patients with virus-related cancers have better 
survival rates than the two other cancer groups. A study in Brazil found that patients 
infected with HIV who developed Hodgkin’s lymphoma had high rates of remission, and 
overall survival rates were comparable to those in patients without HIV infection674. Studies 
have also found the survival rate after a diagnosis of anal cancer is similar to that of the 
general population675-677. One study reported that the two year survival rate after a 
diagnosis of anal cancer was 77% in HIV-positive and 75% HIV-negative patients, and HIV 
infection was not found to be significantly associated with outcome 675. Another study into 
treatment of anal cancer found that the 5 year overall survival was 65% in HIV-negative 
patients and 61% in HIV positive patients, again these differences were not significant676. 
Liver disease including HCC is now a leading cause of death among HIV-HCV co-infected 
patients and is becoming an important cause of death among HIV-HBV co-infected 
patients360. Brau et al413 reported that HCC developed faster in patients co-infected with 
HIV and HCV compared to patients infected with HCV alone. However median survival 
times were similar at 6.9 months and 7.5 months respectively (p=0.44).  
 
The highest number of deaths due to NADM were lung cancer related. Studies have 
reported that the prognosis after a diagnosis of lung cancer is poor in HIV-positive patients 
because it is often diagnosed later 678;679 and the response to therapy is poor 665. Surgery is 
the treatment of choice for some lung cancer cases, but prognosis remains poor665;666. 
However, studies have reported that surgery improves outcome in much the same way as 
in the general population665. A study in Maryland, of patients diagnosed with lung cancer 
between 1996 and 2003, found that HIV-positive patients were able to receive standard 
treatment regimens and the overall survival was 5.2 months, which was comparable to 
HIV-negative patients680. Other non-virus related epithelial cancers appear to have similar 
survival rates as the general population. One study reported that the 5 year survival rate 
after a diagnosis of breast cancer was 80%, which was similar to the control group of 
patients with undetermined HIV status681, and no association has been found between HIV 
status and outcome after a diagnosis of prostate cancer682. This analysis looking at death 
rates was very exploratory, as there was no information available on the treatment that 
each individual received or how advanced the cancer was at diagnoses; thus it is 
impossible to speculate the impact that this may have had on the results.  
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The patients enrolled in the EuroSIDA study are a very diverse and heterogeneous group 
which provide an ideal population for considering the development of NADM over many 
years of follow-up. However, there are a number of limitations of our work. Excessive 
alcohol use has been shown to be significant in predicting the risk of developing cancer416, 
as has smoking, both of which have been found at an increased level in the HIV-positive 
population compared to the general population18. We were able to adjust for smoking 
status in patients with this data recorded although we do not have information on the 
amount smoked (e.g. pack years). Also, we do not currently collect data on alcohol intake. 
Further, anaemia was included in the multivariate model as a time-updated covariate 
under the assumption that anaemia may be predictive of the development of an NADM, 
but the exact date of the development of the NADM cannot be established, only the date of 
diagnosis, and it may be the case that the NADM was the reason for the individual 
developing anaemia. The interpretation of the role of anaemia in the development of 
NADM should therefore be interpreted with caution. In addition, the centres included in 
EuroSIDA may not be representative of all clinics in Europe, as patients in EuroSIDA are 
those attending clinics for routine outpatient appointments, they have good access to care 
and may be monitored more frequently than other HIV-positive patients. This may have led 
higher rates of malignancies being reported and perhaps earlier detection. The NADM 
were grouped into 3 categories a priori, as there was insufficient power to consider them 
all individually. This has the advantage that we can look in detail in three broad categories 
which have many features in common, but one of the main disadvantages is that the 
groupings are heterogeneous, particularly in the ‘other’ group.  
 
Centres participating in the study may have become more aware of the importance of non-
AIDS diagnoses and have recorded more NADM in recent years, although EuroSIDA has 
an extensive quality assurance program and the data on NADM has been part of the 
quality assurance exercise since 2003. However, a sensitivity analysis in which follow-up 
was left censored at 1st January 2003 showed consistent results. Furthermore, the death 
rates analysis after a NADM diagnosis should be interpreted with caution. The one 
important limitation to this analysis is that no information was available on the type of 
treatment patients may have received for their NADM diagnosis. Additionally, the cause of 
death was not known for all patients.  
 
 
Currently there is debate over whether starting cART earlier provides any beneficial effect 
for NADM683 and there have been conflicting reports from other studies on trends of cancer 
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incidence over time406;614;684. For example, one study reported that there had been an 
increase in the incidence of anal cancer in the cART era, but a decrease in the incidence 
of HCC685. Other studies have shown that the use of cART does not appear to affect the 
incidence or overall survival of anal cancer686;687.  
 
Additionally, some studies have actually demonstrated an increased risk of HL in the cART 
era407;410;614;684, with one study reporting HL incidence was higher in HIV-positive patients 
using cART than those not415. Furthermore, the incidence of HIV-related lung cancer was 
reported to have increased from 0.008 per 1,000 PFYU in the pre-HAART era to 0.7 per 
patient-years follow-up in the post-HAART era688. In our study we observed a significant 
increase in non-virus related epithelial cancer, anal cancer and breast, colon, and prostate 
combined with increasing calendar year of follow-up. No significant difference was 
observed over time for the other groups after adjustment for other factors. Some of the 
increase in rate may in part be due to competing risk, in that individuals in the cART era 
are not dying from AIDS and are thus surviving longer, and therefore have a higher chance 
of developing a NADM or another illness. 
 
Whilst our study is not based on data from a strategic trial, and cannot establish that 
increasing the CD4 counts after starting cART would cause a decrease in NADM, it does 
suggest that earlier treatment may be beneficial for reducing the incidence of NADM by 
reducing the risk of severe immunosuppression. Since the introduction of cART, overall 
survival of HL has improved, with studies reporting a 2 year overall survival rate of 45% in 
the pre-cART era and 62% in the post cART era689. Furthermore, a recent study looking at 
cancer incidence in transplant patients found that the effects of immunosuppression were 
reversible for some cancer types690. The risk of developing infection related cancers was 
reversed with the reversal of immunosuppression, whereas other cancer types remained 
significantly increased after a reduction in immunosuppression690. In support of this, some 
HL tumours have reportedly undergone spontaneous remission when immunosuppressive 
therapy was discontinued662. The START (Strategic Timing of Antiretroviral Therapy) trial 
to determine whether starting cART early (before CD4 drops to less than 500 cells/mm³), 
rather than waiting until CD4 drops to less than 350 cells/mm³ as current guidelines 
recommend, reduces the occurrence of serious morbidity and mortality will also explore 
whether cART protects against NADM691. 
 
Our study has shown a link with immunodeficiency and the development of certain NADM, 
particularly those that are virus-related. Starting cART earlier to reduce the proportion of 
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patients with a low CD4 count may decrease the rate of developing many common non-
AIDS related malignancies, although the potential harms for longer exposure to drugs and 
risks of toxicities would have to be balanced against the potential benefits. Cohorts and 
clinical trials need to collect data on both AIDS and non-AIDS related illnesses to obtain a 
better understanding of the incidence and risk factors for the development of non-AIDS 
illnesses including cancer. Greater understanding of how these cancers develop and their 
risk factors may help in the prevention and treatment of malignancies in both the HIV-
positive and HIV-negative populations.  
 
A manuscript of this analysis was published in Cancer in November 2010 and can be 
found in Appendix VII. 
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Chapter 7 Regional differences in the incidence of AIDS and 
non-AIDS related mortality in HIV-positive patients 
across Europe 
7.1 Introduction 
This thesis has so far looked at the long term outcomes of HIV-positive patients across 
Europe and Argentina. A number of surrogate markers have been used to measure this, 
such as viral load, CD4 count, and the development of serious clinical events including 
both AIDS and non-AIDS related, with the last chapter having a particular focus on non-
AIDS defining malignancies. However, the overall aim of a long term durable cART 
regimen is to reduce the patient’s risk of mortality.  
7.1.1 All-cause mortality 
Mortality rates in the USA and Europe peaked in the mid90s540;692;693, just prior to the 
introduction of cART when a dramatic decline in mortality rates was seen156;157;234;272;692. 
Figure 7.1 shows the decrease in the rate of AIDS or death by calendar year within 
EuroSIDA. The risk of death for an HIV-positive patient in the cART era has been 
estimated to be >85% lower than in the pre-cART era272. Further, reports from studies in 
the more recent cART era show that mortality rates continue to decrease694-696, due to 
improvements in cART, both in terms of efficacy and less toxicity6, and its availability. 
Table 7.1 summarises the mortality rates observed in different studies of HIV positive 
patients, from around the time when cART was first available (1996) to the current 
treatment era. In the cART era all cause-mortality rates have been estimated to range 
from 9.4 to 24 per 1,000 PYFU.  
 
Studies conducted in the current treatment era have found the patients successfully 
treated with cART have a moderate excess mortality rate compared to the general 
population that is comparable with patients having other chronic conditions, such as 
diabtetes538. Further, Sighem et al.697 reported that the life expectancy of asymptomatic 
HIV-positive patients, who are still treatment naïve and have not experienced any CDC 
stage B or C events 24 weeks after diagnoses, approaches that of non-infected 
individuals. Using stochastic computer simulation, it has been estimated in homosexual 
men in the UK, 7.0 years of life are lost due to HIV698. 
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Figure 7.1 Incidence rate of AIDS or death per 100 person years of follow-up in EuroSIDA by 
calendar year  
 
Table 7.1 Mortality rates in developed countries in the cART era 
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Other studies have also identified subgroups of HIV-positive individuals that have 
mortality rates approaching that of the general population538;697;704;705. In particular, the 
Swiss HIV cohort compared mortality rates in their cohort to those of the Swiss general 
population from 1997-2001. They found that those who were successfully treated with 
cART and who were not co-infected with hepatitis C had an excess death rate that was < 
6 per 1,000 per year, similar to those with successfully treated cancer539. Zwahlen et 
al.538 also identified a subgroup of homosexuals who were AIDS free at starting cART, 
and had a CD4 count ≥ 350 cells/mm3 and a viral load ≤500 copies/ml 6 months after 
starting cART, where the mortality rate was estimated to be 5% higher than the 
corresponding gender and age matched general population538. Similarly, a recent study 
by Obel et al.704 (figure 7.2), reported that HIV-positive patients on cART did have a 
substantially increased risk of death compared to the general population, but that this 
increased risk was associated with well known HIV and non-HIV related risk factors that 
were identifiable prior to or in the first year after cART initiation. These risk factors 
included detectable viral load (>49copies/ml), CD4 count <200cells/mm3, AIDS defining 
disease, comorbidities, drug or alcohol abuse. Obel et al. also identified a sub-group of 
HIV-positive individuals, who had no identifiable risk factors, that had an almost identical 
risk of death to the general population704.  











Figure not available due to copyright restrictions 
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One of the main problems with comparing mortality rates in HIV-positive patients to that 
of those in the general population is finding a suitable comparison group. Various non-
HIV specific factors have been identified as being associated with a risk of all-cause 
mortality including Hepatitis C co-infection703;706, older age696, IDU transmission route707, 
poor socio-economic status708, low haemoglobin and creatinine levels708, low vitamin D 
levels709, smoking and alcohol abuse696. Many of these factors occur at higher rates in 
the HIV-positive population372;417;667 than in the general population, so a direct 
comparison may be biased. Additionally, HIV associated risk factors such as lower CD4 
cell counts and higher plasma viral load at cART initiation701 have been found to be 
associated with an increased risk of all-cause mortality. 
 
7.1.2 AIDS related mortality  
 
The main reason for the decline in all-cause mortality in HIV-positive patients, is that 
deaths due to AIDS-related causes have declined significantly in the cART era, both in 
absolute terms and in the proportion of deaths attributed to AIDS related causes234;272;692. 
The percentage of deaths attributed to AIDS was estimated to be as high as 90% in the 
pre-cART era703, to as low as 25% in the current treatment era695. In 2009, UNAIDS 
estimated that there was approximately 1.6 million deaths due to AIDS related causes 
worldwide710.  
 
Figure 7.3 shows the change in the proportion of deaths attributed to AIDS and non-
AIDS related causes in the EuroSIDA study over time. At the start of the study 70% of 
the deaths were due to AIDS related causes whereas in the current treatment era just 
over 20% of the deaths are attributed to AIDS related causes. AIDS related death is 
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One study reported the median CD4 count of those dying from AIDS to be 15 cells/mm3 
(IQR 6-42), with little difference between the pre and current cART periods703. 
Additionally, age, infection via intravenous drug use, previous AIDS diagnosis, CD4 
count at cART initiation and a viral load at cART initiation >100,000 copies/ml have been 
found to be strongly associated with progression to AIDS and death538;711;713. Further, not 
all AIDS events have been found to be associated with the same risk of death714;715. The 
risk of death from non-Hodgkin’s lymphoma has been found to be particularly high714;716, 
and previous EuroSIDA analysis has reported that the decreasing incidence of NHL was 
not as great as for other AIDS defining events after the introduction of cART622. 
However, the survival rate has improved in recent years due to more intensive 
chemotherapy regimens, increased complete remission rates and the use of effective 
cART689. In the current treatment era (2000-2005), the proportion of deaths attributed to 
non-Hodgkin’s lymphoma, Kaposi’s sarcoma or cervical carcinoma remained stable 
between 2000 and 2005717.  
 
The overall continued decrease in AIDS related deaths is due to improvements in the 
effectiveness, tolerability and availability of cART regimens over time155;718. The clinical 
benefit of cART is largely a result of its ability of produce sustained suppression of viral 
replication466, with the proportion of deaths classed as AIDS related decreasing with 
increasing duration on cART699.  
 
In studies where specific causes of death have been investigated, AIDS-related deaths 
still account for the highest proportion of death, followed by non-AIDS defining infections, 
non-AIDS defining malignancies, liver related causes, cardiovascular disease, 
violence/drug related cause359;363;694-696;699;703;717. The role of non-AIDS related deaths is 
discussed in more detail in the following section.  
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7.1.3 Non-AIDS related deaths 
As shown in figure 7.3, a high proportion of the mortality observed in HIV-positive 
individuals is now due to non-AIDS related causes354;359;695. It has been reported that 
deaths due to non-AIDS related causes now account for between 50-66% of all deaths 
that occur in HIV-positive patients363;364;719. The most common non-AIDS related deaths 
have been reported to be cardiovascular disease, liver related, non-AIDS defining 
infections, non-AIDS defining malignancies and deaths due to violence/substance 
abuse359;363;694-696;699;703;711;717. Some studies have shown that the incidence of non-AIDS 
related mortality, from causes specific such as cardiovascular disease (CVD), liver 
disease, and cancer, has also declined in the cART era 354;720.  
 
Figure 7.4 shows the results from the D:A:D study looking at the association between 
calendar time and rate of death696. They found that for many of the specific causes the 
rate of death decreased over time. Rates of death also fell for chronic viral hepatitis, liver 
failure, myocardial infarction, suicide and drug overdose. They reported no other obvious 
trends observed in relation to specific causes of death, with the exception of deaths in 
the ‘unknown’ category, which increased from 0.34 per 1000 person years in 1999/2000 
to 1.05 in 2007/2008, which is likely due to reporting delays. However, a study of 
individuals living in Southern Alberta in Canada between 1984 to 2003 reported that 
deaths from non-AIDS related conditions had increased both as an absolute number of 
deaths and as a proportion of all deaths in HIV-positive patients703. It has also been 
reported that death due to liver disease and non-AIDS defining infections have been 
found to be significantly increasing over time397;694;701;721. The Mortalité study also 
reported that, adjusted for age and gender, the proportion of death attributable to non-
AIDS related malignancies increased significantly from 2000 to 2005717 
 
Many non-HIV related risk factors are associated with an increased risk of non-AIDS 
related mortality, such as age696;711, co-nifections255;628;706 and other lifestyle factors such 
as smoking, alcohol and drug misuse. Smoking has been found to be associated with an 
increased risk of death, particularly from CVD and non-AIDS malignancies665;696. 
Additionally, studies have reported a significant association between alcohol abuse, 
which is high in the HIV-positive population411, and the development of some non-AIDS 
defining mailgnancies417;722, and as a consequence mortality364;385.  
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Figure 7.4. Rate of death in the D:A:D study according to calendar year and specific cause of death. 
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Further, individuals infected via IDU have been found to have higher rates of non-AIDS 
related mortality711, with particularly high rates of liver-related and violent death699. The 
increased rate of liver related mortality is thought to be in large part due to co-infection 
with hepatitis B and C364;706;723. However, survival of IDUs with and without HCV co-
infection has been shown to be similar721. Co-infection with other viruses such as the 
human papilloma virus or the Epstein Barr virus may also increase the risk of developing 
a non-AIDS defining event and in turn, a higher risk of death255;628;629.  
 
Other HIV-associated factors have also been identified for many of specific cause of 
non-AIDS related death, including immunodeficiency and inflammation attributable to 
uncontrolled viremia724;725. Immunodeficiency has been found to be associated with most 
non-AIDS related deaths, in particular non-AIDS malignancies, liver disease and renal 
failure361;699;711. The only exception appears to be cardiovascular disease353. Additionally, 
some evidence has found that HIV-infection may increase the risk of some serious non-
AIDS related events such as cardiovascular, renal, hepatic and malignancies353 , even in 
individuals with high CD4 counts356;726. HIV has been found to be an independent risk 
factor for cardiovascular disease720;727, and deaths due to cardiovascular disease have 
been found to be associated with viral replicaion363.  
 
Little variation in the rates of non-AIDS related deaths and the time on cART have been 
observed699;728. Individuals dying from non-AIDS related causes tend to have initiated 
cART at higher CD4 counts, have more cART experience and been receiving cART 
close to the time of death695. Martinez et al.701 reported that almost one third of patients 
in their study, in the cART era, died with optimal virologic suppression. The causes of 
death in these patients were commonly non-infectious diseases.  
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7.1.4 Differences in prevalence, access to cART and mortality rates 
across Europe 
In 1999, shortly after the introduction of cART, the EuroSIDA study reported that the 
mortality rate in West Central Europe was significantly lower than in North and South 
Europe729. The epidemic in North, South, and West Central Europe began in the late 
1980s730, and although the number of people living with HIV has risen by around 30% 
from 2000 to 2.3 million in 2009, the number of new infections has remained relatively 
stable at around 100,000 new infections each year731. Mortality rates in this region of 
Europe peaked in the mid 90s693, and since then widespread access to antiretroviral 
therapy has led to considerable drops in mortality732. UNAIDS reported that in North 
America and Western Europe (grouped together in UNAIDS reports), the number of 
deaths due to AIDS related causes has remained relatively stable in the current 
treatment era, with approximately 35,000 AIDS related deaths in 2009 compared to 
37,000 in 2001731.  
 
The epidemic in East Europe is more recent; the first outbreaks were reported among 
injection drug users in southern Ukraine in 1995, which were rapidly followed by other 
drug related outbreaks in Russia in 1996733. From then on, there has been a rapid 
increase in HIV infections in East Europe8;150, and this region now has one of the fastest 
growing HIV epidemics worldwide8. In East Europe and Central Asia (grouped together 
in UNAIDS reports), the number of people living with HIV almost tripled between 2000 
and 2009 and is now estimated to be around 1.4 million734, with Russia and the Ukraine 
accounting for nearly 90% of all new infections734. Additionally, a 4-fold rise has been 
reported in AIDS related deaths from an estimated 18,000 in 2001 to 76,000 in 2010734.  
 
The differences in mortality rates observed in the previous EuroSIDA analysis were 
attributed to different treatment policies and drug availability in these regions729. The 
uptake of cART in East Europe remains low, and previous studies have reported 
substantial differences in access to care and treatment compared to the rest of 
Europe424;735. A recent UNAIDS report estimated that in 2009, 19% (15%-21%) of those 
eligible for treatment in East Europe were accessing it, and although low, this proportion 
was estimated to have increased by 34%733.  
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More recent analysis within EuroSIDA has sought to develop a concise set of indicators 
to assess and compare the delivery of healthcare in the large, and heterogeneous, 
population of HIV-positive patients across Europe, in countries with highly varying levels 
of resources. These health care indicators looked at adherence to treatment guidelines 
and ability to achieve a clinical response of cART initiation. Only a few, and generally 
minor, differences were seen between South, North, and West Central Europe in most 
healthcare indicators. However, East Europe, Argentina and to some extent East Central 
Europe differed significantly from the rest of the regions735. The figure below, using the 
same variable described in chapter 3 (figure 3.2), shows that compared to North Europe, 
individuals form South (SE), East Central (ECE) and East (EE) Europe had significantly 
lower odd of being suppressed (HIC-RNA <500 copies/ml) >90% of the time they were 
on cART.  
 
Figure 7.5 Odds Ratio (OR) of having suppressed HIV-RNA (<500 copies/ml) during more than 90% of 
















Figure not available due to copyright restrictions 
  228 
Previous analysis within this thesis has also identified differences in various outcomes 
across the regions. In chapter 5, assessing the long term durability of nevirapine, 
efavirenz and lopinavir based cART regimens, a higher rate on non-AIDS events was 
observed in North Europe compared to South Europe. Additionally, the last chapter 
found that those in East Europe had a lower risk of developing an NADM. One theory 
was that this may, in part, be due to competing risks from AIDS related events and 
mortality. 
 
The EuroSIDA study has grown substantially since the last reports on mortality 
rates10;354, particularly in Eastern Europe where few cohort studies are established. The 
study therefore provides a unique opportunity to establish whether, in the current 
treatment era, regional differences in the mortality rate of HIV-positive individuals 
remain, to try and understand the factors underlying any such differences and whether 
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7.2 Aim 
The aim of this chapter was therefore to report rates of all-cause, AIDS and non-AIDS 
related mortality, in the current treatment era, across different regions of Europe and 
Argentina and to investigate trends over time. Furthermore we aimed to try and 
understand the factors attributable to any differences observed across the regions.  
 
7.3 Methods 
7.3.1 Patient selection 
There were 16,599 patients included in the D32 update. To investigate mortality rates 
across the different regions of Europe, patients were included who had some 
prospective follow-up after 1st January 2002, as this was the median date of first visit for 
patient enrolled in Cohort V. Cohort V was the first cohort to enrol a significant number of 
patients from Eastern Europe into EuroSIDA. Therefore, patients were included from 
baseline, which was defined as either 1st January 2002 or enrolment into EuroSIDA, 
whichever occurred later. Figure 7.6 shows the number of patients selected for inclusion 
into this analysis by region.  
 
Figure 7.6 Selection of patients for inclusion into this analysis 
 
16599 patients 
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As discussed in Chapter 2, EuroSIDA individuals were divided into 6 regions (figure 7.7) 
according to country of residence as follows: 
 South Europe: Greece, Israel, Italy, Portugal, Spain.  
 West Central Europe: Austria, Belgium, France, Germany, Luxembourg, 
Switzerland.  
 North Europe: Denmark, Finland, Ireland, the Netherlands, Norway, Sweden, 
United Kingdom 
 East Central Europe: Bulgaria, Croatia, the Czech Republic, Hungary, Poland, 
Romania, Serbia, Slovakia 




Figure 7.7 Map depicting the 6 geographical regions 
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Patients were followed until their death, or 6 months after their last recorded visit 
reported on EuroSIDA follow-up forms, whichever occurred first. Some centres may be 
linked to death registries, and therefore following all individuals until death, including 
those who had been lost to follow-up, may introduce differential censoring between 
those who did and did not die.  
 
7.3.2 Coding causes of death 
For patients enrolled in the EuroSIDA cohort who died, date and cause of death are 
reported by the site investigator on the EuroSIDA follow-up forms and, since 2004, a 
Coding of Death in HIV (CoDe) case report form is additionally completed for each fatal 
case736. For this analysis, deaths were classified into AIDS-related deaths or non-AIDS 
related deaths using a three step hierarchical process737. 
 
The Coding of Death in HIV (CoDe) project started in 2004, is a uniform coding system 
applied to studies of individuals with HIV infection (full details available at 
www.cphiv.dk). It consists of a form providing detailed data on the causes of death and 
contributing factors, and a centralised review process of the data collected (see 
Appendix III). The underlying cause of death was defined as the disease or injury that 
initiated the morbid trend of events. If a CoDe form was available, deaths attributed to 
AIDS infections (CoDe 1.11) or AIDS malignancy (CoDe 1.12) were classed as AIDS 
related and all other deaths non-AIDS related. 
 
If no CoDe form was available, then EuroSIDA follow-up forms were assessed (see 
Appendix I). If the illness causing death reported on the EuroSIDA follow-up forms was 
HIV related, an AIDS defining event or an invasive bacterial infection then the death was 
classed as AIDS related and all other deaths non-AIDS related.  
 
Finally, to allow for patients with missing information on the cause of death to be 
included in the analysis, if the cause of death could not be determined using either CoDe 
or EuroSIDA follow-up forms then a computer based algorithm was used to determine if 
the death was AIDS related or non AIDS-related738, as shown in figure 7.8.  
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In this case, if the patient had experienced an AIDS defining event within the upper limit 
of survival time for the preceding AIDS defining event (table 7.2), or within 17 months 
prior to death (if the survival time was not known) then the death was classified as AIDS 
related causes739;740. If the patient had never experienced an AIDS defining event, or the 
most recent AIDS defining event was out with the upper limit of survival (or 17 months), 
then the patient was classed as dying from non-AIDS related causes.  
 
Deaths classed as non-AIDS related were further classified into non-AIDS related 
infection, liver related (including deaths due to hepatitis B or C, liver failure or cirrhosis 
and liver cancer), non-AIDS defining malignancies (including all malignancies excluding 
AIDS defining cancers [Kaposi’s Sarcoma, Non-Hodgkin’s Lymphoma and cervical 
carcinoma} and liver cancer), cardiovascular disease (including a stroke, Myocardial 
Infarction [MI], heart or vascular disease), violent (including an accident or violence, 
suicide, euthanasia, substance abuse or overdose), other (causes associated with < 20 
deaths) or unknown (deaths with insufficient information to determine cause of death 









Figure not available due to copyright restrictions 
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7.3.3 Statistical methods 
The incidence of all-cause, AIDS and non-AIDS related mortality was calculated per 
1000 person years of follow-up (PYFU), and stratified by region and calendar year. 
 
Poisson regression analyses were used to investigate factors associated with the 
incidence of mortality from all-cause, AIDS and non-AIDS related causes. Variables 
investigated were age, gender, ethnic origin, smoking status, anaemia, hypertension, 
diabetes, hepatitis B and C status, and year of follow-up. Age and year of follow-up were 
treated as continuous variables. Factors that were significant in univariable analysis 
(p<0.1) were included in the multivariable model.  
 
Individuals were classed as Hepatitis B positive if they had a positive HBV surface 
antigen test recorded and Hepatitis C positive if they had a positive HCV antibody test. 
Hypertension was defined as a diastolic blood pressure ≥ 90 or a systolic blood pressure 
≥ 140 mmHg or receiving anti-hypertensive medication. If a diagnosis of insulin-
dependent diabetes was reported by the investigating centre, or if an individual was 
receiving anti-diabetic medication they were classed as diabetic. Anaemia was defined 
as a haemoglobin level ≤ 12 or ≤14 mg/dl for females and males respectively598. In 
addition, variables related to HIV infection were also investigated including HIV 
transmission group, any previous AIDS defining illnesses, CD4 count, on cART viral load 








Figure not available due to copyright restrictions 
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7.3.3.1 Categorisation of CD4 count and viral load   
In chapter 3, the median time between successive CD4 and viral load measurements 
was 3 months (IQR 3–4 months) in patients who were maintained on a stable and fully 
suppressed cART regimen for at least 1 year. However, in that analysis a high 
proportion of patients in East Europe were excluded, due to missing values. Current 
guidelines recommend clinical and laboratory evaluation of HIV-disease status at least 
every half year before initiation of cART and on a 6-12 month basis in clinically stable 
patients on cART with suppressed HIV-RNA214;223;498. Adequate monitoring of untreated 
patients is important in terms of the timely initiation of cART and the prevention of AIDS 
and, ultimately, death735.  
 
Table 7.3 below shows the differences in the frequency of CD4 count and viral load 
monitoring across the 6 different regions. A substantial number of patients in East 
Europe have missing CD4 counts and viral loads for a significant proportion of their 
follow-up. This is particularly true for viral load measurements in patients who have not 
yet started cART.  
 
Table 7.3 Time between CD4 count and viral load measurements by region 
 Time in months between 
CD4 measurements 
Median (IQR) 
Time in months between viral 
load measurements 
Median (IQR) 
South Europe 3.7 (3.0-4.1) 3.8 (3.0-4.2) 
West Central Europe 3.0 (2.6-3.4) 3.0 (2.7-3.4) 
North Europe 3.0 (3.0-3.7) 3.0 (3.0-3.6) 
East Central Europe 4.1 (3.2-5.6) 5.3 (3.9-6.3) 
East Europe 5.2 (3.7-7.3) 6.1 (3.9-9.2) 
Argentina 6.5 (4.7-9.0) 6.7 (4.6-8.9) 
 
Therefore, in this analysis CD4 count was included as a categorical variable <200, 200-
349, 350-500, ≥500 cell/mm3, and missing (no CD4 count measured in the previous 6 
months), to allow for patients with missing values to remain in the analysis. Further, 
treatment for HIV was split into 4 categories, not on cART, on cART with a viral load 
<500 copies/ml, on cART with a viral load ≥500 copies/ml, or on cART with no viral load 
measurement available in the previous 6 months. cART was defined as receiving ≥ 3 
antiretrovirals. Both current and baseline values were investigated for variables that 
could change over time, such as age, and CD4 count 
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7.4 Results 
7.4.1 Baseline characteristics 
13,280 HIV-positive individuals were included in the analysis. There were clear 
differences in demographics across the regions at baseline (table 7.4). In East Europe, 
individuals were more likely to be younger (median age 30), female (43%) and infected 
via intravenous drug use [IDU] (48%) or heterosexual sex (40%). In contrast, the 
majority of the individuals in West Central (45%), and North Europe (59%) were infected 




3,666 patients had an AIDS diagnosis prior to baseline. Table 7.5 shows the five most 
common AIDS diagnosis overall and the proportion of each observed in each region. 
The most commonly observed prior AIDS diagnosis was Oesophageal candidiasis 
(16.6%), it was the most commonly reported AIDS diagnosis in West Central (19.8%), 
East Central (20.0%) and East Europe (24.4%) and the second most common in North 
Europe (16.9%). The most commonly reported AIDS diagnosis in South, and North 
Europe and Argentina was Pneumocystis jiroveci pneumonia (PCP), which was the 
second most common overall. A higher proportion of prior AIDS was due to Pulmonary 
Mycobacterium Tuberculosis (TB) and HIV wasting syndrome (14%) in East Europe 
(18%) compared to the other regions.  
 
 
10,263 ( 77.3%) patients had started cART prior to baseline, as shown in table 7.6, In 
South, West Central, North, East Central Europe and Argentina, around 80% had started 
cART prior to baseline, compared to only 31% in East Europe. Median CD4 count and 
viral load in those starting cART were similar across the regions. However, 7% of those 
who had started cART in East Europe did not have a viral load measurement available 
at the time of starting. In South, West Central, North and East Central Europe over 50% 
of patients starting cART started on a PI based regimen whereas in East Europe and 
Argentina a higher proportion started on an NNRTI based regimen.  
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Table 7.4 Baseline characteristics (baseline was defined as either 1
st
 January 2002 or enrolment into EuroSIDA which ever occurred 
later) 




North Europe East Central 
Europe 
East Europe Argentina 
Total  3226 2916 2865 1699 2078 496 
Gender (N.%) Male 2379 (73.7) 2244 (77.0) 2330 (81.3) 1220 (71.8) 1170 (56.3) 308 (62.1) 
Race (N.%) White 2956 (92.4) 2098 (75.2) 2423 (85.5) 1667 (99.6) 2069 (99.9) 48 (98.6)8 
Exposure Group Homosexual 1099 (34.1) 1306 (44.8) 1692 (59.1) 626 (36.9) 154 (7.4) 126 (25.4) 
(N.%) Injection Drug User 946 (29.3) 404 (13.9) 317 (11.1) 447 (26.3) 995 (47.9) 62 (12.5) 
 Heterosexual 978 (30.3) 848 (29.1) 684 (23.9) 489 (28.8) 827 (39.8) 292 (58.9) 
Hepatitis B (N.%) Negative 2171 (67.3) 2308 (79.2) 2337 (81.6) 1405 (82.7) 1647 (79.3) 357 (72.0) 
 Positive 160 (5.0) 201 (6.9) 207 (7.2) 81 (4.8) 114 (5.5) 26 (5.2) 
 Unknown 895 (27.7) 407 (13.9) 321 (11.2) 213 (12.5) 317 (15.2) 113 (22.8) 
Hepatitis C (N.%) Negative 1586 (49.2) 1984 (68.0) 1839 (64.2) 996 (58.6) 698 (33.6) 294 (59.3) 
 Positive 751 (23.3) 457 (15.7) 327 (11.4) 478 (28.1) 1011 (48.7) 94 (19.0) 
 Unknown 889 (27.6) 475 (16.3) 699 (24.4) 225 (13.2) 369 (17.8) 108 (21.8) 
Hypertension No 197 (6.1) 179 (6.1) 170 (5.9) 249 (14.7) 438 (21.1) 57 (11.5) 
 Yes 130 (4.0) 265 (9.1) 221 (7.7) 153 (9.0) 54 (2.6( 26 (5.2) 
 Unknown 2899 (89.9) 2772 (84.8) 2474 (86.4) 1297 (76.3_ 1586 (76.3) 413 (83.3) 
Diabetes No 2898 (89.8) 202 (69.3) 2623 (91.6) 1610 (94.8) 2060 (99.1) 490 (98.8) 
 Yes 177 (5.5) 149 (5.1) 92 (3.2) 43 (2.5) 5 (0.2) 4 (0.8) 
 Unknown 152 (4.7) 747 (25.6) 148 (5.2) 46 (2.7) 13 (0.6) 2 (0.4) 
Anaemia No 2180 (67.6) 1899 (65.1) 1622 (56.6) 773 (45.5) 183 (8.8) 187 (37.7) 
 Yes 755 (24.0) 747 (25.6) 910 (31.8) 296 (17.4) 101 (4.9) 204 (41.1) 
 Unknown 271 (8.4) 270 (9.3) 333 (11.6) 630 (37.1) 1794 (86.3) 105 (21.2) 
Smoking          Never 698 (21.6) 755 (25.9) 567 (19.8) 417 (24.5) 387 (18.6) 153 (30.9) 
                 Current 1469 (45.5) 1196 (41.0) 11554 (40.3) 868 (51.1) 1120 (53.9) 163 (32.9) 
                 Previous 625 (19.4) 648 (21.8) 624 (21.8) 291 (17.1) 377 (18.1) 143 (28.8) 
                 Unknown 434 (13.5) 317 (10.9) 520 (18.2) 123 (7.2) 194 (9.3) 37 (7.5) 
Age (median, IQR)  40 (35-45) 42 (37-49) 43 (37-50) 35 (30-42) 30 (25-36) 37 (31-43) 














Missing CD4 count (N, %) 17 (0.5) 11 (0.4) 15 (0.5) 6 (0.4) 110 (5.3) 5 (1.0) 












IQR: Interquartile range 
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Prior AIDS diagnosis (N,% of total) 827 (25.6) 951 (32.6) 907 (31.7) 420 (24.7) 401 (19.3) 160 (32.3)  
Oesophageal candidiasis (N,%) 76 (9.2) 188 (19.8) 153 (16.9) 84 (20.0) 98 (24.4) 9 (5.6) 
Pneumocystis jiroveci pneumonia (PCP) (N,%) 148 (17.9) 131 (13.8) 190 (20.9) 63 (15.0) 33 (8.2) 36 (22.5) 
Pulmonary Mycobacterium Tuberculosis (TB) (N,%)  130 (15.7) 54 (5.7) 53 (5.8) 54 (12.9) 72 (18.0) 20 (12.5) 
Kaposi’s’ Sarcoma (N,%) 102 (12.3) 95 (10.0) 124 (13.7) 17 (4.0) 8 (2.0) 14 (8.8) 
HIV wasting syndrome (N,%) 38 (4.6) 49 (5.2) 24 (2.6) 54 (12.9) 56 (14.0) 9 (5.6) 
 
 












N started cART (N,%) 2776 (86.1) 2577 (88.4) 2523 (88.1) 1336 (78.6) 654 (31.5) 397 (80.0) 
CD4 count at starting cART  













Missing CD4 count (N, %)  0 0 0 0 2 (0.3) 1 (0.3) 














Missing Viral load (N,%) 0 0 0 11 (0.8) 46 (7.0) 6 (1.5) 
Initial cART regimen started (N, %)       
NNRTI based cART 488 (17.6) 501 (19.4) 524 (20.8) 398 (29.8) 355 (54.3) 199 (50.1) 
PI based cART 1592 (57.4) 1404(54.5) 1398 (55.4) 734 (54.9) 258 (39.5) 157 (39.6) 
Other 696 (25.1) 672 (26.1) 601 (23.8) 204 (15.3) 41 (6.3) 41 (10.3) 














IQR:Interquartile range, NNRTI: Non-nucleoside reverse transcript inhibitor, PI: Protease Inhibitor 
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7.4.2 All-cause mortality 
From 2002 to 2010, individuals were followed for a total of 67,905 PYFU. During this 
time 1,038 patients died; the crude mortality rate was 15·3 per 1,000 PYFU (95% 
confidence interval [CI] 14·4-16·2). Significant differences in mortality rates were seen 
across the 6 different regions (global p<0·0001). Figure 7.9 shows that higher all-cause 
mortality rates were observed in North (IR 18.5 per 1,000 PYFU, 95% CI 16.4-20.6) and 
East (IR 23.23 per 1,000 PYFU, 95% CI 19.4-27.0) Europe compared to the other 
regions.  
Figure 7.9: Crude all-cause mortality rate by region 
 
Compared to South Europe, before adjustment, individuals in North Europe had a 1.35 
times higher rate of all-cause mortality and individuals in East Europe had a 1.59 times 
higher rate (table 7.7). There was no significant difference in the risk of all-cause 
mortality between South Europe and West Central, East Central or Argentina. After 
adjustment for fixed variables (gender and HIV exposure group), and baseline variables 
(age, CD4 count, treatment, hepatitis B and C status, hypertension, diabetes, anaemia, 
smoking status and prior AIDS diagnosis) there remained a significantly increased risk of 
all cause-mortality in North and East Europe compared to South Europe. 
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 IRR 95% CI 
p-
value IRR 95% CI 
p-
value IRR 95% CI 
p-
value 
South 1.00   1.00   1.00   
West Central 0.86 0.72-1.04 0.12 0.97 0.80-1.19 0.80 0.93 0.76-1.14 0.48 
North 1.35 1.14-1.60 0.0004 1.48 1.24-1.78 <.0001 1.40 1.18-1.68 0.0001 
East Central 1.02 0.82-1.27 0.87 1.39 1.10-1.75 0.005 1.35 1.09-1.69 0.007 
East 1.59 1.29-1.95 <.0001 2.07 1.53-2.80 <.0001 1.76 1.39-2.22 <.0001 
Argentina 0.69 0.45-1.07 0.095 0.94 0.60-1.48 0.79 0.75 0.48-1.18 0.21 
a
adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior 
AIDS diagnosis, hypertension, diabetes, anaemia, smoking status, CD4 count, baseline date and 
on cART viral load 
b
adjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, smoking 




Additionally, after adjustment for these baseline variables a higher rate of mortality was 
also observed in East Central Europe compared to South. The higher risk of all-cause 
mortality observed in North, East Central and East Europe compared to South Europe 
remained after adjustment for time-updated variables rather than those measured at 
baseline (table 7.6). 
 
Other factors found to be significantly associated with the risk of all-cause mortality are 
shown in table 7.8. Having been infected with HIV via IDU was associated with a high 
risk of mortality compared to homosexual transmission. Older age, being hepatitis B or C 
positive, diabetic, anaemic, a current smoker compared to having never smoked, or 
having a prior AIDS diagnosis were also associated with an increased all-cause mortality 
rate. Calendar year of follow-up was associated with a lower risk of all-cause mortality 
 
A lower CD4 count was associated with an increased risk of all-cause mortality. 
Individuals with a current CD4 count < 200 copies/ml had over a 7 times higher risk of 
mortality compared to those with a CD4 count ≥ 500 copies/ml. Individuals not on cART 
had an almost three times higher risk of mortality compared to those on cART with a 
suppressed viral load. Those on cART with uncontrolled viral replication had a borderline 
significantly increased risk of mortality; although it was lower than those not on cART. 
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 IRR 95% CI 
Global  
p-value IRR 95% CI p-value IRR 95% CI 
p-
value 
Gender (male vs. female) 0.68 0.58-0.79 <.0001 0.85 0.72-1.01 0.07 0.82 0.69-0.98 0.02 
Race (white vs. other) 0.76 0.62-0.94 0.01       
Age 10 year older 1.42 1.35-1.50 <.0001 1.63 1.53-1.75 <.0001 1.64 1.54-1.75 <.0001 
HIV exposure 
group 
Homosexual 1.00  <.0001 1.00   1.00   
IDU 2.03 1.76-2.35  2.06 1.65-2.56 <.0001 1.78 1.42-2.24 <.0001 
Heterosexual 0.87 0.74-1.03  1.07 0.89-1.30 0.46 1.04 0.86-1.25 0.69 
 Other 1.27 0.99-1.62  1.19 0.92-1.53 0.18 1.10 0.86-1.42 0.44 
CD4 count ≥500 1.00  <.0001       
 350-499 1.34 1.10-1.63  1.14 0.94-1.40 0.19 1.32 1.03-1.71 0.03 
 200-349 1.95 1.62-2.34  1.36 1.13-1.64 0.001 2.25 1.78-2.83 <.0001 
 <200 4.71 3.98-5.58  2.65 2.21-3.19 <.0001 7.38 5.97-9.14 <.0001 
 Missing 22.46 16.4-30.6  8.66 5.97-12.56 <.0001 3.82 3.00-4.86 <.0001 
Treatment On cART VL ≤500 1.00  <.00001 1.00   1.00   
 Not on cART 1.85 1.60-2.14  1.96 1.67-2.30 <.0001 2.82 2.40-3.31 <.0001 
 On cART VL >500 2.43 2.09-2.83  1.98 16.9-2.32 <.0001 1.21 0.99-1.49 0.06 
 On cart missing VL  13.24 8.97-19.55  5.13 3.24-8.12 <.0001 1.40 1.12-1.75 0.002 
Hepatitis B (negative vs. positive) 1.55 1.25-1.92 0.0008 1.43 1.15-1.77 0.001 1.43 1.18-1.73 0.0003 
Hepatitis C (negative vs. positive) 2.04 1.78-2.35 <.0001 1.38 1.13-1.69 0.001 1.36 1.10-1.68 0.005 
Hypertensive (no vs. yes) 1.77 1.16-2.71 0.01 0.89 0.55-1.44 0.62 0.76 0.58-1.01 0.05 
Diabetic (no vs. yes) 2.18 1.74-2.73 <.0001 1.86 1.47-2.37 <.0001 1.44 1.16-1.79 0.001 
Anaemic (no vs. yes) 2.37 2.07-2.71 <.0001 1.64 1.42-1.89 <.0001 3.57 2.94-4.33 <.0001 
Smoking status Never 1.00  <.0001 1.00   1.00   
 Current 1.64 1.37-1.96  1.27 1.05-1.53 0.01 1.30 1.07-1.57 0.007 
 Previous 1.27 1.03-1.56  1.11 0.90-1.37 0.31 1.13 0.92-1.38 0.25 
Prior AIDS diagnosis (no vs. yes) 1.96 1.74-2.22 <.0001 1.54 1.36-1.76 <.0001 1.53 1.34-1.74 <.0001 
Calendar year 0.89 0.86-0.93 <.0001 0.83 0.78-0.83 <.0001 0.88 0.85-0.91 <.0001 
*Also adjusted for region, IDU: Injection drug user 
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Figure 7.10 shows how many causes of death were determined to be AIDS or non-AIDS 
related at each stage in the hierarchical process for coding causes of death. The majority 
of the deaths (56%) were coded using CoDe. The computer algorithm was used to code 
the causes of death in 13.1% of the cases. 
 





The proportions of deaths classified at each stage are shown in table 7.9, stratified by 
region. A marginally higher proportion of deaths in East Europe, East and Argentina 
were classified using CoDe. This is probably due to more of the deaths in these regions 
being in the more recent time period when CoDe was available (as shown in table 7.9).  
 
Table 7.9 Number of death classified at each stage by region 









Total 246 195 314 118 143 22 
CoDe 136 (55.3) 96 (49.2) 169 (53.8) 80 (67.8) 84 
(58.7) 
19 (86.4) 
EuroSIDA forms 76 (30.9) 63 (32.3) 100 (31.9) 28 (34.3) 49 
(34.3) 
2 (9.0) 
Computer algorithm 34 (13.8) 36 (18.5) 45 (14.3) 10 (8.5) 10 (7.0) 1 (4.6) 
Median date of 
death  
7/05  1/05  3/05 10/06 7/07 3/06 
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7.4.3  AIDS related mortality  
 
Of the 1,038 patients who died, AIDS was attributed as the cause of death in 284 (27%) 
patients. The crude rate of death due to AIDS related causes from 2002-2010 was 4·2 
AIDS related deaths per 1,000 PYFU (95% CI 3·7-4·7). Figure 7.11 shows the crude 
mortality rate for AIDS related causes by region. East Europe had the highest rate of 
AIDS related mortality (IR 12.0 per 1,000 PYFU, 95% CI 9.3-14.7). The crude mortality 
rate due to AIDS related causes in East Europe was over three times higher than in 
South Europe (incidence rate ratio [IRR] 3.63, 95%CI 2.57-5.10, p<·0001). A similar 
mortality rate was observed in the other five regions, ranging from 2.8 per 1000 PYFU 
(95%CI 2.0-3.6) in West Central Europe to 4.8 per 1,000 PYFU (95%CI 2.0-3.6) in 
Argentina.  
 
Figure 7.11 Crude incidence rate of AIDS related mortality by region  
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Table 7.10 Patient characteristics at the time of AIDS related death 
 South West Central North East Central East Argentina p-value 
Total (N,% of total) 59 (20.8) 46 (16.2) 59 (20.8) 35 (12.3) 74 (26.1) 11 (3.9)  
Age (median, IQR) 45 (41-50) 48 (39-58) 48 (42-57) 40 (34-53) 35 (30-39) 36 (34-47) <.0001 
CD4 count within 6 months (median, IQR) 43 (18-150) 73 (17-240) 66 (10-153) 91 (28-290) 117 (32-231) 76 (44-136) 0.20 
Missing CD4 (N,%) 16 (27.1) 8 (17.4) 16 (27.1) 4 (11.4) 30 (40.5) 5(45.5)  













Started cART (N,%) 55 (93.2) 43 (93.5) 58 (98.3) 32 (91.4) 37 (50.0) 9 (81.8) <.0001 
Most recent AIDS diagnosis (N, %)        
   Non-Hodgkin’s lymphoma 17 (28.8) 9 (19.6) 14 (19.6) 7 (20.0) 1 (1.4) 1 (9.1) <.0001 
   Oesophageal candidiasis 3 (5.1) 4 (8.7) 5 (8.5) 0 (0) 16 (21.6) 1 (9.1)  
   HIV wasting syndrome 2 (3.4) 5 (10.9) 6 (10.2) 2 (5.7) 8 (10.8) 1 (9.1)  















Patients reporting ≥1 non-AIDS event  14 (23.7) 7 (15.2) 7 (11.9) 6 (17.1%) 14 (18.9%) 1 (9.1%) 0.58 
  Non-AIDS defining malignancy 8 (13.6) 2 (4.3) 1 (1.7) 1 (2.9) 1 (1.4) 1 (9.1)  
  Cardiovascular disease 4 (6.8) 3 (6.5) 4 (6.8) 3 (8.6) 1 (1.4) 0 (0)  
  Liver disease 1 (1.7) 1 (2.2) 1 (1.7) 0 (0) 5 (6.8) 0 (0)  
  End stage renal disease 0 (0) 1 (2.2) 1 (1.7) 0 (0) 2 (2.7) 0 (0)  
  Pancreatitis 1 (1.7) 1 (2.2) 0 (0) 2 (5.7) 6 (8.1) 0 (0)  
 






 IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value 
South 1.00 - - 1.00 - - 1.00 - - 
West Central 0.85 0.58-1.25 0.41 0.90 0.61-1.34 0.60 0.82 0.56-1.20 0.29 
North 1.06 0.74-1.52 0.76 1.13 0.77-1.66 0.52 1.04 0.72-1.48 0.84 
East Central 1.26 0.83-1.91 0.27 1.42 0.92-2.21 0.11 1.54 1.01-2.36 0.04 
East 3.43 2.44-2.44 <.0001 2.44 1.46-4.08 0.0006 3.26 2.19-4.84 <.0001 
Argentina 1.44 0.76-2.74 0.26 1.00 0.51-1.97 0.99 1.01 0.52-1.95 0.98 
a
adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, AIDS diagnosis prior to baseline, hypertension, 
anaemia, CD4 count, baseline date and on cART viral load. 
b
adjusted as in c but age, hepatitis B and C status, hypertension, anaemia, CD4 
count, year of follow-up and on cART viral load were included as time-updated covariates 
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Patients dying from AIDS related causes in East Europe, and Argentina were younger 
than those in other regions (table 7.10). A high proportion of the most recent AIDS 
diagnosis prior to baseline was Non-Hodgkin’s lymphoma in South, West Central, North 
and East Central Europe. In East Europe the most common recent AIDS related 
diagnosis prior to death was oesophageal candidiasis.  
 
Table 7.11 gives the results of the Poisson regression analysis and presents the 
incidence rate ratios for AIDS related mortality. Adjusting for gender, age, HIV exposure 
group, AIDS diagnosis prior to baseline, hypertension, anaemia, baseline CD4 count, 
baseline date and baseline treatment accounted for some of the higher rate of AIDS-
related mortality observed in East Europe. However, the rate of AIDS-related mortality 
was still more than double the rate in South Europe (IRR 2·40, 95%CI 1·44-4·02, 
p=0·0008). The increased incidence of AIDS related mortality in East Europe remained 
after modelling age, hypertension, anaemia, CD4 count, year of follow-up and treatment 
as time updated covariates.  
 
Table 7.12 shows the other factors that were found to be associated with risk of AIDS 
related mortality. As with all-cause mortality older age, anaemia, and a prior AIDS 
diagnoses were associated with an increased risk of death from AIDS related causes. 
Similarly, increasing calendar year of follow-up was associated with a decreased risk of 
AIDS related mortality  
 
A lower CD4 count was associated with an increased risk of AIDS related mortality. Not 
being on cART was associated with a 6.3 times higher rate (95% CI 4.38-8.97), and 
being on cART with a uncontrolled viral replication was associated with a 1.75 time 
higher rate (95% CI 1.16-2.64, p=0.0007) of AIDS related mortality compared to being 
on cART with a suppressed viral load.  
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 IRR 95% CI 
Global 
p-value IRR 95% CI p-value IRR 95% CI 
p-
value 
Gender (male vs. female) 0.75 0.56-1.00 0.04 
0.72 0.52-1.00 0.05 0.70 0.51-0.97 0.03 
Race (white vs. other) 0.80 0.54-1.17 0.25       
Age 10 year older 1.06 0.95-1.19 0.30 1.33 1.17-1.50 <.0001 1.28 1.12-1.46 0.0003 
HIV exposure 
group 
Homosexual 1.00  0.0003 1.00   1.00   
IDU 1.94 1.45-2.60  1.55 1.02-.35 0.03 1.26 0.92-1.73 0.14 
Heterosexual 1.35 1.01-1.82  1.39 0.98-1.96 0.06 1.37 0.98-1.91 0.06 
 Other 1.17 0.71-1.95  1.05 0.63-1.77 0.84 1.05 0.63-1.76 0.84 
CD4 count ≥500 1.00  <.0001 1.00      
 350-499 1.73 1.08-2.79  1.45 0.90-2.34 0.12 1.72 0.79-3.72 0.17 
 200-349 2.64 1.70-4.09  1.79 1.15-2.79 0.01 3.33 1.67-6.66 0.0007 
 <200 12.99 8.90-18.95  5.90 3.95-8.80 <.0001 27.0 14.80-50.02 <.0001 
 missing 54.0 30.40-95.89  11.96 6.34-22.56 <.0001 8.01 4.27-15.04 <.0001 
Treatment on cART VL ≤500 1.00  <.0001 1.00      
 Not on cART 5.78 4.15-8.05  5.06 3.54-7.25 <.0001 6.27 4.38-8.97 <.0001 
 on cART VL >500 7.51 5.35-10.55  4.35 3.06-6.19 <.0001 1.75 1.16-2.64 0.007 
 on cart missing VL  36.66 18.01-74.62  9.60 4.44-20.78 <.0001 2.08 1.35-3.20 0.0009 
Hepatitis B (negative vs. positive) 1.66 1.11-2.50 0.02 1.63 1.08-2.47 0.02 1.64 1.14-2.34 0.007 
Hepatitis C (negative vs. positive) 1.48 1.12-1.95 0.02 1.21 0.82-1.78 0.33 0.92 0.64-1.32 0.66 
Hypertensive (no vs. yes) 0.21 0.08-0.52 0.001 0.23 0.08-0.67 0.007 0.71 0.41-1.26 0.24 
Diabetic (no vs. yes) 0.81 0.42-1.58 0.24       
Anaemic (no vs. yes) 3.12 2.35-4.15 <.0001 1.80 1.34-2.42 <.0001 6.11 3.71-10.05 <.0001 
Smoking status Never 1.00  0.24       
 Current 1.13 0.82-1.56        
 Previous 1.27 0.89-1.81        
Prior AIDS diagnosis (no vs. yes) 2.85 2.36-3.60 <.0001 2.23 1.73-2.88 <.0001 2.11 1.62-2.74 <.0001 
Calendar year 1.03 0.97-1.09 0.36 0.87 0.79-0.95 0.003 0.89 0.84-0.94 <.0001 
*also adjusted for region 
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7.4.4 Non-AIDS related mortality  
The majority (754, 73%) of the observed deaths during follow-up were attributed to non-
AIDS related causes, the crude mortality rate was 11·1 non-AIDS related deaths per 
1,000 PYFU (95% CI 10·3-11·9). From figure 7.12, the region with the highest rate of 
non-AIDS related mortality was in North Europe (IR 15.0 per 1,000 PYFU, 95% 13.2-
16.8). Compared to South Europe, the rate of non-AIDS related mortality in North 
Europe was 1.4 times higher (IRR 1·44, 95% CI 1·19-1·73, p=0·0001). Argentina had 
the lowest crude rate on non-AIDS related mortality (IR 4.8 per 1,000 PYFU, 95% CI 2.4-
8.6) which was significantly lower than South Europe ( IRR 0.45, 95%CI 0.25-0.83, 
p=0.01) 
 
Figure 7.12 Crude rate of death due to non-AIDS related causes by region 
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Figure 7.13 shows the percentage of non-AIDS related deaths attributed to each specific 
cause by region. In South, West Central and North Europe the three most common 
causes of non-AIDS related death were due to NADM, CVD and liver related causes. A 
similar pattern was also seen in East Central Europe. In East Europe deaths due to 
violent causes were the most common cause of non-AIDS related death, they accounted 
for 40.1% of the non-AIDS related deaths in this region, death due to liver related causes 
was the next most common accounting for 17.4%.  
 
Figure 7.13 Proportion of specific non-AIDS related causes of death by region 
 
NADM: non-AIDS defining malignancies excluding liver cancer, CVD: cardiovascular disease, 
NAI: non-AIDS related infection, Liver: liver related including deaths due to hepatitis B or C, liver 
failure or cirrhosis and liver cancer, violent: deaths due to unnatural causes including an accident 
or violence, suicide, euthanasia, substance abuse or overdose), other: causes associated with < 
20 deaths, unknown: deaths with insufficient information to determine cause of death.  
 
Table 7.13 shows the patient characteristics at the time of non-AIDS related death. 
Individuals in East Europe dying from non-AIDS related causes were younger than those 
dying in the 5 other regions. There was also a higher percentage with no CD4 count 
measured in the 6 months prior to death in East Europe. Further, a lower percentage of 
prior non-AIDS events had been reported for patients in East Europe how died from a 
non-AIDS related cause.  
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Table 7.13 Patient characteristics at non-AIDS related death 
 Region  
 South West Central North East Central East Argentina p-value 
Total (N,% of total) 187 149 255 83 69 11  
Age (median, IQR) 47 (42-59) 48 (42-59) 50 (43-59) 44 (37-54) 34 (30-41) 41 (32-48) <.0001 
CD4 count within 6 months 
 (median, IQR) 
232 (113-408) 275 (178-479) 315 (162-476) 260 (141-420) 261 (130-355) 130 (19-415) 0.10 
Missing CD4 (N,%) 32 (17.1) 28 (18.8) 54 (21.2) 16 (19.3) 40 (58.0) 5 (45.5)  















Started cART (N,%) 179 (95.7) 142 (95.3) 244 (95.7) 72 (86.8) 27 (39.1) 11 (100)  
Prior AIDS diagnosis (N,%) 87 (46.5%) 77 (51.7%) 109 (42.8%) 38 (45.8%) 29 (42.0%) 5 (45.5%) 0.62 
Years since last AIDS diagnosis 














Patients reporting ≥1 non-AIDS event  83 (44.4) 51 (34.2) 88 (34.5) 34 (40.1) 14 (20.0) 5(45.5) 0.01 
Non-AIDS defining malignancy 33 (17.6) 19 (12.8) 37 (14.5) 14 (16.9) 2 (2.9) 2 (18.2)  
Cardiovascular disease 25 (13.3) 24 (16.1) 42 (16.5) 14 (16.9) 1 (1.4) 1 (9.1)  
Liver disease 22 (11.8) 8 (5.4) 10 (3.9) 9 (10.8) 9 (13.0) 2 (18.2)  
End stage renal disease 9 (4.8) 5 (3.3) 7 (2.7) 1 (1.2) 4 (5.7) 0 (0)  
Pancreatitis 8 (4.2) 5 (3.3) 3 (1.2) 0 (0) 1 (1.4) 0 (0)  
  






 IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value 
South 1.00   1.00   1.00   
West Central 0.87 0.70-1.08 0.20 0.98 0.78-1.23 0.83 0.89 0.71-1.13 0.34 
North 1.44 1.19-1.74 0.0001 1.59 1.30-1.96 <.0001 1.43 1.17-1.73 0.0004 
East Central 0.94 0.73-1.22 0.65 1.37 1.04-1.80 0.02 1.22 0.94-1.58 0.12 
East 1.01 0.77-1.33 0.95 1.71 1.16-2.52 0.007 1.24 0.91-1.68 0.16 
Argentina 0.45 0.25-0.83 0.01 0.81 0.43-1.51 0.50 0.55 0.29-1.04 0.06 
aalso adjusted for variable in table 8: gender, age, HIV exposure group, hepatitis B and C status, prior AIDS diagnosis, hypertension, 
diabetes, anaemia, smoking status, CD4 count, baseline date and treatment 
badjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, smoking status, CD4 count, treatment and 
calendar year of follow-up included as time-updated variables.  
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Table 7.14 shows that a higher incidence of non-AIDS related mortality was observed, 
after adjusting for gender, age, HIV exposure group, hepatitis B and C status, prior AIDS 
diagnosis, hypertension, diabetes, anaemia, smoking status, CD4 count, baseline date 
and treatment in North Europe (IRR 1·58, 95%CI 1·29-1·94, p<·0001), East Central 
Europe (IRR 1·36, 95%CI 1·03-1·78, p=0·02) and East Europe (IRR 1·75, 95%CI 1·18-
2·60, p=0·05), compared to South Europe. No significant difference was observed 
between West Central Europe (p=0.83), Argentina (p=0.50) and South Europe after 
adjustment.  
 
After including age, hepatitis B and C status, hypertension, diabetes, anaemia, smoking 
status, CD4 count, year of follow-up and on cART viral load in the model as time-
updated covariates the increased rate was no longer significant in East Central Europe 
(IRR 1·22, 95% CI 0·94-1·58,p=0·12) or East Europe (IRR 1·.24, 95% CI 0·91-1·68, 
p=0·16) but there remained a significantly increased rate of mortality in North Europe 
(IRR 1·43, 95% CI 1·17-1·73, p<·0001). 
 
Table 7.15 shows the other factors that were found to be associated with non-AIDS 
related mortality. Consistent with all-cause mortality, older age, hepatitis B and C status, 
diabetes, being a current smoker compared to having never smoked, prior AIDS 
diagnosis and calendar year of follow-up were all associated with an increased risk of 
non-AIDS related mortality. Additionally, a current CD4 count < 500 cells/mm3 was 
associated with an increased risk of non-AIDS related mortality. Not being on cART was 
associated with a 2.3 times higher rate of non-AIDS related mortality compared to being 
on cART with a suppressed viral load. Interestingly, there was no significant difference 
observed in non-AIDS related mortality rate in individuals on cART with uncontrolled viral 
replication and those on cART with a suppressed viral load (p=0.43).  
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 IRR 95% CI 
Global 
p-value IRR 95% CI p-value IRR 95% CI p-value 
Gender (male vs. female) 0.65 0.54-0.78 <.0001 0.89 0.73-1.09 0.27 0.94 0.77-1.16 0.56 
Race (white Vs. other) 0.75 0.59-0.96 0.02       
Age 10 year older 1.57 1.48-1.68 <.0001 1.79 1.65-1.93 <.0001 1.76 1.63-1.89 <.0001 
HIV exposure 
group 
Homosexual 1.00  <.0001 1.00   1.00   
IDU 2.07 1.75-2.44  2.24 1.73-2.90 <.0001 1.95 1.48-2.57 <.0001 
Heterosexual 0.71 0.58-0.58  0.95 0.75-1.19 0.64 0.90 0.71-1.13 0.35 
 Other 1.30 0.98-1.72  1.24 0.93-1.66 0.14 1.13 0.85-1.51 0.38 
CD4 count ≥500 1.00  <.0001 1.08 0.86-1.34 0.50 1.00   
 350-499 1.83 1.50-2.24  1.27 1.03-1.56 0.02 2.19 1.71-2.80 <.0001 
 200-349 3.22 2.63-3.93  1.91 1.54-2.38 <.0001 5.06 3.97-6.45 <.0001 
 <200 16.77 11.46-24.56  8.23 5.08-13.33 <.0001 3.63 2.75-4.80 <.0001 
 missing 1.27 1.02-1.58  1.08 0.86-1.34 0.50 1.76 1.63-1.89 <.0001 
Treatment on cART VL ≤500 1.00  <.0001 1.00   1.00   
 Not on cART 1.31 1.11-1.56  1.51 1.25-1.82 <.0001 2.31 1.91-2.79 <.0001 
 on cART VL >500 1.73 1.45-2.08  1.60 1.32-1.93 <.0001 1.10 0.86-1.42 0.43 
 on cart missing VL  10.04 6.25-16.11  4.39 2.43-7.94 <.0001 1.20 0.92-1.57 0.18 
Hepatitis B (negative vs. positive) 1.51 1.17-1.64 0.005 1.38 1.07-1.78 0.01 1.36 1.08-1.72 0.009 
Hepatitis C (negative vs. positive) 2.29 1.95-2.68 <.0001 1.63 1.29-2.07 <.0001 2.29 1.90-2.76 <.0001 
Hypertensive (no vs. yes) 3.82 2.12-6.91 <.0001 1.34 0.69-2.59 0.39 0.76 0.55-1.05 0.10 
Diabetic (no vs. yes) 2.75 2.15-3.50 <.0001 2.08 1.61-2.69 <.0001 1.66 1.31-2.11 <.0001 
Anaemic (no vs. yes) 2.19 1.87-2.55 <.0001 1.60 1.36-1.87 <.0001 3.19 2.58-3.95 <.0001 
Smoking status Never 1.00  <.0001 1.00   1.00   
 Current 1.90 1.53-2.36  1.50 1.19-1.90 0.0006 1.65 1.31-2.07 <.0001 
 Previous 1.27 0.98-1.63  1.05 0.81-1.37 0.68 1.11 0.87-1.43 0.40 
Prior AIDS diagnosis (no vs. yes) 1.70 1.47-1.97 <.0001 1.36 1.16-1.58 <.0001 1.32 1.14-1.54 0.0003 
Calendar year 0.83 0.78-0.87 <.0001 0.81 0.76-0.87 <.0001 0.88 0.85-0.91 <.0001 
a and b also adjusted for region of Europe 
  251 
7.4.5 Additional investigatory analysis 
In order to try and further understand the reasons behind these differences observed in 
mortality rate, the interaction between age or calendar year of follow-up and region was 
tested. Further, to identify whether the differences in non-AIDS related mortality were 
due to a higher rate of mortality from a specific cause of death in North Europe, where 
there were sufficient events, the rates of specific causes of non-AIDS related death 
across the regions were investigated.  
 
7.4.5.1 Age and region 
From the baseline demographics, individuals in North Europe were on average older, 
median age 43 (IQR 37-50) and those in East Europe younger, median age 30 (IQR 25-
36). For all three endpoints older age was associated with an increased risk of mortality. 
The test for interaction with age and region was non-significant for all three endpoints 
(all-cause p=0.11, AIDS related p=0.59, non-AIDS related p=0.19), indicating that the 
effect of age on mortality was not significantly different across the regions.  
7.4.5.2 Calendar year of follow-up and region 
For all three endpoints, the test for interaction between region and calendar year of 
follow-up was significant (p=0·04, 0·02 and 0·04 respectively), indicating that there is 
evidence of a difference in effect of calendar time across the regions. The crude 
incidence rates for all-cause, AIDS related and non-AIDS related mortality and how they 
vary with calendar year of follow-up are shown in figure 7.14, 7.15 and 7.16 respectively. 
In univariable analysis, there was a significantly decreased rate of all-cause mortality 
with increasing calendar year of follow-up in South (IRR 0.89 per calendar year, 95%CI 
0.85-0.93, p<.0001), West Central (IRR 0.83 per calendar year, 95%CI 0.78-0.87, 
p<.0001), North (IRR 0.85 per calendar year, 95%CI 0.82-0.89, p<.0001), East Central 
(IRR 0.93 per calendar year, 95%CI 0.87-0.99, p=0.02), East (IRR 0.85 per calendar 
year, 95%CI 0.79-0.92, p<.0001) and Argentina (IRR 0.76 per calendar year, 95% CI 
0.66-0.87, p=0.0001). Similar trends were seen in both AIDS and non-AIDS related 
mortality across the regions.  
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Figure 7.14 Crude incidence rate of all-cause mortality by region and year of follow-up 
 
Figure 7.15 Crude incidence rate of AIDS related mortality by year of follow-up 
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Figure 7.16 Crude incidence rate of non-AIDS related mortality by region and year of follow-up 
 
Figure 7.17 shows the association with mortality and calendar year of follow-up stratified 
by region, after adjustment. In multivariable adjusted analysis, significant decreases in 
all-cause mortality rates over time were observed in West Central (IRR 0.85 per calendar 
year later, 95%CI 0.79-0.91, p<.0001), North (IRR 0.85 per calendar year later, 95%CI 
0.80-0.89, p<.0001), and East Europe (IRR 0 0.83 per calendar year later, 95%CI 0.76-
0.90, p<.0001). No significant decreases were observed in South (IRR 0.96 per calendar 
year later, 95%CI 0.90-1.02, p=0.21) or East Central Europe (IRR 0.96 per calendar year 
later, 95%CI 0.87-1.07, p=0.46). Argentina was excluded from this analysis due to the 
limited number of patients. Despite the observed decrease in mortality in East Europe 
over time, in the most recent period, 2008-2010, there remained a significantly higher 
rate of all-cause (1·73, 95%CI 1·05-2·84, p=0·03) and AIDS-related mortality (IRR 4·68, 
95%CI 2·20-10·97, p=0·0004) compared to South Europe in adjusted analysis. 
However, the higher rate observed in North Europe compared to South Europe was no 
longer significant in 2008-2010 for all-cause (IRR 1·34, 95%CI 0·87-2·11, p=0·18) or 
non-AIDS related mortality (IRR 1·43, 95%CI 0·86-2·38, p=0·16), suggesting that the 
regional differences between North Europe and South Europe may be decreasing over 
time.  
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Figure 7.17 Adjusted incidence rate ratio by calendar year of follow-up stratified by region 
  255 
7.4.5.3 Specific causes of non-AIDS related mortality 
 
Figure 7.18 shows the crude death rates for specific non-AIDS related causes of death. 
The most common specific cause of non-AIDS related death was due to liver related 
causes (n=145, 19.2%), followed by non-AIDS defining malignancies (n=132, 17.5%), 
and cardiovascular disease (m=104, 13.8%). In univariable analysis, patients from North 
Europe had a significantly higher rate of death due to non-AIDS defining malignancies 
(IRR 1.71, 95% CI 1.10-2.65, p=0.01) and cardiovascular events (IRR 2.10 per 1000 
PYFU, 95%CI 1.21-3.64, p=0.008) compared to South Europe. In East Europe, the main 
cause of non-AIDS related death was due to violence/accident, the rate of 
violence/accidental death was significantly higher compared to South Europe (IRR 13.49 
per 1000 PFYU, 95%CI 5.58-32.57, p<.0001). The number of events for each specific 
cause of death was too small to investigate these differences further in adjusted 
analysis.  
 
Figure 7.18 Crude incidence rate of specific non-AIDS related deaths by region of Europe 
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7.4.6 Sensitivity analysis 
  
To investigate whether the overall differences in the incidence rates observed across the 
regions were observed in different subgroups of patients, sensitivity analysis excluding 
those patients infected via IDU was performed. 10,109 patients were included in this 
analysis and 655 deaths were observed (193 AIDS related and 462 non-AIDS related). 
Table 7.16 summarises the results of this analysis. After adjustment, patients in East 
Europe had a 2.37 times higher AIDS related mortality rate than South Europe (95%CI 
1.38-4.08, p=0.001), lower than the 3.26 times higher rate in the main analysis. The 
incidence rate of non-AIDS related mortality remained significantly higher in North 
Europe (IRR 1.36, 95%CI 1.06-1.75, p=0.01) compared to South Europe, 
 
Table 7.16 Multivariable Poisson regression analysis excluding those with injection drug use as HIV 
transmission route 
Region   Multivariable (time-updated) 
All-cause  N included  PYFU IRR 95% CI p-value 
South 2280 13336 1.00 - - 
West Central 2512 15099 0.95 0.74-1.20 0.64 
North 2548 16294 1.27 1.02-1.57 0.02 
East Central 1252 6460 1.65 1.25-2.17 0.0003 
East 1083 3684 1.60 1.13-2.27 0.008 
Argentina 434 2158 0.72 0.43-1.21 0.21 
 AIDS related  N included PYFU IRR 95% CI p-value 
South 2280 13336 1.00 - - 
West Central 2512 15099 0.96 0.62-1.48 0.84 
North 2548 16294 1.07 0.70-1.64 0.75 
East Central 1252 6460 2.18 1.35-3.51 0.001 
East 1083 3684 2.37 1.38-4.08 0.001 
Argentina 434 2158 0.94 0.44-1.97 0.85 
Non-AIDS related  N included PYFU IRR 95% CI p-value 
South 2280 13336 1.00   
West Central 2512 15099 0.93 0.70-1.23 0.60 
North 2548 16294 1.36 1.06-1.75 0.01 
East Central 1252 6460 1.49 1.06-2.08 0.02 
East 1083 3684 1.31 0.82-2.11 0.25 
Argentina 434 2158 0.57 0.27-1.20 0.14 
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To investigate biases caused by under ascertainment of death, we varied the right 
censoring interval from 6 months after last follow-up visit to 3 months and 1 year. The 
results remained consistent with the main analysis (table 7.17).  
 
Table 7.17 Mulitvariable Poisson regression analysis varying the right censoring interval  
Region Censored 3 months 
after last follow-up visit 
Censored 1 year 
after last follow-up visit 
All-cause  IRR 95% CI p-value IRR 95% CI p-value 
South 1.00 - - 1.00 - - 
West Central 0.93 0.76-1.14 0.51 0.92 0.75-1.12 0.40 
North 1.41 1.18-1.68 0.0001 1.42 1.19-1.69 <.0001 
East Central 1.34 1.08-1.68 0.009 1.40 1.13-1.75 0.002 
East 1.75 1.38-2.21 <.0001 1.86 1.47-2.34 <.0001 
Argentina 0.73 0.47-1.15 0.17 0.86 0.55-1.34 0.50 
 AIDS related  IRR 95% CI p-value IRR 95% CI p-value 
South 1.00 - - 1.00 - - 
West Central 0.86 0.58-1.26 0.43 0.83 0.57-1.23 0.35 
North 1.09 0.75-1.58 0.64 1.09 0.76-1.58 0.63 
East Central 1.58 1.03-2.42 0.03 1.63 1.07-2.50 0.02 
East 3.25 2.18-4.84 <.0001 3.44 2.31-5.12 <.0001 
Argentina 1.01 0.52-1.97 0.96 1.20 0.62-2.31 0.58 
Non-AIDS 
related  
IRR 95% CI p-value IRR 95% CI p-value 
South 1.00 - - 1.00 - - 
West Central 0.90 0.71-1.14 0.37 0.88 0.70-1.11 0.28 
North 1.42 1.17-1.73 0.0004 1.44 1.18-1.75 0.0003 
East Central 1.21 0.96-1.57 0.14 1.27 0.98-1.64 0.07 
East 1.23 0.91-1.67 0.18 1.30 0.96-1.77 0.08 
Argentina 0.54 0.29-1.01 0.05 0.63 0.33-1.18 0.14 
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As a number of patients had missing CD4 count data a sensitivity analysis was 
performed excluding all those with missing CD4 counts. Patients excluded from this 
analysis because of missing CD4 count data were more likely to come from North or 
East Europe, be IDU, current smokers, have hepatitis C, hypertension and diabetes.  
Individuals excluded were also less likely to have a suppressed viral load whilst on 
cART. Indicating that part of the association between missing CD4 count and all-cause 
mortality may be due to some sicker individuals who stop having their CD4 count 
measured routinely prior to their death and also those from high risk groups such as IDU 
being less likely to have a CD4 count available. A total of 13,111 patients with 784 
events (579 AIDS related deaths and 205 non-AIDS related deaths) in 62,522 PYFU 
were included. The results were broadly consistent with the main analysis (table 7.18) 
although a higher rate of all-cause mortality was also seen in East Central Europe after 
adjustment.  
 
Table 7.18 Multivariate Poisson regression analysis excluding those with missing CD4 count 
measurements 
Region Multivariable (time-updated) 
All-cause  IRR 95% CI p-value 
South 1.00   
West Central 0.91 0.73-1.13 0.38 
North 1.34 1.10-1.64 0.003 
East Central 1.53 1.20-1.96 0.007 
East 1.54 1.14-2.08 0.004 
Argentina 0.83 0.46-1.53 0.55 
 AIDS related  IRR 95% CI p-value 
South 1.00   
West Central 0.91 0.58-1.42 0.67 
North 1.05 0.68-1.63 0.83 
East Central 2.15 1.33-3.49 0.001 
East 3.36 2.04-5.52 <.0001 
Argentina 1.14 0.47-2.74 0.77 
Non-AIDS related  IRR 95% CI p-value 
South 1.00   
West Central 0.88 0.68-1.14 0.32 
North 1.44 1.15-1.81 0.001 
East Central 1.37 1.03-1.84 0.03 
East 0.90 0.59-1.39 0.65 
Argentina 0.66 0.29-1.53 0.38 
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7.5 Discussion 
EuroSIDA is unique amongst studies of HIV-positive individuals in terms of its coverage 
across the entire continent of Europe, including the East. The results of this study with 
over 67,000 PYFU found significant differences in mortality rates across regions of 
Europe and Argentina. In particular, individuals in East Europe were found to have a 
higher mortality rate from AIDS related causes and individuals in North Europe a higher 
rate of non-AIDS related mortality. Similar rates of both AIDS and non-AIDS related 
mortality was seen across the other regions of Europe and Argentina. The mortality rate 
decreased over time particularly in West Central, North and East Europe. 
 
Differences in the incidence of AIDS related mortality could partly be explained by 
variations in patient demographics, including CD4 count and use of effective cART 
regimens. The epidemic in East Europe is more recent, the first outbreaks were reported 
among injection drug users in southern Ukraine in 1995733. Since then a number of 
countries in the region have expanded access to antiretroviral coverage, although 
treatment coverage remains low8;733. UNAIDS estimated that <25% of patients in need of 
antiretroviral therapy in East Europe and Asia were receiving it in 20088. This is below 
the global average for low and middle income countries which was 42%741. In our study, 
after adjustment, the rate of AIDS related mortality appeared to be decreasing over time 
in East Europe, which may in part be due to improvements in antiretroviral coverage. 
Continued efforts to improve access to treatment in this region may help to reduce the 
incidence of AIDS related mortality in East Europe to a level similar to that in the rest of 
Europe. Improving access to optimal cART regimens to allow patients to achieve and 
maintain virological suppression could help reduce the rates of AIDS related mortality in 
East Europe to a level closer to the rest of Europe. However, after adjustment for time 
updated CD4 count, use of cART, viral load and other factors, regional differences in 
AIDS related mortality were still significantly different, indicating that the differences 
cannot be fully explained by those variables collected and included in our models.  
 
A particular risk factor for mortality in HIV-positive patients is the mode through which 
HIV transmission occurred.  
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Before cART became available, mortality in persons who acquired HIV infection via 
intravenous drug use was similar to mortality in other HIV-positive individuals540. However, 
in the cART era mortality is higher for IDUs than non-IDUs538;540;701;707. EuroSIDA has 
demonstrated previously that IDUs who started cART had a similar CD4 count and viral 
load response to those in other exposure categories, but that IDU were 27% less likely to 
start cART742. Further, studies have shown that HIV-positive individuals infected via IDU 
are at an increased risk of mortality from causes not directly related to HIV infection, 
including overdose, suicide and homicide354;743. The greatest differences have been 
observed in deaths as a result of hepatitis and liver failure, and deaths as a result of 
substance abuse707. Several factors have been identified as contributing to the excess risk 
of mortality observed in IDUs in the cART era, including decreased access and adherence 
to cART744;745 and more comorbidities such as co-infection with hepatitis C361;707;746. 
Additionally, HCV co-infection has been found to increasingly contribute to the overall 
number of deaths in the cART period, with one study reporting that 66% of all patients who 
died were co-infected703. 
 
A high proportion of patients in East Europe are infected via IDU150. This was accounted 
for in the adjusted analysis, but IDU populations may differ across the regions. Some may 
have been infected several years ago and have access to opiate substitution therapy and 
treatment9, rather than actively injecting drug users who are less likely to access cART, 
have lower treatment adherence744 and are at an increased risk of AIDS related 
mortality747;748. In West Central Europe coverage of HIV services in IDU populations has 
been reported to be high, particularly access to cART for HIV-positive749. However, in East 
Europe services are low, largely due to low levels of needle exchange programmes750. 
Opiate substitution programs are available in most countries, with the exception of Russia. 
However, the programs have been found to be very limited in East Europe. Further, very 
few IDUs in East Europe have been found to be receiving cART749. Detailed information on 
opiate substitution programmes, or whether individuals were actively injecting drug users, 
was not available for individuals in this analysis. However, a sensitivity analysis, excluding 
those where the reported transmission route was IDU, found a slightly lower but still 
increased incidence rate for East compared to South Europe, indicating that the higher 
prevalence of IDU does not explain all the differences. 
 
State-of-the-art care of HIV patients requires the utilisation of multiple health care 
interventions. These include laboratory and clinical procedures for disease monitoring, but 
also involving health system interventions such as the procurement of antiretroviral drugs, 
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laboratory equipment, and health care infrastructure in general. Not all differences in 
patient care will have been captured by the use of effective cART, and overall lower levels 
of patient care in East Europe may play a significant role in the higher rate of AIDS related 
mortality in East Europe. The increase in differences in mortality rates in East Europe 
compared to South, when time-updated variables were included in the model, indicates 
that current measurements of variables such as CD4 count, on cART viral load, are not the 
only measures of health. Further, there were quite high levels of missing values so it was 
difficult to fully adjust for CD4 count or viral load. These missing values were found to be 
strongly associated with risk of all-cause mortality. Part of the reason for this may be that 
sicker individuals particularly those who are near to death are maybe less likely to attend 
the clinic for the scheduled appointments and routine laboratory testing. However, these 
missing values may also be an indicator of poorer healthcare and less frequent monitoring 
of patients in some clinics. The results of the sensitivity analysis excluding those with 
missing CD4 count were consistent with the main analysis.    There might be some factors, 
such as socio-economic and infrastructure aspects, which play a role and for which we do 
not have data730. 
 
An increased rate of non-AIDS mortality was found in patients in North Europe compared 
to South Europe. These differences could not be explained by adjusting for differences in 
patient demographics, treatment or other measured risk factors, such as smoking status, 
co-infection and CVD risk factors (diabetes and hypertension), either at baseline or time-
updated. After adjustment for baseline factors, an increased rate of non-AIDS related 
mortality was also observed in East Central and East Europe compared to South Europe. 
However, after adjusting for time-updated variables these differences were no longer 
observed.  
 
Geographical differences in non-AIDS mortality may be driven by underlying differences in 
population morbidity and mortality. For example, lifestyle factors associated with drug use 
and homosexuality may account for some of the differences in regions. An elevated risk of 
suicide has been observed in men in same sex partnerships751. However, a recent study in 
the USA found that mortality risk from non-HIV related causes including suicide was not 
elevated among homosexual men752. Smoking, excessive alcohol and drug use are found 
at an increased level in the HIV-positive population compared to the general 
population18;364;372, and may also differ between the regions. This could not be fully 
adjusted for in our models. However, we have recently started to collect data on alcohol 
intake.  
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A recent study using data from 12 Western European countries found that, in the general 
population, middle-aged men in North Europe had a 5% higher risk of all-cause mortality 
and woman 28% higher risk compared to the South Europe753. Additionally, in the general 
population, some North European countries are reported to be at a higher risk of CVD754 
and have poorer cancer survival rate755 than those in other regions. Mediterranean diet 
has been found to be associated with a lower risk of all-cause mortality, and in particular, 
mortality due to CVD and cancer in the general population756 although we have accounted 
for CVD factors such as diabetes, and hypertension these data were not available for all 
patients. Hypertension and diabetes have previously been identified in EuroSIDA356, and in 
other studies696, as potential modifiable risk factors associated with liver, CVD and NADM 
related deaths. 
 
Unsurprisingly, older age was associated with an increased risk of all-cause, AIDS and 
non-AIDS related mortality. The effects of age on the risk of mortality were similar in each 
region. It has been proposed the HIV-positive patients may suffer from accelerated aging 
driven by residual immune activation720;757. Despite years of successful treatment and 
virological suppression, the immune system may have persistent defects720. These defects 
are similar to those seen in normal aging, but in HIV-positive patients occur at an earlier 
age than normal758. Most of these abnormalities have been seen in patients who start 
cART in the later stages of the disease, when the CD4 count has already fallen to low 
levels (<200cells/mm3)720. Certain biomarkers that predict morbidity in the very old are 
higher than expected in younger HIV-positive patients, and this consistent observation 
provides indirect evidence that HIV infection might accelerate the ageing process757. The 
National Institute of Aging has sponsored a collaborative program aimed at identifying 
possible therapeutic agents that delay physiologic aging759. It may be that differences in 
lifestyle factors, discussed above, such as dietary intake or exercise levels of exercise, 
may be adding to this accelerated aging process in North Europe and having a greater 
impact on mortality.  
It has been reported that on-going viral replication is associated with an excess risk of 
opportunistic infection and death after accounting for CD4 count534. In this analysis, due to 
a high proportion of missing viral load measurements in individuals off cART, only viral 
load levels in patients receiving cART were included. 
 
For each endpoint, being off cART was associated with a significantly higher rate of 
mortality compared to those on cART with a suppressed viral load. Individuals on cART 
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with uncontrolled viral replication also had a higher risk of AIDS related mortality which is 
supported by other studies696;699;711. In our analysis, no significant difference in the rate of 
non-AIDS related mortality was observed in patients on cART, with uncontrolled viral 
replication compared to those on cART with a suppressed viral load. Some studies support 
this for all non-AIDS mortalitiy711 and others only for specific non-AIDS related causes 
such as NADM363. An association with viral load and deaths due to infections and 
cardiovascular disease has been reported in a number of studies363;699;699. Due to the 
number of deaths we could not investigate the impact of viral replication on specific 
causes, so we are unable to fully investigate this. However, the previous chapter found no 
association with viral replication and the risk of developing an NADM. 
 
It is unlikely that the higher rate of non-AIDS mortality in North Europe is driven by poor 
patient care. EuroSIDA has previously found, through different measures of healthcare in 
HIV-positive individuals, that North Europe has a high level of healthcare735. It has been 
speculated that an increase in the prevalence of certain diseases, such as cancer, may be 
expected with economic development and thus a higher mortality rate from certain causes 
might be observed despite a generally high quality of healthcare760.  
 
Long-term retention of individuals in care is important to ensure they receive the optimum 
level of care, and a better understanding of factors that prevent this is also needed. 
Factors that may contribute include overly centralised treatment programmes that limit 
geographical accessibility, shortages of healthcare workers, drug stock-outs and weak 
community treatment literacy733. In particular, it has been reported that Russia and the 
Ukraine, two countries in East Europe with the highest HIV prevalence, are spending 
relatively low levels on AIDS responses given their disease burden and ability to pay733.  
 
Another explanation, is the under ascertainment or incomplete report of deaths in other 
regions. Centres in some countries may be linked to national death registers allowing more 
complete reporting of mortality or have better methods of finding patients lost to follow-up 
(LTFU). As part of new survey, EuroSIDA is planning on collecting detailed information on 
this which may provide increased insight into the difference observed. The incidence of 
LTFU in EuroSIDA is low, and has previously been reported to be fairly consistent over 
time at < 5% per 100 PYFU, with individuals in North and West Central Europe having the 
lowest, and those in East Europe the highest rate of LTFU427. To investigate biases 
caused by under ascertainment of death, we varied the right censoring interval from 6 
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months after last follow-up visit to 3months and 1 year. The results remained consistent 
with the main analysis. 
 
In the more recent time periods, it is more likely that the specific cause of death was more 
accurately diagnosed. Prior to CoDe being introduced in 2004, it is more likely that 
misclassification may have occurred. Countries with a high prevalence of AIDS events and 
a low prevalence of non-AIDS events screening, such as those in East Europe, may have 
overestimated the role of HIV infection in fatal outcome in this earlier period. In contrast, in 
North Europe it may be that in the early 2000s attention focused on the adverse events 
associated with cART and non-AIDS related events, which may have led to an 
underestimation of the causal relationship of HIV with mortality in this region. 
 
It would be of interest to compare mortality rates to those of the general population for 
each of the regions. However, it is hard to find a suitable population as HIV-positive 
patients tend to have higher rates of many other risk factors associated with all-cause 
mortality411;412. Demographically, individuals enrolled in the EuroSIDA study are fairly 
representative of HIV-positive individuals in each region based on comparisons with data 
from UNAIDS9. However, centres included in EuroSIDA are often university-associated 
clinics in larger cities. Thus, individuals in these clinics may have better access to care and 
may not be representative of all clinics in Europe. This raised most concern in Eastern 
Europe, where the least favourable outcomes were seen, suggesting that improvements in 
this region are urgently needed. In future years, with expansion of the database to collect 
more detailed information on factors such as opiate substation therapy and alcohol use, 
and a better understanding of how deaths are ascertained at each of the centres, the 
regional differences observed can be further explored. This will be discussed more fully in 
the next chapter. As mentioned in the introduction to this chapter, previous EuroSIDA 
analyses identified four healthcare indicators (table 7.18) that measure adherence to 
current guidelines and outcome after cART initiation. These healthcare indicators may 
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1. Compliance with current guidelines on when to start cART, based on CD4-cell 
count and presence of AIDS diagnosis 
2. Compliance with current guidelines on prophylaxis of opportunistic infections, i.e. 
initiating of Pneumocystis jiroveci pneumonia (PCP) chemoprophylaxis at CD4-cell 
count <200 cells/µL and no prior diagnosis of PCP 
3. Laboratory evaluation of HIV-disease status: median number of CD4-cell count and 
HIV-RNA measurements performed per patient per follow-up year, stratified by 
whether patients were off or on cART; 
4. Virologic response to cART, assessed by the proportion of patients spending more 
than 90% of the follow-up time on cART with suppressed HIV-RNA 
 
In conclusion, differences were observed in the rate of all-cause mortality among HIV-
positive patients across different regions of Europe. Individuals in Eastern Europe had an 
increased risk of mortality from AIDS related causes in part due to differences in use of 
effective cART. Patients in North Europe had the highest rate on non-AIDS related 
mortality which could not easily be explained but did appear to decrease over time. 
Research investigating regional differences across Europe, particularly allowing a 
comparison with East Europe, is limited. EuroSIDA includes HIV-positive individuals from a 
wide range of countries across all the regions, including a significant proportion from 
Eastern Europe, typically underrepresented or absent in other studies of the HIV epidemic. 
There is an urgent need to better understand the poor outcomes in East Europe including 
a comprehensive measure of healthcare indicators that capture the wide aspect of HIV 
treatment and outcomes. 
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Chapter 8 Conclusions 
 
8.1 Summary of main findings 
The focus of HIV research has changed since the introduction of cART, which saw 
dramatic improvements in the quantity and quality of life for HIV-positive individuals. 
Once initiated, cART is a lifelong commitment; a high proportion of patients have now 
been on cART for over 10 years. It is therefore important that patients are on an 
effective, safe and durable cART regimen, that allows them to be monitored by 
clinicians closely enough to receive effective treatment, but not too closely that it 
impacts unnecessarily on the patient’s quality of life. Effective durable cART has led to 
an increase in life expectancy and we now have an ageing HIV-positive population in 
Europe. This ageing population may be at an increased risk of developing a variety of 
different clinical events not traditionally seen as AIDS related, but that occur at a higher 
rate than in the HIV-negative population. It is important for cohort studies to identify new 
and emerging trends in clinical events, and to understand what factors are related to the 
development of these events. Cohort studies can also help investigate the impact HIV 
and non-HIV related risk factors are having on the development on these new clinical 
events and on mortality rates across the HIV positive population in Europe. The aim of 
this thesis was, therefore, to assess the long term durability of cART through assessing 
various clinical, virological and immunological outcomes including mortality in HIV-
positive patients across Europe. 
 
8.1.1 Investigation into whether frequency of monitoring can be 
reduced in a sub-group of HIV-positive patients across Europe 
 
Treatment guidelines in developed countries such as Britain and the US have 
recommended that individuals on cART should be seen in clinics every 3-4 months for 
CD4 count and viral load monitoring, regardless of their response to therapy or how 
long they have been on their current cART regimen. In Chapter 3, a subgroup of 
otherwise healthy HIV-positive patients were identified who had responded well to 
therapy and were on a well-tolerated and fully suppressive cART regimen. This 
subgroup were found to have a low chance of immunological or virological failure or an 
AIDS, non-AIDS defining event or death, occurring in the next 3-6 months. 
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The most common event was viral rebound, which was defined as two consecutive viral 
load measurements above 500 copies/ml. Very few serious clinical events were 
observed, and the probability of developing an AIDS defining illness, non-AIDS defining 
illness, full suppressed cART regimen for a year was less than 1%. The probability of 
the CD4 count dropping substantially to either below 200/mm3 or below the CD4 at 
starting cART was also less than 1%. Further, patients who had spent less than 70% of 
their follow-up whilst on cART (excluding the first four months after starting a new 
regimen) with uncontrolled viremia had an increased risk of experiencing disease 
progression.  
 
These findings suggest that it may be reasonable to consider increasing visit intervals 
from 3 to 6 months in HIV-positive patients who are otherwise healthy, and have 
maintained a stable and fully suppressed cART regimen for at least one year, 
particularly if the patient has experienced sustained periods of virological suppression 
since cART initiation. Extending the time between clinic visits would benefit the patient, 
in that it would make treatment less intrusive on their lives, with fewer reminders to 
patients of their illness, and would benefit out-patient clinics through saving 
considerable resources, by freeing up clinicians to allocate more resources to those 
patients at greatest risk of treatment failure and clinical disease progression.  
 
Since this analysis was performed, treatment guidelines494;761 have been modified and 
currently recommend that, in patients with consistently suppressed viral loads whose 
CD4 cell count has increased well above the threshold for opportunistic infection risk, 
the CD4 count may be monitored every 6 to 12 months, unless there are changes in the 
patient’s clinical status. The recommendations also state that adherent patients with 
suppressed viral load and stable clinical and immunologic status for >2–3 years, the 
interval between HIV RNA monitoring may be extended to every 6 months. Results 
from this analysis provide some direct evidence to support these recommendations761.  
  
A manuscript of this analysis was published in AIDS in May 2008, and can be found in 
Appendix IV. 
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8.1.2 History of viral suppression on cART as a predictor of 
virological failure after starting at least one new antiretroviral  
 
The analysis performed in Chapter 3 looked at a subgroup of patients on a stable and 
fully suppressed cART regimen, and found that even in the subgroup of individuals who 
were doing well on therapy, patients who had spent < 70% of their follow-up time on 
cART with a suppressed viral load had a higher risk of experiencing an event, the most 
common of which was virological failure. In Chapter 4, the association between history 
of viral suppression and future virological failure was investigated in more detail. All 
patients who were on cART, and starting a new ARV(s), were included and the chapter 
investigated whether there was an association between different measures of 
describing a patient’s history of viral suppression after cART initiation, and risk of future 
viral failure after starting a new ARV(s). The 6 measures of previous responses to cART 
investigated were, time in months to initial suppression (HIV-RNA ≤ 500 copies/ml) after 
starting cART, number of viral rebounds after initial suppression, size of the highest 
viral rebound, time since most recent viral rebound, viral rebound above viral load at 
first starting cART (yes versus no), and the proportion of time spent with a viral load ≤ 
500copies/ml while receiving cART.  
 
The most important factor for predicting virologic failure after starting a new ARV(s) was 
the percentage of time spent with a suppressed viral load whilst on cART prior to 
starting a new ARV(s), both in patients virologically suppressed and those virologically 
failing at the time of starting new ARV(s). In addition, in patients who were virologically 
suppressed at baseline, time since last viral rebound prior to starting new ARV(s) was 
also an important factor in predicting the risk for future virologically failure. Individuals 
who had spent <70% of their time on cART (excluding the first four months after starting 
a new regimen) with a suppressed viral load had a higher risk of future virological 
failure, consistent with the analysis in Chapter 3. In individuals virologically suppressed 
at the time of making a treatment switch, a higher rate of virological failure was also 
observed in those suppressed between 70-90% compared to >90% on the time on 
cART. Further, in those who were suppressed at the time of starting new ARV(s), the 
time since last virological rebound was also associated with risk of future virological 
failure after starting the new ARV(s). A decreasing risk of virological failure was found 
with increasing time since last virological rebound.  
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These findings suggest that when patients on cART are making a change in their 
treatment regimen, patients who have previously spent a low percentage of time on 
cART with a suppressed viral load and those who have recently rebounded may require 
more intensive monitoring and consideration should also be made to increasing 
adherence counselling.  
 
These results have also been used to provide support to treatment recommendations 
and compliment the results from Chapter 3. Based on results from both these analyses, 
guidelines now recommend that, once viral replication is suppressed, monitoring 
intervals may be extended up to every 6 months, among patients who remain 
virologically suppressed and have CD4 cell counts greater than 350cells/mm3. 
However, more frequent monitoring is required for patients who have changed therapy 
because of virologic failure761. 
 
A manuscript of this analysis was published in HIV Medicine in August 2010 and can be 
found in Appendix V. 
 
8.1.3 A comparison of the long term durability of nevirapine, 
efavirenz and lopinavir in routine clinical practice across 
Europe 
 
In Chapter 3, patients who had maintained a fully suppressed cART regimen for at least 
a year had a very low risk of disease progression in the next 6 months. Additionally, 
results for Chapters 3 and 4 found that an important predictor of virological rebound and 
disease progression in patients on cART was the proportion of time patients had spent 
on cART with a suppressed viral load. The virological efficacy of a number of ARVs has 
already been demonstrated in a number of clinical trials and prior cohort studies. 
However, it is not only important for a regimen to be virologically effective; it also needs 
to have long term durability. Durability can be assessed by the rate and reasons for 
treatment discontinuation and the risk of developing long term adverse events, such as 
such as cardiovascular disease or pancreatitis.  
 
Nevirapine, efavirenz, or lopinavir, together with two NRTIs are three of the most 
commonly used regimens across Europe.  
  270 
Previous studies have investigated the virological efficacy and incidence of AIDS 
related events in patients on these three regimens, but less is known about the long 
term durability of each regimen. Therefore, the analysis in Chapter 5 compared the long 
term durability of regimens including nevirapine, efavirenz and lopinavir. As the focus 
was long-term durability, patients were only included once virological suppression had 
been achieved, and after at least 3 months exposure to either nevirapine, efavirenz or 
lopinavir based cART, to exclude discontinuations due to early-onset potentially 
treatment limiting toxicities, such as central nervous system (CNS) disturbances or 
hypersensitivity reactions (rash, hepatotoxicity).  
 
No significant difference was found in the rate of discontinuation for any reason 
between the three treatment regimens, although differences were found in the rate of 
discontinuation for specific reasons. Patients on nevirapine had a higher rate of 
discontinuation due to reported treatment failure, and a lower rate of discontinuation 
due to toxicity or patient/physician choice compared to those on efavirenz and lopinavir. 
There was no significant difference in the development of any non-AIDS clinical events, 
worsening in anaemia, severe weight loss, or increasing in ALT or AST levels. Patients 
on lopinavir had a higher rate of low HDL cholesterol compared to patients on 
nevirapine. However, there was no difference in low HDL cholesterol between patients 
on efavirenz and nevirapine. Furthermore, patients on lopinavir had a marginally higher 
mortality rate compared to nevirapine, but there was no significant difference between 
efavirenz and nevirapine. 
 
This analysis, based on data from patients under routine follow-up across Europe, 
found that nevirapine based cART regimens have similar durability based on risk of all-
cause discontinuation and development of serious clinical events compared to efavirenz 
and lopinavir. However, patients on nevirapine had a higher rate of discontinuation due 
to reported treatment failure, and those on efavirenz and lopinavir had a higher rate of 
discontinuation due to toxicity or patient physician choice. As a choice of first-line cART, 
all three regimens appear to have similar long-term durability. However, it is also worth 
noting that treatment for HIV is currently expected to be lifelong, and it is possible that 
there will be long-term differences in outcomes for those who discontinued treatment 
due to treatment failure, and those who discontinue due to toxicities or patient/physician 
choice due to the rate at which available alternative regimens are used and new drugs 
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become available. A real strength of this analysis was the long term follow-up available 
for each of the ARVs investigated, something rarely available in clinical trials where the 
results focus on short-term outcomes, particularly virological response.  
 
A manuscript to this analysis was published in HIV medicine in May 2011 and can be 
found in Appendix VI. 
 
8.1.4 The relationship between current level of immunodefiency and 
non-AIDS defining malignancies 
In developed countries, the use of effective, durable cART has led to a decrease in the 
incidence of many AIDS-defining illnesses, including two AIDS defining malignancies 
(ADM); Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL). In the current 
treatment era, a higher portion of malignancies in HIV-positive patients are non-AIDS 
defining malignancies (NADM) rather than ADM. Further, many of these NADM have 
been found to occur at higher rates in HIV-positive patients compared to the general 
population. Although some of this increased risk can be explained by the higher 
prevalence of associated risk factors, such as smoking, alcohol, drug use and co-
infection with a number of oncogenic viruses, such as EBV, HPV, and hepatitis, it does 
not account for all of the increased risk. One theory is that impaired immune function 
may result in the general reduced immune surveillance for malignant cells, or it may 
impair the ability to suppress oncogenic viruses, and this may result in a higher risk of 
developing some cancers. To explore the link between immune suppression and the 
development of NADM, the incidence of NADM across Europe in HIV-positive patients 
and the risk factors associated with the development of NADM were investigated in 
Chapter 6.  
 
The incidence of NADM in EuroSIDA from 1994-2007 was 4.3 per 1000 PYFU. After 
adjustment, a higher current CD4 count was independently associated with a 
decreased incidence of NADM. In addition, an increased rate of ‘virus-related’ cancers 
and ‘non-virus related epithelial’ cancers was found in immunodeficient patients. 
Hodgkin’s lymphoma, anal, and lung cancers were all found at a higher rate in patients 
with lower current CD4 counts after adjustment for other demographic and traditional 
risk factors.  
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Further, individuals in East Europe had a significantly lower risk of developing an NADM 
which may be due in part to competing risks from other events such as a higher rate of 
mortality.  
 
This analysis demonstrated a link with immunodeficiency and the development of 
certain NADM, particularly those that are virus-related. Starting cART earlier to reduce 
the proportion of patients with a low CD4 count may decrease the rate of developing 
many common non-AIDS related malignancies, although the potential harms for longer 
exposure to drugs and risk of toxicities would have to be balanced against the potential 
benefits. Current guidelines using evidence from this study, together with a number of 
other cohort studies, agree that the evidence suggests that initiating ART to suppress 
HIV replication and maintain CD4 counts at above 350–500 cells/mm3 may reduce the 
risk of both AIDS defining and non-AIDS-defining malignancies494. The European AIDS 
clinical society guidelines include details on the prevention and management of non-
infectious co-morbidites in HIV. Within this section there are guidelines on the screening 
of six NADM (anal cancer, breast cancer, cervical cancer, colorectal cancer, 
hepatocellular carcinomas, and prostate cancer)762. The screening recommendations 
are derived from the general population, and reflect the increasing importance of co-
morbidities for HIV-postitive persons as a consequence of increased life expectancy 
resulting from durable and effective cART, and concerns that several risk factors 
including immunodeficiency may result in an increased risk of these of events in HIV-
positive persons.  
 
A manuscript of this analysis was published in Cancer in November 2010 and can be 
found in Appendix VII. 
 
8.1.5 Regional differences in the incidence of AIDS and non-AIDS 
related mortality in HIV-positive patients across Europe 
 
Eastern Europe has one of the fastest growing HIV epidemics worldwide8. The uptake 
of cART in Eastern Europe remains low, and previous studies have reported substantial 
differences in access to care and treatment compared to the rest of Europe424;735. 
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In Chapter 3, a subgroup of patients were selected for the analysis who had maintained 
a stable and fully suppressed cART regimen for at least 1 year, and compared to the 
other regions a higher proportion of patients in East Europe were excluded from this 
analysis. This was due to a higher proportion of patients in East Europe having missing 
CD4 count and viral load measurements and being unable to maintain a stable and fully 
suppressed cART regimen. In Chapter 5, long term durability of nevirapine, efavirenz 
and lopinavir based cART regimens, although no differences were observed across the 
different regimens in the incidence of serious non-AIDS clinical events, a higher rate of 
non-AIDS events was observed in North Europe compared to South Europe. 
Additionally in the last chapter, patients in East Europe had a lower risk of developing 
an NADM and it was speculated that this may, in part, be due to competing risks from 
AIDS related events and mortality. All these factors indicate that there may be 
differences in the mortality rates in the current treatment era, across different regions of 
Europe and Argentina and, in particular, differences in the specific causes of death. 
Chapter 8, the final chapter, aimed to investigate whether differences are seen on the 
rate of all-cause, AIDS-related, and non-AIDS related mortality across the regions.  
 
Significant differences in all-cause, AIDS and non-AIDS related mortality rates were 
seen across the 6 different regions. In particular, individuals in East Europe were found 
to have a higher mortality rate from AIDS related causes compared to South Europe. 
Some, but not all, of this increased rate could be explained by variations in patient 
demographics, including CD4 count and use of effective cART regimens. Further, an 
increased rate of non-AIDS mortality was found in patients in North Europe compared 
to South Europe, and these differences could not be explained by adjusting for 
differences in patient demographics, treatment or other risk factors. However, the rate 
of non-AIDS related mortality appeared to be decreasing over time in North Europe, 
with no difference observed in the most recent time period. Similar rates of both AIDS 
and non-AIDS related mortality were seen across the other regions of Europe and 
Argentina. 
 
Differences in the incidence of AIDS related mortality could potentially be explained by 
variations in patient demographics, including CD4 count and use of effective cART 
regimens. 
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The differences in the rate of non-AIDS mortality, particularly the higher rate observed 
in North Europe compared to South Europe, could not be explained by adjusting for 
differences in patient demographics, treatment or other risk factors that were measured 
such as smoking status, co-infection and CVD risk factors (diabetes and hypertension), 
either at baseline or time-updated.  
 
Some of the differences in non-AIDS mortality may be driven by underlying differences 
in population morbidity and mortality, which could not be accounted for in this analysis. 
However, another, perhaps more likely, explanation is the under ascertainment or 
incomplete report of deaths in other regions. Centres in some countries may be linked 
to national death registers allowing more complete reporting of mortality or have better 
methods of finding patients lost to follow-up (LTFU).  
 
Research investigating regional differences across Europe, particularly allowing a 
comparison with East Europe, is limited. EuroSIDA includes HIV-positive individuals 
from a wide range of countries across all the regions, including a significant proportion 
from Eastern Europe, typically underrepresented or absent in other studies of the HIV 
epidemic. There is an urgent need to better understand the poor outcomes in East 
Europe, including a comprehensive measure of healthcare indicators that capture the 
wide aspect of HIV treatment and outcomes. To fully understand these differences, a 
comparison with the HIV-negative population is probably needed.  
 
8.2 Limitations  
 
8.2.1 Observational studies  
 
To answer the research questions addressed in this thesis, data were selected from a 
large prospective observational cohort study. Although statistical methods, such as 
adjusting for confounding variables, can account for some of the biases, there may 
remain unmeasured or unknown confounding that cannot be adjusted for, and therefore 
we cannot fully exclude the possibility of some bias763. 
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For example, in Chapter 5, the long term durability of nevirapine, efavirenz and lopinavir 
based cART regimens were compared. Randomised controlled trials are the gold 
standard for comparisons of drug interventions, and this analysis would possibly benefit 
from trial data to address this question, as observational cohort studies are likely to be 
affected by confounding because of the non-randomized selection treatment regimen in 
clinical practice764. For example, factors such as the patients disease status or 
underlying risk factors may influence which treatment is selected for a given patient764. 
However, the focus of this analysis was comparing the long-term durability of the three 
treatment regimens. The median follow-up time for this analysis was 2.6 years, and a 
number of different clinical outcomes were assessed. To carry out the same analysis in 
a randomised controlled trial with enough power to detect differences in clinical 
outcomes would be very costly and time consuming.   
 
The benefits of observational studies include longer follow-up time, the lack of strict 
inclusion/exclusion criteria, that patients are under routine clinical management, the 
opportunity to study long-term or rare effects of treatment and more power to detect 
clinical outcomes.  
8.2.2 Data limitations 
 
There were a number of limitations to these analyses, some of these are discussed as 
the end of each of the chapters but there are a few that require discussion in more 
detail. Firstly, a number of the endpoints that were analysed were rare, and in order for 
there to be sufficient power to perform the analysis some endpoints were grouped 
together to form a composite end point. A consequence of this may be that there are 
other risk factors associated with some rarer events that could not be identified, and the 
risk factors that were identified are most likely to be those associated with the most 
common events in the composite endpoint. For example, in Chapter 3, the most 
common event was virological failure, so the risk factors that were identified are most 
likely to be predictive of virological failure, and there may have been other factors that 
were associated with, for example, the risk of death that were not identified. Similarly, in 
the analysis looking at the association between NADM and immunosuppression, a lot of 
consideration was put into grouping the malignancies, with input from an expert 
oncologist. 
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However, in the virus-related group, Hodgkin’s lymphoma, anal and liver cancer made 
up the majority of the events, and it may be the associations identified are different for 
some of the other rarer cancers.  
 
Another limitation that was of concern when looking at the long term durability of 
nevirapine, efavirenz and lopinavir was the information collected on the reason for 
patients making a treatment switch. Table 8.11 lists the reasons that are collected on 
the EuroSIDA follow-up forms (see Appendix I) and were used in the analysis in 
Chapter 5. Reasons for discontinuation of antiretrovirals have been collected since 
1999. This information is only collected for the ARV(s) that are being stopped, not those 
that are started. Additionally, only one reason is given per ARV.  
 






















Reason for stopping antiretroviral 
1:  Treatment failure ( i.e. virological, immunological and/or clinical failure) 
2:  Abnormal fat redistribution 
3:  Concern of cardiovascular disease 
3.1: Dyslipidemia 
3.2: Cardiovascular disease 
4:  Hypersensitivity reaction 
5:  Toxicity, predominantly from abdomen/GI tract 
5.1: Toxicity - GI tract 
5.2: Toxicity - Liver 
5.3: Toxicity - Pancreas 
6:  Toxicity, predominantly from nervous system 
7:  Toxicity, predominantly from kidneys 
8:   Toxicity, predominantly from the endocrine system 
8.1: Diabetes 
9:   Hematological toxicity 
10:  Hyperlactataemia/lactic acidosis 
90:  Toxicity, not mentioned above 
91:  Patient's wish/decision, not specified above 
92:  Physician's decision, not specified above 
94:  Other causes, not specified above 
94.1:Out of stock 
93:  STI - Structured Treatment Interruption 
99:  Unknown 
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Focusing on treatment failure first, only one category was available, and this covers a 
range of possible reasons for treatment failure, including virological, immunological or 
clinical reasons. These reasons likely have quite different consequences in terms of 
clinical outcome and patient management. In addition, it was not based on a predefined 
definition, but at the clinician’s discretion as to whether they felt this was the reason for 
stopping. One possible solution is to look at whether the patient was failing virologically 
at the time of stopping treatment. This was done in Chapter 5, and the majority of those 
who stopped due to treatment failure were virologically failing at the time of stopping. 
Further, if the treatment change was due to patient or physician choice, this was 
grouped with stopping due to toxicities, as this had been found to be a good marker for 
generalized toxicities causing treatment interruption400;589. The exact reasons for the 
patient or physician choosing to stop treatment are not known. 
 
In a number of the chapters, Chapter 4 in particular, the analysis was focused around 
viral suppression or viral rebound. Arbitrary decisions on how to measure variation in 
viral load, and what constitutes a failure, may have a serious effect on how the results 
of a study are interpreted126. Throughout the thesis when viral load was used as an 
outcome, a number of sensitivity analyses were performed looking at different cut offs 
for the outcome. In particular, sensitivity analyses were performed in a subgroup of 
patients who had their viral load consistently measured with a lower limit of detection of 
50copies/ml. However, this substantially reduced our power to detect a difference, but 
the results remained consistent. European AIDS clinical society guidelines now define 
virological failure as a confirmed viral load > 50 copies/l (or > than the lower limit of 
detection of the viral load assay) 6 months after starting therapy (initiation or 
modification)762.  
 
A further general limitation of the EuroSIDA data set is that there were missing values 
for a number of the variables used in each analysis. There are a number of reasons 
why individuals may have had missing values. If the data are missing at random, then 
this should not impact on the results of our analysis. However, some of the missing 
values may have been down to differences in monitoring strategies and availability of 
tests and diagnostic facilities across the centres. 
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Patients in East Europe were found to have higher rates of missing CD4 counts and 
viral loads than the other regions. This is likely due to less frequent monitoring of 
patients in this region. In order to account for this in the analysis comparing mortality 
rates across Europe, both CD4 count and viral load were included as categorical 
variables with a category for missing values. Alongside this, in order to reduce the 
number of individuals lost to follow-up, at each 6-monthly update of the database, the 
percentage lost to follow-up in each centre is reported back to the co-ordinating centre. 
Individual centres with the highest rates of loss to follow-up are contacted, and often a 
site monitor will visit these sites to try to address any issues they may be having with 
completing the follow-up forms. As mentioned in the last chapter, loss to follow-up in 
EuroSIDA is low, it has been reported to be <5% per year. Older patients, those with 
higher CD4 count, and those who have started cART had lower incidence of loss to 
follow-up and has been found to be higher in those from East Europe427.  
 
8.2.3 Changes in data collection 
 
As the focus of HIV research has changed, so have the variables collected on the 
EuroSIDA follow-up forms, and the attention placed on ascertaining and verifying 
certain clinical events. For example, data on NADM has been systematically collected 
and included as part of the quality assurance process from 2001, after it emerged that 
NADM were increasing in HIV-positive patients. Therefore, any association observed 
with an increase in the number of events over time may simply reflect changes in data 
collection and better ascertainment of events, rather than a true increase in the rate of 
NADM over time.  
 
Further changes include the use of CoDe for assigning the cause of death. CoDe was 
developed by a multidisciplinary team of experts in 2004 to help with accurately coding 
the causes of death in HIV-positive patients. Since then, clinics are requested to 
complete a CoDe form for any patient that dies, together with completing a final follow-
up form. Thus from 2004 onwards, more detailed and accurate information has been 
available on causes of death. Further work more recently has allowed the development 
of an algorithm to classify deaths as AIDS or non-AIDS. These changes may have had 
an impact on our results, as some countries may have focused on monitoring non-AIDS 
related causes.  
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It is therefore important to adjust for calendar year of follow up, as it may reflect 
underlying factors such as treatment management practices, concomitant care and 
available drugs764.  
 
Since the analysis in this thesis began, the EuroSIDA follow-up forms have again been 
modified. In particular, it has become apparent that it is important for observational 
studies to not only collect information on risk factors thought to be associated with HIV 
disease progression, but also on risk factors associated with the risk of developing 
other serious clinical events. The latest version of the EuroSIDA follow-up form is 
available online at www.cphiv.dk and in Appendix I of this thesis. 
 
An additional limitation of the EuroSIDA data is that we cannot adjust for current IDU 
status, as this information was not collected. This lead to a number of sensitivity 
analyses being performed, excluding individuals where the transmission route was IDU. 
The updated follow up forms now also collect information on current intravenous drug 
use, and opiate maintenance therapy. Numerous studies have reported the difference 
in treatment adherence and outcome in IDUs compared to the rest of the HIV-positive 
population, and once there is sufficient data available it would be interesting to compare 
outcomes and the long term durability of cART specifically in this subgroup of patients, 
as they are probably at the highest risk of virological failure, disease progression, and 
mortality. Additionally, if there were sufficient active IDUs enrolled across the regions, it 
would be interesting to repeat the regional comparisons in this subgroup of patients.  
 
Another addition to our data collection concerns alcohol abuse, and whether or not the 
patient is currently suffering from alcohol abuse or has done in the past. This will help 
provide information on a modifiable lifestyle factor that is likely to significantly contribute 
to an individual’s risk of non-AIDS events and mortality. It may also have an impact on 
individual’s adherence to treatment and drug tolerability, which are all important for 
long-term durable cART regimens. However, this information is collected in a similar 
way to smoking status and therefore has some limitations. For example, we do not 
collect data on the amount of alcohol being consumed, frequency of binge drinking or 
type of alcohol consumed.  
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As mentioned in Chapter 7, no information is currently available on which centres are 
routinely linked with death registries and would therefore have complete information on 
death. It is important for any analysis looking at death rates, particularly comparing 
regions, that data are as complete as possible. Future work could include a sensitivity 
analysis only including centres known to link to death registries. It is unlikely that this 
occurs equally in different countries or regions however, which would introduce a further 
bias.  
8.3 Further Research 
The analysis in Chapter 5 looked at the long term durability of three main cART 
regimens. It would be interesting to repeat this analysis with current state of the art 
regimens. Further, to look at whether the risk of certain clinical events, such as non-
AIDS defining malignancies, is the same for different antiretrovirals at a given CD4 
count and viral load.  
 
As previously discussed, non-AIDS defining malignancies were split into three 
categories based on cancer type. These groups were still very heterogeneous; 
highlighted by the results of the limited analysis that was performed on specific NADM. 
With longer follow-up, and more events, it would be interesting to look at risk factors for 
specific type of malignancies. It may also have been interesting to split the CD4 count 
into smaller categories, but there was insufficient power for this type of analysis. As 
more events are reported in EuroSIDA allowing for analysis on specific types of 
malignancies it would also be interesting to use the plasma viral load samples that are 
stored for EuroSIDA patients to investigate whether certain bio-markers could be 
identified that predict a risk of developing a specific non-AIDS defining malignancy . 
 
Similarly, when looking at mortality rates grouping all non-AIDS related deaths into one 
category resulted in a very heterogeneous grouping. With the improvement in the 
coding of death within EuroSIDA using the CoDe form, it will be important to investigate 
whether regional differences in mortality rates exist due to specific non-AIDS related 
events and also whether certain risk factors have different impacts on the risk of 
mortality from a specific cause. The additional information that is now being collected 
on alcohol abuse and current IDU status would also provide additional valuable 
information, which could be used to help develop a list of healthcare indicators. 
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These healthcare indicators could be for measuring and comparing the different regions of 
Europe, to identify areas where improvements could be made.  
 
8.4 Concluding remarks 
The aim of this thesis was to assess the long term durability of cART through assessing 
various clinical, virological and immunological outcomes, including mortality in HIV-positive 
patients across Europe. Results showed that HIV-positive patients on a well-tolerated and 
fully suppressive cART regimen have a small risk of treatment failure occurring over the 
next 6 months, and could therefore be monitored less frequently. In contrast, patients who 
have spent a low percentage of time with a suppressed viral load whilst on cART, or who 
have recently rebounded may require more intensive monitoring after making a treatment 
switch. In patients who have achieved an initial response and tolerated the first three 
months of treatment, nevirapine efavirenz and lopinavir based cART regimens all have 
similar durability based on risk of all-cause discontinuation and development of serious 
clinical events. Starting cART earlier to reduce the proportion of patients with a low CD4 
count may decrease the rate of developing many common non-AIDS related malignancies. 
Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes, 
in part due to differences in use of effective cART.  
 
The continued expansion of EuroSIDA will allow for more powerful and detailed analysis 
on specific clinical events, and further stratifications of variables of interest. Several 
findings from my research have already been incorporated into treatment guidelines and 
used in the clinical management of patients. It is hoped that the results from this thesis will 
continue to provide evidence that will help improve the long term durability of cART and 


















Appendix I. EuroSIDA sample follow-up form 2012
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Appendix II. The EuroSIDA study group 
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The multi-centre study group on EuroSIDA (national coordinators in parenthesis).  
Argentina: (M Losso), C Elias, Hospital JM Ramos Mejia, Buenos Aires. 
Austria: (N Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical 
University Innsbruck, Innsbruck.  
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, 
Gomel State Medical University, Gomel; O Suetnov, Regional AIDS Centre, Svetlogorsk.  
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; R 
Colebunders, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University 
Ziekenhuis Gent, Gent.  
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, 
Sarajevo. 
Bulgaria: (K Kostov), Infectious Diseases Hospital, Sofia.  
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. 
Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, 
Charles University Hospital, Plzen.  
Denmark: (J Nielsen), G Kronborg,T Benfield, M Larsen, Hvidovre Hospital, Copenhagen; 
J Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C 
Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus. 
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond 
Siseklinik, Kohtla-Järve.  
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki.  
France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P Viard, Hôpital Necker-
Enfants Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital 
Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital 
de l'Archet, Nice; F Dabis, D Neau, Unité INSERM, Bordeaux.  
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule 
Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, 
Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S 
Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, 
Munich; G. Fätkenheuer, Universität Köln, Cologne.  
Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; 
G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration 
Genereal Hospital, Athens.  
Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest.  
Ireland: (F Mulcahy), St. James's Hospital, Dublin.  
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, 
Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem.  
Italy: (S Vella), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale 
Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, 
Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E 
Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G 
Antonucci, A Testa, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale Malattie Infettive 
Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, 
Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte, Istituto Di Clinica 
Malattie Infettive e Tropicale, Milan.  
Latvia: (B Rozentale), I Zeltina, Infectology Centre of Latvia, Riga.  
Lithuania: (S Chaplinskas), Lithuanian AIDS Centre, Vilnius.  
Luxembourg: (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.  
Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, 
Amsterdam. 
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Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.  
Poland: (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska, 
Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical University, 
Bialystok; A Boron-Kaczmarska, M Pynka, M Parczewski, Medical Univesity, Szczecin; M 
Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical 
University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital 
Specjalistyczny, Lodz.  
Portugal: (F Antunes), M Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, 
Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; N Zakharova, 
St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre for AIDS, 
Novgorod.  
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bratislava.  
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (J González-Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; 
S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C 
Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, 
Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, 
Hospital Sant Pau, Barcelona.  
Sweden: (A Karlsson), Venhaelsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö 
University Hospital, Malmö.  
Switzerland: (B Ledergerber), R Weber, University Hospital, Zürich; P Francioli, M 
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, 
Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M 
Battegay, L Elzi, University Hospital Basel.  
Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, 
Luhansk State Medical University; Luhansk; S Servitskiy, Odessa Region AIDS Center, 
Odessa; M Krasnov, Kharkov State Medical University, Kharkov.  
United Kingdom: (S Barton), St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, D Mercey, Royal Free and University College London Medical 
School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, Royal 
Free and University College Medical School, London (Royal Free Campus); M Murphy, 
Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial 
College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County 
Hospital, Brighton; C Leen, Western General Hospital, Edinburgh. 
Steering Committee: J Gatell, B Gazzard, A Horban, B Ledergerber, M Losso, J 
Lundgren, A d’Arminio Monforte, C Pedersen, A Phillips, A Rakhmanova, P Reiss, M 
Ristola, J Rockstroh (Chair), S De Wit (Vice-Chair) 
Coordinating Centre Staff: J Lundgren, O Kirk, A Mocroft, A Cozzi-Lepri, D Grint, M 
Ellefson, D Podlekareva, J Kjær, L Peters, J Reekie, J Kowalska, J Tverland, A H Fischer, 
J Nielse
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Appendix IV. Does less frequent routine monitoring of 
patients on a stable, fully suppressed cART regimen 
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Appendix V. History of viral suppression on 
combination antiretroviral therapy as a predictor of 
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Appendix VI. A comparison of the long-term durability 
of nevirapine, efavirenz and lopinavir in routine clinical 
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Appendix VII. Relationship between current level of 
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